Profil

Reginster Jean-Yves

Département des sciences de la santé publique

See author's contact details
ORCID
0000-0001-6290-752X
Main Referenced Co-authors
Bruyère, Olivier  (965)
Beaudart, Charlotte  (264)
Henrotin, Yves  (224)
Buckinx, Fanny  (190)
Deroisy, Rita  (152)
Main Referenced Keywords
Humans (137); Female (90); Aged (87); osteoporosis (87); Osteoporosis (69);
Main Referenced Unit & Research Centers
Centre Interfacultaire de Recherche du Médicament - CIRM (3)
Département des Sciences de la Santé Publique de l'Université de Liège (3)
d‐BRU - Dental Biomaterials Research Unit - ULiège [BE] (3)
Département des Sciences de la Santé Publique de la Faculté de Médecine, Ecole de Santé Publique, Université de Liège (2)
Département des Sciences de la Santé Publique (1)
Main Referenced Disciplines
General & internal medicine (1633)
Public health, health care sciences & services (840)
Rheumatology (393)
Endocrinology, metabolism & nutrition (158)
Geriatrics (66)

Publications (total 2467)

The most downloaded
7009 downloads
Henrotin, Y., Deby-Dupont, G., & Reginster, J.-Y. (June 2001). Les mediateurs biochimiques de l'inflammation. Revue Médicale de Liège, 56 (6), 433-42. https://hdl.handle.net/2268/118957

The most cited

6744 citations (Scopus®)

CRUZ-JENTOFT, J., BAHAT, G., BAUER, J., BOIRIE, Y., Bruyère, O., CEDERHOLM, T., Cooper, C., LANDI, F., ROLLAND, Y., SAYER, A. A., SCHNEIDER, M., SIEBER, C. C., TOPINKOVA, E., VANDEWOUDE, M., VISSER, M., ZAMBONI, M., BAUTMANS, I., BAEYENS, J. P., CESARI, M., ... SCHOLS, J. (2019). Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing, 48, 16-31. doi:10.1093/ageing/afy169 https://hdl.handle.net/2268/233755

Westbury, L. D., Harvey, N. C., Beaudart, C., Bruyère, O., Cauley, J. A., Cawthon, P., Cruz-Jentoft, A. J., Curtis, E. M., Ensrud, K., Fielding, R., Johansson, H., Kanis, J. A., Karlsson, M. K., Lane, N. E., Lengele, L., Lorentzon, M., McCloskey, E., Mellström, D., Newman, A. B., ... and the International Musculoskeletal Ageing Network. (06 June 2024). Predictive value of sarcopenia components for all-cause mortality: findings from population-based cohorts. Aging Clinical and Experimental Research, 36 (1), 126. doi:10.1007/s40520-024-02783-x
Peer Reviewed verified by ORBi

Buckinx, F., Reggers, C., Frankinet, P., Reginster, J.-Y., & Bruyère, O. (14 April 2024). ASSESSING GAMOTION'S ADAPTATION FOR REVALIDATION CENTERS: ENHANCING REHABILITATION PERSPECTIVES [Poster presentation]. Congrès WCO-IOF-ESCEO.
Peer reviewed

Millet, M., Auroux, M., Beaudart, C., Demonceau, C., Ladang, A., Cavalier, E., Reginster, J.-Y., Bruyère, O., Chapurlat, R., & Rousseau, J.-C. (14 March 2024). Association of circulating hsa-miRNAs with sarcopenia: the SarcoPhAge study. Aging Clinical and Experimental Research, 36 (1), 70. doi:10.1007/s40520-024-02711-z
Peer Reviewed verified by ORBi

Fuggle, N. R., Beaudart, C., Bruyère, O., Abrahamsen, B., Al-Daghri, N., Burlet, N., Chandran, M., Rosa, M. M., Cortet, B., Demonceau, C., Dere, W., Halbout, P., Hiligsmann, M., Kanis, J. A., Kaufman, J.-M., Kurth, A., Lamy, O., Laslop, A., Maggi, S., ... Harvey, N. C. (14 March 2024). Evidence-Based Guideline for the management of osteoporosis in men. Nature Reviews Rheumatology, 20 (4), 241-251. doi:10.1038/s41584-024-01094-9
Peer Reviewed verified by ORBi

Sanchez-Rodriguez, D., Bruyère, O., Surquin, M., Reginster, J.-Y., & Beaudart, C. (05 March 2024). Towards a core outcome set (COS) for intrinsic capacity (IC) intervention studies in adults in midlife and beyond: a scoping review to identify frequently used outcomes and measurement tools. Aging Clinical and Experimental Research, 36 (1), 54. doi:10.1007/s40520-023-02681-8
Peer Reviewed verified by ORBi

Kirk, B., Cawthon, P. M., Arai, H., Ávila-Funes, J. A., Barazzoni, R., Bhasin, S., Binder, E. F., Bruyère, O., Cederholm, T., Chen, L.-K., Cooper, C., Duque, G., Fielding, R., Guralnik, J., Kiel, D. P., Landi, F., Reginster, J.-Y., Sayer, A. A., Visser, M., ... Global Leadership Initiative in Sarcopenia (GLIS) group. (01 March 2024). The Conceptual Definition of Sarcopenia: Delphi Consensus from the Global Leadership Initiative in Sarcopenia (GLIS). Age and Ageing, 53 (3). doi:10.1093/ageing/afae052
Peer Reviewed verified by ORBi

Beaudart, C., Sharma, M., Clark, P., Fujiwara, S., Adachi, J. D., Messina, O. D., Morin, S. N., Kohlmeier, L. A., Sangan, C. B., Nogues, X., Cruz-Priego, G. A., Cavallo, A., Cooper, F., Grier, J., Leckie, C., Montiel-Ojeda, D., Papaioannou, A., Raskin, N., Yurquina, L., ... Hiligsmann, M. (March 2024). Patients' preferences for fracture risk communication: the Risk Communication in Osteoporosis (RICO) study. Osteoporosis International, 35 (3), 451-468. doi:10.1007/s00198-023-06955-9
Peer Reviewed verified by ORBi

Kim, A., Hong, J. H., Shin, W., Yoo, H., Jung, J.-G., Reginster, J.-Y., Kim, S., Bae, Y., Suh, J., Kim, S., Lee, E., & Silverman, S. (2024). A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males. Expert Opinion on Biological Therapy, 1 - 9. doi:10.1080/14712598.2024.2316846
Peer Reviewed verified by ORBi

Herrero-Beaumont, G., Castro-Dominguez, F., Migliore, A., Naredo, E., Largo, R., & Reginster, J.-Y. (20 February 2024). Systemic osteoarthritis: the difficulty of categorically naming a continuous condition. Aging Clinical and Experimental Research, 36 (1), 45. doi:10.1007/s40520-024-02714-w
Peer Reviewed verified by ORBi

Hiligsmann, M., Silverman, S. L., Singer, A. J., Pearman, L., Wang, Y., Caminis, J., & Reginster, J.-Y. (30 January 2024). Comparison of the cost-effectiveness of sequential treatment with abaloparatide in US men and women at very high risk of fractures. Aging Clinical and Experimental Research, 36 (1), 14. doi:10.1007/s40520-023-02682-7
Peer Reviewed verified by ORBi

Vendrami, C., Shevroja, E., Gonzalez Rodriguez, E., Gatineau, G., Elmers, J., Reginster, J.-Y., Harvey, N. C., Lamy, O., & Hans, D. (2024). Muscle parameters in fragility fracture risk prediction in older adults: A scoping review. Journal of Cachexia, Sarcopenia and Muscle. doi:10.1002/jcsm.13418
Peer Reviewed verified by ORBi

van Heden, S., Bruyère, O., Reginster, J.-Y., Surquin, M., Sanchez Rodriguez, M. D. C., & Beaudart, C. (2024). Towards developing a core outcome set (COS) for sarcopenia intervention studies. Aging Clinical and Experimental Research.
Peer Reviewed verified by ORBi

Calluy, E., Beaudart, C., Alokail, M. S., Al-Daghri, N., Bruyère, O., Reginster, J.-Y., Cavalier, E., & Ladang, A. (2024). Confounding factors of the expression of MTBI biomarkers, S100B, GFAP and UCH-L1, in an aging population. Aging Clinical and Experimental Research.
Peer Reviewed verified by ORBi

Honvo, G., Lengelé, L., Reginster, J.-Y., & Bruyère, O. (2024). Safety of anti-osteoarthritis medications: preliminary findings from a systematic review of post-marketing safety surveillance studies. Aging Clinical and Experimental Research.
Peer Reviewed verified by ORBi

Ladang, A., GENDEBIEN, A.-S., KOVACS, S., Demonceau, C., Beaudart, C., Le Goff, C., Reginster, J.-Y., Bruyère, O., Al-Daghri, N., Alokail, M. S., & Cavalier, E. (2024). Vitamin D metabolite ratio (VMR) offers the best approach to evaluate functional vitamin D deficiency: results of the Sarcophage study. Aging Clinical and Experimental Research.
Peer Reviewed verified by ORBi

Bruyère, O., & Reginster, J.-Y. (2024). Cost-effectiveness analysis of pharmaceutical-grade chondroitin sulfate in the treatment of knee osteoarthritis: a post hoc assessment derived from individual patient data from a randomised clinical triall. Aging Clinical and Experimental Research.
Peer Reviewed verified by ORBi

Beaudart, C., Tilquin, N., Abramowicz, P., Baptista, F., Peng, D. J., de Souza Orlandi, F., Drey, M., Dzhus, M., Fábrega-Cuadros, R., Fernandez-Garrido, J., Laurindo, L. F., Gasparik, A.-I., Geerinck, A., Emin, G., Iacob, S., Kilaitė, J., Kumar, P., Lee, S.-C., Lou, V. W. Q., ... Bruyère, O. (15 December 2023). Quality of life in sarcopenia measured with the SarQoL questionnaire: A meta-analysis of individual patient data. Maturitas, 180, 107902. doi:10.1016/j.maturitas.2023.107902
Peer Reviewed verified by ORBi

Buckinx, F., Rezoulat, M., Lefranc, C., Reginster, J.-Y., & Bruyère, O. (15 November 2023). Comparing remote and face-to-face assessments of physical performance in older adults: A reliability study. Geriatric Nursing, 55, 71 - 78. doi:10.1016/j.gerinurse.2023.11.004
Peer Reviewed verified by ORBi

Buckinx, F., Adam, S., Aubertin-Leheudre, M., De Saint Hubert, M., Mouton, A., Potier, F., Reginster, J.-Y., & Bruyère, O. (06 November 2023). Quality of Life and Health Determinants of Informal Caregivers Aged 65 Years and Over. Epidemiologia (Basel, Switzerland), 4 (4), 464 - 482. doi:10.3390/epidemiologia4040039
Peer reviewed

Demonceau, C., Buckinx, F., Reginster, J.-Y., & Bruyère, O. (2023). Assessment of risk factors associated with long-term mortality in nursing homes: result from the SENIOR cohort. Aging Clinical and Experimental Research. doi:10.1007/s40520-023-02579-5
Peer Reviewed verified by ORBi

Honvo, G., Sabico, S., Veronese, N., Bruyère, O., Rizzoli, R., Amuthavalli Thiyagarajan, J., Mikton, C., Diaz, T., Cooper, C., & Reginster, J.-Y. (28 October 2023). Measures of attributes of locomotor capacity in older people: a systematic literature review following the COSMIN methodology. Age and Ageing, 52 (Supplement_4), 44 - iv66. doi:10.1093/ageing/afad139
Peer Reviewed verified by ORBi

Sanchez-Rodriguez, D., Demonceau, C., Bruyère, O., Cavalier, E., Reginster, J.-Y., & Beaudart, C. (October 2023). Intrinsic capacity and risk of death: Focus on the impact of using different diagnostic criteria for the nutritional domain. Maturitas, 176, 107817. doi:10.1016/j.maturitas.2023.107817
Peer Reviewed verified by ORBi

Veronese, N., Soysal, P., Demurtas, J., Solmi, M., Bruyère, O., Christodoulou, N., Ramalho, R., Fusar-Poli, P., Lappas, A. S., Pinto, D., Frederiksen, K. S., Corbi, G. M., Karpenko, O., Georges, J., Durães, J., Schlögl, M., Yilmaz, O., Sieber, C., Shenkin, S. D., ... endorsed by the European Academy of Neurology. (October 2023). Physical activity and exercise for the prevention and management of mild cognitive impairment and dementia: a collaborative international guideline. European Geriatric Medicine, 14 (5), 925 - 952. doi:10.1007/s41999-023-00858-y
Peer reviewed

Ladang, A., KOVACS, S., Lengele, L., Locquet, M., Beaudart, C., Reginster, J.-Y., Bruyère, O., & Cavalier, E. (October 2023). Neurofilament-light chains (NF-L), a biomarker of neuronal damage, is increased in patients with severe sarcopenia: results of the SarcoPhAge study. Aging Clinical and Experimental Research, 35 (10), 2029 - 2037. doi:10.1007/s40520-023-02521-9
Peer Reviewed verified by ORBi

Beaudart, C., Demonceau, C., Sabico, S., Veronese, N., Cooper, C., Harvey, N., Fuggle, N., Bruyère, O., Rizzoli, R., & Reginster, J.-Y. (September 2023). Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis. Aging Clinical and Experimental Research, 35 (9), 1789 - 1806. doi:10.1007/s40520-023-02478-9
Peer Reviewed verified by ORBi

Ladang, A., Beaudart, C., Reginster, J.-Y., Al-Daghri, N., Bruyère, O., Burlet, N., Cesari, M., Cherubini, A., da Silva, M. C., Cooper, C., Cruz-Jentoft, A. J., Landi, F., Laslop, A., Maggi, S., Mobasheri, A., Ormarsdottir, S., Radermecker, R., Visser, M., Yerro, M. C. P., ... Cavalier, E. (September 2023). Correction: Biochemical Markers of Musculoskeletal Health and Aging to be Assessed in Clinical Trials of Drugs Aiming at the Treatment of Sarcopenia: Consensus Paper from an Expert Group Meeting Organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the Centre Académique de Recherche et d'Expérimentation en Santé (CARES SPRL), Under the Auspices of the World Health Organization Collaborating Center for the Epidemiology of Musculoskeletal Conditions and Aging. Calcified Tissue International, 113 (3), 357 - 358. doi:10.1007/s00223-023-01114-y
Peer Reviewed verified by ORBi

Moon, R. J., Reginster, J.-Y., Al-Daghri, N., Thiyagarajan, J. A., Beaudart, C., Bruyère, O., Burlet, N., Chandran, M., da Silva, M. C., Conaghan, P. G., Dere, W. H., Diez-Perez, A., Hadji, P., Halbout, P., Hiligsmann, M., Kanis, J. A., McCloskey, E. V., Ormarsdottir, S., Prieto-Alhambra, D., ... Harvey, N. C. (August 2023). Real-world evidence: new opportunities for osteoporosis research. Recommendations from a Working Group from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Osteoporosis International, 34 (8), 1283 - 1299. doi:10.1007/s00198-023-06827-2
Peer Reviewed verified by ORBi

Buckinx, F., Reginster, J.-Y., & Bruyère, O. (2023). Frailty Change Based on Minimally Important Difference in Nursing Home Residents: The SENIOR Cohort Findings. Journal of the American Medical Directors Association. doi:10.1016/j.jamda.2023.06.005
Peer Reviewed verified by ORBi

Cooper, C., Dawson-Hughes, B., Halbout, P., Harvey, N., Kanis, J. A., Reginster, J.-Y., Rizzoli, R., & International Osteoporosis Foundation. (July 2023). In Memoriam : Lorie Fitzpatrick MD - 1954-2023. Osteoporosis International, 34 (7), 1281 - 1282. doi:10.1007/s00198-023-06767-x
Peer Reviewed verified by ORBi

Demonceau, C., Buckinx, F., Reginster, J.-Y., & Bruyère, O. (July 2023). Investigation of the relationships between frailty, nutritional status and muscle strength and the incidence and severity of Covid-19 among the residents of nursing homes. Results from the SENIOR cohort. Maturitas, 177, 107800. doi:10.1016/j.maturitas.2023.107800
Peer Reviewed verified by ORBi

Pegreffi, F., Reginster, J.-Y., Bruyère, O., & Veronese, N. (June 2023). Comment on: The Effect of Intra-articular Hyaluronic Acid Injections and Payer Coverage on Total Knee Arthroplasty Procedures: Evidence From Large US Claims Database. Arthroplasty Today, 21, 101128. doi:10.1016/j.artd.2023.101128
Peer Reviewed verified by ORBi

Messina, O. D., Vidal, M., Adami, G., Vidal, L. F., Clark, P., Torres, J. A. M., Lems, W., Zerbini, C., Arguissain, C., Reginster, J.-Y., & Lane, N. E. (2023). Chronic arthritides and bone structure: focus on rheumatoid arthritis-an update. Aging Clinical and Experimental Research. doi:10.1007/s40520-023-02432-9
Peer Reviewed verified by ORBi

Beaudart, C., Reginster, J.-Y., Amuthavalli Thiyagarajan, J., Bautmans, I., Bauer, J., Burlet, N., Cesari, M., Cherubini, A., Cooper, C., Cruz-Jentoft, A. J., Dawson-Hughes, B., Fielding, R. A., Harvey, N. C., Landi, F., Laslop, A., Maggi, S., Montero-Errasquin, B., Concepción, P. Y. M., Rolland, Y., ... Bruyère, O. (23 May 2023). Measuring health-related quality of life in sarcopenia: summary of the SarQoL psychometric properties. Aging Clinical and Experimental Research, 35, 1581-1593. doi:10.1007/s40520-023-02438-3
Peer Reviewed verified by ORBi

Demonceau, C., Buckinx, F., Reginster, J.-Y., & Bruyère, O. (06 May 2023). Predictors of 8-year survival in nursing homes : Results from the SENIOR cohort [Paper presentation]. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, Barcelone, Spain.

Beaudart, C., Demonceau, C., Reginster, J.-Y., Locquet, M., Cesari, M., Cruz Jentoft, A. J., & Bruyère, O. (2023). Sarcopenia and health-related quality of life: A systematic review and meta-analysis. Journal of Cachexia, Sarcopenia and Muscle. doi:10.1002/jcsm.13243
Peer Reviewed verified by ORBi

Hiligsmann, M., Silverman, S. S., Singer, A. J., Pearman, L., Mathew, J., Wang, Y., Caminis, J., & Reginster, J.-Y. (2023). Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States. PharmacoEconomics. doi:10.1007/s40273-023-01270-x
Peer Reviewed verified by ORBi

Li, N., Beaudart, C., Cauley, J. A., Ing, S. W., Lane, N. E., Reginster, J.-Y., Silverman, S., Singer, A. J., & Hiligsmann, M. (April 2023). Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review. PharmacoEconomics, 41 (4), 363 - 391. doi:10.1007/s40273-022-01239-2
Peer Reviewed verified by ORBi

Prokopidis, K., Giannos, P., Reginster, J.-Y., Bruyère, O., Petrovic, M., Cherubini, A., Triantafyllidis, K. K., Kechagias, K. S., Dionyssiotis, Y., Cesari, M., Ibrahim, K., Scott, D., Barbagallo, M., Veronese, N., & Special interest group in Systematic Reviews and Meta-analyses and the Task Force on Pharmaceutical Strategy of the European Geriatric Medicine Society (EuGMS). (April 2023). Sarcopenia is associated with a greater risk of polypharmacy and number of medications: a systematic review and meta-analysis. Journal of Cachexia, Sarcopenia and Muscle, 14 (2), 671 - 683. doi:10.1002/jcsm.13190
Peer Reviewed verified by ORBi

Li, N., Beaudart, C., Cauley, J. A., Ing, S. W., Lane, N. E., Reginster, J.-Y., Silverman, S., Singer, A. J., & Hiligsmann, M. (April 2023). Correction to: Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review. PharmacoEconomics, 41 (4), 393. doi:10.1007/s40273-023-01255-w
Peer Reviewed verified by ORBi

Bruyère, O., Detilleux, J., & Reginster, J.-Y. (08 March 2023). Health Technology Assessment of Different Glucosamine Formulations and Preparations Currently Marketed in Thailand. Medicines, 10 (3), 23. doi:10.3390/medicines10030023
Peer Reviewed verified by ORBi

Ladang, A., Beaudart, C., Reginster, J.-Y., Al-Daghri, N., Bruyère, O., Burlet, N., Cesari, M., Cherubini, A., da Silva, M. C., Cooper, C., Cruz-Jentoft, A. J., Landi, F., Laslop, A., Maggi, S., Mobasheri, A., Ormarsdottir, S., Radermecker, R., Visser, M., Yerro, M. C. P., ... Cavalier, E. (12 January 2023). Biochemical Markers of Musculoskeletal Health and Aging to be Assessed in Clinical Trials of Drugs Aiming at the Treatment of Sarcopenia: Consensus Paper from an Expert Group Meeting Organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the Centre Académique de Recherche et d'Expérimentation en Santé (CARES SPRL), Under the Auspices of the World Health Organization Collaborating Center for the Epidemiology of Musculoskeletal Conditions and Aging. Calcified Tissue International, online. doi:10.1007/s00223-022-01054-z
Peer Reviewed verified by ORBi

Westbury, L. D., Beaudart, C., Bruyère, O., Cauley, J. A., Cawthon, P., Cruz-Jentoft, A. J., Curtis, E. M., Ensrud, K., Fielding, R., Johansson, H., Kanis, J. A., Karlsson, M. K., Lane, N. E., Lengele, L., Lorentzon, M., McCloskey, E., Mellström, D., Newman, A. B., Ohlsson, C., ... International Musculoskeletal Ageing Network. (05 January 2023). Recent sarcopenia definitions-prevalence, agreement and mortality associations among men: Findings from population-based cohorts. Journal of Cachexia, Sarcopenia and Muscle, online. doi:10.1002/jcsm.13160
Peer Reviewed verified by ORBi

Fuggle, N., Al-Daghri, N., Bock, O., Branco, J., Bruyère, O., Casado, E., Cavalier, E., Cortet, B., de Wit, M., Giusti, A., Halbout, P., Harvey, N. C., Hiligsmann, M., Kaufman, J.-M., Kurth, A., Maggi, S., Matijevic, R., Minisola, S., Palacios, S., ... Cooper, C. (03 January 2023). Correction: Novel formulations of oral bisphosphonates in the treatment of osteoporosis. Aging Clinical and Experimental Research, online. doi:10.1007/s40520-022-02319-1
Peer Reviewed verified by ORBi

Beaudart, C., Demonceau, C., Reginster, J.-Y., Locquet, M., Cesari, M., Cruz Jentoft, A. J., & Bruyère, O. (2023). Health-related quality of life in sarcopenia: a systematic review and meta-analysis. Aging Clinical and Experimental Research, 35 (suppl 1), 58-59.
Peer Reviewed verified by ORBi

Demonceau, C., Buckinx, F., Reginster, J.-Y., & Bruyère, O. (2023). Investigation of the factors associated with the incidence and severity of COVID-19 in nursing home. Results from the SENIOR cohort. Aging Clinical and Experimental Research, 35 (suppl 1), 306.
Peer Reviewed verified by ORBi

Demonceau, C., Buckinx, F., Reginster, J.-Y., & Bruyère, O. (2023). Investigation of the factors associated with the incidence and severity of Covid-19 in nursing home. Results from the SENIOR cohort [Paper presentation]. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, Barcelone, Spain.

Beaudart, C., Sanchez Rodriguez, M. D. C., Demonceau, C., Cavalier, E., Reginster, J.-Y., & Bruyère, O. (2023). Screening for malnutrition by the MNA-SF, diagnosis by the Global Leadership Initiative on Malnutrition (GLIM) criteria, or both? Predictive capacity for mortality in a 9-year follow-up in the SarcoPhAge cohort. Aging Clinical and Experimental Research, 35 (suppl 1), 335.
Peer Reviewed verified by ORBi

Demonceau, C., Buckinx, F., Reginster, J.-Y., & Bruyère, O. (2023). Predictors of 8-year survival in nursing homes: results from the SENIOR cohort. Aging Clinical and Experimental Research, 35 (suppl 1), 60.
Peer Reviewed verified by ORBi

Buckinx, F., Adam, S., Aubertin-Leheudre, M., De Saint Hubert, M., Mouton, A., Potier, F., Reginster, J.-Y., & Bruyère, O. (2023). Health determinants of informal caregivers aged 65 years and over. Aging Clinical and Experimental Research, 35 (suppl 1), 288.
Peer Reviewed verified by ORBi

Demonceau, C., Beaudart, C., Reginster, J.-Y., Veronese, N., & Bruyère, O. (2023). The interconnection between Covid-19, sarcopenia and lifestyle. Maturitas, 169, 56-57. doi:10.1016/j.maturitas.2022.09.009
Peer Reviewed verified by ORBi

Zhao, X.-X., Xie, W.-Q., Xiao, W.-F., Li, H.-Z., Naranmandakh, S., Bruyere, O., Reginster, J.-Y., & Li, Y.-S. (2023). Perlecan: Roles in osteoarthritis and potential treating target. Life Sciences, 312. doi:10.1016/j.lfs.2022.121190
Peer Reviewed verified by ORBi

Beaudart, C., Demonceau, C., Sabico, S., Veronese, N., Cooper, C., Harvey, N., Bruyère, O., Rizzoli, R., & Reginster, J.-Y. (2023). Efficacy of osteoporosis treatments in men: a systematic review and meta-analysis. Aging Clinical and Experimental Research, 35 (suppl 1), 249.
Peer Reviewed verified by ORBi

Beaudart, C., Demonceau, C., Reginster, J.-Y., & Bruyère, O. (2023). Measure of health-related quality of life in interventional studies aiming at the management of sarcopenia: results from a systematic literature review. Aging Clinical and Experimental Research, 35 (suppl 1), 190.
Peer Reviewed verified by ORBi

Tenti, S., Bruyère, O., Cheleschi, S., Reginster, J.-Y., Veronese, N., & Fioravanti, A. (2023). An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis. Therapeutic Advances in Musculoskeletal Disease, 15, 1759720X231158618. doi:10.1177/1759720X231158618
Peer Reviewed verified by ORBi

Veronese, N., Honvo, G., Bruyère, O., Rizzoli, R., Barbagallo, M., Maggi, S., Smith, L., Sabico, S., Al-Daghri, N., Cooper, C., Pegreffi, F., & Reginster, J.-Y. (2023). Knee osteoarthritis and adverse health outcomes: an umbrella review of meta-analyses of observational studies. Aging Clinical and Experimental Research, 35 (2), 245-552. doi:10.1007/s40520-022-02289-4
Peer Reviewed verified by ORBi

Buckinx, F., Charles, A., Demonceau, C., Reginster, J.-Y., & Bruyère, O. (2023). Etude de la survenue des événements de santé indésirables en maison de repos : apports de la cohorte Liégeoise SENIOR. Revue Médicale de Liège, 78, 715-718.
Editorial Reviewed verified by ORBi

Buckinx, F., Maton, L., Dalimier, V., Mouton, A., Lengele, L., Reginster, J.-Y., & Bruyère, O. (2023). Development and validation of new exercises to promote physical activity in nursing home settings, through qualitative method. Aging Clinical and Experimental Research, 35 (suppl 1), 51.
Peer Reviewed verified by ORBi

Veronese, N., Honvo, G., Bruyère, O., Rizzoli, R., Barbagallo, M., Maggi, S., Sabico, S., Al-Daghri, N., Cooper, C., Pegreffi, F., & Reginster, J.-Y. (2023). Knee osteoarthritis and adverse health outcomes: an umbrella review of meta-analyses of observational studies. Aging Clinical and Experimental Research, 35 (suppl 1), 271.
Peer Reviewed verified by ORBi

Beaudart, C., Sanchez Rodriguez, M. D. C., Demonceau, C., Cavalier, E., Reginster, J.-Y., & Bruyère, O. (2023). Intrinsic capacity using the MNA-SF and the Global Leadership Initiative of Malnutrition (GLIM) criteria in the nutritional domain and mortality-risk: A 9-year follow-up in the SarcoPhAge cohortr. Aging Clinical and Experimental Research, 35 (suppl 1), 334-S335.
Peer Reviewed verified by ORBi

Buckinx, F., Charles, A., Demonceau, C., Reginster, J.-Y., & Bruyère, O. (2023). L’activité physique en maison de repos : contributions de la cohorte SENIOR. Revue Médicale de Liège.
Editorial Reviewed verified by ORBi

Kanis, J. A., McCloskey, E. V., Harvey, N. C., Cooper, C., Rizzoli, R., Dawson-Hughes, B., Maggi, S., & Reginster, J.-Y. (07 November 2022). Intervention thresholds and diagnostic thresholds in the management of osteoporosis. Aging Clinical and Experimental Research, 34, 3155-3157. doi:10.1007/s40520-022-02216-7
Peer Reviewed verified by ORBi

Fuggle, N., Al-Daghri, N., Bock, O., Branco, J., Bruyère, O., Casado, E., Cavalier, E., Cortet, B., de Wit, M., Giusti, A., Halbout, P., Harvey, N. C., Hiligsmann, M., Kaufman, J.-M., Kurth, A., Maggi, S., Matijevic, R., Minisola, S., Palacios, S., ... Cooper, C. (November 2022). Novel formulations of oral bisphosphonates in the treatment of osteoporosis. Aging Clinical and Experimental Research, 34 (11), 2625 - 2634. doi:10.1007/s40520-022-02272-z
Peer Reviewed verified by ORBi

Chevalley, T., Brandi, M. L., Cashman, K. D., Cavalier, E., Harvey, N. C., Maggi, S., Cooper, C., Al-Daghri, N., Bock, O., Bruyère, O., Rosa, M. M., Cortet, B., Cruz-Jentoft, A. J., Cherubini, A., Dawson-Hughes, B., Fielding, R., Fuggle, N., Halbout, P., Kanis, J. A., ... Rizzoli, R. (November 2022). Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group. Aging Clinical and Experimental Research, 34 (11), 2603 - 2623. doi:10.1007/s40520-022-02279-6
Peer Reviewed verified by ORBi

Kanis, J. A., McCloskey, E. V., Harvey, N. C., Cooper, C., Rizzoli, R., Dawson-Hughes, B., Maggi, S., & Reginster, J.-Y. (2022). The need to distinguish intervention thresholds and diagnostic thresholds in the management of osteoporosis. Osteoporosis International. doi:10.1007/s00198-022-06567-9
Peer Reviewed verified by ORBi

Veronese, N., & Reginster, J.-Y. (18 October 2022). Authors' Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations. Drugs, 82 (14), 1513-1514. doi:10.1007/s40265-022-01789-x
Peer Reviewed verified by ORBi

Veronese, N., Cooper, C., Bruyère, O., Al-Daghri, N., Branco, J., Cavalier, E., Cheleschi, S., da Silva Rosa, M. C., Conaghan, P. G., Dennison, E. M., de Wit, M., Fioravanti, A., Fuggle, N. R., Haugen, I. K., Herrero-Beaumont, G., Honvo, G., Laslop, A., Matijevic, R., Migliore, A., ... Reginster, J.-Y. (16 September 2022). Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations. Drugs, 82 (13), 1347-1355. doi:10.1007/s40265-022-01773-5
Peer Reviewed verified by ORBi

Buckinx, F., Maton, L., Dalimier, V., Mouton, A., Lengele, L., Reginster, J.-Y., & Bruyère, O. (16 September 2022). Development and Validation of New Exercises to Promote Physical Activity in Nursing Home Settings. Geriatrics, 7 (5), 100. doi:10.3390/geriatrics7050100
Peer reviewed

Veronese, N., Bolzetta, F., Cacco, C., Cester, A., Smith, L., Demurtas, J., Cooper, C., Rizzoli, R., Caruso, M. G., Notarnicola, M., Reginster, J.-Y., Maggi, S., Barbagallo, M., Trott, M., & Dominguez, L. J. (13 August 2022). Dietary acrylamide and incident osteoporotic fractures: an 8-year prospective cohort study. Aging Clinical and Experimental Research, 34 (10), 2441-2448. doi:10.1007/s40520-022-02214-9
Peer Reviewed verified by ORBi

BRUYERE, O., Reginster, J.-Y., & Honvo, G. (August 2022). Health Economic Evaluation of a High and Low Molecular Weight Hyaluronic Acid Formulation for the Treatment of Knee Osteoarthritis. Post Hoc Analyses from a Randomized Clinical Trial. Rheumatology and Therapy, 9 (4), 1119-1128. doi:10.1007/s40744-022-00466-5
Peer Reviewed verified by ORBi

BRUYERE, O., Reginster, J.-Y., & Beaudart, C. (July 2022). Lifestyle approaches to prevent and retard sarcopenia: A narrative review. Maturitas, 161, 44-48. doi:10.1016/j.maturitas.2022.02.004
Peer Reviewed verified by ORBi

Demonceau, C., Reginster, J.-Y., & Bruyère, O. (2022). Ostéosarcopénie : quand les deux ne font qu'un. Medi-Sphere, (705), 14-16.
Editorial reviewed

Hiligsmann, M., Li, N., Cooper, C., Reginster, J.-Y., Silverman, S., Carswell, C., & Husereau, D. (12 April 2022). Improving the reporting of economic evaluation in osteoporosis: the value of CHEERS 2022 statement. Osteoporosis International, 33 (8), 1641-1642. doi:10.1007/s00198-022-06400-3
Peer Reviewed verified by ORBi

Cheleschi, S., Tenti, S., Seccafico, I., Mondanelli, N., Reginster, J.-Y., & Fioravanti, A. (2022). MicroRNA as possible mediators of celecoxib and glucosamine sulfate-induced effects on apoptosis and oxidative stress: an in vitro study on human osteoarthritic chondrocytes. Aging Clinical and Experimental Research, 34 (S1), 239-240.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2022). Multimodal pharmacological approach: from evidence-based to daily practice. Aging Clinical and Experimental Research, 34 (S1), 103.
Peer Reviewed verified by ORBi

Veronese, N., Smith, L., Zigoura, E., Barbagallo, M., Dominguez, L. J., Barone, A., Cella, A., Cooper, C., Rizzoli, R., Reginster, J.-Y., Maggi, S., & Pilotto, A. (2022). Multidimensional prognostic index and the risk of fractures: an 8-year longitudinal cohort study in the Osteoarthritis Initiative. Archives of Osteoporosis, 17 (1), 5. doi:10.1007/s11657-021-01015-3
Peer Reviewed verified by ORBi

Geerinck, A., Locquet, M., Hiligsmann, M., Reginster, J.-Y., Bruyère, O., & Beaudart, C. (2022). Patients' preferences for quality-of-life aspects in sarcopenia: a best-worst scaling study. European Geriatric Medicine, 13 (2), 483-91. doi:10.1007/s41999-021-00563-8
Peer reviewed

Veronese, N., Honvo, G., Amuthavalli Thiyagarajan, J., Rizzoli, R., Cooper, C., BRUYERE, O., Mikton, C., Sumi, Y., Diaz, T., Reginster, J.-Y., Banerjee, A., & members of the WHO Collaborating Center Working Group on Locomotor Capacity. (2022). Attributes and definitions of locomotor capacity in older people: a World Health Organisation (WHO) locomotor capacity working group meeting report. Aging Clinical and Experimental Research, 34 (3), 481-483. doi:10.1007/s40520-022-02080-5
Peer Reviewed verified by ORBi

Tenti, S., Veronese, N., Cheleschi, S., Seccafico, I., BRUYERE, O., Reginster, J.-Y., & Fioravanti, A. (2022). Prescription-grade crystalline glucosamine sulfate as an add-on therapy to conventional treatments in erosive osteoarthritis of the hand: results from a 6-month observational retrospective study. Aging Clinical and Experimental Research, 34 (7), 1613-1625. doi:10.1007/s40520-022-02151-7
Peer Reviewed verified by ORBi

Honvo, G., Veronese, N., Bruyère, O., Rizzoli, R., Amuthavalli Thiyagarajan, J., Cooper, C., & Reginster, J.-Y. (2022). Measurement tools for attributes of locomotor capacity in older people: protocol for a systematic review of available tools and evidence-based recommendations. Aging Clinical and Experimental Research, 34 (S1), 450.
Peer Reviewed verified by ORBi

Veronese, N., Stefanac, S., Koyanagi, A., Al-Daghri, N., Sabico, S., Cooper, C., Rizzoli, R., Reginster, J.-Y., Barbagallo, M., Di Bella, G., Mandalà, C., Dominguez, L., Smith, L., & Maggi, S. (2022). Lower limb muscle strength and muscle mass are associated with incident symptomatic knee osteoarthritis: a longitudinal cohort study. Aging Clinical and Experimental Research, 34 (S1), 50.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2022). Шановні читачі! Bolʹ, Sustavy, Pozvonočnik, 12 (1), 1. doi:10.22141/pjs.12.1.2022.321
Peer Reviewed verified by ORBi

Locquet, M., Sanchez Rodriguez, M. D. C., Bruyère, O., Geerinck, A., Lengele, L., Reginster, J.-Y., & Beaudart, C. (2022). Intrinsic Capacity Defined Using Four Domains and Mortality Risk: A 5-Year Follow-Up of the SarcoPhAge Cohort. The journal of nutrition, health & aging, 26 (1), 23-29. doi:10.1007/s12603-021-1702-7
Peer reviewed

Honvo, G., Reginster, J.-Y., Mobasheri, A., Lengele, L., Avouac, B., Rizzoli, R., & Bruyère, O. (2022). Post-marketing safety surveillance of anti-osteoarthritis drugs: a protocol for a systematic review of published literature. Osteoporosis International, 32 (Suppl 1), 242-243.
Peer Reviewed verified by ORBi

LADANG, A., KOVACS, S., Lengele, L., Reginster, J.-Y., Bruyère, O., & Cavalier, E. (2022). Neurofilament-light chains (NF-L), a biomarker of neuronal damage, is increased in sarcopenic patients: results of the sarcophage study. Osteoporosis International, 32 (Suppl 1), 53.
Peer Reviewed verified by ORBi

Arden, N., Perry, T. A., Bannuru, R. R., Bruyère, O., Cooper, C., Haugen, I. K., Hochberg, M. C., McAlindon, T. E., Mobasheri, A., & Reginster, J.-Y. (2022). How can we explain the differences between the OARSI and ESCEO Guidelines for the management of knee osteoarthritis? Osteoporosis International, 32 (Suppl 1), 57-58.
Peer Reviewed verified by ORBi

Bruyère, O., Detilleux, J., & Reginster, J.-Y. (2022). Health technology assessment of different glucosamine formultaions and preparations currently marketed in Thailand: impact of their clinical effect and selling price. Aging Clinical and Experimental Research, 34 (S1), 285.
Peer Reviewed verified by ORBi

Hiligsmann, M., Silverman, S., Singer, A., Pearman, L., Mathew, J., Wang, Y., Caminis, J., & Reginster, J.-Y. (2022). Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate in US men at imminent risk of fracture. Journal of Managed Care and Specialty Pharmacy, 28, 105.
Peer Reviewed verified by ORBi

Tenti, S., Veronese, N., Cheleschi, S., Seccafico, I., Reginster, J.-Y., & Fioravanti, A. (2022). Erosive osteoarthritis of the hand: efficacy of prescription-grade crystalline glucosamine sulfate as an add-on therapy to conventional treatments. Aging Clinical and Experimental Research, 34 (S1), 49-50.
Peer Reviewed verified by ORBi

Bruyère, O., Reginster, J.-Y., & Honvo, G. (2022). Health economics evaluation of a high and low molecular weight hyaluronic acid formulation in patients with knee osteoarthritis. Analysis from a randomized clinical trial. Aging Clinical and Experimental Research, 34 (S1), 50.
Peer Reviewed verified by ORBi

Kanis, J. A., Harvey, N. C., McCloskey, E., Veronese, N., Lorentzon, M., Cooper, C., Rizzoli, R., Adib, G., Al-Daghri, N., Campusano, C., Chandran, M., Dawson-Hughes, B., Javaid, K., Jiwa, F., Johansson, H., Lee, J. K., Liu, E., Messina, D., Minski, O., ... Reginster, J.-Y. (2022). Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporosis International, 33 (Suppl 1), 24.
Peer Reviewed verified by ORBi

Lengele, L., Locquet, M., Moutschen, M., Beaudart, C., Kaux, J.-F., Gillain, S., Shadouh, C., Reginster, J.-Y., & Bruyère, O. (2022). Relationships between malnutrition, sarcopenia, and frailty and the incidence of Covid-19 in older adults: data from the sarcophage cohort. Osteoporosis International, 32 (Suppl 1), 50.
Peer Reviewed verified by ORBi

Veronese, N., Demurtas, J., Smith, L., Reginster, J.-Y., Bruyère, O., Honvo, G., & Maggi, S. (2022). Glucosamine sulphate: an umbrella review of health outcomes. Osteoporosis International, 32 (Suppl 1), 43.
Peer Reviewed verified by ORBi

Willers, C., Norton, N., Harvey, N. C., Jacobson, T., Johansson, H., Lorentzon, M., McCloskey, E. V., Borgström, F., Kanis, J. A., Kaux, J.-F. (Other coll.), Reginster, J.-Y. (Other coll.), Bruyère, O. (Other coll.), Cavalier, E. (Other coll.), & LECART, M.-P. (Other coll.). (January 2022). Osteoporosis in Europe: a compendium of country-specific reports. Archives of Osteoporosis, 17 (1), 23. doi:10.1007/s11657-021-00969-8
Peer Reviewed verified by ORBi

Lengele, L., Locquet, M., Moutschen, M., Beaudart, C., KAUX, J.-F., Gillain, S., Reginster, J.-Y., & Bruyère, O. (January 2022). Frailty but not sarcopenia nor malnutrition increases the risk of developing COVID-19 in older community-dwelling adults. Aging Clinical and Experimental Research, 34 (1), 223-234. doi:10.1007/s40520-021-01991-z
Peer Reviewed verified by ORBi

Beaudart, C., Boonen, A., Li, N., Bours, S., Goemaere, S., Reginster, J.-Y., Roux, C., McGowan, B., Diez-Perez, A., Rizzoli, R., Cooper, C., & Hiligsmann, M. (2022). Patient preferences for lifestyle behaviours in osteoporotic fracture prevention: a cross-European discrete choice experiment. Osteoporosis International, 33, 1335-1346. doi:10.1007/s00198-022-06310-4
Peer Reviewed verified by ORBi

Curtis, E. M., Reginster, J.-Y., Al-Daghri, N., Biver, E., Brandi, M. L., CAVALIER, E., Hadji, P., Halbout, P., Harvey, N. C., Hiligsmann, M., Javaid, M. K., Kanis, J. A., Kaufman, J.-M., Lamy, O., Matijevic, R., Perez, A. D., RADERMECKER, R., Rosa, M. M., Thomas, T., ... Cooper, C. (2022). Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clinical and Experimental Research, 34, 695-714. doi:10.1007/s40520-022-02100-4
Peer Reviewed verified by ORBi

Locquet, M., Bonnard, F., Beaudart, C., COENDO, C., Gillain, S., Reginster, J.-Y., & Bruyère, O. (2022). An assessment of the Toulouse Saint Louis University mini falls assessment tool to predict incident falls among older adults residing in nursing homes: a 6-month prospective study. Osteoporosis International, 32 (Suppl 1), 230.
Peer Reviewed verified by ORBi

Geerinck, A., Beaudart, C., Reginster, J.-Y., Wojszel, Z. B., De Souza Orlandi, F., Bahat, G., Erdogan, T., Montero-Errasquin, B., Alekna, V., & Bruyère, O. (2022). Measurement properties of the Short Form Sarcopenia Quality of Life (SF-SARQOL) Questionnaire in an international dataset. Osteoporosis International, 32 (Suppl 1), 249.
Peer Reviewed verified by ORBi

Beaudart, C., Boonen, A., Li, N., Bours, S., Goemaere, S., Reginster, J.-Y., Roux, C., McGowan, B., Diez-Perez, A., Rizzoli, R., Cooper, C., & Hiligsmann, M. (2022). Patient’s preferences for lifestyle changes in osteoporotic fracture prevention: a cross-european discrete-choice experiment. Osteoporosis International, 32 (supp1), 89 and 46-47.
Peer Reviewed verified by ORBi

Messina O.D., Clarck, P. E. C., Mendez-Sanchez L.M.S., Peralta, M. L. P., Cerdas, S., Campusano, C., Visal Neira, L. F., Lasaretti Castro, M. L., Morales Torres, J., Harvey, N. C., Reginster, J.-Y., & Zerbini, C. F. (2022). Latin American consensus on the management of glucocorticoid induces osteoporosis : a preliminary communication. Osteoporosis International, 32 (supp 1), 288-289.
Peer Reviewed verified by ORBi

Veronese, N., Smith, L., ZIGOURA, E., BARBAGALLO, M., DOMINGUEZ, M., COOPER, C., RIZZOLI, R., Reginster, J.-Y., MAGGI, S., & PILOTTO, A. (2022). Multidimensional prognostic index and the risk of fractures: an 8-year longitudinal cohort study in the osteoarthritis initiative. Osteoporosis International, 32 (supp1), 46.
Peer Reviewed verified by ORBi

Bahat, G., Muge Catikkas, N., Yavuz, D. G., Borman, P., Guzel, R., Esra Bozkurt, M., & Reginster, J.-Y. (2022). The current situation in the approach to osteoporosis in older adults in Turkey: aeas in need of improvement with a model for other populations. Aging Clinical and Experimental Research, 34 (S1), 96.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2022). Management of hand osteoarthritis: how can the ACR guidelines be applied to an European population in a patient-centric approach. Aging Clinical and Experimental Research, 34 (S1), 55.
Peer Reviewed verified by ORBi

Ladang, A., Kovacs, S., Lengele, L., Locquet, M., Reginster, J.-Y., Bruyère, O., & Cavalier, E. (2022). Neurofilament light chain concentration in an aging population. Aging Clinical and Experimental Research, 34 (2), 331-339. doi:10.1007/s40520-021-02054-z
Peer Reviewed verified by ORBi

Chevalley, T., Brandi, M., Cavalier, E., Harvey, N., Iolascon, G., Cooper, C., Hannouche, D., Kaux, J.-F., Kurth, A., Maggi, S., Maier, G., Papavasiliou, K., Al-Daghri, N., Sosa-Henriquez, M., Suhm, N., Tarantino, U., Reginster, J.-Y., & Rizzoli, R. (October 2021). How can the orthopedic surgeon ensure optimal vitamin D status in patients operated for an osteoporotic fracture? Osteoporosis International, 32 (10), 1921-1935. doi:10.1007/s00198-021-05957-9
Peer Reviewed verified by ORBi

Fuggle, N. R., Singer, A., Gill, C., Patel, A., Medeiros, A., Mlotek, A. S., Pierroz, D. D., Halbout, P., Harvey, N. C., Reginster, J.-Y., Cooper, C., & Greenspan, S. L. (April 2021). Correction to: How has COVID-19 affected the treatment of osteoporosis? An IOF-NOF-ESCEO global survey. Osteoporosis International, 32 (4), 801. doi:10.1007/s00198-021-05905-7
Peer Reviewed verified by ORBi

Chandran, M., Ganesan, G., Tan, K. B., Reginster, J.-Y., & Hiligsmann, M. (January 2021). Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Singaporean women. Osteoporosis International, 32 (1), 133-144. doi:10.1007/s00198-020-05536-4
Peer Reviewed verified by ORBi

Hiligsmann, M., Maggi, S., Veronese, N., Sartori, L., & Reginster, J.-Y. (2021). Cost-effectiveness of buffered soluble alendronate 70mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy. Osteoporosis International, 32, 595-606. doi:10.1007/s00198-020-05802-5
Peer Reviewed verified by ORBi

Geerinck, A., Locquet, M., Reginster, J.-Y., Bruyère, O., & Beaudart, C. (2021). Letter to the Editor: Discriminative Power of the Sarcopenia Quality of Life (SarQoL®) Questionnaire with the EWGSOP2 Criteria [letter to the editor]. The Journal of frailty & aging, 10 (2), 193-194. doi:10.14283/jfa.2020.47
Peer reviewed

Geerinck, A., Locquet, M., Bruyère, O., Reginster, J.-Y., & Beaudart, C. (2021). Evaluating quality of life in frailty: applicability and clinimetric properties of the SarQoL(®) questionnaire. Journal of Cachexia, Sarcopenia and Muscle, 12 (2), 319-330. doi:10.1002/jcsm.12687
Peer Reviewed verified by ORBi

Slomian, J., Reginster, J.-Y., Emonts, P., & Bruyère, O. (2021). Identifying maternal needs following childbirth: comparison between pregnant women and recent mothers. BMC Pregnancy and Childbirth, 21 (1), 405. doi:10.1186/s12884-021-03858-7
Peer Reviewed verified by ORBi

Cheleschi, S., Tenti, S., Giannotti, S., Veronese, N., Reginster, J.-Y., & Fioravanti, A. (2021). A combination of celecoxib and glucosamine sulfate has anti-inflammatory and chondroprotective effects: results from an in vitro study on human osteoarthritic chondrocytes. International Journal of Molecular Sciences, 22, 8980. doi:10.3390/ijms22168980
Peer Reviewed verified by ORBi

Arden, N. K., Perry, T. A., Bannuru, R. R., Bruyère, O., Cooper, C., Haugen, I. K., Hochberg, M. C., McAlindon, T. E., Mobasheri, A., & Reginster, J.-Y. (2021). Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nature Reviews Rheumatology, 17, 59-66. doi:10.1038/s41584-020-00523-9
Peer Reviewed verified by ORBi

Parsons, C. M., Judge, A., Meyer, R., Bruyère, O., Petit-Dop, F., Chapurlat, R., Reginster, J.-Y., Cooper, C., & Inskip, H. (January 2021). Determining individual trajectories of joint space loss: improved statistical methods for monitoring knee osteoarthritis disease progression. Osteoarthritis and Cartilage, 29 (1), 59-67. doi:10.1016/j.joca.2020.09.009
Peer Reviewed verified by ORBi

Cooper, C., Halbout, P., Dawson-hughes, B., Harvey, N. C., Kanis, J. A., Reginster, J.-Y., & Rizzoli, R. (2021). In memory of Harry K. Genant. Osteoporosis International, 32, 607-608. doi:10.1007/s00198-021-05857-y
Peer Reviewed verified by ORBi

Locquet, M., Bonnard, F., Beaudart, C., COENDO, C., Gillain, S., Reginster, J.-Y., & Bruyère, O. (2021). An Assessment of the Toulouse Saint Louis University Mini Falls Assessment Tool to Predict Incident Falls among Older Adults Residing in Nursing Homes: A 6-Month Prospective Study. Journal of Nutrition, Health and Aging, 25 (7), 933-937. doi:10.1007/s12603-021-1651-1
Peer Reviewed verified by ORBi

Lengele, L., Bruyère, O., Beaudart, C., Reginster, J.-Y., & Locquet, M. (2021). Malnutrition, assessed by the Global Leadership Initiative on Malnutrition (GLIM) criteria but not by the mini nutritional assessment (MNA), predicts the incidence of sarcopenia over a 5-year period in the SarcoPhAge cohort. Aging Clinical and Experimental Research, 33 (6), 1507-1517. doi:10.1007/s40520-021-01880-5
Peer Reviewed verified by ORBi

Li, N., Cornelissen, D., Silverman, S., Pinto, D., Si, L., Kremer, I., Bours, S., de Bot, R., Evers, S., van den Bergh, J., Reginster, J.-Y., & Hiligsmann, M. (2021). An Updated Systematic Review of Cost‑Effectiveness Analyses of Drugs for Osteoporosis. PharmacoEconomics, 39, 181-209. doi:10.1007/s40273-020-00965-9
Peer Reviewed verified by ORBi

Migliore, A., Blicharski, T., Plebanski, R., Zegota, Z., Gyula, G., Rannou, F., & Reginster, J.-Y. (2021). Knee Osteoarthritis Pain Management with an Innovative High and Low Molecular Weight Hyaluronic Acid Formulation (HA-HL): A Randomized Clinical Trial. Rheumatology and Therapy, 8 (4), 1617-1636. doi:10.1007/s40744-021-00363-3
Peer Reviewed verified by ORBi

Fuggle, N. R., Singer, A., Gill, C., Patel, A., Medeiros, A., Mlotek, A. S., Pierroz, D. D., Halbout, P., Harvey, C. N., Reginster, J.-Y., Cooper, C., & Greenspan, S. L. (2021). How has COVID-19 affected the treatment of osteoporosis? An IOF-NOF-ESCEO global survey. Osteoporosis International, 32, 611-617. doi:10.1007/s00198-020-05793-3
Peer Reviewed verified by ORBi

Geerinck, A., Locquet, M., Reginster, J.-Y., Bruyère, O., & Beaudart, C. (2021). Discriminative power of the Sarcopenia Quality of Life (SarQoL) questionnaire with the EWGSOP2 criteria [letter to the editor]. Journal of Frailty and Aging, 10 (2), 193-194.
Peer Reviewed verified by ORBi

Lengele, L., Bruyère, O., Beaudart, C., Reginster, J.-Y., & Locquet, M. (2021). Impact of malnutrition status on muscle parameter changes over a 5-year follow-up of community-dwelling older adults from the SarcoPhage Cohort. Nutrients, 13 (2), 407. doi:10.3390/nu13020407
Peer Reviewed verified by ORBi

Chandran, M., Ganesan, G., Tan, K. B., Reginster, J.-Y., & Hiligsmann, M. (2021). Using health-economic evidence to support policy-level decision-making in Singapore-sensitivity analysis that provides further confidence in fracture probability-based cost-effective intervention thresholds. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 32, 787-789. doi:10.1007/s00198-021-05876-9
Peer reviewed

Beaudart, C., Bauer, J. M., Landi, F., Bruyère, O., Reginster, J.-Y., & Hiligsmann, M. (2021). Experts' preferences for sarcopenia outcomes: a discrete-choice experiment from a working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) in collaboration with the European Union of Geriatric Medicine Society (EUGMS). Aging Clinical and Experimental Research, 33, 1079-1083. doi:10.1007/s40520-021-01794-2
Peer Reviewed verified by ORBi

Grygorieva, N., Povoroznyuk, R., Matijevic, R., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2021). In memoriam: Vladyslav Povoroznyuk. Osteoporosis International, 32 (9), 1905-1906. doi:10.1007/s00198-021-06048-5
Peer Reviewed verified by ORBi

Bahat, G., Catikkas, N. M., KARAN, M. A., & Reginster, J.-Y. (2021). Orthogeriatrics: a vital requirement for improving fragility fracture patient care internationally with particular reference to Turkey. Archives of Osteoporosis, 16. doi:10.1007/s11657-021-00967-w
Peer Reviewed verified by ORBi

Lengele, L., Bruyère, O., Beaudart, C., Reginster, J.-Y., & Loquet, M. (2021). Correction to: Malnutrition, assessed by the Global Leadership Initiative on Malnutrition (GLIM) criteria but not by the mini nutritional assessment (MNA), predicts the incidence of sarcopenia over a 5‑year period in the SarcoPhAge cohort. Aging Clinical and Experimental Research. doi:10.1007/s40520-021-01901-3
Peer Reviewed verified by ORBi

McClung, M. R., Bolognese, M. A., Brown, J. P., Reginster, J.-Y., Langdahl, B. L., Shi, Y., Timoshanko, J., Libanati, C., Chines, A., & Oates, M. K. (2021). Skeletal responses to romosozumab after 12 months of denosumab. Journal of Bone and Mineral Research Plus, 5 (7), 10512. doi:10.1002/jbm4.10512
Peer reviewed

Zhang, Z., Huang, C., Cao, Y., Mu, R., Zhang, M. C., Xing, D., Fan, D., Ding, Y., Guo, J., Hou, Y., Jianhao, L., Veronese, N., Reginster, J.-Y., Bruyère, O., Cavalier, E., & Zhang, H. (2021). 2021 revised algorithm for the management of knee osteoarthritis-the Chinese viewpoint. Aging Clinical and Experimental Research, 33 (8), 2141-2147. doi:10.1007/s40520-021-01906-y
Peer Reviewed verified by ORBi

Bruyère, O., Detilleux, J., & Reginster, J.-Y. (2021). Cost-Effectiveness Assessment of Different Glucosamines in Patients with Knee Osteoarthritis: A Simulation Model Adapted to Germany. Current Aging Science, 14 (3), 242-248. doi:10.2174/1874609814666210415092845
Peer reviewed

Sanchez Rodriguez, M. D. C., Locquet, M., Bruyère, O., Lengele, L., CAVALIER, E., Reginster, J.-Y., & Beaudart, C. (2021). Prediction of 5-year mortality risk by malnutrition according to the GLIM format using seven pragmatic approaches to define the criterion of loss of muscle mass. Clinical Nutrition, 40 (4), 2188-2199. doi:10.1016/j.clnu.2020.09.047
Peer Reviewed verified by ORBi

Yeap, S. S., Tanavalee, A., Perez, E. C., Tan, M. P., Reyes, B. H. M., Lee, J. K., Norhamdan, M. Y., Vista, E. S., Chan, W. S., Cong, S. B., Tam, P. T. T., Kaufman, J.-M., Reginster, J.-Y., Veronese, N., & Penserga, E. (2021). 2019 revised algorithm for the management of knee osteoarthritis: the Southeast Asian viewpoint. Aging Clinical and Experimental Research, 33, 1149-1156. doi:10.1007/s40520-021-01834-x
Peer Reviewed verified by ORBi

Geerinck, A., Dawson-Hughes, B., Beaudart, C., Locquet, M., Reginster, J.-Y., & Bruyère, O. (2021). Assessment of the performance of the SarQoL questionnaire in screening for sarcopenia in older people. Aging Clinical and Experimental Research, 33, 2149-2155. doi:10.1007/s40520-021-01913-z
Peer Reviewed verified by ORBi

Neuprez, A., Kaux, J.-F., Locquet, M., Beaudart, C., & Reginster, J.-Y. (January 2021). The presence of erosive joints is a strong predictor of radiological progression in hand osteoarthritis: results of a 2-year prospective follow-up of the Liège Hand Osteoarthritis Cohort (LIHOC). Arthritis Research and Therapy, 23 (1), 12 (9. doi:10.1186/s13075-020-02390-x
Peer Reviewed verified by ORBi

Rolland, Y., Cesari, M., Fielding, R. A., Reginster, J.-Y., Vellas, B., & Cruz-Jentoft, A. J. (2021). Osteoporosis in Frail Older Adults: Recommendations for Research from the ICFSR Task Force 2020. The Journal of frailty & aging, 10 (2), 168-175. doi:10.14283/jfa.2021.4
Peer reviewed

Reginster, J.-Y., & Veronese, N. (2021). Highly purified chondroitin sulfate: a literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment. Aging Clinical and Experimental Research, 33, 37-47. doi:10.1007/s40520-020-01643-8
Peer Reviewed verified by ORBi

Reginster, J.-Y., Beaudart, C., Al-Daghri, N., Avouac, B., Bauer, J., Bere, N., Bruyère, O., Cerreta, F., Cesari, M., Rosa, M. M., Cooper, C., Cruz Jentoft, A. J., Dennison, E., Geerinck, A., Gielen, E., Landi, F., Laslop, A., Maggi, S., Prieto Yerro, M. C., ... Fielding, R. A. (2021). Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults. Aging Clinical and Experimental Research, 33, 3-17. doi:10.1007/s40520-020-01663-4
Peer Reviewed verified by ORBi

Geerinck, A., Beaudart, C., Reginster, J.-Y., Locquet, M., Monseur, C., GILLAIN, S., & Bruyère, O. (2021). Development and validation of a short version of the Sarcopenia Quality of Life questionnaire: the SF‑SarQoL. Quality of Life Research, 30 (8), 2349-2362. doi:10.1007/s11136-021-02823-3
Peer Reviewed verified by ORBi

Locquet, M., Bruyère, O., Lengele, L., Reginster, J.-Y., & Beaudart, C. (2021). Relationship between smoking and the incidence of sarcopenia: The SarcoPhAge cohort. Public Health, 193, 101-108. doi:10.1016/j.puhe.2021.01.017
Peer Reviewed verified by ORBi

Bahat, G., Catikkas, N. M., Yavuz, D. G., Borman, P., Guzel, R., & Reginster, J.-Y. (2021). The current situation in the approach to osteoporosis in older adults in Turkey: areas in need of improvement with a model for other populations. Archives of Osteoporosis, 16 (1). doi:10.1007/s11657-021-01038-w
Peer Reviewed verified by ORBi

Veronese, N., Stefanac, S., Koyanagi, A., Al-Daghri, N. M., Sabico, S., Cooper, C., Rizzoli, R., Reginster, J.-Y., Barbagallo, M., Dominguez, L. J., Smith, L., & Maggi, S. (2021). Lower Limb Muscle Strength and Muscle Mass Are Associated With Incident Symptomatic Knee Osteoarthritis: A Longitudinal Cohort Study. Frontiers in Endocrinology, 12. doi:10.3389/fendo.2021.804560
Peer Reviewed verified by ORBi

Beaudart, C., Bonnefoy, M., Gilbert, T., Paillaud, E., Raynaud-Simon, A., Guérin, O., Jeandel, C., Le Sourd, B., Haine, M., Ferry, M., Rolland, Y., Berrut, G., Reginster, J.-Y., & Bruyère, O. (2021). Quelle qualité de vie pour le patient sarcopénique ? Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 19 (3), 245-252. doi:10.1684/pnv.2021.0948
Peer reviewed

DEROISY, R., NEUPREZ, A., LEONARD, Y., LECART, M.-P., MASSENET, V., GILLET, P., Reginster, J.-Y., & KAUX, J.-F. (December 2020). Identification, through a Fracture Liaison Service, of undiagnosed vertebral fractures in patients hospitalized for a prevalent hip fragility fracture. Osteoporosis International, 31 (S1), 200.
Peer Reviewed verified by ORBi

Beaudart, C., Lengele, L., Leclercq, V., Geerinck, A., Sanchez Rodriguez, M. D. C., Bruyère, O., & Reginster, J.-Y. (December 2020). Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta‑Analysis with a 6‑Month Time Horizon. Drugs, 80 (18), 1947-1959. doi:10.1007/s40265-020-01423-8
Peer Reviewed verified by ORBi

Geerinck, A., Reginster, J.-Y., Locquet, M., Monseur, C., Gillain, S., Bruyère, O., & Beaudart, C. (December 2020). Clinimetric properties of the newly developed short form sarcopenia quality of life (SF-SarQoL) questionnaire [Poster presentation]. Society on Sarcopenia, Cachexia and Wasting Disorders conference.

Honvo, G., Lengele, L., Charles, A., Reginster, J.-Y., & Bruyère, O. (December 2020). Role of Collagen Derivatives in Osteoarthritis and Cartilage Repair: A Systematic Scoping Review With Evidence Mapping. Rheumatology and Therapy, 7 (4), 703-740. doi:10.1007/s40744-020-00240-5
Peer Reviewed verified by ORBi

NEUPREZ, A., DEROISY, R., LEONARD, Y., LECART, M.-P., MASSENET, V., GILLET, P., KAUX, J.-F., & Reginster, J.-Y. (December 2020). Secondary fracture prevention in hip fracture patients: 6-year impact of a Fracture Liaison Service. Osteoporosis International, 31 (S1), 199-200.
Peer Reviewed verified by ORBi

Buckinx, F., Lecocq, G., Bornheim, S., Van Beveren, J., VALCU, C.-A., DANIEL, C., Bruyère, O., Reginster, J.-Y., D'Hooghe, P., & Kaux, J.-F. (August 2020). French translation and validation of the Achilles Tendon Total Rupture Score "ATRS". Foot and Ankle Surgery, 26 (6), 662-668. doi:10.1016/j.fas.2019.08.010
Peer Reviewed verified by ORBi

Locquet, M., Willems, T., Specque, C., Beaudart, C., Bruyère, O., Van Beveren, J., Dardenne, N., Reginster, J.-Y., & Kaux, J.-F. (July 2020). Cross-cultural adaptation, translation, and validation of the functional assessment scale for acute hamstring injuries (FASH) questionnaire for French-speaking patients. Disability and Rehabilitation, 42 (14), 2076-2082. doi:10.1080/09638288.2018.1544669
Peer Reviewed verified by ORBi

Fuggle, N. R., Cooper, C., Oreffo, R. O. C., Price, A. J., Kaux, J.-F., Maheu, E., Cutolo, M., Honvo, G., Conaghan, P. G., Berenbaum, F., Branco, J., Brandi, M. L., Cortet, B., Veronese, N., Kurth, A. A., Matijevic, R., Roth, R., Pelletier, J. P., Martel-Pelletier, J., ... Reginster, J.-Y. (April 2020). Alternative and complementary therapies in osteoarthritis and cartilage repair. Aging Clinical and Experimental Research, 32 (4), 547-560. doi:10.1007/s40520-020-01515-1
Peer Reviewed verified by ORBi

Geiker, N. R. W., Mølgaard, C., Iuliano, S., Rizzoli, R., Manios, Y., van Loon, L. J. C., Lecerf, J.-M., Moschonis, G., Reginster, J.-Y., Givens, I., & Astrup, A. (April 2020). Correction to: Impact of whole dairy matrix on musculoskeletal health and aging–current knowledge and research gaps (Osteoporosis International, (2019), 10.1007/s00198-019-05229-7). Osteoporosis International, 31 (4), 795. doi:10.1007/s00198-019-05262-6
Peer Reviewed verified by ORBi

Geerinck, A., Beaudart, C., Locquet, M., Reginster, J.-Y., & Bruyère, O. (March 2020). Association between frailty and quality of life measured with the SarQoL®, SF-36 and EQ-5D questionnaires in older people from the SarcoPhAge cohort [Poster presentation]. International Conference on Frailty and Sarcopenia Research, Toulouse, France.

Neuprez, A., Neuprez, A., KAUX, J.-F., KURTH, W., DANIEL, C., THIRION, T., Hustin, J.-P., Gillet, P., Bruyère, O., & Reginster, J.-Y. (March 2020). Total joint replacement improves pain, functional quality of life, and health utilities in patients with late-stage knee and hip osteoarthritis for up to 5 years. Clinical Rheumatology, 39 (3), 861-871. doi:10.1007/s10067-019-04811-y
Peer Reviewed verified by ORBi

Hiligsmann, M., Reginster, J.-Y., & Silverman, S. (March 2020). The Value of a Patient-Level Modeling Approach and Need for Better Reporting in Economic Evaluations of Osteoporosis [letter to the editor]. Journal of Managed Care and Specialty Pharmacy, 26 (3), 334-335. doi:10.18553/jmcp.2020.26.3.334
Peer Reviewed verified by ORBi

Locquet, M., Bornheim, S., Colas, L., Van Beveren, J., Bruyère, O., Reginster, J.-Y., & Kaux, J.-F. (March 2020). Erratum à « Traduction en langue française, adaptation transculturelle et validation du questionnaire “Victorian Institute of Sport Assessment Scale for Proximal Hamstring Tendinopathy” (VISA-H) [J. Traumatol. Sport 36 (2019) 217–221](S0762915X19300385)(10.1016/j.jts.2019.04.001). Journal de Traumatologie du Sport, 37 (1), 62. doi:10.1016/j.jts.2020.01.001
Peer reviewed

Fuggle, N. R., Kassim Javaid, M., Fujita, M., Halbout, P., Dawson-Hughes, B., Rizzoli, R., Reginster, J.-Y., Kanis, J., & Cooper, C. (2020). Fracture risk assessment and how to implement a Fracture Liaison Service. In Orthogeriatrics: The management of older patients with fragility fractures (Second Edition, pp. 241-256). Paolo Falaschi, David Marsh Eds. doi:10.1007/978-3-030-48126-1

Ruiz, J. G., Dent, E., Morley, J. E., Merchant, R. A., Beilby, J., Beard, J., Tripathy, C., Sorin, M., Andrieu, S., Aprahamian, I., Arai, H., Aubertin-Leheudre, M., Bauer, J. M., Cesari, M., Chen, L.-K., Cruz-Jentoft, A. J., Barreto, P. D. S., Dong, B., Ferrucci, L., ... Vellas, B. (2020). Erratum to: Screening for and Managing the Person with Frailty in Primary Care: ICFSR Consensus Guidelines (The journal of nutrition, health & aging, (2020), 10.1007/s12603-020-1492-3). Journal of Nutrition, Health and Aging. doi:10.1007/s12603-020-1547-5

Veronese, N., Demurtas, J., Smith, L., Reginster, J.-Y., Bruyère, O., Beaudart, C., Honvo, G., & Maggi, S. (2020). Glucosamine sulphate: an umbrella review of health outcomes. Therapeutic Advances in Musculoskeletal Disease, 12, 1-12. doi:10.1177/1759720X20975927
Peer Reviewed verified by ORBi

Kanis, J. A., Harvey, N. C., McCloskey, E. V., Bruyère, O., Veronese, N., Lorentzon, M., Cooper, C., Rizzoli, R., Adib, G., Al-Daghri, N., Campusano, C., Chandran, M., Dawson-Hughes, B., Javaid, M. K., Jiwa, F., Johansson, H., Lee, J. K., Liu, E., Messina, O., ... Reginster, J.-Y. (2020). ESCEO-IOF algorithm for the management of low/high/very high risk of fracture. Osteoporosis International, 31 (S1), 33.
Peer Reviewed verified by ORBi

Parsons, C. M., Judge, A., Meyer, R., Bruyère, O., Petir-Dop, F., Chapurlat, R., Reginster, J.-Y., Inskip, H., & Cooper, C. (2020). Improved statistical methods for monitoring knee osteoarthritis disease progression. Osteoporosis International, 31 (S1), 524.
Peer Reviewed verified by ORBi

Sanchez Rodriguez, M. D. C., Locquet, M., Reginster, J.-Y., Cavalier, E., Bruyère, O., & Beaudart, C. (2020). Mortality in malnourished older adults diagnosed by ESPEN and GLIM criteria in the SarcoPhAge study. Journal of Cachexia, Sarcopenia and Muscle, 11 (5), 1200-1211. doi:10.1002/jcsm.12574
Peer Reviewed verified by ORBi

Sanchez Rodriguez, M. D. C., Locquet, M., Reginster, J.-Y., CAVALIER, E., Bruyère, O., & Beaudart, C. (2020). Diagnosis of malnutrition using GLIM criteria : validity of 7 pragmatic approaches which do not require the measurement of muscle mass. Osteoporosis International, 31 (S1), 618.
Peer Reviewed verified by ORBi

Geerinck, A., Bruyère, O., Locquet, M., Gillain, S., Monseur, C., Reginster, J.-Y., & Beaudart, C. (2020). Development of a short version of the sarcopenia quality of life (SARQOL®) questionnaire. Osteoporosis International, 31 (S1), 450-451.
Peer Reviewed verified by ORBi

Lengele, L., Beaudart, C., Locquet, M., Reginster, J.-Y., & Bruyère, O. (2020). 5-year adverse outcomes of sarcopenia diagnosed according to six different definitions. Osteoporosis International, 31 (S1), 47-48.
Peer Reviewed verified by ORBi

Guralnik, J., Bandeen-Roche, K., Bhasin, S. A. R., Eremenco, S., Landi, F., Muscedere, J., Perera, S., Reginster, J.-Y., Woodhouse, L., & Vellas, B. (2020). Clinically Meaningful Change for Physical Performance: Perspectives of the ICFSR Task Force. Journal of Frailty and Aging, 9 (1), 9-13. doi:10.14283/jfa.2019.33
Peer Reviewed verified by ORBi

Charles, A., Buckinx, F., Mouton, A., Reginster, J.-Y., & Bruyère, O. (2020). Motivational climate of group exercise sessions in nursing homes. Archives of Public Health, 78 (1), 43. doi:10.1186/s13690-020-00425-y
Peer Reviewed verified by ORBi

Hiligsmann, M., Beaudart, C., Bruyère, O., Biver, E., Bauer, J., Cruz-Jentoft, A. J., Gesmundo, A., Goissier, S., Landi, F., Locquet, M., Maggi, S., Rizzoli, R., Rolland, Y., Vaquero, N., Cooper, C., & Reginster, J.-Y. (2020). Outcome priorities for older persons with sarcopenia. Journal of the American Directors Associations, 21 (2), 267-271.e2. doi:10.1016/j.jamda.2019.08.026
Peer reviewed

Buckinx, F., Bruyère, O., Lengele, L., Reginster, J.-Y., Marchal, Q., Hurtrez, P., & Mouton, A. (2020). The effects of GAMotion (a giant exercising board game) on physical capacity, motivation and quality of life among nursing home residents: A pilot interventional study. Experimental Gerontology, 138, 110983. doi:10.1016/j.exger.2020.110983
Peer Reviewed verified by ORBi

Charles, A., Detilleux, J., Buckinx, F., Reginster, J.-Y., Gruslin, B., & Bruyère, O. (2020). Physical performance trajectories and mortality among nursing home residents: results of the SENIOR cohort. Age and Ageing, 49 (5), 800-806. doi:10.1093/ageing/afaa034
Peer Reviewed verified by ORBi

Ruiz, J. G., Dent, E., Morley, J. E., Merchant, R. A., Beilby, J., Beard, J., Tripathy, C., Sorin, M., Andrieu, S., Aprahamian, I., Arai, H., Aubertin-Leheudre, M., Bauer, J. M., Cesari, M., Chen, L.-K., Cruz-Jentoft, A. J., De Souto Barreto, P., Dong, B., Ferrucci, L., ... Vellas, B. (2020). Screening for and Managing the Person with Frailty in Primary Care: ICFSR Consensus Guidelines. Journal of Nutrition, Health and Aging, 24 (9), 920-927. doi:10.1007/s12603-020-1492-3
Peer reviewed

Cornelissen, D., de Kunder, S., Si, L., Reginster, J.-Y., Evers, S., Boonen, A., & Hiligsmann, M. (2020). Interventions to improve adherence to anti-osteoporosis medications: an updted systematic review. Osteoporosis International, 31 (9), 1645-1669. doi:10.1007/s00198-020-05378-0
Peer Reviewed verified by ORBi

Bruyère, O., Dardenne, N., Donneau, A.-F., & Reginster, J.-Y. (2020). Responder Profile to Pharmaceutical-Grade Chondroitin Sulfate: An Analysis of the CONCEPT Trial. Advances in Therapy, 37 (11), 4641-4648. doi:10.1007/s12325-020-01484-x
Peer Reviewed verified by ORBi

Hiligsmann, M., Maggi, S., Onder, G., Galluzzo, L., & Reginster, J.-Y. (2020). Cost-effectiveness of BINISTO (buffered soluble alendronate 70 mg) effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy. Osteoporosis International, 31 (S1), 58.
Peer Reviewed verified by ORBi

Veronese, N., Cacco, C., Smith, L., Dermutas, J., Cooper, C., Reginster, J.-Y., Barbagallo, M., & Maggi, S. (2020). Dietary acrylamide and incident osteoporotic fractures: an 8-year longitudinal cohort study. Osteoporosis International, 31 (S1), 383.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2020). What’s makes a difference between SYSADOAs. Osteoporosis International, 31 (S1), 624.
Peer Reviewed verified by ORBi

Kanis, J. A., Harvey, N. C., McCloskey, E., Bruyère, O., Veronese, N., Lorentzon, M., Cooper, C., Rizzoli, R., Adib, G., Al-Daghri, N., Campusano, C., Chandran, M., Dawson-Hughes, B., Javaid, K., Jiwa, F., Johansson, H., Lee, J. K., Liu, E., Messina, D., ... Reginster, J.-Y. (2020). Algorithm for the management of patients at low, high and vey high risk of osteoporotic fractures. Osteoporosis International, 31 (1), 1-12. doi:10.1007/s00198-019-05176-3
Peer Reviewed verified by ORBi

Mavungu Landu, D. J., Marini Djang'Eing'A, R., Hubert, P., Frederich, M., Michel, B., Gretry, L., Messina Ndzomo, J. P., Bruyère, O., Reginster, J.-Y., & Manzambi Kuwekita, J. (2020). Les déterminants de l’accès à des médicaments antipaludiques de qualité en territoires périurbains africains : résultats d’une enquête menée à Kinshasa (Congo). Journal d’Épidémiologie et de Santé Publique, 21, 85-100.
Peer reviewed

Geiker, N. R. W., Molgaard, C., Iuliano, S., Rizzoli, R., Manios, Y., van LOON, L. J. C., Lecerf, J. M., Moschonis, G., Reginster, J.-Y., Givens, I., & Astrup, A. (2020). Impact of whole dairy matrix on musculoskeletal health and aging-current knowledge and research gaps. Osteoporosis International, 31, 601–615. doi:10.1007/s00198-019-05229-7
Peer Reviewed verified by ORBi

ALLEPAERTS, S., Buckinx, F., Bruyère, O., Reginster, J.-Y., PAQUOT, N., & GILLAIN, S. (2020). Clinical impact of nutritional status and energy balance in elderly hospitalized patients. Journal of Nutrition, Health and Aging, 24 (10), 1073-79. doi:10.1007/s12603-020-1527-9
Peer Reviewed verified by ORBi

Beaudart, C., Lengele, L., Geerinck, A., Leclercq, V., Sanchez Rodriguez, M. D. C., Bruyère, O., & Reginster, J.-Y. (2020). Efficacy of symptomatic treatments for knee OA: a systematic review and network meta-analysis with a 6-month time-horizon. Osteoporosis International, 31 (S1), 56.
Peer Reviewed verified by ORBi

Charles, A., Girard, A., Buckinx, F., Mouton, A., Reginster, J.-Y., & Bruyère, O. (2020). Senior physical activity contests in nursing homes: a feasibility study. Osteoporosis International, 31 (S1), 217.
Peer Reviewed verified by ORBi

LADANG, A., Beaudart, C., Locquet, M., Reginster, J.-Y., & Bruyère, O. (2020). Evaluation of a panel of microRNAs that predicts fragility fracture risk: a pilot study. Calcified Tissue International, 106 (3), 239-247. doi:10.1007/s00223-019-00628-8
Peer Reviewed verified by ORBi

Beaudart, C., Bruyère, O., Geerinck, A., Hajaoui, M., Scafoglieri, A., Perkisas, S., Bautmans, I., Gielen, E., Reginster, J.-Y., & Buckinx, F. (2020). Equation models developed with bioelectric impedance analysis tools to assess muscle mass: A systematic review. Clinical Nutrition ESPEN, 35, 47-62. doi:10.1016/j.clnesp.2019.09.012
Peer reviewed

Hiligsmann, M., Williams, S. A., Fitzpatrick, L. A., Silverman, S. S., Weiss, R., & Reginster, J.-Y. (2020). Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs alendronate monotherapy in women at increased risk of fracture: a US payer perspective. Seminars in Arthritis and Rheumatism, 50, 394-400. doi:10.1016/j.semarthrit.2020.02.004
Peer Reviewed verified by ORBi

Chiu, W.-Y., Lin, C.-J., Yang, W.-S., Tsai, K.-S., & Reginster, J.-Y. (2020). Racial difference in bioavailability of oral ibandronate between Caucasian and Taiwanese postmenopausal women. Osteoporosis International. doi:10.1007/s00198-019-05127-y
Peer Reviewed verified by ORBi

Charles, A., Girard, A., Buckinx, F., Mouton, A., Reginster, J.-Y., & Bruyère, O. (2020). Senior physical activity contests in nursing homes: a feasibility study. Aging Clinical and Experimental Research, 32 (5), 869-876. doi:10.1007/s40520-020-01529-9
Peer Reviewed verified by ORBi

Charles, A., Buckinx, F., Locquet, M., Reginster, J.-Y., Petermans, J., Gruslin, B., & Bruyère, O. (2020). Prediction of adverse outcomes in nursing home residents according to intrinsic capacity proposed by the World Health Organization. Journal of Gerontology: Series A, Biological Sciences and Medical Sciences, 75 (8), 1594-1599. doi:10.1093/gerona/glz218
Peer reviewed

Rozenberg, S., Al-Daghri, N., Aubertin-Leheudre, M., Brandi, M.-L., Cano, A., Collins, P., Cooper, C., Genazzani, A. R., Hillard, T., Kanis, J. A., Kaufman, J.-M., Lambrinoudaki, I., Laslop, A., McCloskey, E., Palacios, S., Prieto-Alhambra, D., Reginster, J.-Y., Rizzoli, R., Rosano, G., ... Harvey, N. C. (2020). Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis? Osteoporosis International, 31, 2271-2286. doi:10.1007/s00198-020-05497-8
Peer Reviewed verified by ORBi

McClung, M. R., Bolognese, M. A., Brown, J. P., Reginster, J.-Y., Langdahl, B. L., Ruiz-Santiago, N., Shi, Y., Rojeski, M., Timoshanko, J., Libanati, C., Kassahun, H., & Oates, M. (2020). Romosozumab after Denosumab improves lumbar spine and maintains total hip bone mineral density in postmenopausal women with low bone mass. Osteoporosis International, 31 (S1), 41-42.
Peer Reviewed verified by ORBi

Chandran, M., Ganesan, G., Tan, K. B., Reginster, J.-Y., Yong, E. L., & Hiligsmann, M. (2020). Cost-effectiveness of FRAX® based intervention tresholds for management of osteoporosis in Singaporean women. Osteoporosis International, 31 (S1), 459.
Peer Reviewed verified by ORBi

Geerinck, A., Beaudart, C., Locquet, M., Reginster, J.-Y., & Bruyère, O. (2020). Association between SARC-F and quality of life measured by SARQOL® questionnaire in older, community-dwelling subjects friom the SarcoPhAge cohort. Osteoporosis International, 31 (S1), 451.
Peer Reviewed verified by ORBi

Geerinck, A., Locquet, M., Bruyère, O., Reginster, J.-Y., & Beaudart, C. (2020). Evaluating quality of life in frailty: applicability and psychometric properties of the SARQOL® questionnaire. Osteoporosis International, 31 (S1), 450.
Peer Reviewed verified by ORBi

Charles, A., Buckinx, F., Reginster, J.-Y., Mouton, A., & Bruyère, O. (2020). Motivational climate of group exercise sessions in nursing homes. Osteoporosis International, 31 (S1), 217-218.
Peer Reviewed verified by ORBi

Beaudart, C., Bauer, J., Landi, F., Bruyère, O., Reginster, J.-Y., & Hiligsmann, M. (2020). A discrete-choice experiment to assess experts’ preferences for sarcopenia outcomes. Osteoporosis International, 31 (S1), 320.
Peer Reviewed verified by ORBi

Lengele, L., Moehlinger, P., Bruyère, O., Locquet, M., Reginster, J.-Y., & Beaudart, C. (2020). Association between Changes in Nutrient Intake and Changes in Muscle Strength and Physical Performance in the SarcoPhAge Cohort. Nutrients, 12 (11), 3485, 1-16. doi:10.3390/nu12113485
Peer Reviewed verified by ORBi

Beaudart, C., Bruyère, O., Cruz-Jentoft, A. J., Vaquero-Pinto, M. N., Locquet, M., Bauer, J., Cooper, C., Rolland, Y., Dupuy, C., Landi, F., Reginster, J.-Y., Maggi, S., Rizzoli, R., & Hiligsmann, M. (2020). Patient’s engagement in the identification of critical outcomes in sarcopenia. Journal of the American Directors Associations, 21 (2), 284-286. doi:10.1016/j.jamda.2019.09.004
Peer reviewed

Borgström, F., Karlsson, L., Ortsäter, G., Norton, N., Halbout, P., Cooper, C., Lorentzon, M., McCloskey, E. V., Harvey, N. C., Javaid, M. K., Kanis, J. A., Reginster, J.-Y., Ferrari, S., & for the International Osteoporosis Foundation. (2020). Fragility fractures in Europe: burden, management and opportunities. Archives of Osteoporosis, 15 (1). doi:10.1007/s11657-020-0706-y
Peer Reviewed verified by ORBi

McClung, M. R., Bolognese, M. A., Brown, J. P., Reginster, J.-Y., Langdahl, B. L., Maddox, J., Shi, Y., Rojeski, M., Meisner, P. D., & Grauer, A. (2020). A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab. Osteoporosis International, 31 (11), 2231-2241. doi:10.1007/s00198-020-05502-0
Peer Reviewed verified by ORBi

Kanis, J. A., Cooper, C., Dawson-Hughes, B., Harvey, N. C., Johansson, H., Lorentzon, M., McCloskey, E. V., Reginster, J.-Y., & Rizzoli, R. (2020). FRAX and ethnicity. Osteoporosis International, 31, 2063-2067. doi:10.1007/s00198-020-05631-6
Peer Reviewed verified by ORBi

Al-Saleh, Y., Al-Daghri, N. M., Sabico, S., Alessa, T., Al Emadi, S., Alawadi, F., Al Qasaabi, S., Alfutaisi, A., Al Izzi, M., Mukhaimer, J., Suhaili, A. R., Reginster, J.-Y., & Sulimani, R. (2020). Diagnosis and management of osteoporosis in postmenopausal women in Gulf Cooperation Council (GCC) countries: consensus statement of the GCC countries’ osteoporosis societies under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Archives of Osteoporosis, 15 (1), 109. doi:10.1007/s11657-020-00778-5
Peer Reviewed verified by ORBi

Al-Daghri, N. M., Yakout, S., Aljohani, N., Al-Saleh, Y., Al-Attas, O. S., Reginster, J.-Y., Al-Disi, D., & Alokail, M. S. (2020). Vitamin D Status and its correlation with Parathyroid Hormone level among population in Riyadh, Saudi Arabia. Journal of King Saud University - Science, 32 (3), 2016-2019. doi:10.1016/j.jksus.2020.02.002

Dzhus, M., Dzhus, M., Masnyi, M., Kulyk, M., Mostbauer, H., Ivashkivsky, O., Boyko, Y., Cherchenko, K., Geerinck, A., Reginster, J.-Y., Bruyère, O., & Beaudart, C. (2020). Cross-sectional evaluation of the sarcopenia quality of life (Sarqol) questionnaire: Translation and validation of its psychometric properties. Annals of Geriatric Medicine and Research, 24 (2), 139-147. doi:10.4235/AGMR.20.0020
Peer Reviewed verified by ORBi

Ansari, M. G. A., Hussain, S. D., Wani, K. A., Yakout, S. M., Al-Disi, D., Alokail, M. S., Reginster, J.-Y., & Al-Daghri, N. M. (January 2020). Influence of bone mineral density in circulating adipokines among postmenopausal Arab women. Saudi Journal of Biological Sciences, 27 (1), 374-379. doi:10.1016/j.sjbs.2019.10.007
Peer Reviewed verified by ORBi

Kanis, J. A., Harvey, N. C., McCloskey, E., Bruyère, O., Veronese, N., Lorentzon, M., Cooper, C., Rizzoli, R., Adib, G., Al-Daghri, N., Campusano, C., Chandran, M., Dawson-Hughes, B., Javaid, K., Jiwa, F., Johansson, H., Lee, J. K., Liu, E., Messina, D., ... Reginster, J.-Y. (2020). Correction to: Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 31 (4), 797-798. doi:10.1007/s00198-020-05297-0
Peer reviewed

Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2020). Correction to: European guidance for the diagnosis and management of osteoporosis in postmenopausal women (Osteoporosis International, (2019), 30, 1, (3-44), 10.1007/s00198-018-4704-5). Osteoporosis International, 31, 801. doi:10.1007/s00198-020-05303-5
Peer Reviewed verified by ORBi

Li, N., Cornelissen, D., Silverman, S., Pinto, D., Si, L., Kremer, I., Bours, S., Boonen, A., Evers, S., van den Bergh, J., Reginster, J.-Y., & Hiligsmann, M. (2020). An updated systematic review of cost-effectiveness analysis of drugs for osteoporosis. Osteoporosis International, 31 (S1), 491.
Peer Reviewed verified by ORBi

Fuggle, N. R., Cooper, C., Harvey, N. C., Al-Daghri, N., Brandi, M.-L., Bruyère, O., Cano, A., Dennison, E. M., Diez-Perez, A., Kaufman, J.-M., Palacios, S., Prieto-Alhambra, D., Rozenberg, S., Thomas, T., Tremollieres, F., Rizzoli, R., Kanis, J. A., & Reginster, J.-Y. (2020). Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs. Drugs, 80 (15), 1537-52. doi:10.1007/s40265-020-01364-2
Peer Reviewed verified by ORBi

Buckinx, F., Marchal, Q., Hurtrez, P., Bruyère, O., Reginster, J.-Y., & Mouton, A. (2020). The effects of GAMotion (a giant exercising board game) on physical capacity, motivation and quality of life among nursing home residents: a randomized controlled trial. Osteoporosis International, 31 (S1), 261.
Peer Reviewed verified by ORBi

Charles, A., Detilleux, J., Buckinx, F., Reginster, J.-Y., Gruslin, B., & Bruyère, O. (2020). Physical performance trajectories and mortality among nursing-home residents: the results of the SENIOR Cohort. Osteoporosis International, 31 (S1), 57.
Peer Reviewed verified by ORBi

Beaudart, C., Locquet, M., Lengele, L., Reginster, J.-Y., & Bruyère, O. (2020). Performance of the “Yubi-wakka (finger-ring) test as self-screening method for sarcopenia using the SarcoPhAge, Belgian cohort study. Osteoporosis International, 31 (S1), 85 and 302.
Peer Reviewed verified by ORBi

Beaudart, C., Locquet, M., Lengele, L., Reginster, J.-Y., & Bruyère, O. (2020). The different diagnosis criteria of the EWGSOP2 definition and long-term clinical outcomes. Osteoporosis International, 31 (S1), 58.
Peer Reviewed verified by ORBi

Veronese, N., Demurtas, J., Soysal, P., Smith, O., Bruyère, O., Reginster, J.-Y., Beaudart, C., Cooper, C., Mirko, M., & Maggi, S. (2020). Sarcopenia and health-related outcomes: an umbrella review of observational studies. Osteoporosis International, 31 (S1), 198-199.
Peer Reviewed verified by ORBi

Lorentzon, M., Branco, J., Brandi, M. L., Bruyère, O., Chapurlat, R., Cooper, C., Cortet, B., Diez-Perez, A., Ferrari, S., Gasparik, A., Herrman, M., Jorgensen, N. R., Kanis, J. A., Kaufman, J. M., Laslop, A., Locquet, M., Matijevic, R., McCloskey, E. V., Minisola, S., ... CAVALIER, E. (2020). Clinical application of bone turnover markers in postmenopausal osteoporosis. Osteoporosis International, 31 (S1), 65-66.
Peer Reviewed verified by ORBi

Locquet, M., Beaudart, C., Reginster, J.-Y., Bruyère, O., & Croisier, J.-L. (2020). Muscle strengthevaluated using the hand-held dynamometer MicroFET2 in older adults: a reliability study. Osteoporosis International, 31 (S1), 301-302.
Peer Reviewed verified by ORBi

Hiligsmann, M., Dennison, E., Beaudart, C., Herrero-Beaumont, G., Branco, J., Bruyère, O., Conaghan, P. G., Cooper, C., Al-Daghri, N., Jiwa, F., Lems, W., Pinto, D., Rizzoli, R., Thomas, T., Uebelhart, D., Veronese, N., & Reginster, J.-Y. (2020). A discrete-choice experiment to assess patients’preferences for osteoarthritis treatment: an ESCEO working group. Seminars in Arthritis and Rheumatism, 50 (5), 859-866. doi:10.1016/j.semarthrit.2020.08.005
Peer Reviewed verified by ORBi

Locquet, M., Bornheim, S., Colas, L., Van Beveren, J., Bruyère, O., Reginster, J.-Y., & Kaux, J.-F. (December 2019). Traduction en langue française, adaptation transculturelle et validation du questionnaire « Victorian Institute of Sport Assessment Scale for Proximal Hamstring Tendinopathy » (VISA-H). Journal de Traumatologie du Sport, 36 (4), 217-221. doi:10.1016/j.jts.2019.04.001
Peer reviewed

Geerinck, A., Beaudart, C., Dardenne, N., Reginster, J.-Y., & Bruyère, O. (December 2019). An exploration of the structural validity of the Sarcopenia Quality of Life (SarQoL) questionnaire with exploratory and confirmatory factor analysis [Paper presentation]. Journée des doctorants en Santé Publique.

McClung, M. R., O'Donoghue, M. L., Papapoulos, S. E., Bone, H., Langdahl, B., Saag, K. G., Reid, I. R., Cavallari, I., Bonaca, M. P., Wiviott, S. D., de Villers, T., Ling, X., Lippuner, K., Nakamura, T., Reginster, J.-Y., Rodrigez-Portales, J. A., Roux, C., Zanchetta, J., Zerbini, C. A. F., ... LOFT Ivestigators. (19 October 2019). Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicenter, randomized, double-blind, placebo-controlled trial and LOFT Extension Study. The Lancet Diabetes and Endocrinology, published online. doi:10.1016/S2213-8587(19)30346-8
Peer Reviewed verified by ORBi

Gillain, S., Boutaayamou, M., Schwartz, C., BRUYERE, O., Bruls, O., CROISIER, J.-L., SALMON, E., Reginster, J.-Y., GARRAUX, G., & PETERMANS, J. (October 2019). Using supervised learning machine algorithm to identify future fallers based on gait patterns: a two-year longitudinal study [Poster presentation]. XXIIèmes Journées d'Automne de la SBGG, LIEGE, Belgium.

Gillain, S., Boutaayamou, M., Schwartz, C., Dardenne, N., BRUYERE, O., Bruls, O., Croisier, J.-L., SALMON, E., Reginster, J.-Y., GARRAUX, G., & Petermans, J. (October 2019). Identify future fallers based on gait symmetry dual task changes: a two-year longitudinal study [Poster presentation]. 22èmes Journées d'Automne de la SBGG, LIEGE, Belgium.

Bauer, J. M., Cruz-Jentoft, A. J., Fielding, R. A., Kanis, J. A., Reginster, J.-Y., Bruyère, O., Cesari, M., Chapurlat, R., Al-Daghri, N., Dennison, E., Kaufman, J.-M., Landi, F., Laslop, A., Locquet, M., Maggi, S., McCloskey, E., Perna, S., Rizzoli, R., Rolland, Y., ... FMedSci, C. C. (August 2019). Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review. Calcified Tissue International, 105 (2), 109-24. doi:10.1007/s00223-019-00561-w
Peer Reviewed verified by ORBi

Veronese, N., Cooper, C., Reginster, J.-Y., Hochberg, M., Branco, J., Bruyère, O., Chapurlat, R., Al-Daghri, N., Dennison, E., Herrero-Beaumont, G., Kaux, J.-F., Maheu, E., Rizzoli, R., Roth, R., Rovati, L. C., Uebelhart, D., Vlaskovska, M., & Scheen, A. (August 2019). Type 2 diabetes mellitus and osteoarthritis. Seminars in Arthritis and Rheumatism, 49 (1), 9-19. doi:10.1016/j.semarthrit.2019.01.005
Peer Reviewed verified by ORBi

Bruyère, O., Detilleux, J., & Reginster, J.-Y. (July 2019). Cost-effectiveness assessment of different glucosamines in patients with knee osteoarthritis: A simulation model adapted to Germany. Osteoporosis International, 30 (S2), 181-S182.
Peer Reviewed verified by ORBi

Hiligsmann, M., & Reginster, J.-Y. (July 2019). Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France. Osteoporosis International, 30 (S2), 182.
Peer Reviewed verified by ORBi

Hiligsmann, M., Beaudart, C., Bruyère, O., Biver, E., Bauer, J., Cruz-Jentoft, A. J., Gesmundo, A., Goisser, S., Lansi, F., Locquet, M., Maggi, S., Rizzoli, R., Rolland, Y., Vaquero, N., & Reginster, J.-Y. (July 2019). A cross-european discrete choice experiment to assess patients’ preferences for sarcopenia outcomes. Osteoporosis International, 30 (S2), 190.
Peer Reviewed verified by ORBi

Veronese, N., Cooper, C., Guglielmi, G., Rizzoli, R., Punzi, L., Al-Daghri, N., Smith, L., Reginster, J.-Y., & Maggi, S. (July 2019). Mediterranean diet and knee osteoarthritis outcomes: a longitudinal cohort study. Osteoporosis International, 30 (S2), 457.
Peer Reviewed verified by ORBi

Honvo, G., Bannuru, R. R., Bruyère, O., Rannou, F., Herrero-Beaumont, G., Uebelhaert, D., Cooper, C., Arden, N., Conaghan, P. G., Reginster, J.-Y., Thomas, T., & McAlindon, T. (July 2019). Recommendations for the reporting of harms in manuscripts on studies assessing osteoarthritis drugs: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Osteoporosis International, 30 (S2), 569-S570.
Peer Reviewed verified by ORBi

Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (July 2019). SL2. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International, 30 (S2), 153-S154.
Peer Reviewed verified by ORBi

Hajaoui, M., Locquet, M., Beaudart, C., Reginster, J.-Y., PETERMANS, J., & Bruyère, O. (July 2019). Sarcopenia : performance of the SARC-F questionnaire according to the european consensus criteria, EWGSOP1 vs. EWGSOP2. Osteoporosis International, 30 (S2), 539-S540.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (July 2019). ESCEO recommendations for clinical trials for hand osteoarthritis. Osteoporosis International, 30 (S2), 776.
Peer Reviewed verified by ORBi

Beaudart, C., Bruyère, O., Reginster, J.-Y., Bauer, J., Cooper, C., Cruz-Jentoft, A. J., Dupuy, C., Landi, F., Locquet, M., Maggi, S., Rizzoli, R., Rolland, Y., Vaquero, N., & Hiligsmann, M. (July 2019). Identification and prioritization of important oucomes for patients in sarcopenia. Osteoporosis International, 30 (S2), 189-S190.
Peer Reviewed verified by ORBi

LADANG, A., Beaudart, C., Locquet, M., Reginster, J.-Y., Bruyère, O., & Cavalier, E. (July 2019). Fragility fracture risk prediction in elderly people based on a micro RNA panel. Osteoporosis International, 30 (S2), 299-S300.
Peer Reviewed verified by ORBi

Locquet, M., Beaudart, C., Durieux, N., Reginster, J.-Y., & Bruyère, O. (July 2019). Relationship between the changes over time of bone and muscle health in children and adults : a systematic review and meta-analysis. Osteoporosis International, 30 (S2), 176-S177.
Peer Reviewed verified by ORBi

Al-Daghri, N., Abdi, S., Mohammed, A., Ansari, M. G., Amer, O., Hussain, S. D., Aljohani, N., Al-Disi, D., & Reginster, J.-Y. (July 2019). Associations of Rankl and OPG gene polymorphisms in arab women with and without osteoporosis. Osteoporosis International, 30 (S2), 307.
Peer Reviewed verified by ORBi

Honvo, G., Bruyère, O., Geerinck, A., Veronese, N., & Reginster, J.-Y. (July 2019). Effect of oral chondroitin sulfate on functional status in patients with knee osteoarthritis: outcomes of a comprehensive meta-analysis exploring inconsistencies in randomized, placebo-controlled trials. Osteoporosis International, 30 (S2), 452-S453.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Honvo, G., Geerinck, A., & Bruyère, O. (July 2019). Efficacy and tolerance of pharmaceutical-grade chondroitin sulfate: what does evidence-based medicine say? Osteoporosis International, 30 (S2), 779.
Peer Reviewed verified by ORBi

Abdi, S., Mohammed, A., Amer, O., Ansari, M. G., Aljohani, N., Alokail, M., Reginster, J.-Y., & Al-Daghri, N. (July 2019). Association of genetic polymorphisms with osteopenia in Saudi postmenopausal women. Osteoporosis International, 30 (S2), 308.
Peer Reviewed verified by ORBi

Honvo, G., Reginster, J.-Y., Rannou, F., Rygaert, X., Geerinck, A., Rabenda, V., McAlindon, T., Charles, A., Fuggle, N. R., Cooper, C., Curtis, E. M., Arden, N., Avouac, B., & Bruyère, O. (July 2019). Safety of an intra-articular hyaluronic acid injections in osteoarthritis: outcomes of a systematic review and meta-analysis. Osteoporosis International, 30 (S2), 290.
Peer Reviewed verified by ORBi

Honvo, G., Bruyère, O., Geerinck, A., Veronese, N., & Reginster, J.-Y. (July 2019). Effect of oral chondroitin on pain in patients with knee osteoarthritis: outcomes of a comprehensive meta-analysis exploring inconsistencies in randomised, placebo-controlled trials. Osteoporosis International, 30 (S2), 175.
Peer Reviewed verified by ORBi

Beaudart, C., Rolland, Y., Cruz-Jentoft, A. J., Bauer, J. M., Sieber, C., Cooper, C., Al-Daghri, N., Araujo de Carvalho, I., Bautmans, I., Bernabei, R., Bruyère, O., Cesari, M., Cherubini, A., Dawson-Hughes, B., Kanis, J. A., Kaufman, J. M., Landi, F., Maggi, S., McCloskey, J., ... Fielding, R. A. (July 2019). Assessment of muscle function and physical performance in daily clinical practice: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Calcified Tissue International, 105 (1), 1-14. doi:10.1007/s00223-019-00545-w
Peer Reviewed verified by ORBi

Parsons, C. M., Meyer, R., Judge, A., Bruyère, O., Petit-Dop, F., Chapurlat, R., Reginster, J.-Y., Inskip, H., & Cooper, C. (July 2019). Determining individual trajectories of joint space loss: a Bayesian approach for assessing osteoarthritis progression. Osteoporosis International, 30 (S2), 537-S538.
Peer Reviewed verified by ORBi

Kaux, J.-F., Bornheim, S., Remy, G., Van Beveren, J., Reginster, J.-Y., Bruyère, O., Dardenne, N., & Buckinx, F. (2019). Cross-cultural adaptation, translation in French and validation of the Anterior Knee Pain Scale (AKPS). In V. Bunc & E. Tsolakidis, Book of abstracts - 24th Annual Congress of the European College of Sport Science (pp. 400).
Peer reviewed

Charles, A., Buckinx, F., Mouton, A., Reginster, J.-Y., Gruslin, B., & Bruyère, O. (July 2019). Energy expenditure of nursing home residents and participation in exercise classes: an analysis of the SENIOR cohort. Osteoporosis International, 30 (S2), 430.
Peer Reviewed verified by ORBi

Buckinx, F., Beaudart, C., Reginster, J.-Y., Rolland, Y., Cesari, M., Rizzoli, R., PETERMANS, J., & Bruyère, O. (July 2019). Development of a frailty specific patient reported outcome (PRO): the FRAILQOL. Osteoporosis International, 30 (S2), 465-S466.
Peer Reviewed verified by ORBi

Hiligsmann, M., Williams, S. A., Fitzpatrick, L. A., Silverman, S., Weiss, R., & Reginster, J.-Y. (July 2019). Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy for USA women at increased risk of fracture. Osteoporosis International, 30 (S2), 503-S504.
Peer Reviewed verified by ORBi

Sabico, S., Bassam, R., Alnaami, A., Khattak, M., Lei, K., Al-Daghri, N., Reginster, J.-Y., & Alokail, M. (July 2019). Associations of bone metabolism markers with neck circumference in adult arab women. Osteoporosis International, 30 (S2), 307-S308.
Peer Reviewed verified by ORBi

Fuggle, N. R., Curtis, E. M., Shaw, S., Spooner, L., Bruyère, O., Ntanil, G., Parsons, C., Conaghan, P. G., Corp, N., Honvo, G., Maggi, S., Uebelhart, D., Baird, J., Dennison, E. M., Reginster, J.-Y., & Cooper, C. (July 2019). Safety of analgesics, non-steroidal anti-inflammatory drugs and opioids. Osteoporosis International, 30 (S2), 186-S187.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (July 2019). Management of knee osteoarthritis in 2019: an updated algorithm from the European society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Osteoporosis International, 30 (S2), 158-S159.
Peer Reviewed verified by ORBi

Locquet, M., Beaudart, C., Croisier, J.-L., Reginster, J.-Y., & Bruyère, O. (July 2019). Determinants and health consequences of a rapid muscle health decline in older adults from the SacoPhAge study. Osteoporosis International, 30 (S2), 211 and S275.
Peer Reviewed verified by ORBi

Honvo, G., Bruyère, O., & Reginster, J.-Y. (June 2019). Update on the role of pharmaceutical‑grade chondroitin sulfate in the symptomatic management of knee osteoarthritis. Aging Clinical and Experimental Research, 31 (8), 1163-1167. doi:10.1007/s40520-019-01253-z
Peer Reviewed verified by ORBi

Buckinx, F., Bornheim, S., Remy, G., Van Beveren, J., Reginster, J.-Y., Bruyère, O., Dardenne, N., & Kaux, J.-F. (May 2019). French translation and validation of the “Anterior Knee Pain Scale” (AKPS). Disability and Rehabilitation, 41 (9), 1089-1094. doi:10.1080/09638288.2017.1419288
Peer Reviewed verified by ORBi

Geerinck, A., Alekna, V., Beaudart, C., Bautmans, I., Cooper, C., De Souza Orlandi, F., Konstantynowicz, J., Monterro-Errasquin, B., Topinkova, E., Tsekoura, M., Reginster, J.-Y., & Bruyère, O. (29 April 2019). Standard error of measurement and smallest detectable change of the Sarcopenia Quality of Life (SarQoL) questionnaire: An analysis of subjects from 9 validation studies. PLoS ONE, 14 (4). doi:10.1371/journal.pone.0216065
Peer Reviewed verified by ORBi

Honvo, G., Bruyère, O., Geerinck, A., & Reginster, J.-Y. (April 2019). Symptomatic efficacy of oral chondroitin sulfate in knee osteoarthritis: A systematic review and meta-analysis of randomized, placebo-controlled trials. Osteoarthritis and Cartilage, 27 (Suppl 1), 498–S499. doi:10.1016/j.joca.2019.02.558
Peer Reviewed verified by ORBi

LADANG, A., Beaudart, C., Locquet, M., Reginster, J.-Y., Bruyère, O., & CAVALIER, E. (April 2019). Risk-fracture prediction in elderly people based on a microRNA panel [Poster presentation]. IOF-WHO osteoporosis congress.

Honvo, G., Reginster, J.-Y., Geerinck, A., & Bruyère, O. (April 2019). Safety of oral chondroitin sulfate in the management of knee osteoarthritis: results of a new meta-analysis of randomized. Placebo-controlled trials. Osteoarthritis and Cartilage, 27 (Suppl 1), 499. doi:10.1016/j.joca.2019.02.559
Peer Reviewed verified by ORBi

Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (22 February 2019). Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcified Tissue International, online. doi:10.1007/s00223-018-00512-x
Peer Reviewed verified by ORBi

Charles, A., Buckinx, F., Cataldo, D., Rygaert, X., Gruslin, B., Reginster, J.-Y., & Bruyère, O. (2019). Relationship between peak expiratory flow and incidence of frailty, deaths and falls among nursing home residents: Results of the SENIOR cohort. Archives of Gerontology and Geriatrics, 85. doi:10.1016/j.archger.2019.103913
Peer Reviewed verified by ORBi

Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2019). Executive summary of European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Aging Clinical and Experimental Research, 31, 15-17. doi:10.1007/s40520-018-1109-4
Peer Reviewed verified by ORBi

Martel-Pelletier, J., Maheu, E., Pelletier, J. P., Alekseeva, L., Mkinsi, O., Branco, J., Monod, P., Planta, F., Reginster, J.-Y., & Rannou, F. (January 2019). A new decision tree for diagnosis and management of osteoarthritis in primary care: international consensus of experts. Aging Clinical and Experimental Research, 31 (1), 19-30. doi:10.1007/s40520-018-1077-8
Peer Reviewed verified by ORBi

Yakout, S. M., Alkahtani, S. A., Al-Disi, D., Aljaloud, K. S., Khattak, M. N. K., Alokail, M. S., Reginster, J.-Y., Sabico, S., & Al-Daghri, N. M. (2019). Coexistence of pre-sarcopenia and metabolic syndrome in Arab men. Calcified Tissue International, 104, 130-136. doi:10.1007/s00223-018-0477-2
Peer Reviewed verified by ORBi

Biver, E., Berenbaum, F., Valdes, A. M., Araujo de Carvalho, I., Bindels, L. B., Brandi, M. L., Calder, P. C., Castronovo, V., Cavalier, E., Cherubini, A., Cooper, C., Dennison, E., Franceschi, C., Fuggle, N., Laslop, A., Miossec, P., Thomas, T., Tuzun, S., Veronese, N., ... Rizzoli, R. (2019). Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). Ageing Research Reviews, 55. doi:10.1016/j.arr.2019.100946
Peer Reviewed verified by ORBi

Kucharz, E. J., Szántó, S., Ivanova Goycheva, M., Petronijević, M., Šimnovec, K., Domżalski, M., Gallelli, L., Kamenov, Z., Konstantynowicz, J., Radunović, G., Šteňo, B., Stoilov, R., Stok, R., Vrana, R., Bruyère, O., Cooper, C., & Reginster, J.-Y. (2019). Endorsement by Central European experts of the revised ESCEO algorithm for the management of knee osteoarthritis. Rheumatology International, 39, 1117-1123. doi:10.1007/s00296-019-04332-6
Peer Reviewed verified by ORBi

Thiyagarajan, J. A., Araujo de Carvalho, I., Peña-Rosas, J. P., Chadha, S., Mariotti, S. P., Dua, T., Albanese, E., Bruyère, O., Cesari, M., Dangour, A., Dias, A., Guerra, M., Keeffe, J., Kerse, N., Khan, Q. U. A., Liu, C.-J., Murthy, G. V. S., Ndegwa, S. N., Reginster, J.-Y., ... Beard, J. R. (2019). Redesigning care for older people to preserve physical and mental capacity: WHO guidelines on community-level interventions in integrated care. PLoS Medicine, 16 (10). doi:10.1371/journal.pmed.1002948
Peer Reviewed verified by ORBi

Kucharz, E. J., Szántó, S., Ivanova Goycheva, M., Petronijević, M., Šimnovec, K., Domżalski, M., Gallelli, L., Kamenov, Z., Konstantynowicz, J., Radunović, G., Šteňo, B., Stoilov, R., Stok, R., Vrana, R., Bruyère, O., Cooper, C., & Reginster, J.-Y. (2019). Correction to: Endorsement by Central European experts of the revised ESCEO algorithm for the management of knee osteoarthritis (Rheumatology International, (2019), 39, 7, (1117-1123), 10.1007/s00296-019-04332-6). Rheumatology International, 39 (9), 1661-1662. doi:10.1007/s00296-019-04347-z
Peer Reviewed verified by ORBi

Buckinx, F., Croisier, J.-L., Charles, A., Petermans, J., Reginster, J.-Y., Rygaert, X., & Bruyère, O. (2019). Normative data for isometric strength of 8 different muscle groups and their usefulness as a predictor of loss of autonomy among physically active nursing home residents: The senior cohort. Journal of Musculoskeletal Neuronal Interactions, 19 (3), 258-265.
Peer reviewed

Charles, A., Buckinx, F., Mouton, A., Reginster, J.-Y., Petermans, J., Gruslin, B., & Bruyère, O. (2019). Energy expenditure of nursing home residents and participation in exercise classes: an analysis of the SENIOR cohort [letter to the editor]. Journal of the American Medical Directors Association, 20 (9), 1183-1184. doi:10.1016/j.jamda.2019.04.007
Peer Reviewed verified by ORBi

Honvo, G., Bruyère, O., Geerinck, A., Veronese, N., & Reginster, J.-Y. (2019). Efficacy of chondroitin sulfate in patients with knee osteoarthritis: a comprehensive meta-analysis exploring inconsistencies in randomized, placebo-controlled trials. Advances in Therapy, 36 (5), 1085-99. doi:10.1007/s12325-019-00921-w
Peer Reviewed verified by ORBi

CRUZ-JENTOFT, J., BAHAT, G., BAUER, J., BOIRIE, Y., Bruyère, O., CEDERHOLM, T., Cooper, C., LANDI, F., ROLLAND, Y., SAYER, A. A., SCHNEIDER, M., SIEBER, C. C., TOPINKOVA, E., VANDEWOUDE, M., VISSER, M., ZAMBONI, M., BAUTMANS, I., BAEYENS, J. P., CESARI, M., ... SCHOLS, J. (2019). Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing, 48, 16-31. doi:10.1093/ageing/afy169
Peer Reviewed verified by ORBi

Beaudart, C., Sanchez Rodriguez, M. D. C., Locquet, M., Reginster, J.-Y., Lengele, L., & Bruyère, O. (2019). Malnutrition as a strong predictor of the onset of sarcopenia. Nutrients, 11 (12), 2883. doi:10.3390/nu11122883
Peer Reviewed verified by ORBi

Slomian, J., Honvo, G., EMONTS, P., Reginster, J.-Y., & Bruyère, O. (2019). Consequences of maternal postpartum depression: a systematic review of maternal and infant outcomes. Women's Health, 15, 1-55. doi:10.1177/1745506519844044
Peer Reviewed verified by ORBi

Buckinx, F., Charles, A., Reginster, J.-Y., PETERMANS, J., & Bruyère, O. (2019). Apports de la cohorte liégeoise SENIOR dans l’étude de la fragilité en maison de repos. Revue Médicale de Liège, 74 (4), 212-217.
Peer reviewed

Honvo, G., Bannuru, R. R., Bruyère, O., Rannou, F., Herrero-Beaumont, G., Uebelhart, D., Cooper, C., Arden, N., Conaghan, P. G., Reginster, J.-Y., Thomas, T., & McAlindon, T. (2019). Recommendations for the reporting harms in manuscripts on clinical trials assessing osteoarthritis drugs: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Drugs and Aging, 36 (suppl 1), 145-159. doi:10.1007/s40266-019-00667-8
Peer Reviewed verified by ORBi

Hiligsmann, M., Reginster, J.-Y., Tosteson, A. N. A., Bukata, S. V., Saag, K. G., Gold, D. T., Halbout, P., Jiwa, F., Lewiecki, E. M., Pinto, D., Adachi, J. D., Al-Daghri, N., Bruyère, O., Chandran, M., Cooper, C., Harvey, N. C., Einhorn, T. A., Kanis, J. A., Kendler, D. L., ... Silverman, S. (January 2019). Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporosis International, 30 (1), 45-57. doi:10.1007/s00198-018-4744-x
Peer Reviewed verified by ORBi

Bruyère, O., Beaudart, C., Ethgen, O., Reginster, J.-Y., & Locquet, M. (2019). The health economics burden of sarcopenia: a systematic review. Maturitas, 119, 61-9. doi:10.1016/j.maturitas.2018.11.003
Peer Reviewed verified by ORBi

Veronese, N., Koyanagi, A., Stubbs, B., Cooper, C., Guglielmi, G., Rizzoli, R., Schofield, P., Punzi, P., Al-Daghri, N., Smith, L., Maggi, S., & Reginster, J.-Y. (2019). Statin use and knee osteoarthritis outcomes: a longitudinal cohort study. Arthritis Care and Research, 71, 1052-1058. doi:10.1002/acr.23735
Peer Reviewed verified by ORBi

Albassam, R. S., Sabico, S., Alnaami, A. M., Khattak, M. N. K., Lei, K. Y., Al-daghri, N. M., Reginster, J.-Y., & Alokail, M. S. (2019). Bone metabolism markers are associated with neck circumference in adult Arab women. Osteoporosis International. doi:10.1007/s00198-018-04830-6
Peer Reviewed verified by ORBi

Kendler, D. L., Chines, A., Brandi, M. L., Papapoulos, Lewiecki, E. M., Reginster, J.-Y., Munoz Torres, M., Wang, A., & Bone, H. G. (January 2019). The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies. Osteoporosis International, 30 (1), 71-78. doi:10.1007/s00198-018-4687-2
Peer Reviewed verified by ORBi

Buckinx, F., Paquot, N., FADEUR, M., BACUS, L., Reginster, J.-Y., Allepaerts, S., Petermans, J., Biquet, S., & Bruyère, O. (2019). Assessment of the energy expenditure of Belgian nursing home residents using indirect calorimetry. Nutrition, 57, 12-16. doi:10.1016/j.nut.2018.05.010
Peer Reviewed verified by ORBi

Locquet, M., Beaudart, C., Hajaoui, M., PETERMANS, J., Reginster, J.-Y., & Bruyère, O. (2019). Three-Year Adverse Health Consequences of Sarcopenia in Community-Dwelling Older Adults According to 5 Diagnosis Definitions. Journal of the American Medical Directors Association, 20, 43-46. doi:10.1016/j.jamda.2018.06.004
Peer Reviewed verified by ORBi

Bruyère, O., Reginster, J.-Y., Honvo, G., & Detilleux, J. (2019). Cost-effectiveness evaluation of glucosamine for osteoarthritis based on simulation of individual patient data obtained from aggregated data in published studies. Aging Clinical and Experimental Research, 31 (6), 881-887. doi:10.1007/s40520-019-01138-1
Peer Reviewed verified by ORBi

Bruyère, O., Honvo, G., Veronese, N., Arden, N. K., Branco, J., Curtis, E. M., Al-Daghri, N. M., Herrero-Beaumont, G., Martel-Pelletier, J., Pelletier, J.-P., Rannou, F., Rizzoli, R., Roth, R., Uebelhart, D., Cooper, C., & Reginster, J.-Y. (2019). An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Seminars in Arthritis and Rheumatism, 49 (3), 337-350. doi:10.1016/j.semarthrit.2019.04.008
Peer Reviewed verified by ORBi

GILLAIN, S., Boutaayamou, M., Schwartz, C., Dardenne, N., Bruyère, O., Bruls, O., Croisier, J.-L., SALMON, E., Reginster, J.-Y., GARRAUX, G., & PETERMANS, J. (2019). Gait symmetry in the dual task condition as a predictor of future falls among independent older adults: a 2-year longitudinal study. Aging Clinical and Experimental Research, 31 (8), 1057-1067. doi:10.1007/s40520-019-01210-w
Peer Reviewed verified by ORBi

Gillain, S., Boutaayamou, M., Schwartz, C., Bruls, O., Bruyère, O., Croisier, J.-L., Salmon, E., Reginster, J.-Y., Garraux, G., & Petermans, J. (2019). Using supervised learning machine algorithm to identify future fallers based on gait patterns: A two-year longitudinal study. Experimental Gerontology, 127 (first online). doi:10.1016/j.exger.2019.110730
Peer Reviewed verified by ORBi

Buckinx, F., Charles, A., Quabron, A., Van Hees, T., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2019). Impact of frailty status on the cost of drugs and dietary supplements prescribed to nursing home residents: the SENIOR cohort. Aging Clinical and Experimental Research, 31, 875-880. doi:10.1007/s40520-019-01162-1
Peer Reviewed verified by ORBi

Geerinck, A., Beaudart, C., Dardenne, N., Reginster, J.-Y., & Bruyère, O. (2019). An exploration of the structural validity of the sarcopenia quality of life (SARQOL®) questionnaire with exploratory and confirmatory factor analysis. Osteoporosis International, 30 (S2), 537.
Peer Reviewed verified by ORBi

Xia, W., Cooper, C., Li, M., Xu, L., Rizzoli, R., Zhu, M., Lin, H., Beard, J., Ding, Y., Yu, W., CAVALIER, E., Zhang, Z., Kanis, J. A., Cheng, Q., Wang, Q., & Reginster, J.-Y. (2019). East meets West: current practices and policies in the management of musculoskeletal aging. Aging Clinical and Experimental Research, 31 (10), 1351-1373. doi:10.1007/s40520-019-01282-8
Peer Reviewed verified by ORBi

Veronese, N., Shivappa, N., Stubbs, B., Smith, T., Hebert, J. R., Cooper, C., Guglielmi, G., Reginster, J.-Y., Rizzoli, R., & Maggi, S. (2019). The relationship between the dietary inflammatory index and prevalence of radiographic symptomatic osteoarthritis: data from the Osteoarthritis Initiative. European Journal of Nutrition. doi:10.1007/s00394-017-1589-6
Peer Reviewed verified by ORBi

Veronese, N., Demurtas, J., Soysal, P., Smith, L., Torbahn, G., Schoene, D., Schwingshackl, L., Sieber, C., Bauer, J., Cesari, M., Bruyère, O., Reginster, J.-Y., Beaudart, C., Cruz-Jentoft, A. J., Cooper, C., Petrovic, M., Maggi, S., & the Special Interest Groups in Systematic Reviews and Meta-analyses for healthy ageing Sarcopenia and Frailty and resilience in older persons of the European Geriatric Medicine Society (EuGMS). (2019). Sarcopenia and health-related outcomes: an umbrella review of observational studies. European Geriatric Medicine, 10 (6), 853-862. doi:10.1007/s41999-019-00233-w
Peer reviewed

FUGGLE, N., Curtis, E., Shaw, S., Spooner, L., Bruyère, O., Ntani, G., Parsons, C., Conaghan, P. G., Corp, N., Honvo, G., Uebelhart, D., Baird, J., Dennison, E., Reginster, J.-Y., & Cooper, C. (2019). Safety of opioids in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs and Aging, 36 (suppl 1), 129-143. doi:10.1007/s40266-019-00666-9
Peer Reviewed verified by ORBi

Curtis, E., Fuggle, N., Shaw, S., Spooner, S., Ntani, G., Parsons, C., Corp, N., Honvo, G., Baird, J., Maggi, S., Dennison, E., Bruyère, O., Reginster, J.-Y., & Cooper, C. (2019). Safety of cyclooxygenase-2 inhibitors in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs and Aging, 36 (suppl 1), 25-44. doi:10.1007/s40266-019-00664-x
Peer Reviewed verified by ORBi

Ferrari, S., Libanati, C., Lin, C., Brown, J. P., Cosman, F., Czerwinski, E., de Gregorio, L. H., Malouf-Sierra, J., Reginster, J.-Y., Wang, A., Wagman, R. B., & Lewiecki, E. M. (2019). Relationship between bone mineral density T-score and nonvertebral fracture risk over 10 years of denosumab treatment. Journal of Bone and Mineral Research, 34, 1033-1040. doi:10.1002/jbmr.3722
Peer Reviewed verified by ORBi

Reginster, J.-Y., Bruyère, O., Conaghan, P. G., McAlindon, T., & Cooper, C. (2019). Importance of safety in the management of osteoarthritis and the need for updated meta-analyses and recommendations for reporting harms. Drugs and Aging, 36 (Suppl 1), 3-6. doi:10.1007/s40266-019-00659-8
Peer Reviewed verified by ORBi

Honvo, G., Reginster, J.-Y., Rannou, F., Rygaert, X., Geerinck, A., Rabenda, V., McAlindon, T., Charles, A., Fuggle, N., Cooper, C., Curtis, E., Arden, N., Avouac, B., & Bruyère, O. (2019). Safety of intra-articular hyaluronic acid injections in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs and Aging, 36 (suppl 1), 101-127. doi:10.1007/s40266-019-00657-w
Peer Reviewed verified by ORBi

de Wit, M., Cooper, C., Reginster, J.-Y., Tugwell, P., Bere, N., Conaghan, P., Roberts, C., Aujoulat, I., Al-Daghri, N., Araujo de Carvalho, I., Barker, M., Bedlington, N., Brandi, M. L., Bruyère, O., Burlet, N., Halbout, P., Hiligsmann, M., Jiwa, F., Kanis, J. A., ... Vlaskovska, M. (2019). Practical guidance for patient-centred health research. The Lancet, 393, 1095-1096. doi:10.1016/S0140-6736(19)30034-0
Peer Reviewed verified by ORBi

Hiligsmann, M., & Reginster, J.-Y. (2019). Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France. Osteoporosis International, 30, 649-658. doi:10.1007/s00198-018-04821-7
Peer Reviewed verified by ORBi

Wani, K. A., Yakout, S. M., Ansari, M. G. A., Sabico, S., Hussain, S. D., Alokail, M. S., Sheshah, E., Aljohani, N. J., Al-Saleh, Y., Reginster, J.-Y., & Al-Daghri, N. M. (2019). Metabolic syndrome in Arab adults with low bone mineral density. Nutrients. doi:10.3390/nu11061405
Peer Reviewed verified by ORBi

Hajaoui, M., Locquet, M., Beaudart, C., Reginster, J.-Y., Petermans, J., & Bruyère, O. (2019). Sarcopenia: Performance of the SARC-F Questionnaire According to the European Consensus Criteria, EWGSOP1 and EWGSOP2 [letter to the editor]. Journal of the American Medical Directors Association, 20 (9), 1182-1183. doi:10.1016/j.jamda.2019.05.021
Peer Reviewed verified by ORBi

Saengnipanthkul, S., Waikakul, S., Rojanasthien, S., Totemchokchyakarn, K., Srinkapaibulaya, A., Cheh Chin, T., Mai Hong, N., Bruyère, O., Cooper, C., Reginster, J.-Y., & Lwin, M. (2019). Differentiation of patented crystalline glucosamine sulfate from other glucosamine preparations will optimize osteoarthritis treatment. International Journal of Rheumatic Diseases, 22 (3), 376-385. doi:10.1111/1756-185X.13068
Peer Reviewed verified by ORBi

Alekna, V., Kilaite, J., Tamulaitiene, M., Geerinck, A., Mastaviciute, A., Bruyère, O., Reginster, J.-Y., & Beaudart, C. (2019). Validation of the Lithuanian version of sarcopenia‑specific quality of life questionnaire (SarQoL®). European Geriatric Medicine, 10, 761-767. doi:10.1007/s41999-019-00208-x
Peer reviewed

Dent, E., Morley, J. E., Cruz-Jentoft, A. J., Woodhouse, L., Rodriguez-Manas, L., Fried, L. P., Woo, J., Aprahamian, I., Sandford, A., Lundy, J., Landi, F., Beilby, J., Martin, F. C., Bauer, J. M., Ferrucci, L., Merchant, R. A., Dong, B., Arai, H., Hoogendijk, E. O., ... Vellas, D. (2019). Physical frailty: ICFSR International Clinical Practice Guidelines for Identification and Management. Journal of Nutrition, Health and Aging, 23 (9), 771-787. doi:10.1007/s12603-019-1273-z
Peer Reviewed verified by ORBi

Diez-Perez, A., Brandi, M. L., AL-Daghri, N., Branco J.C., Bruyère, O., Cavalli, L., Cooper, C., Cortet, B., Dawson-Hughes, B., Dimai, H. P., Gonnelli, S., Hadji, P., Halbout, P., Kaufman, J. M., Kurth, A., Locquet, M., Maggi, S., Matijevic, R., Reginster, J.-Y., ... Thierry, T. (2019). Radiofrequency echographic multi-spectrometry for the in-vivo assessment of bone strength: state of the art—outcomes of an expert consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clinical and Experimental Research, 31 (10), 1375-1389. doi:10.1007/s40520-019-01294-4
Peer Reviewed verified by ORBi

Hilisgmann, M., Williams, S. A., Fitzpatrick, L. A., Silverman, S. S., Weiss, R., & Reginster, J.-Y. (2019). Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture. Seminars in Arthritis and Rheumatism, 49, 184-196. doi:10.1016/j.semarthrit.2019.01.006
Peer Reviewed verified by ORBi

Locquet, M., Beaudart, C., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2019). EWGSOP2 versus EWGSOP1: impact of the prevalence of sarcopenia and its major health consequences. Journal of the American Medical Directors Association, 20 (3), 384-385. doi:10.1016/j.jamda.2018.11.027
Peer Reviewed verified by ORBi

Eymard, F., Parsons, C., Edwards, M. H., Petit-Dop, F., Reginster, J.-Y., Bruyère, O., Chevalier, X., Cooper, C., & Richette, P. (2019). Impact du traitement par statines dans la progression radiologique de la gonarthrose: résultats issus de l'analyse post-hoc de l'essai SEKOIA. Revue du Rhumatisme, 86, 81-86. doi:10.1016/j.rhum.2018.09.002
Peer Reviewed verified by ORBi

Bauer, J. M., Cruz-Jentoft, A. J., Fielding, R. A., Kanis, J. A., Reginster, J.-Y., Bruyère, O., Cesari, M., Chapurlat, R., Al-Daghri, N., Dennison, E., Kaufman, J.-M., Landi, F., Laslop, A., Locquet, M., Maggi, S., McCloskey, E., Perna, S., Rizzoli, R., Rolland, Y., ... Cooper, C. (2019). Correction to: Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review (Calcified Tissue International, (2019), 105, 2, (109-124), 10.1007/s00223-019-00561-w). Calcified Tissue International, 105 (2), 125-126. doi:10.1007/s00223-019-00587-0
Peer Reviewed verified by ORBi

Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (January 2019). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International, 30 (1), 3-44. doi:10.1007/s00198-018-4704-5
Peer Reviewed verified by ORBi

Beaudart, C., Locquet, M., Touvier, M., Reginster, J.-Y., & Bruyère, O. (2019). Association between dietary nutrient intake and sarcopenia in the SarcoPhAge study. Aging Clinical and Experimental Research, 31, 815-824. doi:10.1007/s40520-019-01186-7
Peer Reviewed verified by ORBi

Locquet, M., Beaudart, C., Reginster, J.-Y., & Bruyère, O. (2019). Association between the decline in muscle health and the decline in bone health in older individuals from the SarcoPhAge Cohort. Calcified Tissue International, 104, 273-284. doi:10.1007/s00223-018-0503-4
Peer Reviewed verified by ORBi

Hiligsmann, M., Pinto, D., Dennison, E., Al-Daghri, N., Beaudart, C., Branco, J., Bruyère, O., Conaghan, P. G., Cooper, C., Herrero-Beaumont, G., Jiwa, F., Lems, W., Rizzoli, R., Thomas, T., Veronese, N., & Reginster, J.-Y. (January 2019). Patients’ preferences for osteoarthritis treatment: the value of stated-preference studies. Aging Clinical and Experimental Research, 31 (1), 1-3. doi:10.1007/s40520-018-1098-3
Peer Reviewed verified by ORBi

Parsons, C., Judge, A., Leyland, K., Bruyère, O., Petit Dop, F., Chapurlat, R., Reginster, J.-Y., Edwards, M., Dennison, E., Cooper, C., Inskip, H., & SEKOIA Study Group. (2019). Novel approach to estimate osteoarthritis progression: use of the reliable change index in the evaluation of joint space loss. Arthritis Care and Research, 71 (2), 300-7. doi:10.1002/acr.23596
Peer Reviewed verified by ORBi

Reginster, J.-Y., Bianic, F., Campbell, R., Martin, M., Williams, S. A., & Fitzpatrick, L. A. (2019). Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporosis International. doi:10.1007/s00198-019-04947-2
Peer Reviewed verified by ORBi

Veronese, N., Koyanagi, A., Stubbs, B., Cooper, C., Guglielmi, G., Rizzoli, R., Punzi, L., Rogoli, D., Caruso, M. G., Rotolo, O., Notarnicola, M., Al-Daghri, N. M., Smith, L., Reginster, J.-Y., & Maggi, S. (2019). Mediterranean diet and knee osteoarthritis outcomes: a longitudinal cohort study. Clinical Nutrition. doi:10.1016/j.clnu.2018.11.032
Peer Reviewed verified by ORBi

de Wit, M., Cooper, C., Tugwell, P., Bere, N., Kirwan, J., Conaghan, P. G., Roberts, C., Aujoulat, I., Al-Daghri, N., Araujo de Carvalho, I., Barker, M., Bedlington, N., Brandi, M. L., Bruyère, O., Burlet, N., Halbout, P., Hiligsmann, M., Jiwa, F., Kanis, J. A., ... Reginster, J.-Y. (2019). Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clinical and Experimental Research, 31 (7), 905-915. doi:10.1007/s40520-019-01193-8
Peer Reviewed verified by ORBi

Alkahtani, S. A., Yakout, S. M., Reginster, J.-Y., & Al-Daghri, N. M. (2019). Effect of acute downhill running on bone markers in responders and non-responders. Osteoporosis International. doi:10.1007/s00198-018-4673-8
Peer Reviewed verified by ORBi

Cooper, C., Chapurlat, R., Al-Daghri, N., Herrero-Beaumont, G., Bruyère, O., Rannou, F., Roth, R., Uebelhart, D., & Reginster, J.-Y. (2019). Safety of oral non-selective non-steroidal anti-inflammatory drugs in osteoarthritis: what does the literature say ? Drugs and Aging, 36 (suppl 1), 15-24. doi:10.1007/s40266-019-00660-1
Peer Reviewed verified by ORBi

Honvo, G., Leclercq, V., Geerinck, A., Thomas, T., Veronese, N., Charles, A., Rabenda, V., Beaudart, C., Cooper, C., Reginster, J.-Y., & Bruyère, O. (2019). Safety of topical non-steroidal anti-inflammatory drugs in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs and Aging, 36 (suppl 1), 45-64. doi:10.1007/s40266-019-00661-0
Peer Reviewed verified by ORBi

Honvo, G., Reginster, J.-Y., Rabenda, V., Geerinck, A., Mkinsi, O., Charles, A., Rizzoli, R., Cooper, C., Avouac, B., & Bruyère, O. (2019). Safety of symptomatic slow-acting drugs for osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs and Aging, 36 (suppl 1), 65-99. doi:10.1007/s40266-019-00662-z
Peer Reviewed verified by ORBi

Lorentzon, M., Branco, J. C., Brandi, M. L., Bruyère, O., Chapurlat, R. D., Cooper, C., Cortet, B., Diez-Perez, A. D., Ferrari, S. L., Gasparik, A. I., Herrmann, M., Jorgensen, N. R., Kanis, J. A., Kaufman, J.-M., Laslop, A., Locquet, M., Matijevic, R., McCloskey, E. V., Minisola, S., ... Cavalier, E. (2019). Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis. Advances in Therapy, 36 (10), 2811-2824. doi:10.1007/s12325-019-01063-9
Peer Reviewed verified by ORBi

Hiligsmann, M., Cornelissen, D., Vrijens, B., Abrahamsen, B., Al-Daghri, N., Biver, E., Brandi, M. L., Bruyère, O., Burlet, N., Cooper, C., Cortet, B., Dennison, E., Diez-Perez, A., Gasparik, A., Grosso, A., Hadji, P., Halbout, P., Kanis, J. A., Kaufman, J. M., ... Reginster, J.-Y. (2019). Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). Osteoporosis International, 30 (11), 2155-2165. doi:10.1007/s00198-019-05104-5
Peer Reviewed verified by ORBi

Locquet, M., Beaudart, C., Durieux, N., Reginster, J.-Y., & Bruyère, O. (2019). Relationship between the changes over time of bone mass and muscle health in children and adults: A systematic review and meta-analysis. BMC Musculoskeletal Disorders, 20, 429. doi:10.1186/s12891-019-2752-4
Peer Reviewed verified by ORBi

Charles, A., Buckinx, F., Locquet, M., Reginster, J.-Y., PETERMANS, J., Gruslin, B., & Bruyère, O. (2019). Intrinsic capacity and its association with mortality over 3 years in nursing homes: Results of the SENIOR cohort. Osteoporosis International, 30 (S2), 177-178.
Peer Reviewed verified by ORBi

Geerinck, A., Beaudart, C., Reginster, J.-Y., & Bruyère, O. (2019). Comparison of the psychometric properties of the SarQoL® questionnaire with the EWGSOP and EWGSOP2 criteria for sarcopenia. Osteoporosis International, 30 (S2), 179.
Peer Reviewed verified by ORBi

Veronese, N., & Reginster, J.-Y. (2019). The effects of calorie restriction, intermittent fasting and vegetarian diets on bone health. Aging Clinical and Experimental Research, 31, 753-758. doi:10.1007/s40520-019-01174-x
Peer Reviewed verified by ORBi

Geerinck, A., Beaudart, C., Bautmans, I., Cooper, C., De Souza Orlandi, F., Konstantynowicz, J., Monterro-Errasquin, B., Topinkova, E., Tsekoura, M., Reginster, J.-Y., & Bruyère, O. (13 November 2018). Standard error of measurement and smallest detectable change of the SarQoL questionnaire: an analysis of subjects from 8 validation studies [Poster presentation]. European congress of the International society for Pharmaeconomics and Outcomes Research (ISPOR), Barcelona, Spain.

Geerinck, A., Bruyère, O., Locquet, M., Reginster, J.-Y., & Beaudart, C. (November 2018). Evaluation of the responsiveness of the SarQoL® questionnaire, a patient-reported outcome measure specific to sarcopenia. Advances in Therapy, 35, 1842-1858. doi:10.1007/s12325-018-0820-z
Peer Reviewed verified by ORBi

Geerinck, A., Beaudart, C., Bautmans, I., Cooper, C., De Souza Orlandi, F., Konstantynowicz, J., Monterro-Errasquin, B., Topinkova, E., Tsekoura, M., Reginster, J.-Y., & Bruyère, O. (11 October 2018). Standard error of measurement and smallest detectable change of the SarQoL questionnaire: an analysis of subjects from 8 validation studies [Paper presentation]. 14th International Congress of the European Geriatric Medicine Society, Berlin, Germany.

Reginster, J.-Y., Bianic, F., Campbell, R., Martin, M., Williams, S. A., & Fitzpatrick, L. A. (September 2018). Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Arthritis and Rheumatology, 70 (S9), 2308.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Bruyère, O., & Cooper, C. (July 2018). Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms. Annals of the Rheumatic Diseases, 77 (7), 1-2. doi:10.1136/annrheumdis-2017-212251
Peer Reviewed verified by ORBi

Vellucci, R., Terenzi, R., Kanis, J. A., Kress, H. G., Mediati, R. D., Reginster, J.-Y., Rizzoli, R., & Brandi, M. L. (July 2018). Understanding osteoporotic pain and its pharmacological treatment. Osteoporosis International, 29 (7), 1477-1491. doi:10.1007/s00198-018-4476-y
Peer Reviewed verified by ORBi

GILLAIN, S., Boutaayamou, M., Schwartz, C., WOJTASIK, V., CHRISTELBACH, S., Dardenne, N., Bruls, O., Bruyère, O., Reginster, J.-Y., CROISIER, J.-L., GARRAUX, G., & PETERMANS, J. (June 2018). Dépister les sujets à risque de chute parmi nos aînés robutes: intérêt de la marche rapide [Poster presentation]. Congrès de la CIFGG, Montreux, Switzerland.

Buckinx, F., Bornheim, S., Remy, G., Van Beveren, J., Reginster, J.-Y., Bruyère, O., Dardenne, N., & Kaux, J.-F. (2018). French cross-cultural adaptation and measurement properties of the “ANTERIOR KNEE PAIN SCALE”. In Abstract Book - 21st European Congress of Physical and Rehabilitation Medicine (pp. 399).
Peer reviewed

Charles, A., Buckinx, F., Cataldo, D., Rygaert, X., Reginster, J.-Y., & Bruyère, O. (22 April 2018). Relationship between peak expiratory flow, physical capacity and incidence of frailty among nursing home residents [Poster presentation]. WCO IOF - ESCEO, Cracovie, Poland.

GEERINCK, A., Bruyère, O., Locquet, M., Reginster, J.-Y., & Beaudart, C. (21 April 2018). Evaluation of the responsiveness of a patient-reported outcome measure specific to sarcopenia: the SarQoL questionnaire [Poster presentation]. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, Krakow, Poland.

Buckinx, F., Charles, A., Quabron, A., Van Hees, T., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2018). Impact du statut de fragilité des résidents de maisons de repos sur le coût lié à la consommation de produits pharmaceutiques : résultats de la cohorte SENIOR. Cahiers de l'Année Gérontologique, 15.
Peer Reviewed verified by ORBi

Buckinx, F., Charles, A., Quabron, A., VAN HEES, T., Petermans, J., Reginster, J.-Y., & Bruyère, O. (05 April 2018). Impact of the frailty status on the cost of drugs consumed in nursing homes: results froim the Senior cohort. Osteoporosis International, 29 S1, 356.
Peer Reviewed verified by ORBi

Buckinx, F., Croisier, J.-L., Charles, A., Petermans, J., Reginster, J.-Y., Rygaert, X., & Bruyère, O. (2018). Valeurs normatives de la force isométrique pour 8 groupes musculaires différents et leur valeur predictive de la perte d’autonomie chez les personnes âgées résidant en maison de repos: l’étude SENIOR. Cahiers de l'Année Gérontologique, 28.
Peer Reviewed verified by ORBi

Buckinx, F., Adam, S., Charles, A., Rygaert, X., Reginster, J.-Y., & Bruyère, O. (2018). Agisme en maison de repos : résultats de la cohorte SENIOR. Cahiers de l'Année Gérontologique, 28.
Peer Reviewed verified by ORBi

Charles, A., Buckinx, F., Cataldo, D., Reginster, J.-Y., Rygaert, X., & Bruyère, O. (05 April 2018). Relation entre le débit expiratoire de pointe, les capacités physiques et l’incidence de la fragilité chez les personnes âgées résidant en maison de repos : résultats de la cohorte SENIOR [Paper presentation]. 6ème Congrès Fragilité du Sujet Âgé Le Vieillissement en Santé Prévention de la Perte d'Autonomie, Paris, France.

Rannou, F., Martel-Pelletier, J., Pelletier, J., Mkinsi, O., Branco, J., Alekseeva, L., Monod, P., Planta, F., Maheu, E., & Reginster, J.-Y. (April 2018). A new decision tree for diagnosis and management of osteoarthritis in primary care: international consensus of experts. Osteoporosis International, 29 S1, 509-510.
Peer Reviewed verified by ORBi

Bruyère, O., Curtis, E., Honvo, G., Fuggle, N., Reginster, J.-Y., & Cooper, C. (April 2018). Reassessment of the safety of anti-osteoarthritis medications. Osteoporosis International, 29 S1, 324-325.
Peer Reviewed verified by ORBi

Buckinx, F., Charles, A., Rygaert, X., Reginster, J.-Y., Petermans, J., & Bruyère, O. (April 2018). Dynamic approach of the frailty status in nursing homes: 2-year prospective follow-up of the Senior cohort. Osteoporosis International, 29 S1, 59.
Peer Reviewed verified by ORBi

Veronese, N., Shivappa, N., Hebert, J., Cooper, C., Guglielmi, G., Reginster, J.-Y., Rizzoli, R., & Maggi, S. (April 2018). Pro-inflammatory dietary pattern is associated with fractures in women: an eight year longitudinal cohort study. Osteoporosis International, 29 S1, 64-65.
Peer Reviewed verified by ORBi

Charles, A., Buckinx, F., Cataldo, D., Reginster, J.-Y., Rygaert, X., & Bruyère, O. (April 2018). Relationship between peak expiratory flow, physical capacity and incidence of frailty among nursing home residents. Osteoporosis International, 29 S1, 548.
Peer Reviewed verified by ORBi

Rabenda, V., Leclercq, V., Reginster, J.-Y., & Bruyère, O. (April 2018). Critical appraisal of psychometric methods used in validation of patient-reported outcomes measures. Osteoporosis International, 29 S1, 480-481.
Peer Reviewed verified by ORBi

Honvo, G., Leclercq, V., GEERINCK, A., Rabenda, V., Beaudart, C., Cooper, C., Reginster, J.-Y., & Bruyère, O. (April 2018). Adverse events associated with topical non-steroidal anti-inflammatory drugs (NSAIDS) in osteoarthritis: a systematic review and meta-analysis of randomized, placebo-controlled trials. Osteoporosis International, 29 S1, 550.
Peer Reviewed verified by ORBi

Neuprez, A., Neuprez, A., Maheu, E., Bruyère, O., Kaux, J.-F., & Reginster, J.-Y. (April 2018). Determinants of clinical and radiological progression of hand osteoarthritis over 2 years. Osteoporosis International, 29 S1, 438.
Peer Reviewed verified by ORBi

Hiligsmann, M., Williams, S. A., Fitzpatrick, L. A., & Reginster, J.-Y. (April 2018). Cost-effectiveness of abaloparatide for the treatment of postmenopausal women with osteoporosis. Osteoporosis International, 29 S1, 43-44.
Peer Reviewed verified by ORBi

Cooper, C., Reginster, J.-Y., & Belissa-Mathiot, P. (April 2018). EE joint replacement in patients with knee osteoarthritis: a long tem follow-up study in patients of the CL3-12911-018 study. Osteoporosis International, 29 S1, 251.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (April 2018). Dairy products in the prevention and treatment of sarcopenia: outcomes of the ESCEO working groups. Osteoporosis International, 29 S1, 78.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (April 2018). Safety of anti-osteoarthtritis medications: results of ESCEO 2017 working groups. Osteoporosis International, 29 S1, 555.
Peer Reviewed verified by ORBi

Neuprez, A., Neuprez, A., KAUX, J.-F., KURTH, W., DANIEL, C., THIRION, T., HUSKIN, J.-P., Gillet, P., Bruyère, O., & Reginster, J.-Y. (April 2018). Early Clinically Relevant Improvement in Quality of Life and Clinical Outcomes 1 Year Postsurgery in Patients with Knee and Hip Joint Arthroplasties. Cartilage, 9 (2), 127-139. doi:10.1177/1947603517743000
Peer Reviewed verified by ORBi

Konstantynowicz, J., Abramowicz, P., Glinkowski, W., Taranta, E., Marcinowicz, L., Reginster, J.-Y., Bruyère, O., & Beaudart, C. (April 2018). The polish validation of the Sarquol®, a quality of life questionnaire specific for sarcopenia: the evidence of a good utility. Osteoporosis International, 29 S1, 541-542.
Peer Reviewed verified by ORBi

Ferrari, S., McCloskey, E., Bouxsein, M., De Schepper, J., & Reginster, J.-Y. (April 2018). AGN1 local osteo-enhancement procedure (LOEP): an emerging, minimally-invasive surgical treatment to address osteoporosis-related bone loss in proximal femurs. Osteoporosis International, 29 S1, 555-556.
Peer Reviewed verified by ORBi

Rabenda, V., Leclercq, V., Reginster, J.-Y., & Bruyère, O. (April 2018). Review of terminology of measurement properties for patient-reported outcomes measures. Osteoporosis International, 29 S1, 482.
Peer Reviewed verified by ORBi

Locquet, M., Beaudart, C., Reginster, J.-Y., Petermans, J., & Bruyère, O. (April 2018). Three-year adverse health consequences of sarcopenia in community-dwelling older adults: Results from the SarcoPhAge cohort study. Osteoporosis International, 29 S1, 60-61.
Peer Reviewed verified by ORBi

Locquet, M., Beaudart, C., Reginster, J.-Y., Hajaoui, M., & Bruyère, O. (April 2018). Association between decline in muscle health and bone health in older individuals fom the SarcoPhAge cohort. Osteoporosis International, 29 S1, 212.
Peer Reviewed verified by ORBi

Beaudart, C., Locquet, M., Touvier, M., Reginster, J.-Y., & Bruyère, O. (April 2018). Association between dietary nutrient intake and sarcopenia: the SarcoPhAge cohort study. Osteoporosis International, 29 S1, 57.
Peer Reviewed verified by ORBi

Buckinx, F., Charles, A., Rygaert, X., Reginster, J.-Y., Adam, S., & Bruyère, O. (April 2018). Own attitude regarding aging among nursing home residents: results of the Senior cohort. Osteoporosis International, 29 S1, 357.
Peer Reviewed verified by ORBi

Hiligsmann, M., Williams, S. A., Fitzpatrick, L. A., Silverman, S., Weiss, R., & Reginster, J.-Y. (April 2018). Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for the prevention of osteoporotic fractures in postmenopausal women at increased risk of fracture. Osteoporosis International, 29 S1, 302.
Peer Reviewed verified by ORBi

GEERINCK, A., Bruyère, O., Locquet, M., Reginster, J.-Y., & Beaudart, C. (April 2018). Evaluation of the responsiveness of the SARQOL® questionnaire: results from the SarcoPhAge study. Osteoporosis International, 29 S1, 300.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Bianic, F., Campbell, R., Martin, M., Williams, S. A., & Fitzpatrick, L. A. (April 2018). Abaloparatide for risk reduction of non-vertebral fractures in postmenopausal women with osteoporosis: an updated network meta-analysis. Osteoporosis International, 29 S1, 42. doi:10.1007/s00198-018-4470-4
Peer Reviewed verified by ORBi

Honvo, G., Rabenda, V., GEERINCK, A., Cooper, C., Reginster, J.-Y., & Bruyère, O. (April 2018). Adverse events associated with symptomatic slow-acting drugs in osteoarthritis (SYSADOAS): a systematic review and stratified meta-analysis of randomized, placebo-controlled trials. Osteoporosis International, 29 S1, 549-550.
Peer Reviewed verified by ORBi

Beaudart, C., Bruyère, O., Reginster, J.-Y., Bauer, J., Cooper, C., Cruz-Jentoft, A., Landi, F., Locquet, M., Maggi, S., Rizzoli, R., Rolland, Y., Vaquero, N., & Hiligsmann, M. (April 2018). Patient’s engagement in the identification of critical outcomes in sarcopenia. Osteoporosis International, 29 S1, 299.
Peer Reviewed verified by ORBi

Felsenberg, D., Chapurlat, R., Rizzoli, R., Reginster, J.-Y., & Belissa-Mathiot, P. (April 2018). A 24 months prospective, randomized, double-blind study to assess the effect of daily oral administration of 2g of strontium ranelate vs placebp on BMD in postmenpausal. Osteoporosis International, 29 S1, 250-251.
Peer Reviewed verified by ORBi

Veronese, N., Maggi, S., Cooper, C., & Reginster, J.-Y. (April 2018). Statins and incident knee osteoarthritis: results from the osteoarthritis initiative. Osteoporosis International, 29 S1, 328.
Peer Reviewed verified by ORBi

Locquet, M., Beaudart, C., Reginster, J.-Y., & Bruyère, O. (April 2018). Consequences of relevant muscle function decline over 1 year in older individuals living in the community: results from the SarcoPhAge study. Osteoporosis International, 29 S1, 339.
Peer Reviewed verified by ORBi

Locquet, M., Beaudart, C., Reginster, J.-Y., & Bruyère, O. (April 2018). Determinants of rapid muscle function declines over 1 year in community-dwelling older adults: the SarcoPhAge study. Osteoporosis International, 29 S1, 339-340.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Arden, N. K., Haugen, I., Rannou, F., Cavalier, E., Bruyère, O., Branco, J., Chapurlat, R., Basset, S., Al-Daghri, N., Dennison, E., Herrero-Beaumont, G., Laslop, A., Leeb, B., Maggi, S., Mkinsi, O., Povzun, A., Prieto-Alhambra, D., Thomas, T., ... Cooper, C. (April 2018). Guidelines for the conduct of pharmacological clinical trials in hand osteoarthritis: consensus of a working group of the ESCEO. Osteoporosis International, 29 (Suppl1), 71-2.
Peer Reviewed verified by ORBi

Hiligsmann, M., Fardellone, P., & Reginster, J.-Y. (2018). Promouvoir la consommation de produits laitiers pour prévenir les fractures: un investissement rentable. Revue du Rhumatisme (Edition Francaise), 85 (3), 220-221. doi:10.1016/j.rhum.2018.01.001
Peer reviewed

Beaudart, C., Locquet, M., Reginster, J.-Y., Delandsheere, L., Petermans, J., & Bruyère, O. (2018). Quality of life in sarcopenia measured with the SarQoL®: impact of the use of different diagnosis definitions. Aging Clinical and Experimental Research, 30, 307-313. doi:10.1007/s40520-017-0866-9
Peer Reviewed verified by ORBi

Vellas, B., Fielding, R. A., Bens, C., Bernabei, R., Cawthon, P. M., Cederholm, T., Cruz-Jentoft, A. J., Del Signore, S., Donahue, S., Morley, J., Pahor, M., Reginster, J.-Y., Rodriguez Manas, L., Rolland, Y., Roubenoff, R., Sinclair, A., & Cesari, M. (2018). Implications of ICD-10 for Sarcopenia Clinical Practice and Clinical Trials: Report by the International Conference on Frailty and Sarcopenia Research Task Force. Journal of Frailty and Aging, 7 (1), 2-9. doi:10.14283/jfa.2017.30
Peer Reviewed verified by ORBi

Reginster, J.-Y., Arden, N. K., Haugen, I. K., Rannou, F., Cavalier, E., Bruyère, O., Branco, J., Chapurlat, R., Collaud Basset, S., Al-Daghri, N. M., Dennison, E. M., Herrero-Beaumont, G., Laslop, A., Leeb, B. F., Maggi, S., Mkinsi, O., Povzun, A. S., Prieto-Alhambra, D., Thomas, T., ... Cooper, C. (2018). Guidelines for the conduct of pharmacological clinical trials in hand osteoarthritis: Consensus of a Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Seminars in Arthritis and Rheumatism, 48, 1-8. doi:10.1016/j.semarthrit.2017.12.003
Peer Reviewed verified by ORBi

Marcucci, G., Masi, L., Ferrari, S., Haffner, D., Javaid, M. K., Kamenicky, P., Reginster, J.-Y., Rizzoli, R., & Brandi, M. L. (2018). Phosphate wasting disorders in adults. Osteoporosis International, 29, 2369-2387. doi:10.1007/s00198-018-4618-2
Peer Reviewed verified by ORBi

Buckinx, F., Bruyère, O., Reginster, J.-Y., Charles, A., DELANAYE, P., & CAVALIER, E. (2018). Plasma Klotho and Mortality Risk Among Nursing Home Residents: Results From the SENIOR Cohort [letter to the editor]. Journal of the American Medical Directors Association, 19 (12), 1139-1140. doi:10.1016/j.jamda.2018.08.010
Peer Reviewed verified by ORBi

Locquet, M., Beaudart, C., Bruyère, O., Kanis, J. A., Delandsheere, L., & Reginster, J.-Y. (2018). Bone health assessment in older people with or without muscle health impairment. Osteoporosis International, 29, 1057-1067. doi:10.1007/s00198-018-4384-1
Peer Reviewed verified by ORBi

Slomian, J., Vigneron, L., EMONTS, P., Reginster, J.-Y., & Bruyère, O. (2018). Evaluation du site internet Happy-Mums.be conçu en vue de tenter d’aider les mères à combler leurs besoins en période postnatale [Poster presentation]. 46ème Assises Nationales des Sages-Femmes, Marseille, France.

Robinson, S. M., Reginster, J.-Y., Rizzoli, R., Shaw, S. C., Kanis, J. A., Bautmans, I., Bischoff-Ferrari, H., Bruyère, O., Cesari, M., Dawson-Hughes, B., Fielding, R. A., Kaufman, J. M., Landi, F., Malafarina, V., Rolland, Y., Van Loon, L. J., Vellas, B., Visser, M., & Cooper, C. (2018). Does nutrition play a role in the prevention and management of sarcopenia? Clinical Nutrition, 37, 1121-1132. doi:10.1016/j.clnu.2017.08.016
Peer Reviewed verified by ORBi

Buckinx, F., Landi, F., Cesari, F., Fielding, R. A., Visser, M., Engelke, K., Maggi, S., Dennison, E., Al-daghri, N. M., ALLEPAERTS, S., Bauer, J., Bautmans, I., Brandi, M. L., Bruyère, O., Cederholm, T., Cerrata, F., Cherubini, A., Cooper, C., Cruz-Jentoft, A., ... Kanis, J. A. (2018). Pitfalls in the measurement of muscle mass; a need for a reference standard. Journal of Cachexia, Sarcopenia and Muscle, 9, 269-278. doi:10.1002/jcsm.12268
Peer Reviewed verified by ORBi

Beaudart, C., Rabenda, V., Simmons, M., Geerinck, A., Araujo De Carvalho, I., Reginster, J.-Y., Amuthavalli Thiyagarajan, J., & Bruyère, O. (2018). Effects of protein, essential amino acids, B-Hydroxy B-Methylbutyrate, creatine, Dehydroepiandrosterone and fatty acid supplementation on muscle mass, muscle strength and physical performance in older people aged 60 years and over. A systematic review of the litterature. Journal of Nutrition, Health and Aging, 22 (1), 117-130. doi:10.1007/s12603-017-0934-z
Peer Reviewed verified by ORBi

Beaudart, C., Biver, E., Bruyère, O., Cooper, C., Al-Daghri, N., Reginster, J.-Y., & Rizzoli, R. (2018). Quality of life assessment in musculo-skeletal health. Aging Clinical and Experimental Research, 30 (5), 413-418. doi:10.1007/s40520-017-0794-8
Peer Reviewed verified by ORBi

Buckinx, F., Landi, F., Cesari, M., Fielding, R., Visser, M., Engelke, K., Maggi, S., Dennison, E., Al-Daghri, N., ALLEPAERTS, S., Bauer, J., Bautmans, I., Brandi, M.-L., Bruyère, O., Cederholm, T., Cerreta, F., Cherubini, A., Cooper, C., Cruz-Jentoft, A., ... Kanis, J. (2018). The authors reply: Letter on: "Pitfalls in the measurement of muscle mass: a need for a reference standard" by Clark et al. Journal of Cachexia, Sarcopenia and Muscle, 9 (7), 1272-1274. doi:10.1002/jcsm.12387
Peer Reviewed verified by ORBi

Buckinx, F., Landi, F., Cesari, M., Fielding, R. A., Visser, M., Engelke, K., Maggi, S., Dennison, E., Al-Daghri, N. M., ALLEPAERTS, S., Bauer, J., Bautmans, I., Brandi, M. L., Bruyère, O., Cederholm, T., Cerreta, F., Cherubini, A., Cooper, C., Cruz-Jentoft, A., ... Kanis, J. A. (2018). The authors reply: Dual energy X-ray absorptiometry: gold standard for muscle mass ? by Scafoglieri et al. Journal of Cachexia, Sarcopenia and Muscle, 9, 788-790. doi:10.1002/jcsm.12329
Peer Reviewed verified by ORBi

Gasparik, A. I., Mihai, G., Beaudart, C., Bruyère, O., Pop, R.-M., Reginster, J.-Y., & Pascanu, I. M. (2018). Correction to: Psychometric performance of the Romanian version of the SarQoL®, a health-related quality of life questionnaire for sarcopenia (Archives of Osteoporosis, (2017), 12, 1, (103), 10.1007/s11657-017-0397-1). Archives of Osteoporosis, 13 (1), 98. doi:10.1007/s11657-018-0516-7
Peer Reviewed verified by ORBi

Locquet, M., Beaudart, C., Delandsheere, L., Reginster, J.-Y., & Bruyère, O. (2018). Subjective sleep quality among sarcopenic and non-sarcopenic older adults - results from the SarcoPhAge Cohort. Journal of Frailty and Aging, 7, 176-181. doi:10.14283/jfa.2018.13
Peer Reviewed verified by ORBi

Vellucci, R., Terenzi, R., Kanis, J. A., Kress, H. G., Mediati, R. D., Reginster, J.-Y., Rizzoli, R., & Brandi, M. L. (2018). Understanding osteoporotic pain and its pharmacological treatment: supplementary presentation. Osteoporosis International, 29, 2153-2154. doi:10.1007/s00198-018-4536-3
Peer Reviewed verified by ORBi

GILLAIN, S., Boutaayamou, M., Beaudart, C., DEMONCEAU, M., Bruyère, O., Reginster, J.-Y., Garraux, G., & PETERMANS, J. (2018). Assessing gait parameters with accelerometer-based methods to identify older adults at risk of falls: a systematic review. European Geriatric Medicine, 9, 435-448. doi:10.1007/s41999-018-0061-3
Peer reviewed

Veronese, N., Stubbs, B., Solmi, M., Smith, T. O., Reginster, J.-Y., & Maggi, S. (2018). Osteoarthritis increases the risk of cardiovascular disease: Data from the osteoarthritis initiative. Journal of Nutrition, Health and Aging, 22 (3), 371-376. doi:10.1007/s12603-017-0941-0
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2018). CONCEPT provides robust evidence that chondroitin sulfate is superior to placebo and similar to celecoxib in the symptomatic management of osteoarthritis. Annals of the Rheumatic Diseases, 77 (2), 1-2. doi:10.1136/annrheumdis-2017-212115
Peer Reviewed verified by ORBi

Buckinx, F., Croisier, J.-L., Reginster, J.-Y., Lenaerts, C., Brunois, T., Rygaert, X., PETERMANS, J., & Bruyère, O. (2018). Prediction of the Incidence of Falls and Deaths Among Elderly Nursing Home Residents: The SENIOR Study. Journal of the American Medical Directors Association, 19 (1), 18-24. doi:10.1016/j.jamda.2017.06.014
Peer Reviewed verified by ORBi

Neuprez, A., Neuprez, A., KURTH, W., Gillet, P., Bruyère, O., & Reginster, J.-Y. (2018). Profile of osteoarthritic patients undergoing hip or knee arthroplasty, a step toward a definition of the “need for surgery”. Aging Clinical and Experimental Research, 30, 315-321. doi:10.1007/s40520-017-0780-1
Peer Reviewed verified by ORBi

Rizzoli, R., Biver, E., Bonjour, J. P., Coxam, V., Goltzam, D., Kanis, J. A., Lappe, J., Rejnmark, L., Sahni, S., Weaver, C., Weiler, H., & Reginster, J.-Y. (2018). Benefits and safety of dietary protein for bone health- an expert consensus paper endorsed by the European Society for Clinical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases and by the International Osteoporosis Foundation. Osteoporosis International, 29, 1933-1948. doi:10.1007/s00198-018-4534-5
Peer Reviewed verified by ORBi

Hiligsmann, M., & Reginster, J.-Y. (2018). The projected public health and economic impact of vitamin D fortified dairy products for fracture prevention in France. Expert Review of Pharmacoeconomics and Outcomes Research, 18, 191-195. doi:10.1080/14737167.2017.1375406
Peer Reviewed verified by ORBi

Veronese, N., Stubbs, B., Koyanagi, A., Hebert, J., Cooper, C., Caruso, M., Guglielmi, G., Reginster, J.-Y., Rizzoli, R., Maggi, S., & Shivappa, N. (2018). Pro-inflammatory dietary pattern is associated with fractures in women: an eight-year longitudinal cohort study. Osteoporosis International, 29 (1), 143-151. doi:10.1007/s00198-017-4251-5
Peer Reviewed verified by ORBi

Cesari, M., Araujo de Carvalho, I., Amuthavalli Thiyagarajan, J., Cooper, C., Martin, F. C., Reginster, J.-Y., Vellas, B., & Beard, J. R. (2018). Evidence for the domains supporting the construct of intrinsic capacity. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 73 (12), 1653-1660. doi:10.1093/Gerona/gly011
Peer Reviewed verified by ORBi

Buckinx, F., Charles, A., Rygaert, X., Reginster, J.-Y., Adam, S.* , & Bruyère, O.*. (2018). Own attitude toward aging among nursing home residents: results of the SENIOR cohort. Aging Clinical and Experimental Research, 10, 1151-1159. doi:10.1007/s40520-018-1013-y
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Locquet, M., Beaudart, C., Reginster, J.-Y., PETERMANS, J., & Bruyère, O. (2018). Comparison of the performance of five screening methods for sarcopenia. Clinical Epidemiology, 10, 71-82. doi:10.2147/CLEP.S148638
Peer Reviewed verified by ORBi

Beaudart, C., Locquet, M., Bornheim, S., Reginster, J.-Y., & Bruyère, O. (2018). French translation and validation of the sarcopenia screening tool SARC-F. European Geriatric Medicine, 9, 29-37. doi:10.1007/s41999-017-0007-1
Peer reviewed

Bruyère, O., Cooper, C., Al-Daghri, N., Dennison, E. M., Rizzoli, R., & Reginster, J.-Y. (2018). Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clinical and Experimental Research, 30, 111-117. doi:10.1007/s40520-017-0861-1
Peer Reviewed verified by ORBi

Dierks, R. M. L., Bruyère, O., & Reginster, J.-Y. (2018). Critical analysis of valuation and strategical orientation of merger and acquisition deals in the pharmaceutical industry. Expert Review of Pharmacoeconomics and Outcomes Research, 18 (2), 147-60. doi:10.1080/14737167.2018.1417040
Peer Reviewed verified by ORBi

Reginster, J.-Y., Hattersley, G., Williams, G., Hu, M. Y., Fitzpatrick, L. A., & Lewiecki, E. M. (2018). Abaloparatide is an effective treatment option for postmenopausal osteoporosis: review of the number needed to treat compared with teriparatide. Calcified Tissue International, 103, 540-545. doi:10.1007/s00223-018-0450-0
Peer Reviewed verified by ORBi

Malafarina, V., Reginster, J.-Y., Cabrerizo, S., Bruyère, O., Kanis, J. A., Martinez, J. A., & Zulet, M. A. (2018). Nutritional status and nutritional treatment are related to outcomes and mortality in older adults with hip fracture. Nutrients, 10, 555. doi:10.3390/nu10050555
Peer Reviewed verified by ORBi

Slomian, J., Vigneron, L., EMONTS, P., Reginster, J.-Y., & Bruyère, O. (2018). The "Happy Mums" website dedicated to the perinatal period: evaluation of its acceptability by parents and professionals. Midwifery, 66, 17-24. doi:10.1016/j.midw.2018.07.009
Peer Reviewed verified by ORBi

Hiligsmann, M., Fardellone, P., & Reginster, J.-Y. (2018). Promoting the consumption of dairy products for fracture prevention: A good value for money? Joint Bone Spine, 85, 403-404. doi:10.1016/j.jbspin.2017.11.009
Peer Reviewed verified by ORBi

Veronese, N., Punzi, L., Sieber, C., Bauer, J., Reginster, J.-Y., Maggi, S., & On behalf of theTask Finish Group on Arthritis of the European Geriatric Medicine Society. (2018). Sarcopenic osteoarthritis: a new entity in geriatric medicine? European Geriatric Medicine, 9 (2), 141-148. doi:10.1007/s41999-018-0034-6
Peer reviewed

Bahat, G., Yilmaz, O., Merve Oren, M., Akif Karan, M., Reginster, J.-Y., Bruyère, O., & Beaudart, C. (2018). Cross-cultural adaptation and validation of the SARC-F to assess sarcopenia: methodological report from European Union Geriatric Medicine Society Sarcopenia Special Interest Group. European Geriatric Medicine, 9, 23-28. doi:10.1007/s41999-017-0003-5
Peer reviewed

Eymard, F., Parsons, C., Edwards, M. H., Petit-Dop, F., Reginster, J.-Y., Bruyère, O., Chevalier, X., Cooper, C., & Richette, P. (2018). Statin use and knee osteoarthritis progression: Results from a post-hoc analysis of the SEKOIA trial. Joint Bone Spine, 85 (5), 609-614. doi:10.1016/j.jbspin.2017.09.014
Peer Reviewed verified by ORBi

Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2018). Review of the guideline of the American College of Physicians on the treatment of osteoporosis. Osteoporosis International, 29, 1505-1510. doi:10.1007/s00198-018-4504-y
Peer Reviewed verified by ORBi

Konstantynowicz, J., Abramowicz, P., Glinkowski, W., Taranta, E., Marcinowicz, L., Dymitrowicz, M., Reginster, J.-Y., Bruyère, O., & Beaudart, C. (2018). Polish Validation of the SarQoL®, a Quality of Life Questionnaire Specific to Sarcopenia. Journal of Clinical Medicine, 7, 323-332. doi:10.3390/jcm7100323
Peer Reviewed verified by ORBi

Mavungu Landu, D. J., Frederich, M., Hubert, P., Manzambi Kuwekita, J., Reginster, J.-Y., Michel, B., Gretry, L., Mbongo Pasi, C., Mavungu Nsiona, J., Mbinze, J., & Marini Djang'Eing'A, R. (23 November 2017). Consommation des médicaments antipaludiques : Analyse des échantillons et caractéristiques des pharmacies en territoires périurbains de Kinshasa [Paper presentation]. Premier Congrès sur la Gestion Intégrée du Risque Sanitaire (COGIRS I), Kinshasa, Congo - Kinshasa.

Mavungu Landu, D. J., Mbuyi Kaluka Tshibanda, J., Dasnoy, C., Gretry, L., Mikobi Mikobi, C., Kayembe, J. M., Longo Mbenza, B., Marini Djang'Eing'A, R., Hubert, P., Reginster, J.-Y., Michel, B., Manzambi Kuwekita, J., Jansen, O., & Frederich, M. (10 November 2017). Processus d’intégration de la Médecine traditionnelle dans le système national de soins de la République Démocratique du Congo : Cas de trois zones de santé de Kinshasa [Paper presentation]. Médecines en Afrique, entre tradition et modernité, Liège, Belgium.

Mavungu Landu, D. J., Mikobi Mikobi, C., Beya, R., Pipo Tshiasuma, M., Kayembe, J. M., Gretry, L., Marini Djang'Eing'A, R., Hubert, P., Reginster, J.-Y., Michel, B., Manzambi Kuwekita, J., & Frederich, M. (10 November 2017). Expérience de l’intégration des cours de Médecine traditionnelle dans la Faculté de Médecine de l’Université Notre-Dame du Kasayi à Kananga [Paper presentation]. Médecines en Afrique, entre tradition et modernité, Liège, Belgium.

Mavungu Landu, D. J., Liégeois, S., Manzambi Kuwekita, J., Mbinze Kindenge, J., Mavungu Nsiona, J., Hubert, P., Michel, B., Reginster, J.-Y., Frederich, M., Marini Djang'Eing'A, R., & Gretry, L. (13 October 2017). The quality of artemether-lumefantrine combination and characteristics of pharmacies in the periurban areas of kinshasa (Kwete Minga, M., Trans.). Tropical Medicine and International Health, 22 (1), 76.
Peer Reviewed verified by ORBi

Tordrup, D., Chouaid, C., Cuijpers, P., Dab, W., van Dongen, J. M., Espin, J., Jönsson, B., Léonard, C., McDaid, D., McKee, M., Pereira Miguel, J., Patel, A., Reginster, J.-Y., Ricciardi, W., Rutten-Van Molken, Prevolnik Rupel, V., Sach, T., Sassi, F., Vaugh, N., & Bertollini, R. (2017). Priorities for health economic methodological research: results of an expert consultation. International Journal of Technology Assessment in Health Care, 1-11. doi:10.1017/S0266462317000666
Peer Reviewed verified by ORBi

Reginster, J.-Y. (September 2017). Chondroitin sulfate reduces pain and improves function in knee osteoarthritis significantly better than placebo, independently of the definition of responders. Arthritis and Rheumatism, 69S10, 1675.
Peer Reviewed verified by ORBi

Buckinx, F., Reginster, J.-Y., Morelle, A., Paquot, N., Labeye, N., Locquet, M., Adam, S.* , & Bruyère, O.*. (04 July 2017). Influence of environmental factors on food intake among nursing home residents: a survey combined with a video approach. Clinical Interventions in Aging, 12, 1055-1064. doi:10.2147/CIA.S135937
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Kanis, J. A., Cooper, C., Rizzoli, R., Abrahamsen, B., Al-Daghri, N. M., BRANDI, M. L., CANNATA-ANDIA, J., Cortet, B., Dimai, H. P., Ferrari, S., Hadji, P., Harvey, N. C., Kraezlin, M., Kurth, A., McCloskey, E., Minisola, S., Thomas, T., & Reginster, J.-Y. (July 2017). Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporosis International, 28 (7), 2023-2034. doi:10.1007/s00198-017-4009-0
Peer Reviewed verified by ORBi

Bone, H. G., Wagman, R. B., Brandi, M. L., Brown, J. P., Chapurlat, R., Cummings, S. R., Czerwiski, E., Fahrleitner-Pammer, A., Kendler, D. L., Lippuner, K., Reginster, J.-Y., Roux, C., Malouf, J., Bradley, N. M., Daizadeh, N. S., Wang, A., Dakin, P., Pannacciulli, N., Dempster, D. W., & Papapopoulos, S. (July 2017). 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. The Lancet Diabetes and Endocrinology, 5, 513-523. doi:10.1016/S2213-8587(17)30138-9
Peer Reviewed verified by ORBi

Slomian, J., Bruyère, O., Reginster, J.-Y., & Emonts, P. (May 2017). The internet as a source of information used by women after childbirth to meet their need for information: A web-based survey. Midwifery, 48, 46-52. doi:10.1016/j.midw.2017.03.005
Peer Reviewed verified by ORBi

Cianferotti, L., Bertoldo, F., Bischoff-Ferrari, H., Bruyère, O., Cooper, C., Cutolo, M., Kanis, J. A., Kaufman, J.-M., Reginster, J.-Y., Rizzoli, R., & Brandi, M. L. (April 2017). Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: research for evidence and a scientific statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO). Endocrine, 56 (2), 245-61. doi:10.1007/s12020-017-1290-9
Peer Reviewed verified by ORBi

Reginster, J.-Y., Dudler, J., Blicharski, T., Pavelka, K., & Lanzarotti, A. (March 2017). Pharmaceutical-grade chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the chondroitin vs celecoxib vs placebo trial (CONCEPT). Osteoporosis International, 28 Suppl 1, 56.
Peer Reviewed verified by ORBi

Locquet, M., Beaudart, C., Delandsheere, L., Reginster, J.-Y., Kanis, J. A., & Bruyère, O. (March 2017). Bone quality assessment among sarcopenic and non sarcopenic elderly subjects from the SarcoPhAge Study. Osteoporosis International, 28 Suppl 1, 206-207.
Peer Reviewed verified by ORBi

Beaudart, C., Locquet, M., Reginster, J.-Y., PETERMANS, J., & Bruyère, O. (March 2017). The SarcoPhAge study: evolution of sarcopenic subjects after 2 years of follow-up. Osteoporosis International, 28 Suppl 1, 208.
Peer Reviewed verified by ORBi

Beaudart, C., Dawson, A., Shaw, S. C., Harvey, N. C., Kanis, J. A., Binkley, N., Reginster, J.-Y., Chapurlat, R., Chan, D. C., Bruyère, O., Rizzoli, R., Cooper, C., & Dennison, E. M. (March 2017). Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. Osteoporosis International, 28 (6), 1817-33. doi:10.1007/s00198-017-3980-9
Peer Reviewed verified by ORBi

Beaudart, C., Edwards, M., Moss, C., Reginster, J.-Y., Moon, R., Parsons, C., DEMOULIN, C., Rizzoli, R., Biver, E., Dennison, E., Bruyère, O., & Cooper, C. (March 2017). English translation and validation of the SarQoL®, a quality of life questionnaire specific for sarcopenia. Age and Ageing, 46 (2), 271-7. doi:10.1093/ageing/afw192
Peer Reviewed verified by ORBi

Buckinx, F., Lenaerts, C., Brunois, T., Rygaert, X., Reginster, J.-Y., PETERMANS, J., & Bruyère, O. (March 2017). Interest of 10 current definitions of frailty to predict the incidence of falls and deaths among elderly nursing home residents. Osteoporosis International, 28 Suppl 1, 69.
Peer Reviewed verified by ORBi

Locquet, M., Beaudart, C., Delandsheere, L., Reginster, J.-Y., & Bruyère, O. (March 2017). Sensitivity and specificity of the sarc-F questionnaire according to different definitions of sarcopenia: results from the SarchoPhAge study. Osteoporosis International, 28 Suppl 1, 201.
Peer Reviewed verified by ORBi

CAVALIER, E., Reginster, J.-Y., & DELANAYE, P. (March 2017). Impact of the renal function on sclerostin determination: illustration with four different ELISA methods in patients undergoing GFR determination with Iohexol. Osteoporosis International, 28 Suppl 1, 629.
Peer Reviewed verified by ORBi

Neuprez, A., KURTH, W., GILLET, P., Bruyère, O., & Reginster, J.-Y. (March 2017). Profile of osteoarthritic patients undergoing total hip and knee arthroplasty. Osteoporosis International, 28 Suppl 1, 252.
Peer Reviewed verified by ORBi

CAVALIER, E., & Reginster, J.-Y. (March 2017). Biomarkers of osteoarthritis : practical considerations. Osteoporosis International, 28 Suppl 1, 625-626.
Peer Reviewed verified by ORBi

Buckinx, F., Reginster, J.-Y., Beaudart, C., Brunois, T., Lenaerts, C., Croisier, J.-L., PETERMANS, J., & Bruyère, O. (March 2017). Sarcopenia in nursing home residents: the senior cohort. Osteoporosis International, 28 Suppl 1, 123-124.
Peer Reviewed verified by ORBi

Locquet, M., Beaudart, C., Delandsheere, L., Reginster, J.-Y., & Bruyère, O. (March 2017). Subjective sleep quality in sarcopenic vs non-sarcopenic older adults from the sarcophage cohort. Osteoporosis International, 28 Suppl 1, 173-174.
Peer Reviewed verified by ORBi

Hiligsmann, M., Burlet, N., Fardellone, P., Al-Daghri, N., & Reginster, J.-Y. (March 2017). Public health and economic impact of vitamin D-fortified dairy products for fracture prevention in France. Osteoporosis International, 28 Suppl 1, 71-72.
Peer Reviewed verified by ORBi

Ethgen, O., Beaudart, C., Buckinx, F., Bruyère, O., & Reginster, J.-Y. (March 2017). The Future Prevalence of Sarcopenia in Europe: A Claim for Public Health Action. Calcified Tissue International, 100 (3), 229-234. doi:10.1007/s00223-016-0220-9
Peer Reviewed verified by ORBi

DIEZ-PEREZ, A., NAYLOR, K. E., ABRAHAMSEN, B., AGNUSDEI, D., Brandi, M. L., COOPER, C., DENNISON, E., ERIKSEN, E. F., GOLD, D. T., GUANABENS, N., HADJI, P., HILIGSMANN, M., HORNE, R., JOSSE, R., KANIS, J. A., OBERMAYER-PIETSCH, B., PRIETO-ALHAMBRA, D., Reginster, J.-Y., Rizzoli, R., ... EASTELL, R. (March 2017). International Osteoporosis Foundation and European Calcified Tissue Society working group. Recommendations for the screening of the adherence to oral bisphosphonates. Osteoporosis International, 28 (3), 767-774. doi:10.1007/s00198-017-3906-6
Peer Reviewed verified by ORBi

HILIGSMANN, M., BURLET, N., FARDELLONE, P., AL-DAGHRI, N., & Reginster, J.-Y. (March 2017). Public Health impact and economic evaluation of vitamin D-fortified dairy products for fracture prevention in France. Osteoporosis International, 28 (3), 833-840. doi:10.1007/s00198-016-3786-1
Peer Reviewed verified by ORBi

Kendler, D. L., Chines, A., Brandi, M. L., Papapoulos, S., Lewiecki, E. M., Reginster, J.-Y., Roux, C., Munos-Torres, M., Wang, A., & Bone, H. G. (March 2017). The risk of subsequent osteoporotic fractures is decreased in patients experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies. Osteoporosis International, 28 Suppl 1, 174-175.
Peer Reviewed verified by ORBi

HADJI, P., Aapro, M. S., BODY, J. J., GNANT, M., BRANDI, M. L., Reginster, J.-Y., ZILLIKENS, M. C., GLÜER, C. C., de VILLIERS, T., BABER, R., ROODMAN, G. D., COOPER, C., LANGDAHL, B., PALACIOS, S., KANIS, J., AL-DAGHRI, N., NOGUES, X., FINK ERIKSEN, E., KURTH, A., ... COLEMAN, R. E. (March 2017). Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS and SIOG. Journal of Bone Oncology, 23 (7), 1-12. doi:10.1016/j.jbo.2017.03.001
Peer Reviewed verified by ORBi

Buckinx, F., Reginster, J.-Y., Beaudart, C., Brunois, T., Lenaerts, C., Croisier, J.-L., PETERMANS, J., & Bruyère, O. (March 2017). Prevalence of sarcopenia according to 10 different operational definitions of frailty. Osteoporosis International, 28 (Supp 1), 317-318.
Peer Reviewed verified by ORBi

Veronese, N., Smith, T., Reginster, J.-Y., & Maggi, S. (March 2017). Osteoarthritis increases the risk of cardiovascular disease: data from the osteoarthritis initiative. Osteoporosis International, 28 Suppl 1, 58-59.
Peer Reviewed verified by ORBi

Libon, F., Courtois, J., LE GOFF, C., LUKAS, P., Fabregat Cabello, N., SEIDEL, L., CAVALIER, E., Reginster, J.-Y., & NIKKELS, A. (March 2017). Effect of body surface, body site and sunscreen application on production of Vitamin D and 25-hydroxyvitamin D after a single narrowband UVB exposure. Osteoporosis International, 28 Suppl 1, 143-144.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Black, D. M., Hattersley, G., Williams, G., Hu, M., Fitzpatrick, L. A., & Lewiecki, E. M. (March 2017). Abaloparatide-SC for postmenopausal osteoporosis: analysis of the number needed to treat compared with teriparatide. Osteoporosis International, 28 Suppl 1, 62-63.
Peer Reviewed verified by ORBi

Veronese, N., Stubbs, B., Crepaldi, G., Solmi, M., Cooper, C., Reginster, J.-Y., Rizzoli, R., & Maggi, S. (March 2017). Low bone mineral density and fractures are associated with incident cardiovascular disease: a systematic review and meta-analysis. Osteoporosis International, 28 Suppl 1, 180-181.
Peer Reviewed verified by ORBi

Veronese, N., Stubbs, B., Smith, T., Reginster, J.-Y., & Maggi, S. (March 2017). The relationship between knee osteoarthritis and incident hypertension: a representative longitudinal study. Osteoporosis International, 28 Suppl 1, 181-182.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (March 2017). Daily management of knee osteoarthritis: from the ESCEO algorithm to the CONCEPT study. Osteoporosis International, 28 Suppl 1, 638.
Peer Reviewed verified by ORBi

Buckinx, F., Mouton, A., Reginster, J.-Y., Croisier, J.-L., Dardenne, N., Beaudart, C., Nelis, J., Lambert, E., Appelboom, G., & Bruyère, O. (February 2017). Relationship between ambulatory physical activity assessed by activity trackers and physical frailty among nursing home residents. Gait and Posture, 54, 56-61. doi:10.1016/j.gaitpost.2017.02.010
Peer Reviewed verified by ORBi

Herrero-Beaumont, G., Roman-Blas, J. A., Bruyère, O., Cooper, C., Kanis, J., Maggi, S., Rizzoli, R., & Reginster, J.-Y. (February 2017). Clinical settings in knee osteoarthritis: Pathophysiology guides treatment. Maturitas, 96, 54-57. doi:10.1016/j.maturitas.2016.11.013
Peer Reviewed verified by ORBi

Harvey, N. C.* , Biver, E.* , Kaufman, J.-M., Bauer, J., Branco, J., Brandi, M. L., Bruyère, O., Coxam, V., Cruz-Jentoft, A., Czerwinski, E., Dimai, H., Fardellone, P., Landi, F., Reginster, J.-Y., Dawson-Hughes, B., Kanis, J. A., Rizzoli, R.* , & Cooper, C.*. (2017). The role of calcium supplementation in healthy musculoskeletal ageing - An expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis ans Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF). Osteoporosis International, 28 (2), 447-62. doi:10.1007/s00198-016-3773-6
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Veronese, N., Stubbs, B., Noale, M., Solmi, M., Luchini, C., Smith, T. O., Cooper, C., Guglielmi, G., Reginster, J.-Y., Rizzoli, R., & Maggi, S. (2017). Adherence to a Mediterranean diet is associated with lower prevalence of osteoarthritis: Data from the osteoarthritis initiative. Clinical Nutrition, 36, 1609-1614. doi:10.1016/j.clnu.2016.09.035
Peer Reviewed verified by ORBi

Beaudart, C., Zaaria, M., Pasleau, F., Reginster, J.-Y., & Bruyère, O. (2017). Health outcomes of sarcopenia: a systematic review and metaanalysis. Osteoporosis International, 28 Suppl 1, 67.
Peer Reviewed verified by ORBi

Beaudart, C., Locquet, M., Reginster, J.-Y., PETERMANS, J., & Bruyère, O. (2017). Results of the SarcoPhAge study after 2 years of follow-up. Journal of Frailty and Aging, 6 Suppl 1, 111-112.
Peer Reviewed verified by ORBi

Locquet, M., Beaudart, C., Delandsheere, L., Reginster, J.-Y., & Bruyère, O. (2017). Sensibilité et spécificité du questionnaire SARC-F selon les différentes définitions de la sarcopénie: résultats de l'étude SarcoPhAge. L'Année Gérontologique, 31 (1), 44.
Peer reviewed

Kanis, J. A., Cooper, C., Rizzoli, R., Abrahamsen, B., Al-Daghri, N. M., Brandi, M. L., Cannata-Andia, J., Cortet, B., Dimai, H. P., Ferrari, S., Hadji, P., Harvey, N. C., Kraenzlin, M., Kurth, A., McCloskey, E., Minisola, S., Thomas, T., Reginster, J.-Y., & for the European Society for Clinical and Economic Aspects of Osteoporosis, O. A. M. D. E. (2017). Erratum to: Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting (Osteoporosis International, (2017), 28, 7, (2023-2034), 10.1007/s00198-017-4009-0). Osteoporosis International, 28 (11), 3285-3286. doi:10.1007/s00198-017-4161-6
Peer Reviewed verified by ORBi

ROUSSEAU, A.-F., Bawin, M., CAVALIER, E., Reginster, J.-Y., DAMAS, P., & Bruyère, O. (2017). Occurrence of bone fracture in the 2 years following a prolonged ICU stay: a retrospective study including a control group. Osteoporosis International, 28 (Suppl 1), 504.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Al-Daghri, N., & Bruyère, O. (2017). Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis. Expert Opinion on Pharmacotherapy, 18 (17), 1811-1813. doi:10.1080/14656566.2017.1395021
Peer Reviewed verified by ORBi

Gasparik, A. I., Mihai, G., Beaudart, C., Bruyère, O., Pop, R. M., Reginster, J.-Y., & Pascanu, I. M. (2017). Psychometric performance of the Romanian version of the SarQoL®, a health-related quality of life questionnaire for sarcopenia. Archives of Osteoporosis, 12, 103. doi:10.1007/s11657-017-0397-1
Peer Reviewed verified by ORBi

Slomian, J., EMONTS, P., Vigneron, L., Acconcia, A., Glowacz, F., Reginster, J.-Y., Oumourgh, M., & Bruyère, O. (2017). Identifying maternal needs following childbirth: A qualitative study among mothers, fathers and professionals. BMC Pregnancy and Childbirth, 17 (1), 213. doi:10.1186/s12884-017-1398-1
Peer Reviewed verified by ORBi

Reginster, J.-Y., Rizzoli, R., Kanis, J. A., & Cooper, C. (2017). Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women [letter to the editor]. Annals of Internal Medicine, 167 (12), 902-903. doi:10.7326/L17-0488
Peer Reviewed verified by ORBi

CIANFEROTTI, L., BERTOLDO, F., CARINI, M., KANIS, J. A., LAPINI, A., LONGO, N., MARTORANA, G., MIRONE, V., Reginster, J.-Y., RIZZOLI, R., & BRANDI, M. L. (2017). The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation. Oncotarget, 8, 75646-75663. doi:10.18632/oncotarget.17980
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2017). Differentiation between various Chondroitin sulfate formulations in symptomatic knee osteoarthritis. Annals of the Rheumatic Diseases. doi:10.1136/annrheumdis-2017-212460
Peer Reviewed verified by ORBi

Buckinx, F., ALLEPAERTS, S., PAQUOT, N., Reginster, J.-Y., De Cock, C., PETERMANS, J., & Bruyère, O. (2017). Energy and nutrient content of food served and consumed by nursing home residents. Journal of Nutrition, Health and Aging, 21 (6), 727-32. doi:10.1007/s12603-016-0782-2
Peer Reviewed verified by ORBi

Bruyère, O., Cavalier, E., Buckinx, F., & Reginster, J.-Y. (January 2017). Relevance of vitamin D in the pathogenesis and therapy of frailty. Current Opinion in Clinical Nutrition and Metabolic Care, 20 (1), 26-29. doi:10.1097/MCO.0000000000000334
Peer Reviewed verified by ORBi

Beaudart, C., Reginster, J.-Y., Geerinck, A., Locquet, M., & Bruyère, O. (2017). Current review of the SarQoL®: a health-related quality of life questionnaire specific to sarcopenia. Expert Review of Pharmacoeconomics and Outcomes Research, 17 (4), 335-341. doi:10.1080/14737167.2017.1360768
Peer Reviewed verified by ORBi

Locquet, M., Honvo, G., Rabenda, V., Van Hees, T., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2017). Adverse Health Events Related to Self-Medication Practices Among Elderly: A Systematic Review. Drugs and Aging, 34 (5), 359-365. doi:10.1007/s40266-017-0445-y
Peer Reviewed verified by ORBi

Locquet, M., Beaudart, C., Reginster, J.-Y., PETERMANS, J., GILLAIN, S., Quabron, A., Slomian, J., Buckinx, F., & Bruyère, O. (2017). Prevalence of concomitant bone and muscle wasting in elderly women from the SarcoPhAge cohort: preliminary results. Journal of Frailty and Aging, 6 (1), 18-23. doi:10.14283/jfa.2016.111
Peer Reviewed verified by ORBi

Beaudart, C., Biver, E., Reginster, J.-Y., Rizzoli, R., Bolland, Y., PETERMANS, J., GILLAIN, S., Buckinx, F., Dardenne, N., & Bruyère, O. (2017). Validation of the SarQoL, a specific health-related quality of life questionnaire for Sarcopenia. Journal of Cachexia, Sarcopenia and Muscle, 8 (2), 238-44. doi:10.1002/jcsm.12149
Peer Reviewed verified by ORBi

Cooper, C., Rannou, F., Richette, P., Bruyère, O., Al-Daghri, N., Altman, R. D., Brandi, M. L., Collaud Basser, S., Herrero-Beaumont, G., Migliore, A., Pavelka, K., Uebelhart, D., & Reginster, J.-Y. (2017). Use of Intra-Articular Hyaluronic Acid in the Management of Knee Osteoarthritis in Clinical Practice. Arthritis Care and Research, 69 (9), 1287-96. doi:10.1002/acr.23204
Peer Reviewed verified by ORBi

Slomian, J., EMONTS, P., Erpicum, M., Vigneron, L., Reginster, J.-Y., & Bruyère, O. (2017). What should a website dedicated to the postnatal period contain? A Delphi survey among parents and professionals. Midwifery, 53, 9-14. doi:10.1016/j.midw.2017.07.004
Peer Reviewed verified by ORBi

Gielen, E., Bergmann, P., Bruyère, O., Cavalier, E., DELANAYE, P., Goemaere, S., Kaufman, J.-M., Locquet, M., Reginster, J.-Y., Rozenberg, S., Vandenbroucke, A.-M., & Body, J.-J. (2017). Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club. Calcified Tissue International, 101 (2), 111-31. doi:10.1007/s00223-017-0266-3
Peer Reviewed verified by ORBi

Beaudart, C., Zaaria, M., Pasleau, F., Reginster, J.-Y., & Bruyère, O. (January 2017). Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis. PLoS ONE, 12 (1), 0169548. doi:10.1371/journal.pone.0169548
Peer Reviewed verified by ORBi

Locquet, M., Beaudart, C., Delandsheere, L., Reginster, J.-Y., & Bruyère, O. (2017). Sensibility and sensitivity of the SARC-F questionnaire according to different definitions of sarcopenia: results from the SarcoPhAge study. Journal of Frailty and Aging, 6 Suppl 1, 119-120.
Peer Reviewed verified by ORBi

Locquet, M., Beaudart, C., Delandsheere, L., Reginster, J.-Y., & Bruyère, O. (2017). Subjective sleep quality in sarcopenic versus non-sarcopenic older adults from the SarcoPhAge study. Journal of Frailty and Aging, 6 Suppl 1, 56.
Peer Reviewed verified by ORBi

Buckinx, F., Lenaerts, C., Brunois, T., Reginster, J.-Y., PETERMANS, J., & Bruyère, O. (2017). Intérêt de 10 définitions actuelles de la fragilité pour prédire l'incidence des décès chez des sujets âgés résidant en maison de repos. L'Année Gérontologique, 31 (1), 11-12.
Peer reviewed

Slomian, J., Emonts, P., Vigneron, L., Acconcia, A., Reginster, J.-Y., Oumourgh, M., & Bruyère, O. (2017). Meeting the Needs of Mothers During the Postpartum Period: Using Co-Creation Workshops to Find Technological Solutions. JMIR Research Protocols, 6 (5), 76. doi:10.2196/resprot.6831
Peer Reviewed verified by ORBi

Buckinx, F., Lenaerts, C., Brunois, T., Reginster, J.-Y., PETERMANS, J., & Bruyère, O. (2017). Interest in 10 current definitions of frailty to predict the incidence of death among elderly nursing home residents. Journal of Frailty and Aging, 6 Suppl 1, 72-73.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Dudler, J., Blicharski, T., & Pavelka, K. (2017). Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the Chondroitin versus Celecoxib versus placebo trial (CONCEPT). Annals of the Rheumatic Diseases, 0n line, 1-7. doi:10.1136/annrheumdis-2016-210860
Peer Reviewed verified by ORBi

Beaudart, C., Zaaria, M., Pasleau, F., Reginster, J.-Y., & Bruyère, O. (2017). Analyse des conséquences cliniques de la sarcopénie: une revue systématique et méta-analyse. L'Année Gérontologique, 31 (1), 18.
Peer reviewed

Al-Daghri, N., Al-Saleh, Y., Aljohani, N., Sulimani, R., Al-Othman, A., Alfawaz, H., Fouda, M., Al-Amri, F., Shahrani, A., Alharbi, M., ALSHAHRANI, F., Tamini, W., Sabico, S., Rizzoli, R., & Reginster, J.-Y. (2017). Vitamin D status correction in Saudi Arabia: an experts' consensus under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (ESCEO). Archives of Osteoporosis, 12, 1. doi:10.1007/s11657-016-0295-y
Peer Reviewed verified by ORBi

ROUSSEAU, A.-F., CAVALIER, E., Reginster, J.-Y., DAMAS, P., & Bruyère, O. (2017). Occurrence of Clinical Bone Fracture Following a Prolonged Stay in Intensive Care Unit: A Retrospective Controlled Study. Calcified Tissue International, 101 (5), 465-472. doi:10.1007/s00223-017-0300-5
Peer Reviewed verified by ORBi

Ferrari, S., Reginster, J.-Y., Brandi, M. L., Kanis, J. A., Devogelaer, J.-P., Kaufman, J.-M., Féron, J.-M., Kurth, A., & Rizzoli, R. (2017). Erratum to: Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture (Archives of Osteoporosis, (2016), 11, 1, (37), 10.1007/s11657-016-0292-1). Archives of Osteoporosis, 12, 25. doi:10.1007/s11657-017-0319-2
Peer Reviewed verified by ORBi

Pavelka, K., Bruyère, O., Cooper, C., Kanis, J. A., Leeb, B. F., Maheu, E., Martel-Pelletier, J., Monfort, J., Pelletier, J.-P., Rizzoli, R., & Reginster, J.-Y. (2017). Erratum to: Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO (Drugs & Aging, (2016), 33, 2, (75-85), 10.1007/s40266-016-0347-4). Drugs and Aging, 34, 413. doi:10.1007/s40266-017-0457-7
Peer Reviewed verified by ORBi

Harvey, N. C. W., McCloskey, E. V., Mitchell, P. J., Dawson-Hughes, B., Pierroz, D. D., Reginster, J.-Y., Rizzoli, R., Cooper, C., & Kanis, A. (2017). Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporosis International, 28, 1507-1529. doi:10.1007/s00198-016-3894-y
Peer Reviewed verified by ORBi

Hiligsmann, M., Neuprez, A., Buckinx, F., Locquet, M., & Reginster, J.-Y. (2017). A scoping review of the public health impact of vitamin D - fortified dairy products for fracture prevention. Archives of Osteoporosis, 12, 57. doi:10.1007/s11657-017-0352-1
Peer Reviewed verified by ORBi

Locquet, M., Beaudart, C., Larbuisson, R., Leclercq, V., Buckinx, F., Kaux, J.-F., Reginster, J.-Y., & Bruyère, O. (January 2017). Self-Administration of Medicines and Dietary Supplements Among Female Amateur Runners: A Cross-Sectional Analysis. Advances in Therapy, 33 (12), 2257-2268. doi:10.1007/s12325-016-0426-2
Peer Reviewed verified by ORBi

Zaaria, M., Pasleau, F., Reginster, J.-Y., & Bruyère, O. (2017). Health outcomes of sarcopenia: a systematic review and meta-analysis. Journal of Frailty and Aging, 6 Suppl 1, 25.
Peer Reviewed verified by ORBi

Beaudart, C., Locquet, M., Reginster, J.-Y., PETERMANS, J., & Bruyère, O. (2017). L'étude SarcoPhAge: devenir des sujets sarcopéniques après 2 ans de suivi. L'Année Gérontologique, 31 (1), 42.
Peer reviewed

VERONESE, B., STUBBS, B., CREPALDI, G., SOLMI, M., COOPER, C., HARVEY, N. C., Reginster, J.-Y., RIZZOLI, R., CIVITELLI, R., SCHOFIELD, P., MAGGI, S., & LAMB, S. E. (2017). Relationship between low bone mineral density and fractures with incident cardiovascular disease: a systematic review and meta-analysis. Journal of Bone and Mineral Research, 32, 1126-1135. doi:10.1002/jbmr.3089
Peer Reviewed verified by ORBi

Bruyère, O., Cooper, C., Cutolo, M., & Reginster, J.-Y. (2017). International endorsement of the ESCEO algorithm for management of knee osteoarthritis in clinical practice [letter to the editor]. Seminars in Arthritis and Rheumatism, 47 (2), 10. doi:10.1016/j.semarthrit.2017.07.002
Peer Reviewed verified by ORBi

Bruyère, O., Cooper, C., Arden, N., Branco, J., Brandi, M. L., Herrero-Beaumont, G., Berenbaum, F., Dennison, E., Devogelaer, J.-P., Hochberg, M., Kanis, J., Laslop, A., McAlindon, T., Reiter, S., Richette, P., Rizzoli, R., & Reginster, J.-Y. (2017). Erratum to: Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Epidemiology and Phenotype of Osteoarthritis (Drugs & Aging, (2015), 32, 3, (179-187), 10.1007/s40266-015-0243-3). Drugs and Aging, 34, 411. doi:10.1007/s40266-017-0456-8
Peer Reviewed verified by ORBi

Buckinx, F., Reginster, J.-Y., GILLAIN, S., PETERMANS, J., Brunois, T., & Bruyère, O. (2017). Prevalence of Frailty in Nursing Home Residents According to Various Diagnostic Tools. Journal of Frailty and Aging, 6 (3), 122-8. doi:10.14283/jfa.2017.20
Peer Reviewed verified by ORBi

Reginster, J.-Y., Al-Daghri, N., Kaufman, J.-M., & Bruyère, O. (2017). Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis. Expert Opinion on Pharmacotherapy, 1-3. doi:10.1080/14656566.2017.1418857
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2017). Ostéoporose et sarcopénie: convergences et divergences. Revue Médicale Suisse, 13 (547), 184-185.
Peer Reviewed verified by ORBi

Buckinx, F., Croisier, J.-L., Reginster, J.-Y., Dardenne, N., Beaudart, C., Slomian, J., Leonard, S., & Bruyere, O. (2017). Reliability of muscle strength measures obtained with a hand-held dynamometer in an elderly population. Clinical Physiology and Functional Imaging, 37 (3), 332-40. doi:10.1111/cpf.12300
Peer Reviewed verified by ORBi

Hiligsmann, M., Dellaert, B. G., Dirksen, C. D., Watson, V., Bours, S., Goemaere, S., Reginster, J.-Y., Roux, C., McGowan, B., Silke, C., Whelan, B., Diez-Perez, A., Torres, E., Papadakis, G., Rizzoli, R., Cooper, C., Pearson, G., & Boonen, A. (2017). Patients' preferences for anti-osteoporosis drug treatment: A cross-European discrete choice experiment. Rheumatology, 56 (7), 1167-1176. doi:10.1093/rheumatology/kex071
Peer Reviewed verified by ORBi

Dierks, R. M. L., Bruyère, O., & Reginster, J.-Y. (2017). Micro Factors Bringing the Pharmaceutical Industry to a Seismic Shaking A Qualitative Research. Expert Review of Pharmacoeconomics and Outcomes Research, 17 (3), 267-74. doi:10.1080/14737167.2017.1351877
Peer Reviewed verified by ORBi

Buckinx, F., Reginster, J.-Y., BRUNOIS, T., Lenaerts, C., Beaudart, C., Croisier, J.-L., PETERMANS, J., & Bruyère, O. (2017). Prevalence of sarcopenia in a population of nursing home residents according to their frailty status: results of the SENIOR cohort. Journal of Musculoskeletal and Neuronal Interactions, 17 (3), 209-17.
Peer Reviewed verified by ORBi

Bruyère, O., CAVALIER, E., & Reginster, J.-Y. (2017). Vitamin D and osteosarcopenia: an update from epidemiological studies. Current Opinion in Clinical Nutrition and Metabolic Care, 20 (6). doi:10.1097/MCO.0000000000000411
Peer Reviewed verified by ORBi

Bruyère, O., Buckinx, F., Beaudart, C., Reginster, J.-Y., Bauer, J., Cederholm, T., Cherubini, A., Cooper, C., Cruz-Jentoft, A. J., Landi, F., Maggi, S., Rizzoli, R., Sayer, A. A., Sieber, C., Vellas, B., & Cesari, M. (2017). How clinical practitioners assess frailty in their daily practice: an international survey. Aging Clinical and Experimental Research, 29, 905-12. doi:10.1007/s40520-017-0806-8
Peer Reviewed verified by ORBi

Neuprez, A., Delcour, J.-P., Fatemi, F., Gillet, P., Crielaard, J.-M., Bruyère, O., & Reginster, J.-Y. (15 December 2016). Patients' expectations impact their satisfaction following total hip or knee arthroplasty. PLoS ONE, 11 (12), 1-14. doi:10.1371/journal.pone.0167911
Peer Reviewed verified by ORBi

Mavungu Landu, D. J., Liégeois, S., Manzambi Kuwekita, J., Mbinze Kindenge, J., Hubert, P., Michel, B., Reginster, J.-Y., Frederich, M., & Marini Djang'Eing'A, R. (14 December 2016). Qualité des médicaments antipaludéens et caractéristiques des pharmacies des territoires périurbains de Kinshasa [Poster presentation]. CONGRES INTERNATIONAL DE LA PATHOLOGIE INFECTIEUSE ET PARASITAIRE, Kinshasa, Congo - Kinshasa.

Buckinx, F., PAQUOT, N., FADEUR, M., Bacus, L., Reginster, J.-Y., ALLEPAERTS, S., PETERMANS, J., Biquet, S., & Bruyère, O. (10 November 2016). Assessment of energy expenditure of nursing home residents with indirect calorimetry [Paper presentation]. International Nursing Home Research Conference - International Working Group, Barcelone, Spain.

Beaudart, C., McCloskey, E., Bruyère, O., Cesari, M., Rolland, Y., Rizzoli, R., Araujo de Carvalho, I., Amuthavalli Thiyagarajan, J., Bautmans, I., Bertière, M.-C., Brandi, M. L., Al-Daghri, N. M., Burlet, N., CAVALIER, E., Cerreta, F., Cherubini, A., Fielding, R., Gielen, E., Landi, F., ... Cooper, C. (October 2016). Sarcopenia in daily practice: assessment and management. BMC Geriatrics, 16 (170). doi:10.1186/s12877-016-0349-4
Peer Reviewed verified by ORBi

Dierks, R. M. L., Bruyère, O., Reginster, J.-Y., & Richy, F. (October 2016). Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry. Expert Review of Pharmacoeconomics and Outcomes Research, 16 (5), 571-8. doi:10.1080/14737167.2016.1239534
Peer Reviewed verified by ORBi

Locquet, M., Beaudart, C., Reginster, J.-Y., PETERMANS, J., GILLAIN, S., Quabron, A., Slomian, J., Buckinx, F., & Bruyère, O. (29 September 2016). Prevalence of concomitant bone and muscle wasting in patients from the SarcoPhAge Study [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Bruxelles, Belgium.

Buckinx, F., Morelle, A., Adam, S., Reginster, J.-Y., Labeye, N., Locquet, M., & Bruyère, O. (29 September 2016). Influence of environmental factors on food intakes of nursing home residents: a survey combined to a video approach [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Bruxelles, Belgium.

Slomian, J., EMONTS, P., Reginster, J.-Y., Vigneron, L., Acconcia, A., & Bruyère, O. (29 September 2016). Identification de solutions technologiques potentielles en réponse aux besoins des mères dans l'année suivant leur accouchement [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Bruxelles, Belgium.

Reginster, J.-Y., & CONCEPT author's group. (September 2016). Pharmaceutical grade chondroitin sulfate improves knee osteoarthritis symptoms more than placebo and as much as celecoxib: results of the chondroitin vs celecoxib vs placebo trial (CONCEPT). Arthritis and Rheumatism, 68S10, 3067-3068.
Peer Reviewed verified by ORBi

Kendler, D. L., Chines, A., Brandi, M. L., Papapoulos, S., Lewiecki, E. M., Reginster, J.-Y., Roux, C., Munos Torres, M., Wang, A., & Bone, H. G. (September 2016). The risk of subsequent osteoporotic fractures is decreased in patients experiencing fracture while on denosumab. Arthritis and Rheumatism, 68S10, 427-429.
Peer Reviewed verified by ORBi

Cavalier, E., Bergmann, P., Bruyère, O., DELANAYE, P., Durnez, A., Devogelaer, J.-P., Ferrari, S. L., Gielen, E., Goemaere, S., Kaufman, J.-M., Nzeusseu Toukap, A., Reginster, J.-Y., ROUSSEAU, A.-F., Rozenberg, S., Scheen, A., & Body, J.-J. (July 2016). The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club. Osteoporosis International, 27, 2181-2195. doi:10.1007/s00198-016-3561-3
Peer Reviewed verified by ORBi

Kucharz, E. J., Kovalenko, V., Szanto, S., Bruyère, O., Cooper, C., & Reginster, J.-Y. (June 2016). A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. Current Medical Research and Opinion, 32 (6), 997-1004. doi:10.1185/03007995.2016.1154521
Peer Reviewed verified by ORBi

Bruyère, O., Beaudart, C., Reginster, J.-Y., Buckinx, F., Schoene, D., Hirani, V., Cooper, C., Kanis, J. A., Rizzoli, R., McCloskey, E., Cederholm, T., Cruz-Jentoft, A., & Freiberger, E. (June 2016). Assessment of muscle mass, muscle strength and physical performance in clinical practice: An international survey. European Geriatric Medicine, 7 (3), 243-6. doi:10.1016/j.eurger.2015.12.009
Peer reviewed

Slomian, J., EMONTS, P., Vigneron, L., Acconcia, A., Glowacz, F., Reginster, J.-Y., Oumourgh, M., & Bruyère, O. (May 2016). Identification des besoins des mères dans l’année suivant leur accouchement : une étude qualitative [Poster presentation]. 44èmes Assises Nationales des Sages-Femmes, Saint-Malo, France.

Locquet, M., Beaudart, C., LARBUISSON, R., Buckinx, F., KAUX, J.-F., Reginster, J.-Y., & Bruyère, O. (May 2016). Self-Medication Practice among Amateur Runners: Prevalence and Associated Factors. Journal of Sports Science and Medicine, 15 (2), 387-8.
Peer Reviewed verified by ORBi

Slomian, J., Bruyère, O., Reginster, J.-Y., & EMONTS, P. (May 2016). Quelle est la place d’internet pour combler le besoin d’information des nouvelles mères ? [Poster presentation]. 44èmes Assises Nationales des Sages-Femmes.

CAVALIER, E., WATAR, F., KOVACS, S., Beaudart, C., Buckinx, F., Bruyère, O., LE GOFF, C., & Reginster, J.-Y. (16 April 2016). Evaluation of the intra-individual variability of Myostatin and Activin A (and PIIINP): impact on the least significant change and follow-up of the patients [Paper presentation]. World Congresse on Osteoporosis Osteoarthritis and musculoskeletal diseases, Malaga, Spain.

Delvaux, F., Rochcongar, P., Bruyère, O., Bourlet, G., DANIEL, C., Diverse, P., Reginster, J.-Y., & Croisier, J.-L. (09 April 2016). Return-to-play criteria after anterior cruciate ligament reconstruction: actual medicine practice in professional soccer teams [Poster presentation]. FIFA - Football Medicine Strategies, London, United Kingdom.
Peer reviewed

CAVALIER, E., CARLISI, I., KOVACS, S., WATAR, F., Beaudart, C., Buckinx, F., Bruyère, O., & Reginster, J.-Y. (April 2016). Brain-derived neurotrophic factor (BDNF) in normal healthy and hemodialyzed populations. Osteoporosis International, 27 (Supplement 1), 512.
Peer Reviewed verified by ORBi

Bone, H. G., Brandi, M. L., Brown, J. P., Chapurlat, R., Cummings, S. R., Czerwinski, E., Fahrleitner-Pammer, A., Kendler, D. L., Lippuner, K., Reginster, J.-Y., Wittinghoff, E., Daizadeh, S., Wang, A., Dakin, P., Wagman, R. B., & Papapoulos, S. E. (April 2016). Ten years of Denosumab (DMAB) treatment in postmenopausal women with osteoporosis. Results from the FREEDOM Extension trial. Osteoporosis International, 27 (Supplement 1), 135-136.
Peer Reviewed verified by ORBi

Buckinx, F., Reginster, J.-Y., Beaudart, C., Croisier, J.-L., PETERMANS, J., & Bruyère, O. (April 2016). Prevalence of sarcopenia in a population of nursing home residents according to their frailty status: results of the Senior cohort. Osteoporosis International, 27 (supplement 1), 55-56.
Peer Reviewed verified by ORBi

Beaudart, C., Edwards, M., Dennison, E. M., Moss, C., Bruyère, O., Reginster, J.-Y., Moon, R. J., Cooper, C., & Demoulin, C. (April 2016). English translation and cross-cultural adaptation of the SarQuoL® questionnaire. Osteoporosis International, 27 (Supplement 1), 221-222.
Peer Reviewed verified by ORBi

Buckinx, F., Reginster, J.-Y., Croisier, J.-L., PETERMANS, J., & Bruyère, O. (April 2016). Physical and muscle performances among elderly nursing home residents. Osteoporosis International, 27 (Supplement 1), 217.
Peer Reviewed verified by ORBi

Miller, P., Pannacciulli, N., Brown, J. P., Czerwinski, E., Nedergaard, S., Bolognese, M. A., Malouf, J., Bone, H. G., Reginster, J.-Y., Singer, A., Wang, A., Wagman, R. B., & Cummings, S. R. (April 2016). A randomized double-blind study of Denosumab (DMAB) compared with Zoledronic acid (ZOL) in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. Osteoporosis International, 27 (SUPPLEMENT1), 42.
Peer Reviewed verified by ORBi

Ferrari, S., ADAMI, S., Brown, J. P., Cosman, F., Czerwinski, E., de Gregorio, L. H., Malouf, J., Reginster, J.-Y., Daizadeh, N. S., Wang, A., Wagman, R. B., & Lewiecki, E. M. (April 2016). relationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 10 years of Denosumab (DMAB) treatment. Osteoporosis International, 27 (Supplement 1), 49-50.
Peer Reviewed verified by ORBi

CAVALIER, E., Piron, C., WATAR, F., KOVACS, S., Beaudart, C., Buckinx, F., Bruyère, O., LE GOFF, C., & Reginster, J.-Y. (April 2016). Evaluation of the intra-individual variability of myostatin and activin A, two biomarkers of sarcopenia: impact on the least significant change and followup of the patients. Osteoporosis International, 27 (supplement 1), 56.
Peer Reviewed verified by ORBi

Rannou, F., Maheu, & Reginster, J.-Y. (April 2016). Efficacy and safety of hyaluronic acid in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Osteoporosis International, 27 (supplement 1), 66.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (April 2016). Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Osteoporosis International, 27 (supplement 1), 65.
Peer Reviewed verified by ORBi

Neuprez, A., KURTH, W., THIRION, T., DANIEL, C., HUSKIN, J.-P., GILLET, P., Bruyère, O., & Reginster, J.-Y. (April 2016). Age-standardized quality of life after hip or knee arthoplasty. Osteoporosis International, 27 (Supplement 1), 541-542.
Peer Reviewed verified by ORBi

Buckinx, F., Reginster, J.-Y., GILLAIN, S., PETERMANS, J., Brunois, T., & Bruyère, O. (April 2016). Prevalence of frailty among nursing home, according to different operational definitions. Osteoporosis International, 27 (Supplement 1), 216-217.
Peer Reviewed verified by ORBi

Ethgen, O., Tchoconte, C., Beaudart, C., Buckinx, F., Reginster, J.-Y., & Bruyère, O. (April 2016). The future prevalence of sarcopenia in Europe. Osteoporosis International, 27 (Supplement 1), 53-54.
Peer Reviewed verified by ORBi

Locquet, M., Beaudart, C., Reginster, J.-Y., PETERMANS, J., GILLAIN, S., Quabron, A., Slomian, J., Buckinx, F., & Bruyère, O. (April 2016). Prevalence of concomitant bone and muscle wasting in patients from the SarcoPhAge study. Osteoporosis International, 27 (supplement 1), 129.
Peer Reviewed verified by ORBi

Pavelka, K., Bruyère, O., Cooper, C., Kanis, J. A., Leeb, B. F., Maheu, E., Martel-Pelletier, J., Monfort, J., Pelletier, J.-P., Rizzoli, R., & Reginster, J.-Y. (February 2016). Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs and Aging, 33 (2), 75-85. doi:10.1007/s40266-016-0347-4
Peer Reviewed verified by ORBi

Cooper, C., Bardin, T., Brandi, M. L., Cacoub, P., Caminis, J., Civitelli, R., Cutolo, M., Dere, W., Devogelaer, J. P., Diez-Perez, A., Einhorn, T. A., Emonts, P., Ethgen, O., Kanis, J. A., Kaufman, J. M., Kvien, T. K., Lems, W. F., McCloskey, E., Miossec, P., ... Reginster, J.-Y. (February 2016). Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Aging Clinical and Experimental Research, 28 (1), 1-16. doi:10.1007/s40520-015-0522-1
Peer Reviewed verified by ORBi

de Carvalho, I. A., Aboderin, I., Arikawa-Hirasawa, E., Cesari, M., Furukawa, Y., Robledo, L. M. G., Morley, J. E., Pot, A. M., Reginster, J.-Y., Shaw, G., Tomita, N., & Beard, J. R. (2016). Innovation for healthy ageing: A call for papers. Bulletin of the World Health Organization, 94 (6), 407-407. doi:10.2471/BLT.16.176743
Peer Reviewed verified by ORBi

Schaap, L. A., Fox, B., Henwood, T., Bruyère, O., Reginster, J.-Y., Beaudart, C., Buckinx, F., Roberts, H., Cooper, C., Cherubini, A., Dell'Aquilla, G., Maggio, M., & Volpato, S. (2016). Grip strength measurement: Towards a standardized approach in sarcopenia research and practice. European Geriatric Medicine, 7 (3), 247-255. doi:10.1016/j.eurger.2015.11.012
Peer reviewed

Bruyère, O., Cooper, C., Pelletier, J. P., Maheu, E., Rannou, F., Branco, J., Brandi, M. L., Kanis, J. A., Altman, R. D., Hochberg, M. C., Martel-Pelletier, J., & Reginster, J.-Y. (2016). A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis - From evidence-based medicine to the real-life setting. Seminars in Arthritis and Rheumatism, 45 (4 Suppl), 3-S11. doi:10.1016/j.semarthrit.2015.11.010
Peer Reviewed verified by ORBi

Reginster, J.-Y., Cooper, C., Rizzoli, R., Kanis, J. A., Appelboom, G., Bautmans, I., Bischoff-Ferrari, H. A., Boers, M., Brandi, M. L., Bruyère, O., Cherubini, A., Flamion, B., Fielding, R. A., Gasparik, A. I., Van Loon, L., McCloskey, E., Mitlak, B. H., Pilotto, A., Reiter-Niesert, S., ... Cruz-Jentoft, A. J. (2016). Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. Aging Clinical and Experimental Research, 28 (1), 47-58. doi:10.1007/s40520-015-0517-y
Peer Reviewed verified by ORBi

Edwards, M. H., Parsons, C., Bruyère, O., Petit Dop, F., Chapurlat, R., Roemer, F. W., Guermazi, A., Zaim, S., Genant, H., Reginster, J.-Y., Dennison, E. M., Cooper, C., & The SEKOIA Study Group. (2016). High Kellgren-Lawrence Grade and Bone Marrow Lesions Predict Worsening Rates of Radiographic Joint Space Narrowing; The SEKOIA Study. Journal of Rheumatology, 43 (3), 657-65. doi:10.3899/jrheum.150053
Peer Reviewed verified by ORBi

Runhaar, J., DEROISY, R., van Middelkoop, M., Barbetta, F., Barbetta, B., Oei, E. H., Vroeginddeweij, D., Giacovelli, G., Bruyère, O., Rovati, L. C., Reginster, J.-Y., & Bierma-Zeinstra, S. M. A. (2016). The role of diet and exercise and of glucosamine sulfate in the prevention of knee osteoarthritis: Further results from the PRevention of knee Osteoarthritis in Overweight Females (PROOF) study. Seminars in Arthritis and Rheumatism, 45 (4 Suppl), 42-S48. doi:10.1016/j.semarthrit.2015.11.001
Peer Reviewed verified by ORBi

Reginster, J.-Y., Beaudart, C., Buckinx, F., & Bruyère, O. (January 2016). Osteoporosis and sarcopenia: two diseases or one? Current Opinion in Clinical Nutrition and Metabolic Care, 19 (1), 31-6. doi:10.1097/MCO.0000000000000230
Peer Reviewed verified by ORBi

Ferrari, S., Reginster, J.-Y., Brandi, M. L., Kanis, J. A., Devogelaer, J. P., Kaufmann, J. P., Feron, J. M., Kurth, A., & Rizzoli, R. (2016). Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture. Archives of Osteoporosis, 11, 37. doi:10.1007/s11657-016-0292-1
Peer Reviewed verified by ORBi

Blain, H., Masud, T., Dargent-Molina, P., Martin, F. C., Rosendahl, E., van der Velde, N., Bousquet, J., Benetos, A., Cooper, C., KANIS, J. A., Reginster, J.-Y., Rizzoli, R., Cortet, B., Barbagallo, M., Dreinhöfer, K. E., Vellas, B., Maggi, S., & Strandberg, T. (2016). A comprehensive fracture prevention strategy in older adults : the European Union Geriatric Medicine Society (EUGMS) statement. Aging Clinical and Experimental Research, 28, 797-803. doi:10.1007/s40520-016-0588-4
Peer Reviewed verified by ORBi

Locquet, M., Bruyère, O., Beaudart, C., & Reginster, J.-Y. (2016). Ostéoporose et sarcopénie: un même combat ? Ortho-Rhumato, 14 (4), 34-36.

Reginster, J.-Y., & Cooper, C. (2016). Optimizing the management of osteoarthritis-Transitioning evidence-based guidelines into practical guidance for real-world clinical practice. Seminars in Arthritis and Rheumatism, 45 (4 Suppl), 1-S2. doi:10.1016/j.semarthrit.2015.10.014
Peer Reviewed verified by ORBi

Buckinx, F., Reginster, J.-Y., Cavalier, E., PETERMANS, J., RICOUR, C., Dardenne, C., & Bruyère, O. (January 2016). Determinants of vitamin D supplementation prescription in nursing homes: a survey among general practitioners. Osteoporosis International, 27, 881-6. doi:10.1007/s00198-015-3469-3
Peer Reviewed verified by ORBi

CAVALIER, E., Piron, C., WATAR, F., KOVACS, S., Beaudart, C., Buckinx, F., Bruyère, O., LE GOFF, C., & Reginster, J.-Y. (2016). Evaluation of the intra-individual variability of myostatin and activin A, two biomarkers of sarcopenia. Impact of the least significant change and follow-up of the patients. Journal of Frailty and Aging, 5 (Supplement 1), 82.
Peer Reviewed verified by ORBi

Beaudart, C., Edwards, M., Dennisson, E., Moss, C., Bruyère, O., Reginster, J.-Y., Moon, R., Demoulin, C., & Cooper, C. (2016). English translation and cross-cultural adaptation of the SARQOL Questionnaire. Journal of Frailty and Aging, 5 (Supplement 1), 58.
Peer Reviewed verified by ORBi

Buckinx, F., Reginster, J.-Y., CROISIER, J.-L., PETERMANS, J., & Bruyère, O. (2016). Physical and muscle performances among elderly nursing home residents. Results fo the senior cohort. Journal of Frailty and Aging, 5 (Supplement 1), 69.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Cooper, C., & Bruyère, O. (2016). Re: Kucharz EJ, Kovalenko V, Szántó S, et al. A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. Curr Med Res Opin 2016;32:997-1004 [letter to the editor]. Current Medical Research and Opinion, 32 (11), 1771-1772. doi:10.1080/03007995.2016.1239575
Peer Reviewed verified by ORBi

Cavalier, E., Beaudart, C., Buckinx, F., Bruyère, O., & Reginster, J.-Y. (2016). Critical analytical evaluation of promising markers for sarcopenia. European Geriatric Medicine, 7 (3), 239-242. doi:10.1016/j.eurger.2015.11.002
Peer reviewed

MILLER, P. D., PANNACCIULLI, N., BROWN, J. P., CZERWINSKI, E., NEDERGAARD, B. S., BOLOGNESE, M. A., MALOUF, J., BONE, H. G., Reginster, J.-Y., SINGER, A., WANG, C., WAGMAN, R. B., & CUMMINGS, S. R. (2016). A randomized double-blind study of denosumab compared with zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonate. Arthritis and Rheumatology, 67 (S10), 1181-1182.
Peer Reviewed verified by ORBi

Bruyère, O., Beaudart, C., Locquet, M., Buckinx, F., PETERMANS, J., & Reginster, J.-Y. (2016). Sarcopenia as a public health problem. European Geriatric Medicine, 7 (3), 272-5. doi:10.1016/j.eurger.2015.12.002
Peer reviewed

Maheu, E., Rannou, F., & Reginster, J.-Y. (2016). Efficacy and safety of hyaluronic acid in the management of osteoarthritis : Evidence from real-life setting trials and surveys. Seminars in Arthritis and Rheumatism, 45 (4 Suppl), 28-S33. doi:10.1016/j.semarthrit.2015.11.008
Peer Reviewed verified by ORBi

Penton, H., Hiligsmann, M., Harrison, M., Reginster, J.-Y., Boonen, A., & Bansback, N. (2016). Potential cost-effectiveness for using patient decision aids to guide osteoporosis treatment. Osteoporosis International, 27, 2697-2707. doi:10.1007/s00198-016-3596-5
Peer Reviewed verified by ORBi

CAVALIER, E., Carlisi, A. S., WATAR, F., KOVACS, S., Beaudart, C., Buckinx, F., Bruyère, O., & Reginster, J.-Y. (2016). Brain-derived neurotrophic factor (BDNF) in normal healthy and hemodialyzed populations. Journal of Frailty and Aging, 5 (Supplement 1), 116.
Peer Reviewed verified by ORBi

Buckinx, F., Reginster, J.-Y., Beaudart, C., CROISIER, J.-L., PETERMANS, J., & Bruyère, O. (2016). Prevalence of sarcopenia in a population of nursing home residents according to their frailty status: Results of the senior cohort. Journal of Frailty and Aging, 5 (Supplement 1), 34.
Peer Reviewed verified by ORBi

Buckinx, F., Reginster, J.-Y., GILLAIN, S., PETERMANS, J., BRUNOIS, T., & Bruyère, O. (2016). Prevalence of frailty among nursing home, according to different operational definitions. Journal of Frailty and Aging, 5 (Supplement 1), 69.
Peer Reviewed verified by ORBi

Detilleux, J., REGINSTER, J.-Y., Chines, A., & Bruyère, O. (2016). A Bayesian path analysis to estimate causal effects of bazedoxifene acetate on incidence of vertebral fractures, either directly or through non-linear changes in bone mass density. Statistical Methods in Medical Research, 25 (1), 400-412. doi:10.1177/0962280212456655
Peer Reviewed verified by ORBi

ROUSSEAU, A.-F., Michel, L., Bawin, M., CAVALIER, E., Reginster, J.-Y., DAMAS, P., & Bruyère, O. (2016). Incidence of bone fractures after critical illness. Intensive Care Medicine Experimental, 4 (Suppl 1), 1131.
Peer Reviewed verified by ORBi

Ethgen, O., Hiligsmann, M., Burlet, N., & Reginster, J.-Y. (January 2016). Cost-effectiveness of personalized supplementation with vitamin D-rich dairy products in the prevention of osteoporotic fractures. Osteoporosis International, 27, 301-308. doi:10.1007/s00198-015-3319-3
Peer Reviewed verified by ORBi

Buckinx, F., Reginster, J.-Y., Petermans, J., Croisier, J.-L., Beaudart, C., BRUNOIS, T., & Bruyère, O. (2016). Relationship between frailty, physical performance and quality of life among nursing home residents: the SENIOR cohort. Aging Clinical and Experimental Research, 28 (6), 1149-57. doi:10.1007/s40520-016-0616-4
Peer Reviewed verified by ORBi

Blain, H., Masud, T., Dargent-Molina, P., Martin, F., Rosendahl, E., van der Velde, N., Bousquet, J., Benetos, A., Cooper, C., Kanis, J. A., Reginster, J.-Y., Rizzoli, R., Cortet, B., Barbagallo, M., Dreinhöfer, K., Vellas, B., Maggi, S., Strandberg, T., Alvarez, M. N., ... Adachi, R. (2016). A comprehensive fracture prevention strategy in older adults: The European union geriatric medicine society (EUGMS) statement. European Geriatric Medicine, 7 (6), 519-525. doi:10.1016/j.eurger.2016.04.012
Peer reviewed

Blain, H., Masud, T., Dargent-Molina, P., Martin, F., Rosendahl, E., van der Velde, N., Bousquet, J., Benetos, A., Cooper, C., Kanis, J. A., Reginster, J.-Y., Rizzoli, R., Cortet, B., Barbagallo, M., Dreinhöfer, K. E., Vellas, B., Maggi, S., & Strandberg, T. (2016). A comprehensive fracture prevention strategy in older adults: The European Union Geriatric Medicine Society (EUGMS) statement. Journal of Nutrition, Health and Aging, 20 (6), 647-652. doi:10.1007/s12603-016-0741-y
Peer Reviewed verified by ORBi

Miller, P. D., Pannacciulli, N., Brown, J. P., Czerwinski, E., Nedergaard, B. S., Bolognese, M. A., Malouf, J., Bone, H. G., Reginster, J.-Y., Singer, A., Wang, C., Wagman, R. B., & Cummings, S. R. (2016). Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. Journal of Clinical Endocrinology and Metabolism, 101 (8), 3163-3170. doi:10.1210/jc.2016-1801
Peer Reviewed verified by ORBi

Rozenberg, S., Body, J.-J., Bruyère, O., Bergmann, P., Brandi, M. L., Cooper, C., Devogelaer, J.-P., Gielen, E., Goemaere, S., Kaufman, J.-M., Rizzoli, R., & Reginster, J.-Y. (2016). Effects of Dairy Products Consumption on Health: Benefits and Beliefs-A Commentary from the Belgian Bone Club and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. Calcified Tissue International, 98 (1), 1-17. doi:10.1007/s00223-015-0062-x
Peer Reviewed verified by ORBi

Bruyère, O., Altman, R. D., & Reginster, J.-Y. (2016). Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Seminars in Arthritis and Rheumatism, 45 (4 Suppl), 12-S17. doi:10.1016/j.semarthrit.2015.11.011
Peer Reviewed verified by ORBi

Slomian, J., EMONTS, P., Glowacz, F., Reginster, J.-Y., Bruyère, O., Vigneron, L., & Acconcia, A. (2016). Identification des besoins des mères dans l’année suivant leur accouchement : une étude qualitative. In De l'expertise scientifique à l'expertise profane : postures, enjeux et méthodes dans le champ de la psychologie de la santé.
Peer reviewed

SMOLEN, J. S., COLLAUD BASSET, S., BOERS, M., BREEDVELD, F., EDWARDS, C. J., KVIEN, T. K., MIOSSEC, P., SOKKA-ISLER, T., van VOLLENHOVEN, R. F., Abadie, E. C., Bruyère, O., COOPER, C., MÄKINEN, H., THOMAS, T., TUGWELL, P., & Reginster, J.-Y. (2016). Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. Annals of the Rheumatic Diseases, 75, 1268-1271. doi:10.1136/annrheumdis-2016-209429
Peer Reviewed verified by ORBi

Locquet, M., Beaudart, C., Reginster, J.-Y., PETERMANS, J., GILLAIN, S., Quabron, A., Slomian, J., Buckinx, F., & Bruyère, O. (2016). Prevalence of concomitant bone and muscle wasting in patients from the SarcoPhAge Study. Journal of Frailty and Aging, 5 (Supplement 1), 84.
Peer Reviewed verified by ORBi

Manzambi Kuwekita, J., Gosset, C., Guillaume, M., Balula Semutsari, M.-P., Tshiama Kabongo, E., Bruyère, O., & Reginster, J.-Y. (30 December 2015). Le couplage « Micro-crédit, Micro-assurance santé et Offre des soins » peut améliorer l’accessibilité aux soins de santé de qualité en milieu urbain africain : Résultats d’une expérience menée dans la zone de santé de Bandalungwa à Kinshasa, Congo. Médecine et Santé Tropicales, 25, 381-385. doi:10.1684/mst.2015.0520
Peer Reviewed verified by ORBi

Ethgen, O., Hiligsmann, M., Burlet, N., & Reginster, J.-Y. (2015). Public health impact and cost-effectiveness of dairy products supplemented with vitamin D in prevention of osteoporotic fractures. Archives of Public Health. doi:10.1186/s13690-015-0099-3
Peer Reviewed verified by ORBi

Manzambi Kuwekita, J., Mbadu Kivuidi, V., Bruyère, O., & Reginster, J.-Y. (2015). Le tradipraticien est un acteur incontournable dans l’offre des soins de santé en territoire péri-urbain : équilibre entre légitimité et illégalité ? In J.-M. Halleux & J. Bogaert (Ed.), Territoires Périurbains (Cette oeuvre est sous licence Creative Commons. Vous êtes libre de reproduire, de modifier, de distribuer et de communiquer cette création au public selon les conditions suivantes : • paternité (BY) : vous devez citer le nom de l’auteur original de la manière indiquée par l’auteur de l’oeuvre ou le titulaire des droits qui vous confère cette autorisation (mais pas d’une manière qui suggérerait qu’ils vous soutiennent ou approuvent votre utilisation de l’oeuvre) ; • pas d’utilisation commerciale (NC) : vous n’avez pas le droit d’utiliser cette création à des fins commerciales ; • partage des conditions initiales à l’identique (SA) : si vous modifiez, transformez ou adaptez cette création, vous n’avez le droit de distribuer la création qui en résulte que sous un contrat identique à celui-ci. À chaque réutilisation ou distribution de cette création, vous devez faire apparaître clairement au public les conditions contractuelles de sa mise à disposition. Chacune de ces conditions peut être levée si vous obtenez l’autorisation du titulaire des droits sur cette oeuvre. Rien dans ce contrat ne diminue ou ne restreint le droit moral de l’auteur, pp. 184-193). Gembloux, Belgium: Presses Agronomiques de Gembloux.
Peer reviewed

PAPAPOULOS, S., LIPPUNER, K., ROUX, C., LIN, C. J., KENDLER, D. L., LEWIECKI, E. M., BRANDI, M. L., CZEWINSKI, E., FRANEK, E., LAKATOS, P., MAUTALEN, C., MINISOLA, S., Reginster, J.-Y., JENSEN, J., DAIZADEH, N. S., WANG, A., GAVIN, M., LIBANATI, C., WAGMAN, R. B., & BONE, H. G. (December 2015). The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporosis International, 26 (12), 2773-2783. doi:10.1007/s00198-015-3234-7
Peer Reviewed verified by ORBi

Beaudart, C., Reginster, J.-Y., PETERMANS, J., & Bruyère, O. (December 2015). Qualité de vie du patient sarcopénique : apport de l’étude liégeoise SarcoPhAge. Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 13 (4), 391-5. doi:10.1684/pnv.2015.0571
Peer reviewed

Bruyère, O., DEROISY, R., Dardenne, N., Cavalier, E., COFFINER, M., da silva, S., De Niet, S., & Reginster, J.-Y. (December 2015). A phase IV, two-armed, randomized, cross-over study comparing compliance with once-a-month administration of vitamin D3 to compliance with daily administration of a fixed-dose combination of vitamin D3 and calcium during two 6-month periods. Osteoporosis International, 26 (12), 2863-8. doi:10.1007/s00198-015-3205-z
Peer Reviewed verified by ORBi

Beaudart, C., Biver, E., Reginster, J.-Y., Rizzoli, R., Rolland, Y., Bautmans, I., PETERMANS, J., GILLAIN, S., Buckinx, F., & Bruyère, O. (17 November 2015). Development and validation of a self-administrated quality of life questionnaire specific to sarcopenia: the SarQoL [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Liège, Belgium.

Bruyère, O., Reginster, J.-Y., Dardenne, N., Nelis, J., Lambert, E., Appelboom, G., & Buckinx, F. (17 November 2015). Relationship between ambulatory physical activity assessed by activity trackers and physical frailty among nursing home residents [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Liège, Belgium.

Slomian, J., EMONTS, P., Reginster, J.-Y., Vigneron, L., Acconcia, A., & Bruyère, O. (17 November 2015). Identification des besoins d'une mère dans l'année suivant son accouchement : comparaison entre les femmes ayant vécu au moins un épisode de détresse psychologique et celles n'en ayant pas vécu [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Liège, Belgium.

Locquet, M., Beaudart, C., LARBUISSON, R., Buckinx, F., KAUX, J.-F., Reginster, J.-Y., & Bruyère, O. (17 November 2015). Prevalence and factors associated with self-medication practice among amateur runners [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Liège, Belgium.

Ferrari, S., Libanati, C., Lin, J., Adami, S., Brown, J., Cosman, F., Czerwinski, E., De Gregorio, L., Malouf, J., Reginster, J.-Y., Daizadeh, N., Wang, A., Wagman, R., & Lewiecki, E. (November 2015). Pourcentage de femmes atteignant des T-scores de DMO non ostéoporotiques au rachis lombaire (RL) et à la hanche totale (HT) après 8 ans de traitement par denosumab (DMAb). Revue du Rhumatisme, 82 (S1), 35-A36.
Peer Reviewed verified by ORBi

Chapurlat, R., Langdahl, B., Teglbjaerg, C., HO, P. R., Czerwinski, E., Kendler, D., Reginster, J.-Y., Kivitz, A., LEWIECKI, E., Miller, P., Bolognese, M., McClung, M., Bone, H., Ljunggren, O., Abrahamsen, B., Gruntmanis, U., Wagman, R., Siddhanti, S., & Orwoll, E. (November 2015). Traitement par denosumab chez des hommes à masse osseuse basse: résultats à 24 mois de l'étude ADAMO. Revue du Rhumatisme, 82 (S1), 123-A124.
Peer Reviewed verified by ORBi

Buckinx, F., Paquot, N., Allepaerts, S., Reginster, J.-Y., Petermans, J., & Bruyère, O. (September 2015). Energy and nutrient contents of food served and consumed by nursing home residents. European Geriatric Medicine, 6S1, 124.
Peer reviewed

Buckinx, F., Croisier, J.-L., Reginster, J.-Y., Petermans, J., & Bruyère, O. (September 2015). Impact of the frailty status on muscle mass and muscle strength of nursing home residents. European Geriatric Medicine, 6S1, 85.
Peer reviewed

Buckinx, F., Croisier, J.-L., Reginster, J.-Y., Petermans, J., & Bruyère, O. (September 2015). Correlation between muscle mass and muscle strength among nursing home residents. European Geriatric Medicine, 6S1, 84-s85.
Peer reviewed

Beaudart, C., Reginster, J.-Y., Rizzoli, R., Biver, E., Rolland, Y., Bautmans, I., Petermans, J., GILLAIN, S., Buckinx, F., Van Beveren, J., Jacquemain, M., Italiano, P., Dardenne, N., & Bruyère, O. (September 2015). Development and validation of a self-administrated quality of life questionnaire specific to sarcopenia: the SarQol. European Geriatric Medicine, 6S1, 84.
Peer reviewed

Buckinx, F., Reginster, J.-Y., Cavalier, E., Petermans, J., Dardenne, C., & Bruyère, O. (September 2015). Derteminants of prescription of vitamin D supplementations in nursing homes: an online survey among general practitioners. European Geriatric Medicine, 6S1, 139.
Peer reviewed

Beaudart, C., Reginster, J.-Y., Petermans, J., GILLAIN, S., Quabron, A., Locquet, M., Slomian, J., Buckinx, F., & Bruyère, O. (September 2015). Quality of life and physical components linked to sarcopenia: baseline data of the SarcoPhAge study. European Geriatric Medicine, 6S1, 7-s8.
Peer reviewed

GILLAIN, S., Petermans, J., Dardenne, N., Beaudart, C., Buckinx, F., GARRAUX, G., REGINSTER, J.-Y., Bruyère, O., DEMONCEAU, M., WOJTASIK, V., & Schwartz, C. (April 2015). Comparison of body composition, muscle force and physical performances between faller and non-faller people included in a cohort of 100 community dwelling volunteers : the Gaby Study. Journal of Frailty and Aging, 4 (S1), 106.
Peer Reviewed verified by ORBi

Manzambi Kuwekita, J., Eloko Eya Matangelo, G., Bruyère, O., Gosset, C., Guillaume, M., & Reginster, J.-Y. (31 March 2015). Financement de la santé et recouvrement des coûts : le lourd fardeau des ménages congolais. Résultats des comptes nationaux de la santé. Journal d’Épidémiologie et de Santé Publique, 15 (Mars 2015), 15-27.
Peer reviewed

Manzambi Kuwekita, J., Bruyère, O., Guillaume, M., Gosset, C., & Reginster, J.-Y. (23 March 2015). Comment optimiser l’efficience de l’aide internationale, dans le domaine de la santé, en République Démocratique du Congo. Santé Publique: Revue Multidisciplinaire pour la Recherche et l'Action, 27 (Janvier-Févier), 129-134. doi:10.3917/spub.151.0129
Peer Reviewed verified by ORBi

Buckinx, F., Reginster, J.-Y., Dardenne, N., Croisier, J.-L., Kaux, J.-F., Beaudart, C., Slomian, J., & Bruyère, O. (March 2015). Concordance between muscle mass assessed by bioelectrical impedance analysis and by dual energy X-ray absorptionmetry among elderly people: a cross-sectional study. BMC Musculoskeletal Disorders, 16 (1), 60-67. doi:10.1186/s12891-015-0510-9
Peer Reviewed verified by ORBi

Buckinx, F., Reginster, J.-Y., Dardenne, N., Croisier, J.-L., Kaux, J.-F., Beaudart, C., Slomian, J., & Bruyère, O. (March 2015). Concordance between muscle mass assessed by bioelectrical impedance analysis and by dual energy X-ray absorptionmetry among elderly people: a cross-sectional study. Osteoporosis International, 26 (S1), 53.
Peer Reviewed verified by ORBi

Neuprez, A., Bruyère, O., Dardenne, N., Distèche, S., Maheu, E., Burlet, N., & Reginster, J.-Y. (March 2015). Assessment and determinants of aesthetic discomfort in hand osteoarthritis: The Liège Hand Osteoarthritis Cohort (LICOH). Osteoporosis International, 26 (S1), 43-S44.
Peer Reviewed verified by ORBi

Cutolo, M., Berenbaum, F., Hochberg, M., Punzi, L., & Reginster, J.-Y. (2015). Commentary on recent therapeutic guidelines for osteoarthritis. Seminars in Arthritis and Rheumatism, 44, 611-617. doi:10.1016/j.semarthrit.2014.12.003
Peer Reviewed verified by ORBi

Eymard, F., Parsons, C., Edwards, M., Petit-Dop, F., Reginster, J.-Y., Bruyère, O., Richette, P., Cooper, C., & Chevalier, X. (2015). Diabetes is a risk factor for knee osteoarthritis progression. Osteoarthritis and Cartilage, 23, 851-859. doi:10.1016/j.joca.2015.01.013
Peer Reviewed verified by ORBi

Slomian, J., Reginster, J.-Y., Gaspard, U., Streel, S., Beaudart, C., Appelboom, G., Buckinx, F., & Bruyère, O. (2015). Exploring the Interest in and the Usage of the Internet Among Patients Eligible for Osteoporosis Screening. Calcified Tissue International, 96, 518-526. doi:10.1007/s00223-015-9987-3
Peer Reviewed verified by ORBi

McClung, M., Langdahl, B., Papapoulos, S., Saag, K., Adami, S., Bone, H., De Villiers, T., Kiel, D., Kung, A., Kumar KM, P., Lim, S., Ling, X., Lippuner, K., Mautalen, C., Nakamura, T., Reginster, J.-Y., Reid, I., Rodriguez-Portales, A., Roux, C., ... Lombardi, A. (2015). Ocanacatib antifracture efficacy and saftey in postmenopausal women with osteoporosis: results from the phase III long-term adonacatib fracture trial (LOFT). Osteoporosis International, 26 (S1), 35-S36.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Brandi, M., Cannata-Andia, J., Cooper, C., Cortet, B., Feron, J., Genant, H., Palacios, S., Ringe, J., & Rizzoli, R. (2015). The position of Strontium ranelate in today's management of osteoporosis. Osteoporosis International, 26 (S1), 39.
Peer Reviewed verified by ORBi

Bruyère, O., Reginster, J.-Y., & Cooper, C. (2015). Should your Algorithm Include Plasma Rich in Growth Factors in the Light of Its Clinical Efficacy and Safety?: By Vaquerizo V. et al. Seminars in Arthritis and Rheumatism, 44 (4), 12-e13. doi:10.1016/j.semarthrit.2014.09.008
Peer Reviewed verified by ORBi

Beaudart, C., Biver, E., Reginster, J.-Y., Rizzoli, R., Rolland, Y., Bautmans, I., PETERMANS, J., GILLAIN, S., Buckinx, F., van beveren, J., Jacqemain, M., Italiano, P., Dardenne, N., & Bruyère, O. (2015). Development of a self-administrated quality of life questionnaire for sarcopenia in elderly subjects: the SarQol. Age and Ageing, 44, 960-966. doi:10.1093/ageing/afv133
Peer Reviewed verified by ORBi

Reginster, J.-Y., REITER-NIESERT, S., Bruyère, O., BERENBAUM, F., BRANDI, M. L., BRANCO, J., DEVOGELAER, J. P., HERRERO-BAUMONT, G., KANIS, J., MAGGI, S., MAHEU, E., RICHETTE, P., RIZZOLI, R., & COOPER, C. (2015). Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medical products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement. Osteoarthritis and Cartilage, 23, 2086-2093. doi:10.1016/j.joca.2015.07.001
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2015). How can we help implementing ESCEO algorithm in real life? Osteoporosis International, 26 (S1), 382.
Peer Reviewed verified by ORBi

FERRARI, S., ADACHI, J. D., LUPPUNER, K., ZAPALOWSKI, C., MILLER, P. D., Reginster, J.-Y., TORRING, O., KENDLER, D. L., DAIZADEH, N. S., WANG, A., O'MALLEY, C. D., WAGMAN, R. B., LIBANATI, C., & LEWICKI, E. M. (2015). Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Osteoporosis International, 26, 2763-2771. doi:10.1007/s00198-015-3179-x
Peer Reviewed verified by ORBi

Neuprez, A., Bruyère, O., Dardenne, N., DISTECHE, S., MAHEU, E., BURLET, N., D'HOOGHE, P., & Reginster, J.-Y. (2015). Assessment and determinants of aesthetic discomfort in hand osteoarthritis. Annals of the Rheumatic Diseases, 74, 1942. doi:10.1136/annrheumdis-2015-207718
Peer Reviewed verified by ORBi

Buckinx, F., Reginster, J.-Y., CROISIER, J.-L., PETERMANS, J., Goffart, E., & Bruyère, O. (2015). Physical abilities of elderly nursing home residents: The SENIOR cohort. The Journal of Nursing Home Research Sciences, 1, 43-44.
Peer reviewed

Buckinx, F., Reginster, J.-Y., CROISIER, J.-L., PETERMANS, J., Goffart, E., & Bruyère, O. (2015). Relationship between isometric strength of 6 muscle groups of the lower limbs and motor skills among nursing home residents. The Journal of Nursing Home Research Sciences, 1, 44.
Peer reviewed

Bruyère, O., & Reginster, J.-Y. (2015). Quels types d'étude pour quels objectifs ? OncoHemato : Revue Multidisciplinaire d'Oncologie et Hématologie, 9 (1), 34-36.

FOX, B., HENWOOD, T., SCHAAP, L., Bruyère, O., Reginster, J.-Y., Beaudart, C., Buckinx, F., ROBERTS, H., COOPER, C., CHERUBINI, A., dell'AQUILLA, G., MAGGIO, M., & VOLPATO, S. (2015). Adherence to a standardized protocol for measuring grip strength and appropriate cut-off values in adults over 65 years with sarcopenia: a systematic review protocol. JBI Database of Systematic Reviews and Implementation Reports, 13 (10), 50-59. doi:10.11124/jbisrir-2015-2256
Peer Reviewed verified by ORBi

Harvey, N. C., Gluer, C. C., Binkley, N., McCloskey, E. V., Brandi, M.-L., Cooper, C., Kendler, D., Lamy, O., Laslop, A., Camargos, B. M., Reginster, J.-Y., Rizzoli, R., & Kanis, J. A. (2015). Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. BONE, 78, 216-224. doi:10.1016/j.bone.2015.05.016
Peer Reviewed verified by ORBi

Buckinx, F., Reginster, J.-Y., CAVALIER, E., PETERMANS, J., RICOUR, C., Dardenne, C., & Bruyère, O. (2015). Determinants of prescription of vitamin D supplementation in nursing homes: a survey among general practitioners. The Journal of Nursing Home Research Sciences, 1, 43.
Peer reviewed

Beaudart, C., Reginster, J.-Y., Croisier, J.-L., Slomian, J., Buckinx, F., Locquet, M., Quabron, A., & Bruyère, O. (2015). Correlation between muscle mass and muscle strength and their association with physical performance and gait speed. Osteoporosis International, 26 (S1), 49.
Peer Reviewed verified by ORBi

Rabenda, V., Bruyère, O., Kanis, J., Cooper, C., Rizzoli, R., Buckinx, F., Quabron, A., & Reginster, J.-Y. (2015). Publication outcomes of the abstracts presented at the 2011 European Congress on Osteoporosis, Osteoarthritis and Musculo-skeletal Diseases (ECCEO-IOF11). Osteoporosis International, 26 (S1), 211.
Peer Reviewed verified by ORBi

Beaudart, C., Reginster, J.-Y., Rizzoli, R., Rolland, Y., Bautmans, I., Biver, E., Petermans, J., GILLAIN, S., Van Beveren, J., Jacquemain, M., Italiano, P., Dardenne, N., & Bruyère, O. (2015). Development of a self-administrated quality of life questionnaire specific to sarcopenia in elderly aged 65 and older : the SarQol. Journal of Frailty and Aging, 4 (S1), 31-32.
Peer Reviewed verified by ORBi

Buckinx, F., Reginster, J.-Y., Dardenne, N., Beaudart, C., Slomian, J., GILLAIN, S., Petermans, J., RICOUR, C., Goffart, E., & Bruyère, O. (2015). Prevalence of frailty in nursing home residents according to various diagnostic tools. Journal of Frailty and Aging, 4 (S1), 61.
Peer Reviewed verified by ORBi

Bruyère, O., & Reginster, J.-Y. (2015). Letter to the Editor. Seminars in Arthritis and Rheumatism, 44 (5), 15. doi:10.1016/j.semarthrit.2014.09.001
Peer Reviewed verified by ORBi

Reginster, J.-Y., & Bruyère, O. (2015). Recommendation for the management of knee osteoarthritis. Bone, Muscle and Joint Diseases, (S35), 40.
Peer reviewed

Buckinx, F., Reginster, J.-Y., Dardenne, N., Beaudart, C., Slomian, J., GILLAIN, S., Petermans, J., RICOUR, C., Goffart, E., & Bruyère, O. (2015). Prevalence of frailty in nursing home residents according to various diagnostic tools. Osteoporosis International, 26 (S1), 160-S161.
Peer Reviewed verified by ORBi

Papapoulos, S., Roux, C., Bone, H., Dakin, P., Czerwinski, E., Frey, D., Kendler, D., Lewiecki, E., Malouf, J., Mellström, D., Reginster, J.-Y., Resch, H., Daizadeh, N., Wang, A., Gavin, M., Wagman, R., & Brandi, M. (2015). Denosumab treatment in postmenopausal women with osteoporosis for up to 9 years: results through year 6 of the freedom extension. Osteoporosis International, 26 (S1), 37-S39.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Reiter-Niesert, S., Bruyère, O., Berenbaum, F., Brandi, M., Branco, J., Devogelaer, J., Herrero-Beaumont, G., Kanis, J., Maggi, S., Maheu, E., Richette, P., Rizzoli, R., & Cooper, C. (2015). Recommendations for an update of the current (2010) European Regulatory Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes. Osteoporosis International, 26 (S1), 59.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Cooper, C., Rizzoli, R., Kanis, J., Appelboom, G., Bautmans, I., Bischoff-Ferrari, H., Boers, M., Brandi, M., Bruyère, O., Cherubini, A., Flamion, B., Fielding, R., Van Loon, L., McCloskey, E., Mitlak, B., Pilotto, A., Reiter-Niesert, S., Rolland, Y., ... Cruz-Jentoft, A. (2015). Recommendations for the registration of drugs to treat sarcopenia. Osteoporosis International, 26 (S1), 62.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2015). Current regulatory requirements for registration of drugs to be used in osteoarthritis in Europe and need for clarification. Osteoporosis International, 26 (S1), 60.
Peer Reviewed verified by ORBi

NEUPREZ, A., Delcour, J.-P., Fatemi, F., GILLET, P., Mawet, M., François, G., Bruyère, O., CRIELAARD, J.-M., Gosset, C., & Reginster, J.-Y. (2015). Development and validation of the French version of a tool assessing patient's expectations in lower limb osteoarthritis. Journal of Orthopaedics, 12, 46-57. doi:10.1016/j.jor.2014.06.002
Peer Reviewed verified by ORBi

Beaudart, C., Reginster, J.-Y., Slomian, J., Buckinx, F., Locquet, M., Quabron, A., & Bruyère, O. (2015). Health related quality of life in sarcopenia. Osteoporosis International, 26 (S1), 148-149.
Peer Reviewed verified by ORBi

Beaudart, C., Reginster, J.-Y., Petermans, J., GILLAIN, S., Quabron, A., Locquet, M., Slomian, J., Buckinx, F., & Bruyère, O. (2015). Clinical components linked to sarcopenia: the sarcophage study. Osteoporosis International, 26 (S1), 144.
Peer Reviewed verified by ORBi

Beaudart, C., Reginster, J.-Y., Petermans, J., GILLAIN, S., Quabron, A., Locquet, M., Slomian, J., Buckinx, F., & Bruyère, O. (2015). Clinical components linked to sarcopenia: the sarcophage study. Journal of Frailty and Aging, 4 (S1), 89.
Peer Reviewed verified by ORBi

Rabenda, V., Bruyère, O., Cooper, C., Rizzoli, R., Buckinx, F., Quabron, A., & Reginster, J.-Y. (2015). Publication outcomes of the abstracts presented at the 2011 European Congress on Osteoporosis, Osteoarthritis and Musculo-Skeletal Diseases (ECCEO-IOF11) : A position paper of the European Society for Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculo-Skeletal Diseases (ESCEO) and the International Osteoporosis and Other Skeletal Diseases Foundation (IOF). Archives of Osteoporosis, 10 (1). doi:10.1007/s11657-015-0216-5
Peer Reviewed verified by ORBi

Buckinx, F., Croisier, J.-L., Reginster, J.-Y., Dardenne, N., Beaudart, C., Slomian, J., & Bruyère, O. (2015). Reliability of muscle strength measures obtained with a hand-held dynamometer in an elderly population. Osteoporosis International, 26 (S1), 161.
Peer Reviewed verified by ORBi

Neuprez, A., Bruyère, O., MAHEU, E., Dardenne, N., Burlet, N., D'HOOGHE, P., DISTECHE, S., & Reginster, J.-Y. (2015). Aesthetic discomfort in hand osteoarthritis: results from the LIège Hand Osteoarthritis Cohort (LIHOC). Arthritis Research and Therapy, 17, 346. doi:10.1186/s13075-015-0807-y
Peer Reviewed verified by ORBi

Reginster, J.-Y., Cooper, C., Hochberg, M., Pelletier, J.-P., Rizzoli, R., Kanis, J., Abadie, E., Maheu, E., Brandi, M. L., Devogelaer, J.-P., Branco, J., Herrero-Beaumont, G., D'Hooghe, P., & Bruyère, O. (2015). Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis. Current Medical Research and Opinion, 31 (5), 1041-1045. doi:10.1185/03007995.2015.1027183
Peer Reviewed verified by ORBi

Hiligsmann, M., Evers, S. M., Ben Sedrine, W., Kanis, J. A., Ramaekers, B., Reginster, J.-Y., Silverman, S., Wyers, C. E., & Boonen, A. (2015). A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis. PharmacoEconomics, 33 (3), 205-224. doi:10.1007/s40273-014-0231-1
Peer Reviewed verified by ORBi

Beaudart, C., Reginster, J.-Y., Petermans, J., GILLAIN, S., Quabron, A., Locquet, M., Slomian, J., Buckinx, F., & Bruyère, O. (2015). Quality of life and physical components linked to sarcopenia: The SarcoPhAge study. Experimental Gerontology, 69, 103-110. doi:10.1016/j.exger.2015.05.003
Peer Reviewed verified by ORBi

Bruyère, O., Reginster, J.-Y., & Ethgen, O. (2015). La médecine personnalisée : aspects pharmacoéconomiques. Revue Médicale de Liège, 70 (5-6), 339-342.
Peer reviewed

NEUPREZ, A., Bruyère, O., Dardenne, N., DISTECHE, S., Maheu, E., Burlet, N., & Reginster, J.-Y. (2015). Baseline characteristics of the Liège Hand Osteoarthritis Cohort (LIHOC). Annals of the Rheumatic Diseases, 74 (Supp2), 1346. doi:10.1136/annrheumdis-2015-eular.3393
Peer Reviewed verified by ORBi

Langdahl, B. L., Teglbjaerg, C. S., Ho, P.-R., Chapurlat, R., Czerwinski, E., Kendler, D. L., Reginster, J.-Y., Kivitz, A., Lewiecki, E. M., Miller, P. D., Bolognese, M. A., McClung, M. R., Bone, H. G., Ljunggren, O., Abrahamsen, B., Gruntmanis, U., Yang, Y.-C., Wagman, R. B., Mirza, F., ... Orwoll, E. (2015). A 24-month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial. Journal of Clinical Endocrinology and Metabolism, 100 (4), 1335-1342. doi:10.1210/jc.2014-4079
Peer Reviewed verified by ORBi

Slomian, J., LECLERC, A.-F., Maquet, D., JERUSALEM, G., LIFRANGE, E., COUCKE, P., Bury, T., TOMASELLA, M., Reginster, J.-Y., Bruyère, O., & Crielaard, J.-M. (2015). Prevalence of endocrine therapies that could affect bone health in women following a rehabilitation program after surgery for breast cancer. Osteoporosis International, 26 (S1), 375.
Peer Reviewed verified by ORBi

Ferrari, S., Libanati, C., Lin, C., Adami, S., Brown, J., Cosman, F., Czerwinski, E., De Gregorio, L., Malouf, J., Reginster, J.-Y., Daizadeh, N., Wang, A., Wagman, R., Lewiecki, E., & Cummings, S. (2015). Percentage of women achieving non-osteoporotic BMD T-scores at the lumbar spine (LS) and total hip (TH) during up to 8 years of Denosumab (Dmab) treatment. Osteoporosis International, 26 (S1), 149-S150.
Peer Reviewed verified by ORBi

Ethgen, O., Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (2015). Cost-effectiveness of dairy products supplemented with vitamin D in the prevention of osteoporotic fractures. Osteoporosis International, 26 (S1), 372-S373.
Peer Reviewed verified by ORBi

Rabenda, V., Bruyère, O., Cavalier, E., DEROISY, R., LECART, M.-P., COLLETTE, J., & Reginster, J.-Y. (2015). Serum concentrations of osteoprotegerin (OPG) and dickkope-1 (DKK1) poorly predict bone mineral density changes and fracture incidence in postmenopausal osteoporotic women. Osteoporosis International, 26 (S1), 240.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2015). Glucosamine and chondroitin salts in the management of osteoarthritis in Europe. Osteoporosis International, 26 (S1), 60-S61.
Peer Reviewed verified by ORBi

Harvey, N., Binkley, N., Brandi, M., Camargos, B., Cooper, C., Glüer, C., Kanis, J., Kendler, D., Lamy, O., Laslop, A., Reginster, J.-Y., & Rizzoli, R. (2015). Trabecular bone score (TBS) as a new complementary appproach for osteoporosis evaluation in clinical practice. Osteoporosis International, 26 (S1), 60.
Peer Reviewed verified by ORBi

Rizzoli, R., Stevenson, J. C., Bauer, J. M., Van Loon, L. J. C., Walrand, S., Kanis, J. A., Cooper, C., Brandi, M.-L., Diez-Perez, A., & Reginster, J.-Y. (2015). Erratum: The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (Maturitas (2014) 79 (122-132)). Maturitas, 80 (3), 337. doi:10.1016/j.maturitas.2014.11.005
Peer Reviewed verified by ORBi

Buckinx, F., Beaudart, C., Slomian, J., Maquet, D., Demonceau, M., Gillain, S., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2015). Added value of a triaxial accelerometer assessing gait parameters to predict falls and mortality among nursing home residents: A two-year prospective study. Technology and Health Care, 23, 195-203. doi:10.3233/THC-140883
Peer Reviewed verified by ORBi

FERRARI, S., LIBANATI, C., LIN, C., ADAMI, S., BROWN, J. P., COSMAN, F., CZERWINSKI, E., de GREGORIO, L. H., MALOUF, J., Reginster, J.-Y., DAIZADEH, N. S., WANG, A., WAGMAN, R. B., & LEWIECKI, E. M. (2015). Relationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 8 years of denosumab treatment. Arthritis and Rheumatology, 67 (s10), 487-489.
Peer Reviewed verified by ORBi

BROWN, J. P., DAKIN, P., HADJI, P., McCLUNG, M. R., MILLER, P. D., Reginster, J.-Y., WAGMAN, R. B., WANG, A., & McCLOSKEY, E. (2015). Can we use bone turnover markers as targets for antiresorptive treatment in postmenopausal osteoporosis ? an analysis from two phase 3 clinical trials. Arthritis and Rheumatology, 67 (S10), 515-517.
Peer Reviewed verified by ORBi

Ayora, A. F., HERION, F., ROMPEN, E., Reginster, J.-Y., Magremanne, M., & LAMBERT, F. (2015). Dramatic osteonecrosis of the jaw associated with oral bisphosphonates, periodontitis and dental implant removal. Journal of Clinical Periodontology, 42, 190-195. doi:10.1111/jcpe.12322
Peer Reviewed verified by ORBi

Bruyère, O., Reginster, J.-Y., Dardenne, N., Nelis, J., Lambert, E., Appelboom, G., & Buckinx, F. (2015). Relationship between ambulatory physical activity assessed by activity trackers and physical frailty among nursing home residents. The Journal of Nursing Home Research Sciences, 1, 28.
Peer reviewed

Beaudart, C., Reginster, J.-Y., Slomian, J., Dardenne, N., Quabron, A., SLANGEN, C., GILLAIN, S., Petermans, J., & Bruyère, O. (2015). Estimation of sarcopenia prevalence using various assessment tools. Experimental Gerontology, 61, 31-37. doi:10.1016/j.exger.2014.11.014
Peer Reviewed verified by ORBi

Beaudart, C., Reginster, J.-Y., Croisier, J.-L., Slomian, J., Buckinx, F., Locquet, M., Quabron, A., & Bruyère, O. (2015). Is there a specific pattern of lean/fat mass ratio in sarcopenic subjects? Osteoporosis International, 26 (S1), 145-S146.
Peer Reviewed verified by ORBi

Beaudart, C., Reginster, J.-Y., Bautmans, I., Croisier, J.-L., Slomian, J., Buckinx, F., Locquet, M., Quabron, A., & Bruyère, O. (2015). Muscle fatigue resistance and self-perceived fatigue in relation with sarcopenia and quality of life. Journal of Frailty and Aging, 4 (S1), 61-62.
Peer Reviewed verified by ORBi

Beaudart, C., Reginster, J.-Y., Slomian, J., Buckinx, F., Locquet, M., Quabron, A., & Bruyère, O. (2015). Health related quality of life in sarcopenia. Journal of Frailty and Aging, 4 (S1), 61.
Peer Reviewed verified by ORBi

Buckinx, F., Rolland, Y., Reginster, J.-Y., RICOUR, C., Petermans, J., & Bruyère, O. (2015). Burden of frailty in the elderly population: perspectives for a public health challenge. Archives of Public Health, 73 (1), 19-25. doi:10.1186/s13690-015-0068-x
Peer Reviewed verified by ORBi

Reginster, J.-Y., Brandi, M. L., Cannata-Andia, J., Cooper, C., Bortet, B., Genant, H., Palacios, S., Ringe, J. D., Rizzoli, R., & Feron, J. M. (2015). The position of Strontium ranelate in today's management of osteoporosis. Osteoporosis International, 26, 1667-1671. doi:10.1007/s00198-015-3109-y
Peer Reviewed verified by ORBi

Arden, N., Richette, P., Cooper, C., Bruyère, O., Abadie, E., Branco, J., Brandi, M.-L., Berenbaum, F., Clerc, C., Dennison, E., Devogelaer, J.-P., Hochberg, M., D'Hooghe, P., Herrero-Baumont, G., Kanis, J. A., Laslop, A., Leblanc, V., Maggi, S., Mautone, G., ... Reginster, J.-Y. (2015). Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on biomarkers ans frailty. Drugs and Aging, 32, 529-535. doi:10.1007/s40266-015-0276-7
Peer Reviewed verified by ORBi

Bruyère, O., Cooper, C., Arden, N., Branco, J., Brandi, M., Herrero-Beaumont, G., Berenbaum, F., Dennison, E., Devogelaer, J., Hochberg, M., Kanis, J., Laslop, A., McAlindon, T., Reiter, S., Richette, P., Rizzoli, R., & Reginster, J.-Y. (2015). Can we identify patients with high risk of osteoarthritis progression who will respond to treatment ? A focus on epidemiology and phenotype of osteoarthritis. Drugs and Aging, 32 (3), 179-187. doi:10.1007/s40266-015-0243-3
Peer Reviewed verified by ORBi

Cianferotti, L., Cricelli, C., Kanis, J. A., Nuti, R., Reginster, J.-Y., Ringe, J. D., Rizzoli, R., & Brandi, M. L. (2015). The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Endocrine. doi:10.1007/s12020-015-0606-x
Peer Reviewed verified by ORBi

CAVALIER, E., GADISSEUR, R., GEBOES, S., BEKAERT, A.-C., CARLISI, I., Bruyère, O., & Reginster, J.-Y. (2015). Critical evaluation of promising markers for sarcopenia. Osteoporosis International, 26 (S1), 49-S50.
Peer Reviewed verified by ORBi

Beaudart, C., Biver, E., Reginster, J.-Y., Rizzoli, R., Rolland, Y., Bautmans, I., Petermans, J., GILLAIN, S., Buckinx, F., Van Beveren, J., Jacquemain, M., Italiano, P., & Bruyère, O. (2015). Development of a self-administrated quality of life questionnaire specific to sarcopenia in elderly aged 65 years and older: the SARQOL. Osteoporosis International, 26 (S1), 145.
Peer Reviewed verified by ORBi

Neuprez, A., Bruyère, O., Dardenne, N., DISTECHE, S., Maheu, E., Burlet, N., & Reginster, J.-Y. (2015). Baseline characteristics of the Liège hand osteoarthritis cohort (LIHOC). Osteoporosis International, 26 (S1), 167.
Peer Reviewed verified by ORBi

Buckinx, F., Croisier, J.-L., Reginster, J.-Y., PETERMANS, J., Goffart, E., & Bruyère, O. (2015). Relationship between isometric strength of six lower limb muscle groups and motor skills among nursing home residents. Journal of Frailty and Aging, 4 (4), 184-7. doi:10.14283/jfa.2015.70
Peer Reviewed verified by ORBi

Buckinx, F., PAQUOT, N., ALLEPAERTS, S., Reginster, J.-Y., PETERMANS, J., Backes, C., & Bruyère, O. (2015). Energy and nutrient contents of food served and consumed by nursing home residents. The Journal of Nursing Home Research Sciences, 1, 43.
Peer reviewed

Reginster, J.-Y., NEUPREZ, A., LECART, M.-P., Beaudart, C., Buckinx, F., Slomian, J., & Bruyère, O. (2015). Ostéoporose et Médecine Personnalisée. Revue Médicale de Liège, 70 (5-6), 321-324.
Peer reviewed

Buckinx, F., Croisier, J.-L., Reginster, J.-Y., Dardenne, N., Beaudart, C., Slomian, J., & Bruyère, O. (2015). Reliability of eight muscle strength measures obtained with a hand-held dynamometer in an elderly population. Journal of Frailty and Aging, 4 (S1), 60-1.
Peer Reviewed verified by ORBi

APPELBOOM, G., TAYLOR, B. E., BRUCE, E., BASSILE, C. C., MALAKIDIS, C., YANG, A., YOUNGERMAN, B., D'AMICO, R., BRUCE, S., Bruyère, O., Reginster, J.-Y., DUMONT, E., & CONNOLLY, E. S. (2015). Mobile phone-connected wearable motion sensors to assess postoperative mobilization. Journal of Medical Internet Research Mobile and Ubiquitous Health, 3 (3), 78.
Peer reviewed

Neuprez, A., Bruyère, O., Dardenne, N., DISTECHE, S., Maheu, E., Burlet, N., & Reginster, J.-Y. (2015). Assessment and determinants of aesthetic discomfort in hand osteoarthritis: the LIège Hand Osteoarthritis Cohort (LIHOC). Annals of the Rheumatic Diseases, 74 (Supp2), 110. doi:10.1136/annrheumdis-2015-eular.2778
Peer Reviewed verified by ORBi

Hiligsmann, M., Ben Sedrine, W., Bruyère, O., Evers, S. M., Rabenda, V., & Reginster, J.-Y. (2015). Cost-effectiveness of vitamin D and calcium supplementation in the treatment of elderly women and men with osteoporosis. European Journal of Public Health, 25 (1), 20-25. doi:10.1093/eurpub/cku119
Peer Reviewed verified by ORBi

Bruyère, O., & Reginster, J.-Y. (2015). Osteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome. Endocrine, 48 (1), 65-68. doi:10.1007/s12020-014-0357-0
Peer Reviewed verified by ORBi

Delvaux, F., Rochcongar, P., Bruyère, O., DANIEL, C., Reginster, J.-Y., & Croisier, J.-L. (2015). Retour au sport après plastie du ligament croisé antérieur : critères utilisés dans les cubs professionnels de football. Science & Sports, 30, 33-40.
Peer Reviewed verified by ORBi

Lo Presti, M.* , Abraham, M.* , Appelboom, G., Bruyère, O., Slomian, J., Reginster, J.-Y., & Connolly Jr, E. S. (2015). Clinical Trials Using Mobile Health Applications. Pharmaceutical Medicine, 29 (1), 17-25. doi:10.1007/s40290-015-0085-7
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Delvaux, F., Rochcongar, P., Bruyère, O., DANIEL, C., Reginster, J.-Y., & Croisier, J.-L. (2015). Retour au sport après plastie du ligament croisé antérieur: Critères utilisés dans les clubs professionnels de football. Science & Sports, 30 (1), 33-40. doi:10.1016/j.scispo.2014.11.001
Peer Reviewed verified by ORBi

Arden, N. K., Richette, P., Cooper, C., Bruyère, O., Abadie, E. C., Branco, J., Brandi, M., Berenbaum, F., Clerc, C., Dennison, E., Devogelaer, J., Hochberg, M., Herrero-Beaumont, G., Kanis, J., Laslop, A., Leblanc, V., Maggi, S., Mautone, G., Pelletier, J., ... Reginster, J.-Y. (2015). Can we identify patients to be treated in osteoarthritis? Osteoporosis International, 26 (S1), 61-62.
Peer Reviewed verified by ORBi

Beaudart, C., Reginster, J.-Y., Bautmans, I., Croisier, J.-L., Slomian, J., Buckinx, F., Locquet, M., Quabron, A., & Bruyère, O. (2015). Grip fatigue resistance and self-perceived fatigue in relation with sarcopenia and quality of life. Osteoporosis International, 26 (S1), 147-S148.
Peer Reviewed verified by ORBi

Beaudart, C., Reginster, J.-Y., Croisier, J.-L., Slomian, J., Buckinx, F., Locquet, M., Quabron, A., & Bruyère, O. (2015). Correlation between muscle mass and muscle strength and their association with physical performance and gait speed. Journal of Frailty and Aging, 4 (S1), 61.
Peer Reviewed verified by ORBi

Beaudart, C., Reginster, J.-Y., Croisier, J.-L., Slomian, J., Buckinx, F., Locquet, M., Quabron, A., & Bruyère, O. (2015). Is there a specific pattern of lean/fat mass ratio in sarcopenic subjects? Journal of Frailty and Aging, 4 (S1), 61.
Peer Reviewed verified by ORBi

Buckinx, F., Reginster, J.-Y., Dardenne, N., Croisier, J.-L., Kaux, J.-F., Slomian, J., Beaudart, C., & Bruyère, O. (November 2014). Concordance entre la masse musculaire mesurée par impédance bioélectrique et par absorptiométrie radiologique à double énergie. Cahiers de l'Année Gérontologique, 6 (Suppl. 1), 182.
Peer Reviewed verified by ORBi

GILLAIN, S., Schwartz, C., Boutaayamou, M., Demonceau, M., CROISIER, J.-L., Bruls, O., GARRAUX, G., REGINSTER, J.-Y., & PETERMANS, J. (October 2014). Validation des paramètres de marche par un système accélérométrique (Locométrix*) à l'aide d'un système opto-électronique 3D (Coda Motion ). Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 12 (supplément 3).
Peer reviewed

Bruyère, O., & Reginster, J.-Y. (May 2014). Quels types d'étude pour quels objectifs? Medi-Sphere, 445, 38-9.

Manzambi Kuwekita, J., Bruyère, O., & REGINSTER, J.-Y. (31 March 2014). Le rôle du tradipraticien dans l’offre des soins de sante de proximité en zones de sante semi-rurales : résultats d’une étude menée dans la commune périphérique de Kisenso à Kinshasa, Congo. Journal d’Épidémiologie et de Santé Publique, XIII, 59-66.
Peer reviewed

Bruyère, O., Reginster, J.-Y., Bellamy, N., Chapurlat, R., Richette, P., & Cooper, C. (March 2014). Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis. Rheumatology, 53, 1457-64. doi:10.1093/rheumatology/keu018
Peer Reviewed verified by ORBi

Ferrari, S., Adachi, J., Lippuner, K., Zapalowski, C., Miller, P., Reginster, J.-Y., Törring, O., Kendler, D., Daizadeh, N., Wang, A., Omalley, C., Libanati, C., Wagman, R., & Lewiecki, E. (2014). Further reduction in nonvertebral fracture rate is observed following 3 years of denosumab treatment: results with up to 7 years in the freedom extension. Osteoporosis International, 25 (2), 56.
Peer Reviewed verified by ORBi

NEUPREZ, A., François, G., KURTH, W., THIRION, T., DANIEL, C., HUSKIN, J.-P., & Reginster, J.-Y. (2014). Quality of life benefits of knee arthroplasty for osteoarthritis. Osteoporosis International, 25 (2), 40.
Peer Reviewed verified by ORBi

Parsons, C., Edwards, M., Bruyère, O., Petit-Dop, F., Beliaa, P., Genant, H., Guermazi, A., Roemer, F., Zaim, S., Chapurlat, R., Reginster, J.-Y., Dennison, E., & Cooper, C. (2014). Impact of bone marrow lesion on the progression of knee osteoarthritis in the Sekoia study. Osteoporosis International, 25 (2), 142.
Peer Reviewed verified by ORBi

Kanis, J., Johansson, H., Odén, A., McCloskey, E., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2014). A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis: the impact of severe osteoporosis and contraindications. Osteoporosis International, 25 (2), 48-49.
Peer Reviewed verified by ORBi

Hiligsmann, M., Dellaert, B., Dirksen, C., Van der Weijden, T., Watson, V., Goemaere, S., Reginster, J.-Y., Roux, C., Mcgowan, B., Silke, C., Whelan, B., Diez-Perez, A., Torres, E., Papadakis, G., Rizzoli, R., Cooper, C., Pearson, G., & Boonen, A. (2014). Preferences of patients for osteoporosis drug treatment: a cross-european discrete choice experiment. Osteoporosis International, 25 (2), 227-228.
Peer Reviewed verified by ORBi

Parsons, C., Edwards, M., Eymard, F., Reginster, J.-Y., Bruyère, O., Petit-Dop, F., Richette, P., Chevalier, X., Dennison, E., & Cooper, C. (2014). Impact of components of the metabolic syndrome on progression of knee osteoarthritis in the Sekoia study. Osteoporosis International, 25 (2), 230.
Peer Reviewed verified by ORBi

Papapoulos, S., Lippuner, K., Roux, C., Lin, C., Kendler, D., Lewiecki, E., Brandi, M., Czerwinski, E., Franek, E., Lakatos, P., Mautalen, C., Minisola, S., Reginster, J.-Y., Jensen, S., Daizadeh, N., Wang, A., Gavin, M., Wagman, R., & Bone, H. (2014). Eight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the freedom extension. Osteoporosis International, 25 (2), 46-47.
Peer Reviewed verified by ORBi

Buckinx, F., Beaudart, C., Slomian, J., Maquet, D., Demonceau, M., GILLAIN, S., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2014). Facteurs de risque de chute chez des sujets résidant en maison de repos : étude prospective d'une durée de 2 ans. Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 12 (1), 164-165.
Peer reviewed

Eymard, F., Edwards, M., Parsons, C., Cooper, C., Petit-Dop, F., Reginster, J.-Y., Bruyère, O., Richette, P., & Chevalier, X. (2014). Impact of components of the metabolic syndrome on knee osteoarthritis progression in the SEKOIA study. Osteoarthritis and Cartilage, 22 (1), 376.
Peer Reviewed verified by ORBi

Chevalier, X., Richette, P., Bruyère, O., Chapurlat, R., Cooper, C., & Reginster, J.-Y. (2014). Strontium ranelate decreases the number of rapid radiological progressors from the first year in SEKOIA study. Osteoarthritis and Cartilage, 22 (1), 461.
Peer Reviewed verified by ORBi

Beaudart, C., Buckinx, F., Rabenda, V., GILLAIN, S., Cavalier, E., Slomian, J., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2014). The effects of vitamin D on skeletal muscle strength, muscle mass and muscle power: a systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Endocrinology and Metabolism, 99 (11), 4336-4345. doi:10.1210/jc.2014-1742
Peer Reviewed verified by ORBi

Rizzoli, R., Branco, J., Brandi, M., Boonen, S., Bruyère, O., Cacoub, P., Cooper, C., Diez-Perez, A., Duder, J., Fielding, R., Harvey, N., Hiligsmann, M., Kanis, J., Petermans, J., Ringe, J., Tsouderos, Y., Weinman, J., & Reginster, J.-Y. (2014). Erratum to: Management of osteoporosis of the oldest old. Osteoporosis International, 25, 2531. doi:10.1007/s00198-014-2830-2
Peer Reviewed verified by ORBi

McClung, M., Langdahl, B., Papapoulos, S., Saag, K., Adami, S., Bone, H., de Villiers, T., Kiel, D., Kung, A., Kumar, P., Lim, S., Ling, X., Lippuner, K., Mautalen, C., Nakamura, T., Reginster, J.-Y., Reid, I., Rodriguez-Portales, J., Roux, C., ... Lombardi, A. (2014). Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial. Arthritis and Rheumatism, 66 (11), 987.
Peer Reviewed verified by ORBi

Papapoulos, S., McClung, M., Langdahl, B., Saag, K., Adami, S., Bone, H., de Villiers, T., Kiel, D., Kung, A., Kumar, P., Lim, S., Ling, X., Lippuner, K., Mautalen, C., Nakamura, T., Reginster, J.-Y., Reid, I., Rodriguez-Portales, J., Roux, C., ... Gurner, D. (2014). Safety and tolerability of odanacatib therapy in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial. Osteoporosis International, 25 (5), 604-605.
Peer Reviewed verified by ORBi

Bruyère, O., & Reginster, J.-Y. (2014). Monitoring of osteoporosis therapy. Best Practice and Research. Clinical Endocrinology and Metabolism, 28, 835-41. doi:10.1016/j.beem.2014.07.001
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2014). Don't drop the guard: osteoporosis is still a fatal disease ! Medicographia, 36 (2), 139-140.
Peer reviewed

Beaudart, C., Rizzoli, R., Bruyère, O., Reginster, J.-Y., & Biver, E. (2014). Sarcopenia: burden and challenges for public health. Archives of Public Health, 72, 45-60. doi:10.1186/2049-3258-72-45
Peer Reviewed verified by ORBi

Hiligsmann, M., Ben Sedrine, W., Bruyère, O., Jeholet, P., Misson, V., Pire, G., & Reginster, J.-Y. (2014). Economic evaluation of an osteoporosis screening campaign: using FRAX as a prescreening tool. Osteoporosis International, 25 (2), 38-39.
Peer Reviewed verified by ORBi

Eymard, F., Parsons, C., Edwards, M., Petit-Dop, F., Reginster, J.-Y., Bruyère, O., Richette, P., Cooper, C., & Chevalier, X. (2014). Implication des troubles métaboliques dans la progression radiologique de la gonarthrose : analyse post-hoc issue de l'essai randomisé SEKOIA. Revue du Rhumatisme, 81 (Suppl. 1), 92.
Peer Reviewed verified by ORBi

REGINSTER, J.-Y. (2014). Response to Dr Bolland's eLetter: Strontium and cardiovascular events. Annals of the Rheumatic Diseases, 73 (2), 9. doi:10.1136/annrheumdis-2013-204535
Peer Reviewed verified by ORBi

Beaudart, C., Reginster, J.-Y., Slomian, J., Buckinx, F., Quabron, A., Dardenne, N., & Bruyère, O. (2014). Prévalence de la sarcopénie : impact de l'utilisation de différentes valeurs seuils de diagnostic. Cahiers de l'Année Gérontologique, 6 (Suppl. 1), 126.
Peer Reviewed verified by ORBi

Buckinx, F., Reginster, J.-Y., Petermans, J., Beaudart, C., & Bruyère, O. (2014). Effets de la vibrotonie corporelle totale sur le risque de chute de la personne âgée: Mise au point. Ortho-Rhumato, 12 (6), 6-9.

Bruyère, O., Cavalier, E., & Reginster, J.-Y. (2014). La prévalence du déficit en vitamine D en Belgique et en Europe chez les femmes âgées. Ortho-Rhumato, 12 (4), 3.

Buckinx, F., Beaudart, C., Slomian, J., Maquet, D., Demonceau, M., GILLAIN, S., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2014). Evolution over two years of functional and motor abilities among nursing home residents. Journal of Frailty and Aging, 3 (1), 45.
Peer Reviewed verified by ORBi

NEUPREZ, A., Rompen, E., Crielaard, J.-M., & Reginster, J.-Y. (2014). Teriparatide Therapy for Denosumab-Induced Osteonecrosis of the Jaw in a Male Osteoporotic Patient. Calcified Tissue International, 95, 94-96. doi:10.1007/s00223-014-9858-3
Peer Reviewed verified by ORBi

Appelboom, G., Yang, A. H., Christophe, B. R., Bruce, E. M., Slomian, J., Bruyère, O., Bruce, S. S., Zacharia, B. E., Reginster, J.-Y., & Sander Connolly, E. J. (2014). The promise of wearable activity sensors to define patient recovery. Journal of Clinical Neuroscience, 21, 1089-1093. doi:10.1016/j.jocn.2013.12.003
Peer Reviewed verified by ORBi

GILLAIN, S., Schwartz, C., Dramé, M., Demonceau, M., Bruyère, O., Croisier, J.-L., Bruls, O., Garraux, G., Reginster, J.-Y., & Petermans, J. (2014). Validation des paramètres de marche par un système accélérométrique (Locométrix ®) à l’aide d’un système opto-électronique 3D (Coda Motion ®). Cahiers de l'Année Gérontologique, 6 (Suppl. 1), 186.
Peer Reviewed verified by ORBi

Beaudart, C., Buckinx, F., Rabenda, V., CAVALIER, E., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2014). The effects of vitamin D on skeletal muscle strength, muscle mass and muscle power: a meta-analysis of randomized controlled trials. Journal of Frailty and Aging, 3 (1), 27.
Peer Reviewed verified by ORBi

Delvaux, F., Rochcongar, P., Bruyère, O., Bourlet, G., DANIEL, C., Diverse, P., Reginster, J.-Y., & Croisier, J.-L. (2014). Return-to-play criteria after hamstring injury: Actual medicine practice in professional soccer teams. Journal of Sports Science and Medicine, 13, 721-723.
Peer Reviewed verified by ORBi

Beaudart, C., Buckinx, F., Slomian, J., Quabron, A., PETERMANS, J., Reginster, J.-Y., Bruyère, O., & GILLAIN, S. (2014). Prevalence of sarcopenia according to different diagnostic tools. Osteoporosis International, 25 (2), 115.
Peer Reviewed verified by ORBi

Appelboom, G., LoPresti, M., Reginster, J.-Y., Sander Connolly, E., & Dumont, E. P. L. (2014). The quantified patient: a patient participatory culture. Current Medical Research and Opinion, 1-3. doi:10.1185/03007995.2014.954032
Peer Reviewed verified by ORBi

Langdahl, B., Teglbjaerg, C., Ho, P., Chapurlat, R., Czerwinski, E., Kendler, D., Reginster, J.-Y., Kivitz, A., Lewiecki, M., Miller, P., Bolognese, M., McClung, M., Bone, H., Ljunggren, O., Abrahamsen, B., Gruntmanis, U., Yang, Y., Wagman, R., Siddhanti, S., & Orwoll, E. (2014). Denosumab for the treatment of men with low bone mineral density: 24-month results from the Adamo Trial. Endocrine Reviews, 35 (3), 22-1.
Peer Reviewed verified by ORBi

Buckinx, F., Beaudart, C., Slomian, J., Maquet, D., Demonceau, M., GILLAIN, S., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2014). Evolution sur deux ans des capacités fonctionnelles et motrices de sujets âgés résidant en maison de repos. Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 12 (1), 57-58.
Peer reviewed

Parsons, C., Edwards, M., Bruyère, O., Belissa, P., Genant, H., Guermazi, A., Roemer, F., Zaim, S., Reginster, J.-Y., Dennison, E., & Cooper, C. (2014). Impact of bone marrow lesion on the progression of knee osteoarthritis in the SEKOIA study. Rheumatology, 53 (1), 130.
Peer Reviewed verified by ORBi

Hiligsmann, M., Dellaert, B. G., Dirksen, C. D., van der Weijden, T., Goemaere, S., Reginster, J.-Y., Watson, V., & Boonen, A. (2014). Patients' preferences for osteoporosis drug treatment: a discrete-choice experiment. Arthritis Research and Therapy, 16 (1), 36. doi:10.1186/ar4465
Peer Reviewed verified by ORBi

McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., Katz, L., Maddox, J., Yang, Y.-C., Libanati, C., & Bone, H. G. (2014). Romosozumab in Postmenopausal Women with Low Bone Mineral Density. New England Journal of Medicine, 370, 412-420. doi:10.1056/NEJMoa1305224
Peer Reviewed verified by ORBi

Rizzoli, R., Dawson-Hughes, B., Kaufman, J.-M., Fardellone, P., Brandi, M. L., Vellas, B., COLLETTE, J., & Reginster, J.-Y. (2014). Correction of vitamin D insufficiency with combined strontium ranelate and vitamin D3 in osteoporotic patients. European Journal of Endocrinology, 170 (3), 441-50. doi:10.1530/EJE-13-0775
Peer Reviewed verified by ORBi

Buckinx, F., Beaudart, C., Slomian, J., Maquet, D., Demonceau, M., GILLAIN, S., PETERMANS, J., Reginster, J.-Y., & Bruyère, O. (2014). Risk factors for falls among elderly nursing home residents: a 2-year prospective study. Osteoporosis International, 25 (2), 36-37.
Peer Reviewed verified by ORBi

Slomian, J., Streel, S., Appleboom, G., Beaudart, C., Buckinx, F., Reginster, J.-Y., & Bruyère, O. (2014). Could internet use be promising in health prevention and promotion in menopausal women ? A preliminary report. Osteoporosis International, 25 (2), 309.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2014). An algorithm guideline for the management of knee osteoarthritis in Europe: A report from a taskforce of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Osteoporosis International, 25 (2), 66.
Peer Reviewed verified by ORBi

Slomian, J., Reginster, J.-Y., Ethgen, O., Appelboom, G., & Bruyère, O. (2014). Opportunity and challenges of eHealth and mHealth for patients and caregivers. Austin Journal of Public Health and Epidemiology, 1 (2), 3-5.
Peer reviewed

Reginster, J.-Y., NEUPREZ, A., Dardenne, N., Beaudart, C., & Bruyère, O. (2014). Efficacy and safety of currently marketed anti-osteoporosis medications. Best Practice and Research. Clinical Endocrinology and Metabolism, 28, 809-34. doi:10.1016/j.beem.2014.09.003
Peer Reviewed verified by ORBi

Hiligsmann, M., Cooper, C., Guillemin, F., Hochberg, M. C., Tugwell, P., Arden, N., Berenbaum, F., Boers, M., Boonen, A., Branco, J. C., Maria-Luisa, B., Bruyère, O., Gasparik, A., Kanis, J. A., Kvien, T. K., Martel-Pelletier, J., Pelletier, J.-P., Pinedo-Villanueva, R., Pinto, D., ... Reginster, J.-Y. (2014). A reference case for economic evaluations in osteoarthritis: An expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 44, 271-282. doi:10.1016/j.semarthrit.2014.06.005
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2014). Algorithm for the symptomatic and structural treatment of osteoarthritis. Osteoporosis International, 25 (5), 564.
Peer Reviewed verified by ORBi

DELANAYE, P., KRZESINSKI, J.-M., Warling, X., Moonen, M., Smelten, N., Médart, M., Bruyère, O., REGINSTER, J.-Y., Pottel, H., & CAVALIER, E. (2014). Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron. Clinical Practice, 128, 127-134. doi:10.1159/000366449
Peer Reviewed verified by ORBi

Buckinx, F., Beaudart, C., Maquet, D., Demonceau, M., Crielaard, J.-M., Reginster, J.-Y., & Bruyère, O. (2014). Evaluation of the impact of 6-month training by whole body vibration on the risk of falls among nursing home residents, observed over a 12-month period: a single blind, randomized controlled trial. Aging Clinical and Experimental Research, 26 (4), 369-376. doi:10.1007/s40520-014-0197-z
Peer Reviewed verified by ORBi

Arden, N., Blanco, F., Cooper, C., Guermazi, A., Hayashi, D., Hunter, D., Javaid, M., Rannou, F., Roemer, F., & Reginster, J.-Y. (2014). Atlas of osteoarthritis. Springer Verlag.

Beaudart, C., Reginster, J.-Y., Slomian, J., Buckinx, F., & Bruyère, O. (2014). Association entre la masse musculaire totale et la densité minérale osseuse de la hanche. Cahiers de l'Année Gérontologique, 6 (Suppl. 1), 125-6.
Peer Reviewed verified by ORBi

Reginster, J.-Y., NEUPREZ, A., Beaudart, C., Buckinx, F., Slomian, J., Distèche, S., & Bruyère, O. (2014). Bone forming agents for the management of osteoporosis. Panminerva Medica, 56 (2), 97-114.
Peer Reviewed verified by ORBi

Reginster, J.-Y., NEUPREZ, A., Beaudart, C., LECART, M.-P., Sarlet, N., Bernard, D., Distèche, S., & Bruyère, O. (2014). Antiresorptive Drugs Beyond Bisphosphonates and Selective Oestrogen Receptor Modulators for the Management of Postmenopausal Osteoporosis. Drugs and Aging, 31, 413-424. doi:10.1007/s40266-014-0179-z
Peer Reviewed verified by ORBi

Ellis, A. G., Reginster, J.-Y., Luo, X., Bushmakin, A. G., Williams, R., Sutradhar, S., Mirkin, S., & Jansen, J. P. (2014). Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women. Current Medical Research and Opinion, 30 (8), 1617-1626. doi:10.1185/03007995.2014.908279
Peer Reviewed verified by ORBi

Beaudart, C., Reginster, J.-Y., Slomian, J., Buckinx, F., Locquet, M., & Bruyère, O. (2014). Prevalence of sarcopenia: the impact of different diagnostic cut-off limits. Journal of Musculoskeletal and Neuronal Interactions, 14 (4), 425-31.
Peer Reviewed verified by ORBi

Beaudart, C., GILLAIN, S., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2014). Sarcopénie. Quoi de neuf en 2014 ? Revue Médicale de Liège, 69 (5-6), 251-257.
Peer reviewed

Beaudart, C., SLANGEN, C., Buckinx, F., Slomian, J., Quabron, A., Petermans, J., GILLAIN, S., Reginster, J.-Y., & Bruyère, O. (2014). Evaluation de la prévalence de la sarcopénie selon différents outils de diagnostic. Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 12 (1), 42.
Peer reviewed

Beaudart, C., Buckinx, F., Slomian, J., Quabron, A., Petermans, J., GILLAIN, S., Reginster, J.-Y., & Bruyère, O. (2014). Prevalence of sarcopenia according to different diagnostic tools. Journal of Frailty and Aging, 3 (1), 43.
Peer Reviewed verified by ORBi

Douxfils, J., Buckinx, F., Mullier, F., Minet, V., Rabenda, V., Reginster, J.-Y., Hainaut, P., Bruyère, O., & Dogne, J.-M. (2014). Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal of the American Heart Association, 3 (3), 000515. doi:10.1161/JAHA.113.000515
Peer Reviewed verified by ORBi

Donneau, A.-F., & Reginster, J.-Y. (2014). Cardiovascular safety of strontium ranelate: real-life assessment in clinical practice. Osteoporosis International, 25, 397-398. doi:10.1007/s00198-013-2583-3
Peer Reviewed verified by ORBi

Bruyère, O., Slomian, J., Beaudart, C., Buckinx, F., CAVALIER, E., GILLAIN, S., PETERMANS, J., & Reginster, J.-Y. (2014). Prevalence of vitamin D inadequacy in European women aged over 80 years. Osteoporosis International, 25 (2), 196.
Peer Reviewed verified by ORBi

Kanis, J. A., McCloskey, E., Branco, J., Brandi, M.-L., Dennison, E., Devogelaer, J.-P., Ferrari, S., Kaufman, J.-M., Papapoulos, S., Reginster, J.-Y., & Rizzoli, R. (2014). Goal-directed treatment of osteoporosis in Europe. Osteoporosis International, 25 (11), 2533-2543. doi:10.1007/s00198-014-2787-1
Peer Reviewed verified by ORBi

Cortet, B., Rizzoli, R., & Reginster, J.-Y. (2014). Ranélate de strontium : diminution du risque cardiaque observé dans le traitement de l'ostéoporose sévère par l'ajout de nouvelles contre-indications cardiovasculaires [Poster presentation]. 27ème Congrès Français de Rhumatologie, Paris, France.

Bruyère, O., Demoulin, M., Beaudart, C., Hill, J. C., Maquet, D., Genevay, S., Mahieu, G., REGINSTER, J.-Y., Crielaard, J.-M., & Demoulin, C. (2014). Validity and Reliability of the French Version of the STarT Back Screening Tool for Patients With Low Back Pain. Spine, 39 (2), 123-E128. doi:10.1097/BRS.0000000000000062
Peer Reviewed verified by ORBi

Buckinx, F., Reginster, J.-Y., Cavalier, E., Slomian, J., Beaudart, C., & Bruyère, O. (2014). Evaluation du nombre de résidents en maison de retraite médicalisée bénéficiant d'une supplémentation en vitamine D. Cahiers de l'Année Gérontologique, 6 (Suppl. 1), 68.
Peer Reviewed verified by ORBi

Buckinx, F., Beaudart, C., Slomian, J., Maquet, D., Demonceau, M., GILLAIN, S., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2014). Prognostic factors of death among nursing homes residents followed prospectively for a period of 2 years. Journal of Frailty and Aging, 3 (1), 40.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Kaufman, J., & Gangjii, V. (2014). Preference for and acceptability of two formulations of a dietary supplement containing calcium plus vitamin D3: a randomized, open-label, crossover trial in adult patients with calcium and vitamin D deficiencies. Current Therapeutic Research, 66 (1), 23-34.
Peer Reviewed verified by ORBi

Beaudart, C., Buckinx, F., Rabenda, V., GILLAIN, S., CAVALIER, E., Slomian, J., PETERMANS, J., Reginster, J.-Y., & Bruyère, O. (2014). The effects of vitamin D on skeletal muscle strength, muscle mass and muscle power: a meta-analysis of randomized controlled trials. Osteoporosis International, 25 (2), 46.
Peer Reviewed verified by ORBi

Buckinx, F., Beaudart, C., Slomian, J., Maquet, D., Demonceau, M., GILLAIN, S., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2014). Evolution over two years of functional and motor abilities among nursing home residents. Osteoporosis International, 25 (2), 121.
Peer Reviewed verified by ORBi

Buckinx, F., Slomian, J., Maquet, D., Demonceau, M., GILLAIN, S., PETERMANS, J., Reginster, J.-Y., & Bruyère, O. (2014). Prognostic factors of death among nursing homes residents followed prospectively for a period of 2 years. Osteoporosis International, 25 (2), 121-122.
Peer Reviewed verified by ORBi

Kanis, J., Rizzoli, R., Cooper, C., & Reginster, J.-Y. (2014). Challenges for the development of bone forming agents in Europe: introduction. Osteoporosis International, 25 (2), 66-67.
Peer Reviewed verified by ORBi

Bruyère, O., & Reginster, J.-Y. (2014). Vitamine D et sujet âgé. Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 12 (1), 5-6.
Peer reviewed

Miller, P., Recker, R., Harris, S., Silverman, S., Felsenberg, D., Reginster, J.-Y., Day, B., Barr, C., & Masanauskaite, D. (2014). Long-term fracture rates seen with continued ibandronate treatment : pooled analysis of DIVA and MOBILE long-term extension studies. Osteoporosis International, 25 (1), 349-357. doi:10.1007/s00198-013-2518-z
Peer Reviewed verified by ORBi

Lotz, M., Martel-Pelletier, J., Christiansen, C., Brandi, M.-L., Bruyère, O., Chapurlat, R., Collette, J., Cooper, C., Giacovelli, G., Kanis, J. A., Karsdal, M. A., Kraus, V., Lems, W. F., Meulenbelt, I., Pelletier, J.-P., Raynauld, J.-P., Reiter-Niesert, S., Rizzoli, R., Sandell, L. J., ... Reginster, J.-Y. (2014). Republished: Value of biomarkers in osteoarthritis: current status and perspectives. Postgraduate Medical Journal, 90 (1061), 171-8.
Peer Reviewed verified by ORBi

Beaudart, C., Reginster, J.-Y., Slomian, J., Buckinx, F., & Bruyère, O. (2014). Association between lean mass and hip bone mineral density. Arthritis and Rheumatism, 66 (11), 95.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2014). Préface. Best Practice and Research. Clinical Endocrinology and Metabolism, 28, 765. doi:10.1016/j.beem.2014.09.005
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2014). L'ostéoporose demeure une maladie fatale : la vigilance reste de mise. Medicographia, 36 (2), 141-142.
Peer reviewed

Bruyère, O., Slomian, J., Beaudart, C., Buckinx, F., Cavalier, E., GILLAIN, S., Petermans, J., & Reginster, J.-Y. (2014). Prevalence of vitamin D inadequacy in European women aged over 80 years. Archives of Gerontology and Geriatrics, 59, 78-82. doi:10.1016/j.archger.2014.03.010
Peer Reviewed verified by ORBi

Edwards, M., Parsons, C., Eymard, F., Reginster, J.-Y., Bruyère, O., Petit-Dop, F., Richette, P., Chavalier, X., Dennison, E., & Cooper, C. (2014). Impact of components of the metabolic syndrome on progression of knee osteoarthritis in the SEKOIA study. Rheumatology, 53 (1), 31.
Peer Reviewed verified by ORBi

Appelboom, G., Camacho, E., Abraham, M., Bruce, S., Dumont, E., Zacharia, B., D'Amico, R., Slomian, J., Reginster, J.-Y., Bruyère, O., & Connolly, E. (2014). Smart wearable body sensors for patient self-assessment and monitoring. Archives of Public Health, 72, 28-44. doi:10.1186/2049-3258-72-28
Peer Reviewed verified by ORBi

Reginster, J.-Y., NEUPREZ, A., LECART, M.-P., Sarlet, N., Distèche, S., & Bruyère, O. (2014). Traitement de l'osteoporose post-menopausique: quoi de neuf en 2014? Revue Médicale de Liège, 69 (7-8), 441-53.
Peer reviewed

LoPresti, M., Appelboom, G., Bruyère, O., Reginster, J.-Y., Klug, E., & Connolly Jr, E. S. (2014). Patient engagement in clinical research through mobile technology. Clinical Practice, 11 (6), 549-51. doi:10.2217/CPR.14.68
Peer Reviewed verified by ORBi

Slomian, J., GASPARD, U., Reginster, J.-Y., Streel, S., Beaudart, C., Appelboom, G., Buckinx, F., & Bruyère, O. (2014). Des interventions de prévention ou de promotion de la santé utilisant Internet pourraient-elles être prometteuses chez des femmes aux alentours de la ménopause ? Cahiers de l'Année Gérontologique, 6 (Suppl. 1), 205.
Peer Reviewed verified by ORBi

NEUPREZ, A., François, G., KURTH, W., THIRION, T., DANIEL, C., HUSKIN, J.-P., Gillet, P., & Reginster, J.-Y. (2014). Radiological and clinical profile of osteoarthritis patients undergoing total knee replacement surgery. Osteoporosis International, 25 (2), 358.
Peer Reviewed verified by ORBi

Slomian, J., Streel, S., Appleboom, G., Beaudart, C., Buckinx, F., Reginster, J.-Y., & Bruyère, O. (2014). Internet as a tool for health: survey on the interest and the use of the internet among subjects from an osteoporosis centre - A preliminary report. Osteoporosis International, 25 (2), 64.
Peer Reviewed verified by ORBi

Roux, C., Binkley, N., Boonen, S., Kiel, D. P., Ralston, S. H., Reginster, J.-Y., Pong, A., Rosenberg, E., & Santora, A. (2014). Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis. Calcified Tissue International, 94 (2), 153-7. doi:10.1007/s00223-013-9763-1
Peer Reviewed verified by ORBi

Slomian, J., Appelboom, G., Ethgen, O., Reginster, J.-Y., & Bruyère, O. (2014). Can new information and communication technologies help in the management of osteoporosis ? Women's Health, 10 (3), 229-232. doi:10.2217/whe.14.15
Peer Reviewed verified by ORBi

Kanis, J. A., Rizzoli, R., Cooper, C., & Reginster, J.-Y. (2014). Challenges for the Development of Bone-Forming Agents in Europe. Calcified Tissue International, 94, 469-473. doi:10.1007/s00223-014-9844-9
Peer Reviewed verified by ORBi

Ellis, A., Reginster, J.-Y., Luo, X., Cappelleri, J., Chines, A., Sutradhar, S., & Jansen, J. (2014). Bazedoxifene versus oral bisphosphonates for the prevention of nonvertebral fractures in postmenopausal women with osteoporosis at higher risk of fracture: a network meta-analysis. Value in Health, 17, 424-432. doi:10.1016/j.jval.2014.01.008
Peer Reviewed verified by ORBi

Buckinx, F., Beaudart, C., Slomian, J., Maquet, D., Demonceau, M., GILLAIN, S., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2014). Facteurs pronostiques de décès chez des sujets résidant en maison de repos suivis d'une manière prospective pendant une période de 2 ans. Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 12 (1), 73-74.
Peer reviewed

Beaudart, C., Buckinx, F., Rabenda, V., GILLAIN, S., CAVALIER, E., Slomian, J., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2014). Les effets d'une supplémentation en vitamine D sur la force, la masse et la puissance musculaire : une méta-analyse d'essais randomisés contrôlés. Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 12 (1), 73.
Peer reviewed

Reginster, J.-Y., Ferrari, S., & Hadji, P. (2014). Current challenges in the treatment of osteoporosis: an opportunity for bazedoxifene. Current Medical Research and Opinion, 30 (6), 1165-1176. doi:10.1185/03007995.2014.890927
Peer Reviewed verified by ORBi

Appelboom, G., Sussman, E. S., Raphael, P., Julliere, Y., Reginster, J.-Y., & Connolly, E. S. (2014). A Critical Assessment of Approaches to Outpatient Monitoring. Current Medical Research and Opinion, 1-2. doi:10.1185/03007995.2014.904774
Peer Reviewed verified by ORBi

GILLAIN, S., ELBOUZ, L., Beaudart, C., Bruyère, O., Reginster, J.-Y., & PETERMANS, J. (2014). Les chutes de la personne âgée. Revue Médicale de Liège, 69 (5-6), 258-264.
Peer reviewed

Beaudart, C., Reginster, J.-Y., Cavalier, E., & Bruyère, O. (2014). Les effets d'une supplémentation en vitamine D sur la fonction musculaire. Ortho-Rhumato, 12 (5), 33-37.

Lewieck, E., Papapoulos, S., Lippuner, K., Roux, C., Lin, C., Kendler, D., Brandi, M., Czerwinski, E., Franek, E., Lakatos, P., Minisola, S., Reginster, J.-Y., Jensen, S., Kaizadeh, N., Wang, A., Gavin, M., Wagman, R., & Bone, H. (2014). Effect of denosumab treatment in postmenopausal women with osteoporosis: eight-year results from the freedom extension, phase 3 clinical trial. Endocrine Reviews, 35 (3), 22-1.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2014). Cardiac concerns associated with strontium ranelate. Expert Opinion on Drug Safety, 13 (9), 1-5. doi:10.1517/14740338.2014.939169
Peer Reviewed verified by ORBi

Rizzoli, R., Stevenson, J., Bauer, J., Van Loon, L., Walrand, S., Kanis, J., Cooper, C., Brandi, M., Diez-Perez, A., & Reginster, J.-Y. (2014). The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women : A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Maturitas, 79, 122-132. doi:10.1016/j.maturitas.2014.07.005
Peer Reviewed verified by ORBi

McClung, M., Langdahl, B., Papapoulos, S., Saag, K., Adami, S., Bone, H., de Villiers, T., Kiel, D., Kung, A., Kumar, P., Lim, S., Ling, X., Lippuner, K., Mautalen, C., Nakamura, T., Reginster, J.-Y., Reid, I., Rodriguez-Portales, J., Roux, C., ... Lombardi, A. (2014). Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial. Osteoporosis International, 25 (5), 573-575.
Peer Reviewed verified by ORBi

Ferrari, S., Libanati, C., Lin, C., Adami, S., Brown, J., Cosman, F., Czerwinski, E., de Gregorio, L., Malouf, J., Reginster, J.-Y., Daizadeh, N., Wang, A., Wagman, R., Lewiecki, E., & Cummings, S. (2014). Percentage of women achieving non-osteoporotic BMD T-scores at the spine and hip over 8 years of denosumab treatment. Arthritis and Rheumatism, 66 (11), 986-S987.
Peer Reviewed verified by ORBi

Bruyère, O., Cooper, C., Pelletier, J., Branco, J., Brandi, L., Guillemin, F., Hochberg, M., Kanis, J., Kvien, T., Martel-Pelletier, J., Rizzoli, R., Silverman, S., & Reginster, J.-Y. (2014). An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 44, 253-263. doi:10.1016/j.semarthrit.2014.05.014
Peer Reviewed verified by ORBi

Marcucci, G., Zimran, A., Bembi, B., Kanis, J., Reginster, J.-Y., Rizzoli, R., Cooper, C., & Brandi, M. L. (2014). Gaucher Disease and Bone Manifestations. Calcified Tissue International, 95 (6), 477-494. doi:10.1007/s00223-014-9923-y
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2014). Introduction: historical and current perspectives on osteoarthritis. In N. Arden, F. Blanco, C. Cooperr, A. Guermazi, D. Hayashi, D. Hunter, M. Jawaid, F. Rannou, F. Roemer, ... J.-Y. Reginster (Eds.), Atlas of Osteoarthritis (pp. 11-19). Springer Verlag.
Peer reviewed

Rizzoli, R., Branco, J., Brandi, M.-L., Boonen, S., Bruyère, O., Cacoub, P., Cooper, C., Diez-Perez, A., Duder, J., Fielding, R. A., Harvey, N. C., Hiligsmann, M., Kanis, J. A., Petermans, J., Ringe, J. D., Tsouderos, Y., Weinman, J., & Reginster, J.-Y. (2014). Management of osteoporosis of the oldest old. Osteoporosis International, 25, 2507-2529. doi:10.1007/s00198-014-2755-9
Peer Reviewed verified by ORBi

NEUPREZ, A., Coste, S., Rompen, E., Crielaard, J.-M., & REGINSTER, J.-Y. (2014). Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab. Osteoporosis International, 25, 393-395. doi:10.1007/s00198-013-2437-z
Peer Reviewed verified by ORBi

Bruyère, O., CAVALIER, E., Souberbielle, J.-C., Bischoff-Ferrari, H., Beaudart, C., Buckinx, F., Reginster, J.-Y., & Rizzoli, R. (2014). Effects of vitamin D in the elderly population : current status and perspectives. Archives of Public Health, 72, 32-42. doi:10.1186/2049-3258-72-32
Peer Reviewed verified by ORBi

Manzambi Kuwekita, J., Bruyère, O., REGINSTER, J.-Y., Buhendwa, E., Bokanga, R., & Mwanyimi, P. (19 December 2013). Les acteurs non étatiques jouent un rôle déterminant dans le fonctionnement des services publics en territoires périurbains [Poster presentation]. Territoires périurbains: développement, enjeux et perspectives dans les pays du Sud, Gembloux, Belgium.

Manzambi Kuwekita, J., Mbadu Kivuidi, V., Bruyère, O., & Reginster, J.-Y. (19 December 2013). Le tradipraticien est un acteur crédible dans l'offre des soins en territoire périurbain: Résultats d'une étude menée dans la commune de Kisenso à Kinshasa, Congo [Paper presentation]. Colloque Territoires périurbains: Développement, Enjeux et Perspectives dans les Pays du Sud, Gembloux, Belgium.

Manzambi Kuwekita, J., Guillaume, M., Balula Semutsari, M.-P., Tshiama Kabongo, E., Mayamba Kilela, J., Bruyère, O., & Reginster, J.-Y. (December 2013). Étude des conditions de vie et d’accessibilité aux soins de santé de qualité des populations en situation de précarité, dans la zone de sante de Bandalungwa à Kinshasa (Congo) grâce à la micro-assurance santé en 2008. Journal d’Épidémiologie et de Santé Publique, 12, 47-61.
Peer reviewed

Beaudart, C., Buckinx, F., Rabenda, V., GILLAIN, S., CAVALIER, E., Slomian, J., PETERMANS, J., Reginster, J.-Y., & Bruyère, O. (28 November 2013). Les effets d’une supplémentation en vitamine D sur la force musculaire : une méta-analyse d’essais randomisés contrôlés [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Bruxelles, Belgium.

Buckinx, F., Beaudart, C., Maquet, D., Demonceau, M., CRIELAARD, J.-M., Reginster, J.-Y., & Bruyère, O. (28 November 2013). Etude de l'impact d'un entraînement de 6 mois par vibrothérapie sur le risque de chute, observé pendant une durée d'un an, chez les patients résidant en maison de repos. Etude randomisée contrôlée menée en simple aveugle [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Bruxelles, Belgium.

Manzambi Kuwekita, J., Gosset, C., Guillaume, M., Nsita Zaya Nsita, B., Tshefu Pongo, G., Eloko Eya Matangelo, G., Balula Semutsari, M.-P., Tshiama Kabongo, E., Bruyère, O., & REGINSTER, J.-Y. (30 September 2013). Micro-crédit, Augmentation du pouvoir d’achat et Amélioration des conditions de vie des populations précaires en milieu urbain africain : Résultats d’une expérience menée dans la zone de santé de Bandalungwa à Kinshasa, Congo. Psychologie et Société Nouvelle, XII (3), 3-14.
Peer reviewed

Bruyère, O., Slomian, J., Beaudart, C., Buckinx, F., Cavalier, E., GILLAIN, S., Petermans, J., & Reginster, J.-Y. (September 2013). Importance du déficit en vitamine D chez les femmes françaises ostéoporotiques et ostéopéniques âgées de plus de 80 ans. Cahiers de l'Année Gérontologique, 5 (1-2), 75.
Peer Reviewed verified by ORBi

Buckinx, F., Beaudart, C., Demonceau, M., Maquet, D., Crielaard, J.-M., Reginster, J.-Y., & Bruyère, O. (September 2013). Evaluation de l'impact d'un entraînement de six mois par vibrotonie corporelle sur le risque de chute des patients résidant en maison de repos, observé pendant une période de 12 mois. Cahiers de l'Année Gérontologique, 5 (1-2), 119-120.
Peer Reviewed verified by ORBi

Beaudart, C., Buckinx, F., Maquet, D., Crielaard, J.-M., Reginster, J.-Y., & Bruyère, O. (September 2013). Caractéristiques cliniques des sujets répondeurs à la vibrotonie corporelle totale. Cahiers de l'Année Gérontologique, 5 (1-2), 118-119.
Peer Reviewed verified by ORBi

Croisier, J.-L., Rochcongar, P., Bruyère, O., Reginster, J.-Y., Bourlet, G., Diverse, P., DANIEL, C., & Delvaux, F. (September 2013). Critères de retour sur le terrain après plastie LCA chez le footballeur professionnel. European Journal of Sports Medicine, 1 (1).
Peer Reviewed verified by ORBi

Beaudart, C., Buckinx, F., Rabenda, V., GILLAIN, S., CAVALIER, E., Petermans, J., Reginster, J.-Y., & Bruyère, O. (September 2013). Les effets d'une supplémentation en vitamine D sur la force musculaire : une méta-analyse d'essais randomisés contrôlés. Cahiers de l'Année Gérontologique, 5 (1-2), 38.
Peer Reviewed verified by ORBi

Bruyère, O., Hiligsmann, M., Zegels, B., NEUPREZ, A., & Reginster, J.-Y. (September 2013). Risk of hip fracture in community-dwelling and institutionalized osteoporotic patients: A 3-year study. International Journal of Gerontology, 7 (3), 167-70. doi:10.1016/j.ijge.2012.11.015
Peer Reviewed verified by ORBi

Rizzoli, R., Reginster, J.-Y., Arnal, J.-F., Bautmans, I., Beaudart, C., Bischoff-Ferrari, H., Biver, E., Boonen, S., Brandi, M.-L., Chines, A., Cooper, C., Epstein, S., Fielding, R. A., Goodpaster, B., Kanis, J. A., Kaufman, J.-M., Laslop, A., Malafarina, V., Rodriguez Mañas, L., ... Bruyère, O. (July 2013). Quality of life in sarcopenia and frailty. Calcified Tissue International, 93, 101-120. doi:10.1007/s00223-013-9758-y
Peer Reviewed verified by ORBi

Bruyère, O., Beaudart, C., Buckinx, F., Reginster, J.-Y., Maquet, D., & Mourey, F. (June 2013). Effets de la Whole body vibration sur le risque de chute de la personne âgée : une mise au point. Kinésithérapie Scientifique, 544, 55-58.
Peer reviewed

Cooper, C., Adachi, J. D., Bardin, T., Berenbaum, F., Flamion, B., Jonsson, H., Kanis, J. A., Pelousse, F., Lems, W. F., Pelletier, J.-P., Martel-Pelletier, J., Reiter, S., Reginster, J.-Y., Rizzoli, R., & Bruyère, O. (June 2013). How to define responders in osteoarthritis. Current Medical Research and Opinion, 29 (6), 719-29. doi:10.1185/03007995.2013.792793
Peer Reviewed verified by ORBi

Delvaux, F., Rochcongar, P., Bruyère, O., Bourlet, G., DANIEL, C., Diverse, P., Reginster, J.-Y., & Croisier, J.-L. (25 April 2013). Return-To-Play criteria after hamstring injury: actual medicine practice in professional soccer [Poster presentation]. 3rd congress of the European College of Sport and Exercise Physicians, Frankfurt am Main, Germany.
Peer reviewed

Reginster, J.-Y., Pelousse, F., & Bruyère, O. (April 2013). Safety concerns with the long-term management of osteoporosis. Expert Opinion on Drug Safety, 12 (4), 507-22. doi:10.1517/14740338.2013.793669
Peer Reviewed verified by ORBi

Lotz, M., Martel-Pelletier, J., Christiansen, C., Berenbaum, F., Brandi, M. L., Bruyère, O., Chapurlat, R., COLLETTE, J., Cooper, C., Heinegard, D., Kanis, J. A., Kraus, V., Laslop, A., Lems, W., Lohmander, S., Meulenbelt, I., Pelletier, J.-P., Raynauld, J.-P., Reiter, S., ... Reginster, J.-Y. (April 2013). What is the value of biomarkers for drug development in osteoarthritis? Osteoporosis International, 24 (Suppl.1), 77-78.
Peer Reviewed verified by ORBi

Hiligsmann, M., Cooper, C., Arden, N., Boers, M., Branco, J., Brandi, M. L., Bruyère, O., Guillemin, F., Hochberg, M., Hunter, D., Kanis, J. A., Kvien, T., Laslop, A., Petit-Dop, F., Pelletier, J.-P., Pinto, D., Reiter, S., Rizzoli, R., Rovati, L. C., ... Reginster, J.-Y. (April 2013). Health economics in osteoarthritis. Osteoporosis International, 24 (Suppl.1), 79-80.
Peer Reviewed verified by ORBi

Pelletier, J.-P., Peterfy, C., Brandi, M. L., Bruyère, O., Chapurlat, R., Cicuttini, F., Conaghan, P., Doherty, M., Genant, H. K., Guermazi, A., Hochberg, M., Hunter, D., Kanis, J. A., Kloppenburg, M., Laredo, J., Martel-Pelletier, J., McAlindon, T., Nevitt, M., Raynauld, J.-P., ... Cooper, C. (April 2013). What is the predictive value of MRI for the occurrence of hard clinical endpoints in knee osteoarthritis? Osteoporosis International, 24 (Suppl.1), 84-85.
Peer Reviewed verified by ORBi

Bruyère, O., Detalle, A.-S., Demonceau, M., Beaudart, C., Croisier, J.-L., Crielaard, J.-M., Reginster, J.-Y., & Maquet, D. (April 2013). Quantitative gait assessment using an accelerometer technology as a predictive tool of falls among nursing home residents: a 6-month prospective study. Osteoporosis International, 24 (Suppl.1), 210.
Peer Reviewed verified by ORBi

Beaudart, C., Buckinx, F., Maquet, D., Crielaard, J.-M., Reginster, J.-Y., & Bruyère, O. (April 2013). Clinical characteristics of patients responsive to whole body vibration. Osteoporosis International, 24 (Suppl.1), 243.
Peer Reviewed verified by ORBi

Bruyère, O., Fossi, M., Zegels, B., LEONORI, L., Hiligsmann, M., Neuprez, A., & Reginster, J.-Y. (April 2013). Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria. Rheumatology International, 33 (4), 973-8. doi:10.1007/s00296-012-2460-y
Peer Reviewed verified by ORBi

Rizzoli, R., Reginster, J.-Y., Arnal, J.-F., Bautmans, I., Bischoff-Ferrari, H., Biver, E., Boonen, S., Brandi, M. L., Chines, A., Cooper, C., Dahlin-Ivanoff, S., Epstein, S., Kanis, J. A., Fielding, R. A., Goodpaster, B., Laslop, A., Malafarina, V., Rodriguez Mañas, L., Mitlak, B., ... Bruyère, O. (April 2013). Quality of life in sarcopenia and frailty. Osteoporosis International, 24 (Suppl.1), 76-77.
Peer Reviewed verified by ORBi

NEUPREZ, A., François, G., Delcour, J., Fatemi, F., Bruyère, O., Gosset, C., Mancuso, C., Gillet, P., & Reginster, J.-Y. (April 2013). Validity of the French hip and knee replacement expectations surveys. Osteoporosis International, 24 (Suppl.1), 374.
Peer Reviewed verified by ORBi

Hiligsmann, M., Ben Sedrine, W., Rabenda, V., Bruyère, O., & Reginster, J.-Y. (April 2013). Cost-effectiveness of vitamin D and calcium supplementation in the treatment of postmenopausal women. Osteoporosis International, 24 (Suppl.1), 198.
Peer Reviewed verified by ORBi

DEROISY, R., Reginster, J.-Y., & Bruyère, O. (April 2013). Reproducibility of joint space width assessment when external calibration on the radiograph is missing. Osteoporosis International, 24 (Suppl.1), 379.
Peer Reviewed verified by ORBi

Beaudart, C., Buckinx, F., Demonceau, M., Maquet, D., Crielaard, J.-M., Reginster, J.-Y., & Bruyère, O. (April 2013). Evaluation of the impact of a 6-month training by whole body vibration on the risk of falls among nursing home residents. Osteoporosis International, 24 (Suppl.1), 246-247.
Peer Reviewed verified by ORBi

Zegels, B., LEONORI, L., Crozes, P., Uebelhart, D., Bruyère, O., & Reginster, J.-Y. (April 2013). Equivalence of a single dose (1200mg) compared to a 3-time a day dose (400mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis: Results of a randomized double blind placebo controlled study. Osteoporosis International, 24 (Suppl.1), 383.
Peer Reviewed verified by ORBi

Bruyère, O., Richette, P., Bellamy, N., Brown, J., Chapurlat, R., Chevalier, X., Czerwinski, E., Devogelaer, J., March, L., Pavelka, K., Punzi, L., Cooper, C., & Reginster, J.-Y. (April 2013). Strontium ranelate improves osteoarthritis symptoms compared to placebo in patients with knee OA: The SEKOIA study. Osteoporosis International, 24 (Suppl.1), 49-51.
Peer Reviewed verified by ORBi

Bruyère, O., Cooper, C., Pavelka, K., Rabenda, V., Buckinx, F., Beaudart, C., & Reginster, J.-Y. (April 2013). Changes in the structure and the symptoms of the osteoarthritis knee and prediction of future knee replacement over an 8-year follow-up period. Osteoporosis International, 24 (Suppl.1), 209.
Peer Reviewed verified by ORBi

Bruyère, O., Nicolet, D., Compère, S., Rabenda, V., Jeholet, P., Zegels, B., Maassen, P., Pire, G., & Reginster, J.-Y. (April 2013). Perception, knowledge, and use by general practitioners of Belgium of a new WHO tool (FRAX ) to assess the 10-year probability of fracture. Rheumatology International, 33 (4), 979-83. doi:10.1007/s00296-012-2461-x
Peer Reviewed verified by ORBi

Devogelaer, J.-P., Sambrook, P., Reid, D. M., Goemaere, S., Ish-Shalom, S., COLLETTE, J., Su, G., Bucci-Rechtweg, C., Papanastasiou, P., & Reginster, J.-Y. (06 March 2013). Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids. Rheumatology, 52 (6), 1058-69. doi:10.1093/rheumatology/kes410
Peer Reviewed verified by ORBi

Manzambi Kuwekita, J., & Reginster, J.-Y. (2013). Financement de la Santé et Extension de la Protection Sociale dans les Pays en Développement - L'expérience du PNPS à Bandalungwa, Kinshasa, Congo. Liège, Belgium: Les Editions du Céfal.

Hiligsmann, M., Kanis, J. A., Compston, J., Cooper, C., Flamion, B., Bergmann, P., Body, J.-J., Boonen, S., Bruyère, O., Devogelaer, J.-P., Goemaere, S., Kaufman, J.-M., Rozenberg, S., & Reginster, J.-Y. (March 2013). Health Technology Assessment in Osteoporosis. Calcified Tissue International, 93 (1), 1-14. doi:10.1007/s00223-013-9724-8
Peer Reviewed verified by ORBi

Bruyère, O., Detalle, A.-S., Demonceau, M., Beaudart, C., Croisier, J.-L., Crielaard, J.-M., Reginster, J.-Y., & Maquet, D. (2013). Quantitative gait assessment using an accelerometer technology as a predictive tool of falls among nursing home residents: a 6-month prospective study. In Proceedings of the meeting.
Peer reviewed

Beaudart, C., Maquet, D., Mannarino, M., Crielaard, J.-M., Reginster, J.-Y., & Bruyère, O. (2013). Effects of 3 months of controlled whole body vibrations with low exposure period on the risk of falls among nursing home residents. In Proceeding of the meeting.
Peer reviewed

Brandi, M., Reginster, J.-Y., Rizzoli, R., & Cannata-Andia, J. (14 February 2013). Comment on Freemantle et al. : Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatements. Osteoporosis International, 24 (6), 1929-30. doi:10.1007/s00198-013-2297-6
Peer Reviewed verified by ORBi

Manzambi Kuwekita, J., & Reginster, J.-Y. (2013). Perception et comportement de recours aux soins de santé dans les pays en voie de développement. Le cas de la République Démocratique du Congo. (Tous droits de reproduction, d'adaptation et de traduction réservés pour tous pays). Liège, Belgium: Les Editions du Céfal.

Hiligsmann, M., Ben Sedrine, W., Bruyère, O., & Reginster, J.-Y. (February 2013). Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis. Osteoporosis International, 24 (8), 2291-300. doi:10.1007/s00198-013-2272-2
Peer Reviewed verified by ORBi

Reginster, J.-Y. (Ed.), Bruyère, O. (Ed.), Cianferotti, L. (Other coll.), Brandi, M. L. (Other coll.), Griffith, J. F. (Other coll.), Genant, H. K. (Other coll.), Gielen, E. (Other coll.), Laurent,, M. (Other coll.), Milisen, K. (Other coll.), Boonen, S. (Other coll.), Holroyd, C. R. (Other coll.), Jagannath, D. (Other coll.), Cooper, C. (Other coll.), & McClung, M. R. (Other coll.). (2013). Osteoporosis. London, United Kingdom: Future Medicine Ltd. doi:10.2217/9781780841687

Zegels, B., Crozes, P., Uebelhart, D., Bruyère, O., & REGINSTER, J.-Y. (2013). Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthritis and Cartilage, 21 (1), 22-27. doi:10.1016/j.joca.2012.09.017
Peer Reviewed verified by ORBi

Hiligsmann, M., VAN DURME, C., Geusens, P., Dellaert, B. G., Dirksen, C. D., van der Weijden, T., Reginster, J.-Y., & Boonen, A. (2013). Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis. Patient Preference and Adherence, 7, 133-9. doi:10.2147/PPA.S38408
Peer Reviewed verified by ORBi

Hiligsmann, M., & Reginster, J.-Y. (2013). Health Economics Analyses in Osteoporosis. In R. Arinoviche Schenker & M. Arriagada Maldini (Eds.), Temas de osteoporosis y otras enfermedades oseas (pp. 337-358). Santiago, Chile: Fundacion Chilena de osteoporosis.
Peer reviewed

McClung, M., Grauer, A., Boonen, S., Brown, J., Diez-Perez, A., Langdahl, B., Reginster, J.-Y., Zanchetta, J., Katz, L., Maddox, J., Yang, Y., Libanati, C., & Bone, H. (2013). Inhibition of sclerostin with romosozumab in postmenopausal women with low BMD : phase 2 trial results. Osteoporosis International, 24 (1), 38-S39.
Peer Reviewed verified by ORBi

Brandi, M., & Reginster, J.-Y. (2013). Nutrition and bone health : turning beliefs into knowledge for healthy behaviour. Osteoporosis International, 24 (1), 388-S389.
Peer Reviewed verified by ORBi

Dere, W., Avouac, B., Boers, M., Buxton, M., Christiansen, C., Dawson, A., Gennari, C., Guillemin, F., Lawaetz, H., Ornskov, F., Roumagnac, I., & Reginster, J.-Y. (2013). Erratum to : Recommendations for the health economics analysis to be performed with a drug to be registered in prevention or treatment of osteoporosis. Calcified Tissue International, 93, 193. doi:10.1007/s00223-013-9760-4
Peer Reviewed verified by ORBi

Rabenda, V., Nicolet, D., Beaudart, C., Bruyère, O., & Reginster, J.-Y. (2013). Relationship between use of antidepressants and risk of fractures: a meta-analysis. Osteoporosis International, 24, 121-137. doi:10.1007/s00198-012-2015-9
Peer Reviewed verified by ORBi

Roux, C., Binkley, N., Boonen, S., Kiel, D. P., Ralston, S. H., REGINSTER, J.-Y., Pong, A., Rosenberg, E., & Santora, A. (2013). Erratum to: Vitamin D Status and Bone Mineral Density Changes During Alendronate Treatment in Postmenopausal Osteoporosis. Calcified Tissue International. doi:10.1007/s00223-013-9791-x
Peer Reviewed verified by ORBi

Lotz, M., Martel-Pelletier, J., Christiansen, C., Brandi, M.-L., Bruyère, O., Chapurlat, R., Collette, J., Cooper, C., Giacovelli, G., Kanis, J. A., Karsdal, M. A., Kraus, V., Lems, W. F., Meulenbelt, I., Pelletier, J.-P., Raynauld, J.-P., Reiter-Niesert, S., Rizzoli, R., Sandell, L. J., ... REGINSTER, J.-Y. (2013). Value of biomarkers in osteoarthritis: current status and perspectives. Annals of the Rheumatic Diseases, 72, 1756-1763. doi:10.1136/annrheumdis-2013-203726
Peer Reviewed verified by ORBi

Kaufman, J., Reginster, J.-Y., Boonen, S., Brandi, M., Cooper, C., Dere, W., Devogelaer, J., Diez-Perez, A., Kanis, J., McCloskey, E., Mitlak, B., Orwoll, E., Ringe, J., Weryha, G., & Rizzoli, R. (2013). Treatment of osteoporosis in men. BONE, 53 (1), 134-44. doi:10.1016/j.bone.2012.11.018
Peer Reviewed verified by ORBi

Bruyère, O., Cooper, C., Pavelka, K., Rabenda, V., Buckinx, F., Beaudart, C., & REGINSTER, J.-Y. (2013). Changes in Structure and Symptoms in Knee Osteoarthritis and Prediction of Future Knee Replacement Over 8 Years. Calcified Tissue International, 93, 502-507. doi:10.1007/s00223-013-9781-z
Peer Reviewed verified by ORBi

Beaudart, C., Buckinx, F., Maquet, D., Crielaard, J.-M., Reginster, J.-Y., & Bruyère, O. (2013). What are the clinical characteristics of patients improving their gait and body balance with whole body vibration ? Results of a 3-month randomized controlled trial. European Geriatric Medicine, 4 (S1), 53.
Peer reviewed

Beaudart, C., Buckinx, F., Rabenda, V., GILLAIN, S., Cavalier, E., Slomian, J., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2013). Les effets d'une supplémentation en vitamine D sur la force, la masse et la puissance musculaire : une méta-analyse d'essais randomisés contrôlés. Revue du Rhumatisme, 80 (S1), 180-A181.
Peer Reviewed verified by ORBi

Bruyère, O., Zegels, B., Crozes, P., Uebelhart, D., & Reginster, J.-Y. (2013). Evaluation de l'amélioration cliniquement pertinente ressentie par les patients sous différents modes d'administration de sulfate de chondroïtine : résultats d'une étude randomisée, contrôlée et en double insu. Revue du Rhumatisme, 80 (S1), 123-A124.
Peer Reviewed verified by ORBi

REGINSTER, J.-Y., Beaudart, C., NEUPREZ, A., & Bruyère, O. (2013). Strontium ranelate in the treatment of knee osteoarthritis: new insights and emerging clinical evidence. Therapeutic Advances in Musculoskeletal Disease, 5 (5), 268-276. doi:10.1177/1759720X13500862
Peer Reviewed verified by ORBi

Hiligsmann, M., Dellaert, B., Dirksen, C., Van der Weijden, T., Goemaere, S., Reginster, J.-Y., Watson, V., & Boonen, A. (2013). Patients' preferences for osteoporosis drug therapy : a discrete choice experiment. Osteoporosis International, 24 (1), 53.
Peer Reviewed verified by ORBi

Cooper, C., Berembaum, F., Nash, P., Zamani, O., Cohen-Solal, M., Bianchi, G., Branco, J., Navarro Sarabia, F., & Reginster, J.-Y. (2013). Strontium ranelate prevents radiological progression in patients with primary knee osteoarthritis. Osteoporosis International, 24 (1), 306-307.
Peer Reviewed verified by ORBi

Cooper, C., Fielding, R., Visser, M., van Loon, L. J., Rolland, Y., Orwoll, E., Reid, K., Boonen, S., Dere, W., Epstein, S., Mitlak, B., Tsouderos, Y., Sayer, A. A., Rizzoli, R., REGINSTER, J.-Y., & Kanis, J. A. (2013). Tools in the assessment of sarcopenia. Calcified Tissue International, 93 (3), 201-10. doi:10.1007/s00223-013-9757-z
Peer Reviewed verified by ORBi

Rizzoli, R., Boonen, S., Brandi, M.-L., Bruyère, O., Cooper, C., Kanis, J. A., Kaufman, J.-M., Ringe, J. D., Weryha, G., & Reginster, J.-Y. (2013). Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Current Medical Research and Opinion, 29 (4), 305-13. doi:10.1185/03007995.2013.766162
Peer Reviewed verified by ORBi

Reginster, J.-Y., Pelousse, F., & Bruyère, O. (2013). Is there potential for strontium ranelate in the management of osteoarthritis ? Clinical Practice, 10 (2), 201-207. doi:10.2217/cpr.12.83
Peer Reviewed verified by ORBi

Hiligsmann, M., Boonen, A., Dirksen, C. D., Ben Sedrine, W., & REGINSTER, J.-Y. (2013). Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women. Expert Review of Pharmacoeconomics and Outcomes Research, 13 (1), 19-28. doi:10.1586/erp.12.76
Peer Reviewed verified by ORBi

Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2013). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International, 24 (1), 23-57. doi:10.1007/s00198-012-2074-y
Peer Reviewed verified by ORBi

REGINSTER, J.-Y., & Pelousse, F. (2013). ACP Journal Club: supplementation with vitamin D did not reduce cartilage volume loss or pain in knee osteoarthritis. Annals of Internal Medicine, 158 (8), 9.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Ellis, A., Luo, X., Bushmakin, A., Mirkin, S., & Jansen, J. (2013). Indirect comparison of bazedoxifene vs. oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women. Osteoporosis International, 24 (1), 37.
Peer Reviewed verified by ORBi

Beaudart, C., Buckinx, F., Rabenda, V., GILLAIN, S., Cavalier, E., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2013). The effects of vitamin D on skeletal muscle strenght : a meta-analysis of randomized controlled trials. European Geriatric Medicine, 4 (S1), 72.
Peer reviewed

NEUPREZ, A., Delcour, J., Fatemi, F., GILLET, P., Mawet, M., François, G., Bruyère, O., Crielaard, J.-M., Gosset, C., & Reginster, J.-Y. (2013). Développement et validation de la version française d'un questionnaire traitant des attentes des patients dans l'arthrose des membres inférieurs. Revue du Rhumatisme, 80 (S1), 181.
Peer Reviewed verified by ORBi

Brown, J., McClung, M., Grauer, A., Boonen, S., Diez-Perez, A., Langdahl, B., Reginster, J.-Y., Zanchetta, J., Katz, L., Maddox, J., Yang, Y., Libanati, C., & Bone, H. (2013). Inhibition de la sclérostine par le romosozumab chez des femmes ménopausées ayant une DMO basse : résultats de l'étude de phase 2. Revue du Rhumatisme, 80 (S1), 73.
Peer Reviewed verified by ORBi

Chevalier, X., Richette, P., Bruyère, O., Chapurlat, R., Cooper, C., & Reginster, J.-Y. (2013). Le ranélate de strontium diminue la proportion de patients progressant rapidement dès la première année : une analyse post hoc de l'étude SEKOIA. Revue du Rhumatisme, 80 (S1), 59-A60.
Peer Reviewed verified by ORBi

Bruyère, O., Slomian, J., Beaudart, C., Buckinx, F., CAVALIER, E., GILLAIN, S., Petermans, J., & REGINSTER, J.-Y. (2013). Prevalence of vitamin D inadequacy in European postmenopausal women aged over 80 years. European Geriatric Medicine, 4 (S1), 13-S14.
Peer reviewed

Ethgen, O., De Lemos Esteves, F., Bruyère, O., & REGINSTER, J.-Y. (2013). What do we know about the safety of corticosteroids in rheumatoid arthritis? Current Medical Research and Opinion, 29 (9), 1147-60. doi:10.1185/03007995.2013.818531
Peer Reviewed verified by ORBi

Buckinx, F., Beaudart, C., Demonceau, M., Maquet, D., Crielaard, J.-M., Reginster, J.-Y., & Bruyère, O. (2013). Impact of a 6-month training by whole body vibration on functional and motor abilities among nursing home residents observed over a 12-months period. European Geriatric Medicine, 4 (S1), 54-S55.
Peer reviewed

Bone, H. G., Chapurlat, R., Brandi, M.-L., Brown, J. P., Czerwinski, E., Krieg, M.-A., Man, Z., Mellstrom, D., Radominski, S. C., REGINSTER, J.-Y., Resch, H., Roman Ivorra, J. A., Roux, C., Vittinghoff, E., Daizadeh, N. S., Wang, A., Bradley, M. N., Franchimont, N., Geller, M. L., ... Papapoulos, S. (2013). The Effect of 3 or 6 Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension. Journal of Clinical Endocrinology and Metabolism. doi:10.1210/jc.2013-1597
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2013). Pharmacological management : osteoporosis and osteoarthritis, similarities and differences. Osteoporosis International, 24 (1), 75-S76.
Peer Reviewed verified by ORBi

Pelletier, J.-P., Cooper, C., Peterfy, C., REGINSTER, J.-Y., Brandi, M.-L., Bruyère, O., Chapurlat, R., Cicuttini, F., Conaghan, P. G., Doherty, M., Genant, H., Giacovelli, G., Hochberg, M. C., Hunter, D. J., Kanis, J. A., Kloppenburg, M., Laredo, J.-D., McAlindon, T., Nevitt, M., ... Guermazi, A. (2013). What is the predictive value of MRI for the occurrence of knee replacement surgery in knee osteoarthritis? Annals of the Rheumatic Diseases, 72 (10), 1594-1604. doi:10.1136/annrheumdis-2013-203631
Peer Reviewed verified by ORBi

Beaudart, C., Maquet, D., Mannarino, M., Buckinx, F., Demonceau, M., Crielaard, J.-M., Reginster, J.-Y., & Bruyère, O. (2013). Effects of 3 months of short sessions of controlled whole body vibrations on the risk of falls among nursing home residents. BMC Geriatrics, 13 (42). doi:10.1186/1471-2318-13-42
Peer Reviewed verified by ORBi

Hiligsmann, M., Ben Sedrine, W., & REGINSTER, J.-Y. (2013). Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women. Journal of Bone and Mineral Research, 28 (4), 807-15. doi:10.1002/jbmr.1819
Peer Reviewed verified by ORBi

Genant, H., Zaim, S., Guermazi, A., Roemer, F., Beaulieu, A., Hall, S., Alekseeva, L., Roorda, L., Verbruggen, G., Wittoek, R., Peterfy, C., Cooper, C., & Reginster, J.-Y. (2013). Strontium ranelate effect on knee osteoarthritis progression : a MRI analysis. Osteoporosis International, 24 (1), 312-313.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2013). The general approach to the patient with osteoarthritis : is a treatment algorithm feasible ? Osteoporosis International, 24 (1), 385.
Peer Reviewed verified by ORBi

Hiligsmann, M., Cooper, C., Arden, N., Boers, M., Branco, J. C., Luisa Brandi, M., Bruyère, O., Guillemin, F., Hochberg, M. C., Hunter, D. J., Kanis, J. A., Kvien, T. K., Laslop, A., Pelletier, J.-P., Pinto, D., Reiter-Niesert, S., Rizzoli, R., Rovati, L. C., Severens, J. L. H., ... REGINSTER, J.-Y. (2013). Health economics in the field of osteoarthritis: An Expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 43 (3), 303-313. doi:10.1016/j.semarthrit.2013.07.003
Peer Reviewed verified by ORBi

Reginster, J.-Y., Badurski, J., Bellamy, N., Bensen, W., Chapurlat, R., Chevalier, X., Christiansen, C., Genant, H., Navarro, F., Sambrook, P., Spector, T., & Cooper, C. (2013). Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Annals of the Rheumatic Diseases, 72 (2), 179-86. doi:10.1136/annrheumdis-2012-202231
Peer Reviewed verified by ORBi

Svedbom, A., Hernlund, E., Ivergard, M., Compston, J., Cooper, C., Stenmark, J., McCloskey, E., Jonsson, B., Kanis, J., Hiligsmann, M., & Reginster, J.-Y. (2013). Osteoporosis in the European Union : a compendium of country-specific reports. Archives of Osteoporosis, 8 (137), 1-218. doi:10.1007/s11657-013-0137-0
Peer Reviewed verified by ORBi

REGINSTER, J.-Y., DEBERG, M., Henrotin, Y., & Christgau, S. (11 December 2012). Detection of specific nitrated markers.

COLSON, L., Vander Rest, C., Reginster, J.-Y., DELANAYE, P., CAVALIER, E., LE GOFF, C., Crielaard, J.-M., & Kaux, J.-F. (December 2012). Ostéomalacie hypophosphatémique hyperphosphaturique avec hypersécrétion de FGF-23. Lettre du Rhumatologue, 387, 26-29.
Peer reviewed

Beaudart, C., Maquet, D., Mannarino, M., Buckinx, F., Demonceau, M., CRIELAARD, J.-M., Reginster, J.-Y., & Bruyère, O. (20 November 2012). Evaluation de l'impact d'un entraînement de trois mois par vibrotonie sur le risque de chute chez des patients résidant en maison de repos [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Liège, Belgium.

Bruyère, O., Bergmann, P., Body, J.-J., Boonen, S., Devogelaer, J.-P., Goemaere, S., Kaufman, J.-M., Rozenberg, S., & Reginster, J.-Y. (October 2012). Nécessité de nouveaux critères de remboursement pour traiter l'ostéoporose en Belgique. Ortho-Rhumato, 10 (5), 3.

REGINSTER, J.-Y., Neuprez, A., LECART, M.-P., SARLET, N., & Bruyère, O. (October 2012). Role of glucosamine in the treatment for osteoarthritis. Rheumatology International, 32 (10), 2959-67. doi:10.1007/s00296-012-2416-2
Peer Reviewed verified by ORBi

Bruyère, O., Detilleux, J., Chines, A., & Reginster, J.-Y. (September 2012). Relationships Between Changes in Bone Mineral Density or Bone Turnover Markers and Vertebral Fracture Incidence in Patients Treated with Bazedoxifene. Calcified Tissue International, 91 (4), 244-9. doi:10.1007/s00223-012-9629-y
Peer Reviewed verified by ORBi

Bruyère, O., Ethgen, O., Neuprez, A., Zegels, B., Gillet, P., HUSKIN, J.-P., & Reginster, J.-Y. (2012). Health-related quality of life after total knee or hip replacement for osteoarthritis: a 7-year prospective study. Archives of Orthopaedic and Trauma Surgery. doi:10.1007/s00402-012-1583-7
Peer Reviewed verified by ORBi

Neuprez, A., François, G., Bruyère, O., Kovats, V., THIRION, T., VAN CAUWENBERGE, H., DANIEL, C., GILLET, P., & Reginster, J.-Y. (June 2012). Assessment of quality of life in patients undergoing total joint replacement for OA of the lower limb. Annals of the Rheumatic Diseases, 71 (Suppl.3), 693.
Peer Reviewed verified by ORBi

Bruyère, O., Buckinx, F., & Reginster, J.-Y. (June 2012). A very high prevalence of vitamin D inadequacy combined with low dietary calcium intake is found in European postmenopausal women. Annals of the Rheumatic Diseases, 71 (Suppl.3), 716.
Peer Reviewed verified by ORBi

Bruyère, O., Demoulin, M., Brereton, C., Humblet, F., Flynn, D., Hill, J. C., Maquet, D., Van Beveren, J., Reginster, J.-Y., CRIELAARD, J.-M., & Demoulin, C. (June 2012). Translation validation of a new back pain screening questionnaire (the STarT Back Screening Tool) in French. Archives of Public Health, 70. doi:10.1186/0778-7367-70-12
Peer Reviewed verified by ORBi

Neuprez, A., François, G., Bruyère, O., Kovats, V., KURTH, W., HUSKIN, J.-P., GILLET, P., & Reginster, J.-Y. (June 2012). Radiological and clinical profil of osteoarthritic patients undergoing of total joint replacement. Annals of the Rheumatic Diseases, 71 (Suppl.3), 693.
Peer Reviewed verified by ORBi

Bruyère, O., Nicolet, D., Compère, S., Rabenda, V., Jeholet, P., ZEGELS, B., Maassen, P., Pire, G., & Reginster, J.-Y. (June 2012). Perception, knowledge and use by general practitioners of Belgium of the FRAX tool. Annals of the Rheumatic Diseases, 71 (Suppl.3), 716.
Peer Reviewed verified by ORBi

Bruyère, O., Roux, C., Nicolet, D., Fechtenbaum, J., DEROISY, R., & Reginster, J.-Y. (June 2012). Severe prevalent vertebral fractures predict subsequent vertebral and nonvertebral fractures: a 3-year prospective study. Annals of the Rheumatic Diseases, 71 (Suppl.3), 588.
Peer Reviewed verified by ORBi

Bruyère, O., Roux, C., Nicolet, D., Fechtenbaum, J., DEROISY, R., & Reginster, J.-Y. (June 2012). Severity of incident vertebral fracture and future fracture risk: a 3-year prospective study. Annals of the Rheumatic Diseases, 71 (Suppl.3), 716.
Peer Reviewed verified by ORBi

Bruyère, O., & Reginster, J.-Y. (June 2012). Relationships between changes in bone mineral density and vertebral fractures incidence: an analysis of the last 2 years of a 10-year treatment with strontium ranelate. Annals of the Rheumatic Diseases, 71 (Suppl.3), 590.
Peer Reviewed verified by ORBi

Rizzoli, R., Dawson-Hughes, B., Kaufman, J., Fardellone, P., Brandi, M., Vellas, B., COLLETTE, J., & Reginster, J.-Y. (May 2012). Efficacy of a strontium ranelate 2 G/vitamin D3 1000 UI combination on the correction of vitamin D insufficiency. Osteoporosis International, 23 (S2), 225.
Peer Reviewed verified by ORBi

Hiligsmann, M., Bruyère, O., Roberfroid, D., Dubois, C., Parmentier, Y., Carton, J., Detilleux, J., GILLET, P., & Reginster, J.-Y. (May 2012). Trends in hip fracture incidence and in the prescription of anti-osteoporosis medications during same time period in Belgium (2000-2007). Arthritis Care and Research, 64 (5), 744-750.
Peer Reviewed verified by ORBi

Bruyère, O., Avouac, B., Richette, P., Maheu, E., Bruel, P., Coxam, V., Guillou, G. B., Lugrin, A.-E., Merceron, C., Pauquai, T., Rannou, F., Ythier-Moury, P., Tsouderos, Y., Urban, N., Rovati, L., Guicheux, J., & Reginster, J.-Y. (April 2012). Health claims assessment in the field of joint and cartilage: a consensus viewpoint of the Group for the Respect of Ethics and Excellence in Science. Current Medical Research and Opinion, 28 (4), 611-6. doi:10.1185/03007995.2012.674934
Peer Reviewed verified by ORBi

Bruyère, O., Roux, C., Nicolet, D., Fechtenbaum, J., DEROISY, R., & Reginster, J.-Y. (March 2012). Severe prevalent vertebral fractures predict subsequent vertebral and nonvertebral fractures: a 3-year prospective study. Osteoporosis International, 23 (Suppl. 2), 361-362.
Peer Reviewed verified by ORBi

Bruyère, O., Zegels, B., LEONORI, L., Rabenda, V., Janssen, A., Bourges, C., & Reginster, J.-Y. (March 2012). Effect of collagen hydrolysate in articular pain: A 6-month randomized, double-blind, placebo controlled study. Osteoporosis International, 23 (Suppl. 2), 362-363.
Peer Reviewed verified by ORBi

Hiligsmann, M., Ben Sedrine, W., Bruyère, O., & Reginster, J.-Y. (March 2012). Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women. Osteoporosis International, 23 (Suppl. 2), 312-313.
Peer Reviewed verified by ORBi

Bruyère, O., Rabenda, V., & Reginster, J.-Y. (March 2012). Prediction of future knee surgery in patient with osteoarhtritis by the use of a new definition of x-ray progression. Osteoporosis International, 23 (Suppl. 2), 363.
Peer Reviewed verified by ORBi

Hiligsmann, M., Van Durme, C., Geusens, P., Dellaert, B., Dirksen, C., Van der Weijden, T., Reginster, J.-Y., & Boonen, A. (March 2012). What are the most important medication attributes for patients with osteoporosis ? Results from a qualitative study. Osteoporosis International, 23 (S2), 81-82.
Peer Reviewed verified by ORBi

COLLETTE, J., & Reginster, J.-Y. (March 2012). Strontium ranelate uncouples bone formation from bone resorption in male osteoporotic patients. Osteoporosis International, 23 (S2), 365-366.
Peer Reviewed verified by ORBi

Ellis, A., Jansen, J., Luo, X., Cappelleri, J., Chines, A., Sutradhar, S., & Reginster, J.-Y. (March 2012). Indirect comparison of bazedoxifene vs. oral bisphosphonates for the prevention of nonvertebral fractures in high-risk postmenopausal osteoporosis population. Osteoporosis International, 23 (S2), 64-65.
Peer Reviewed verified by ORBi

DEROISY, R., Bruyère, O., Gensburger, D., Chapurlat, R., & Reginster, J.-Y. (March 2012). Long-term (3 years) reproducibility for the radiological assessment of knee osteoarthritis. Osteoporosis International, 23 (Suppl. 2), 219-220.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Binkley, N., Boonen, S., Kiel, D., Ralston, S., Roux, C., Pong, A., Rosenberg, E., & Santora, A. (March 2012). Correlations between 25(OH)D and BMD change in postmenopausal osteoporotic women : secondary analyses of a 1-year trial of weekly alendronate (ALN) plus vitamin D3 5600 IU vs. standard care. Osteoporosis International, 23 (S2), 238-239.
Peer Reviewed verified by ORBi

Papapoulos, S., Brown, J., Chapurlat, R., Franchimont, N., Brandi, M., Czerwinski, E., Krieg, M., Man, Z., Mellström, D., Radominski, S., Reginster, J.-Y., Resch, H., Roman, J., Roux, C., Daizadeh, N., Geller, M., Smith, S., Wagman, R., Cummings, S., & Bone, H. (March 2012). Denosumab treatment of postmenopausal women with osteoporosis for 6 years : results from the first 3 years of the freedom extension. Osteoporosis International, 23 (S2), 76.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Chapurlat, R., Christiansen, C., Genant, H., Bellamy, N., Bensen, W., Navarro, F., Badurski, J., Nasonov, E., Chevalier, X., Sambrook, P., Spector, T., & Cooper, C. (March 2012). Strontium ranelate reduces the number of radiological or radioclinical progressors in patients with primary knee osteoarthritis. Osteoporosis International, 23 (S2), 366-367.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Chapurlat, R., Christiaensen, C., Genant, H., Bellamy, N., Bensen, W., Navarro, F., Badurski, J., Nasonov, E., Chevalier, X., Sambrook, P., Spector, T., & Cooper, C. (March 2012). Structure modifying effects of strontium ranelate in knee osteoarthritis. Osteoporosis International, 23 (S2), 58-59.
Peer Reviewed verified by ORBi

Boonen, S., Reginster, J.-Y., Kaufman, J., Lippuner, K., Zanchetta, J., Langdahl, B., Rizzoli, R., Dimai, H., Eriksen, E., Brixen, K., Antunez, O., Su, G., Hruska, J., Vanderschueren, D., & Orwoll, E. (March 2012). Efficacy of once-yearly zoledronic acid 5 mg in men with osteoporosis with different levels of serum total testosterone. Osteoporosis International, 23 (S2), 79-80.
Peer Reviewed verified by ORBi

Bruyère, O., Roux, C., Nicolet, D., Fechtenbaum, J., DEROISY, R., & Reginster, J.-Y. (March 2012). Severity of incident vertebral fracture and future fracture risk: a 3-year prospective study. Osteoporosis International, 23 (Suppl. 2), 60-61.
Peer Reviewed verified by ORBi

Gensburger, D., DEROISY, R., Arlot, M., Bruyère, O., Chapurlat, R., & Reginster, J.-Y. (March 2012). Assessment of joint space narrowing in knee osteoarthritis has good long-term intercentre reproducibility when read in pairs with a semi-automated device. Osteoporosis International, 23 (Suppl. 2), 247-248.
Peer Reviewed verified by ORBi

Bruyère, O., Nicolet, D., Compère, S., Rabenda, V., Jeholet, P., Zegels, B., Maassen, P., Pire, G., & Reginster, J.-Y. (March 2012). Perception, knowledge and use by general practitioners of Belgium of the FRAX tool. Osteoporosis International, 23 (Suppl. 2), 363-364.
Peer Reviewed verified by ORBi

Cooper, C., Deltour, N., Speirs, C., Meyer, O., & Reginster, J.-Y. (March 2012). Strontium ranelate and risk of venous thromboembolism (VTE) : an update of a retrospective cohort study in the UK general practice research database (GPRD). Osteoporosis International, 23 (S2), 364-365.
Peer Reviewed verified by ORBi

Bruyère, O., Buckinx, F., & Reginster, J.-Y. (March 2012). A very high prevalence of vitamin D inadequacy combined with low dietary calcium intake is found in European postmenopausal women. Osteoporosis International, 23 (Suppl. 2), 361.
Peer Reviewed verified by ORBi

Neuprez, A., François, G., Bruyère, O., Kovats, V., KURTH, W., HUSKIN, J.-P., Gillet, P., & Reginster, J.-Y. (March 2012). Radiological and clinical profil of osteoarthritic patients undergoing of total joint replacement. Osteoporosis International, 23 (Suppl. 2), 129-130.
Peer Reviewed verified by ORBi

Hiligsmann, M., Ben Sedrine, W., Bruyère, O., & Reginster, J.-Y. (March 2012). An economic evaluation of strontium ranelate for the treatment of male osteoporosis. Osteoporosis International, 23 (Suppl. 2), 305-306.
Peer Reviewed verified by ORBi

Bruyère, O., & Reginster, J.-Y. (March 2012). Relationships between changes in bone mineral density and vertebral fractures incidence: an analysis of the last 2 years of a 10-year treatment with strontium ranelate. Osteoporosis International, 23 (Suppl. 2), 362.
Peer Reviewed verified by ORBi

Papapoulos, S., Chapurlat, R., Libanati, C., Brandi, M., Brown, J., Czerwinski, E., Krieg, M. A., Man, Z., Mellstrom, D., Radominski, S., Reginster, J.-Y., Resch, H., Roman, J., Roux, C., Vittinghoff, E., Austin, M., Daizadeh, N., Bradley, M., Grauer, A., ... Bone, H. (March 2012). Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension. Journal of Bone and Mineral Research, 27 (3), 694-701. doi:10.1002/jbmr.1479
Peer Reviewed verified by ORBi

Bruyère, O., Rizzoli, R., Coxam, V., Avouac, B., Chevalier, T., Fabien-Soulé, V., Kanis, J. A., Kaufman, J.-M., Tsouderos, Y., & Reginster, J.-Y. (February 2012). Assessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). Osteoporosis International, 23, 193-199. doi:10.1007/s00198-011-1561-x
Peer Reviewed verified by ORBi

Rizzoli, R., Cooper, C., Reginster, J.-Y., Abrahamsen, B., Adachi, J., Brandi, M., Bruyère, O., Compston, J., Ducy, P., Ferrari, S., Harvey, N., Kanis, J., Karsenty, G., Laslop, A., Rabenda, V., & Vestergaard, P. (2012). Antidepressant medications and osteoporosis. BONE, 51, 606-613. doi:10.1016/j.bone.2012.05.018
Peer Reviewed verified by ORBi

Chapurlat, R., Papapoulos, S., Brown, J., Franchimont, N., Brandi, M., Czerwinski, E., Krieg, M., Man, Z., Mellstrom, D., Radominski, S., Reginster, J.-Y., Resch, H., Roman, J., Roux, C., Daizadeh, N., Geller, M., Smith, S., Wagman, R., Cummings, S., & Bone, H. (2012). Treatment of postmenopausal women with osteoporosis for six years with denosumab : three-year results from the freedom extension. Annals of the Rheumatic Diseases, 71 (3), 588.
Peer Reviewed verified by ORBi

Hiligsmann, M., Van Durme, C., Geusens, P., Dellaert, B., Dirksen, C., Van der Weijden, T., Reginster, J.-Y., & Boonen, A. (2012). Nominal group technique to prioritize preferences for medication attributes from the patients’ perspective : the case of osteoporosis. Annals of the Rheumatic Diseases, 71 (3), 597.
Peer Reviewed verified by ORBi

Cooper, C., REGINSTER, J.-Y., Chapurlat, R., Christiansen, C., Genant, H., Bellamy, N., Bensen, W., Navarro, F., Badurski, J., Nasonov, E., Chevalier, X., & Sambrook, P. N. (2012). Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial. Current Medical Research and Opinion, 28 (2), 231-9. doi:10.1185/03007995.2011.648758
Peer Reviewed verified by ORBi

Henrotin, Y., & Reginster, J.-Y. (2012). New drugs and nutraceuticals in the treatment of osteoarthritis. In S. Cox Gad (Ed.), Development of Therapeutic Agents Handbook (pp. 847-880). Hoboken, United States - New Jersey: Wiley.
Peer reviewed

Reginster, J.-Y. (2012). Ranelato de estroncio : Um tratamentao de primeira linha para a osteoporose pos-menopausica. Expert Approaches in Osteoporosis, 13-23.
Peer reviewed

Rizzoli, R., Body, J., De Censi, A., Reginster, J.-Y., Piscitelli, P., & Brandi, M. (2012). Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer : an ESCEO position paper. Osteoporosis International, 23, 2567-2576. doi:10.1007/s00198-011-1870-0
Peer Reviewed verified by ORBi

Rabenda, V., Bruyère, O., & REGINSTER, J.-Y. (2012). Risk of nonvertebral fractures among elderly postmenopausal women using antidepressants. BONE, 51 (4), 674-679. doi:10.1016/j.bone.2012.07.030
Peer Reviewed verified by ORBi

Sambrook, P. N., Roux, C., Devogelaer, J. P., Saag, K., Lau, C. S., Reginster, J.-Y., Bucci-Rechtweg, C., Su, G., & Reid, D. M. (2012). Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. BONE, 50, 289-295. doi:10.1016/j.bone.2011.10.024
Peer Reviewed verified by ORBi

Bolognese, M., Miller, P., Reginster, J.-Y., Franchimont, N., Bianchi, G., Chapurlat, R., Hawkins, F., Kendler, D., Oliveri, B., Zanchetta, J., Daizadeh, N., Wang, A., Wagman, R., & Papapoulos, S. (2012). Relationship between changes in bone mineral density and incidence of fracture with 6 years of Denosumab treatment. Arthritis and Rheumatism, 64 (S10), 847.
Peer Reviewed verified by ORBi

Collette, J., Bruyère, O., & Reginster, J.-Y. (2012). Strontium ranelate decreases the level of urinary CTX-II in patients with knee osteoarthritis. Arthritis and Rheumatism, 64 (S10), 111.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2012). Toujours pas facile de faire des vieux os. Tempo Médical, 348, 204-206.
Peer reviewed

Chevalier, X., Chapurlat, R., Cooper, C., & Reginster, J.-Y. (2012). Le ranélate de strontium diminue le nombre de progresseurs radiologiques ou radiocliniques chez les patients ayant une arthrose primaire du genou. Revue du Rhumatisme, 79 (S1), 270.
Peer Reviewed verified by ORBi

Hiligsmann, M., Boonen, A., Rabenda, V., & REGINSTER, J.-Y. (2012). The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. Expert Review of Pharmacoeconomics and Outcomes Research, 12 (2), 159-66. doi:10.1586/erp.12.8
Peer Reviewed verified by ORBi

Hiligsmann, M., & Reginster, J.-Y. (2012). Incidence des fractures de hanche en fonction des médicaments prescrits contre l'ostéoporose. Ortho-Rhumato, 10 (4), 3.
Peer reviewed

Body, J.-J., Bergmann, P., Boonen, S., Devogelaer, J.-P., Gielen, E., Goemaere, S., Kaufman, J.-M., Rozenberg, S., & REGINSTER, J.-Y. (2012). Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications. Osteoporosis International, 23 Suppl 1, 1-23. doi:10.1007/s00198-011-1891-8
Peer Reviewed verified by ORBi

Goldhahn, J., Feron, J. M., Kanis, J. A., Papapoulos, S., Reginster, J.-Y., Rizzoli, R., Dere, W., Mitlak, B., Tsouderos, Y., & Boonen, S. (2012). Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcified Tissue International, 90, 343-353. doi:10.1007/s00223-012-9587-4
Peer Reviewed verified by ORBi

Reginster, J.-Y., Kaufman, J. M., Goemaere, S., Devogelaer, J. P., Benhamou, C. L., Felsenberg, D., Diaz-Curiel, M., Brandi, M. L., Badurski, J., Wark, J., Balogh, A., Bruyère, O., & Roux, C. (2012). Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporosis International, 23, 1115-1122. doi:10.1007/s00198-011-1847-z
Peer Reviewed verified by ORBi

Kanis, J. A., Reginster, J.-Y., Kaufman, J. M., Ringe, J. D., Adachi, J. D., Hiligsmann, M., Rizzoli, R., & Cooper, C. (2012). A reappraisal of generic bisphosphonates in osteoporosis. Osteoporosis International, 23, 213-221. doi:10.1007/s00198-011-1796-6
Peer Reviewed verified by ORBi

Roux, C., Reid, D. M., Devogelaer, J. P., Saag, K., Lau, C. S., Reginster, J.-Y., Papanastasiou, P., Bucci-Rechtweg, C., Su, G., & Sambrook, P. N. (2012). Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Osteoporosis International, 23, 1083-90. doi:10.1007/s00198-011-1800-1
Peer Reviewed verified by ORBi

Cooper, C., Reginster, J.-Y., Cortet, B., Diaz-Curiel, M., Lorenc, R. S., Kanis, J. A., & Rizzoli, R. (2012). Long-term treatment of osteoporosis in postmenopausal women : a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Current Medical Research and Opinion, 28, 475-491. doi:10.1185/03007995.2012.663750
Peer Reviewed verified by ORBi

Hiligsmann, M., Ben Sedrine, W., & Reginster, J.-Y. (2012). Cost-effectiveness of Bazedoxifene compared with Raloxifene in the treatment of postmenopausal osteoporotic women. Arthritis and Rheumatism, 64 (S10), 834.
Peer Reviewed verified by ORBi

REGINSTER, J.-Y. (2012). Randomised control trial in people with hand osteoarthritis, chondroitin sulphate therapy for 6 months improves pain and function compared with placebo. Evidence-Based Medicine, 17 (5), 152-153. doi:10.1136/ebmed-2011-100515
Peer Reviewed verified by ORBi

Boonen, S., REGINSTER, J.-Y., Kaufman, J.-M., Lippuner, K., Zanchetta, J., Langdahl, B., Rizzoli, R., Lipschitz, S., Dimai, H. P., Witvrouw, R., Eriksen, E., Brixen, K., Russo, L., Claessens, F., Papanastasiou, P., Antunez, O., Su, G., Bucci-Rechtweg, C., Hruska, J., ... Orwoll, E. (2012). Fracture risk and zoledronic acid therapy in men with osteoporosis. New England Journal of Medicine, 367 (18), 1714-1723. doi:10.1056/NEJMoa1204061
Peer Reviewed verified by ORBi

Cooper, C., Chapurlat, R., Christiansen, C., Genant, H., Bellamy, N., Bensen, W., Navarro, F., Badurski, J., Nasonov, E., Chevalier, X., Sambrook, P., Spector, T., & Reginster, J.-Y. (2012). Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis : a randomized, double-blind, placebo-controlled international trial. Annals of the Rheumatic Diseases, 71 (3), 693.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Chapurlat, R., Christiansen, C., Genant, H., Bellamy, N., Bensen, W., Navarro, F., Badurski, J., Nasonov, E., Chevalier, X., Sambrook, P., Spector, T., & Cooper, C. (2012). Strontium ranelate in knee osteoarthritis trial (SEKOIA) : a structural and symptomatic efficacy. Arthritis and Rheumatism, 64 (S10), 681.
Peer Reviewed verified by ORBi

Bruyère, O., Bellamy, N., Brown, J., Richette, P., Punzi, L., Chevalier, X., Cooper, C., & Reginster, J.-Y. (2012). Clinically meaningful effect of strontium ranelate on knee osteoarthritis symptoms. Arthritis and Rheumatism, 64 (S10), 110.
Peer Reviewed verified by ORBi

Hiligsmann, M., McGowan, B., Bennett, K., Barry, M., & REGINSTER, J.-Y. (2012). The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value in Health, 15 (5), 604-12. doi:10.1016/j.jval.2012.02.001
Peer Reviewed verified by ORBi

Wampers, M., Hanssens, L., van Winkel, R., Heald, A., Collette, J., Peuskens, J., Reginster, J.-Y., SCHEEN, A., & De Hert, M. (2012). Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: Results from a 3-month prospective open-label study. European Neuropsychopharmacology, 22, 17-26. doi:10.1016/j.euroneuro.2011.03.010
Peer Reviewed verified by ORBi

NEUPREZ, A., François, G., Bruyère, O., Kovats, V., KURTH, W., HUSKIN, J.-P., GILLET, P., & Reginster, J.-Y. (2012). Evolution temporelle du profil clinique des patients arthrosiques allant bénéficier d’une arthroplastie de hanche ou de genou. Revue du Rhumatisme, 79 (S1), 272.
Peer Reviewed verified by ORBi

Bruyère, O., Rabenda, V., & Reginster, J.-Y. (2012). Utilisation d'une nouvelle définition de la progression radiologique pour prédire la future chirurgie du genou chez des patients arthrosiques. Revue du Rhumatisme, 79 (S1), 266.
Peer Reviewed verified by ORBi

Orwoll, E., Teglbjærg, C. S., Langdahl, B. L., Chapurlat, R., Czerwinski, E., Kendler, D. L., REGINSTER, J.-Y., Kivitz, A., Lewiecki, E. M., Miller, P. D., Bolognese, M. A., McClung, M. R., Bone, H. G., Ljunggren, Ö., Abrahamsen, B., Gruntmanis, U., Yang, Y.-C., Wagman, R. B., Siddhanti, S., ... Boonen, S. (2012). A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. Journal of Clinical Endocrinology and Metabolism, 97 (9), 3161-3169. doi:10.1210/jc.2012-1569
Peer Reviewed verified by ORBi

Rizzoli, R., Adachi, J. D., Cooper, C., Dere, W., Devogelaer, J. P., Diez-Perez, A., Kanis, J. A., Laslop, A., Mitlak, B., Papapoulos, S., Ralston, S., Reiter, S., Werhya, G., & REGINSTER, J.-Y. (2012). Management of glucocorticoid-induced osteoporosis. Calcified Tissue International, 91 (4), 225-243. doi:10.1007/s00223-012-9630-5
Peer Reviewed verified by ORBi

Bruyère, O., Zegels, B., Leonori, L., Rabenda, V., Janssen, A., Bourges, C., & Reginster, J.-Y. (2012). Effect of collagen hydrolysate in articular pain: A 6-month randomized, double-blind, placebo controlled study. Complementary Therapies in Medicine, 20, 124-130. doi:10.1016/j.ctim.2011.12.007
Peer Reviewed verified by ORBi

Rizzoli, R., Dawson-Hughes, B., Kaufman, J., Fardellone, P., Brandi, M., Vellas, B., Collette, J., & Reginster, J.-Y. (2012). Correction of vitamin D insufficiency with the fixed daily combination strontium ranelate 2 g/vitamin D3 1000 IU over 12 months. Arthritis and Rheumatism, 64 (S10), 835.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Chapurlat, R., Bellamy, N., Czerwinski, E., Devogelaer, J., March, L., Pavelka, K., & Cooper, C. (2012). Effects of Strontium ranelate on knee osteoarthritis pain : a responder analysis. Arthritis and Rheumatism, 64 (S10), 110.
Peer Reviewed verified by ORBi

Cooper, C., Dere, W., Evans, W., Kanis, J., Rizzoli, R., Sayer, A., Sieber, C., Kaufman, J., Abellan van Kan, G., Boonen, S., Adachi, J., Mitlak, B., Tsouderos, Y., Rolland, Y., & Reginster, J.-Y. (2012). Frailty and sarcopenia : definitions and outcome parameters. Osteoporosis International, 23, 1839-1848. doi:10.1007/s00198-012-1913-1
Peer Reviewed verified by ORBi

Reginster, J.-Y., & Hiligsmann, M. (2012). Economics in osteoporosis : how can we reconciliate the prescribers and the payer ? Osteoporosis International, 23 (6), 655-S661.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Bruyère, O., & COLLETTE, J. (2012). Strontium ranelate treatment increases osteoprotegerin serum levels in postmenopausal osteoporotic women [letter to the editor]. BONE, 50, 1201-2. doi:10.1016/j.bone.2011.12.024
Peer Reviewed verified by ORBi

NEUPREZ, A., François, G., Bruyère, O., Kovats, V., THIRION, T., Van Cauwenberghe, H., DANIEL, C., GILLET, P., & Reginster, J.-Y. (2012). Profils clinique et radiologique des patients arthrosiques allant bénéficier d'une arthroplastie de hanche ou de genou. Revue du Rhumatisme, 79 (S1), 272.
Peer Reviewed verified by ORBi

Hiligsmann, M., Van Durme, C., Geusens, P., Dellaert, B., Dirksen, C., Van Der Weijden, T., Reginster, J.-Y., & Boonen, A. (2012). Quelles sont les caractéristiques des médicaments les plus importantes pour les patients ostéoporotiques ? Résultats d'une étude qualitative. Revue du Rhumatisme, 79 (S1), 238.
Peer Reviewed verified by ORBi

Chevalier, X., Chapurlat, R., Cooper, C., & Reginster, J.-Y. (2012). Effet structuro-modulateur du ranélate de strontium dans la gonarthrose : l'étude SEKOIA. Revue du Rhumatisme, 79 (S1), 271.
Peer Reviewed verified by ORBi

Hiligsmann, M., & Reginster, J.-Y. (2012). Un monde médical et économique en pleine évolution : maladies complexes et intérêt de l’évaluation économique des technologies de santé. Revue Médicale de Liège, 67 (5-6), 258-262.
Peer reviewed

Hiligsmann, M., Bruyère, O., Roberfroid, D., Dubois, C., Parmentier, Y., Carton, J., Detilleux, J., Gillet, P., & Reginster, J.-Y. (December 2011). Evolution récente de l'incidence des fractures de hanche et de la consommation de médicaments anti-ostéoporotiques en Belgique. Revue du Rhumatisme, 78 (Suppl. 5), 43-44.
Peer Reviewed verified by ORBi

Hiligsmann, M., McGowan, B., Bennett, K., Barry, M., & Reginster, J.-Y. (November 2011). The clinical and economic implications of non-adherence with osteoporosis medications in Ireland [Paper presentation]. ESPACOMP Meeting, Utrecht, Netherlands.

Hiligsmann, M., & Reginster, J.-Y. (04 October 2011). Actualités dans le diagnostic et le traitement de l'ostéoporose: aspects cliniques et pharmaco-économiques [Paper presentation]. Enseignement Post Universitaire, Liège, Belgium.

VAN DER REST, C., CAVALIER, E., KAUX, J.-F., KRZESINSKI, J.-M., HUSTINX, R., REGINSTER, J.-Y., & DELANAYE, P. (October 2011). Tumor-induced osteomalacia: The tumor may stay hidden! Clinical Biochemistry, 44 (14-15), 1264-6. doi:10.1016/j.clinbiochem.2011.07.013
Peer Reviewed verified by ORBi

VAN DER REST, C., CAVALIER, E., COLSON, L., KAUX, J.-F., KRZESINSKI, J.-M., REGINSTER, J.-Y., HUSTINX, R., & DELANAYE, P. (August 2011). Hypophosphatémie et ostéomalacie oncogénique. Revue Médicale Suisse, 7, 1630-3.
Peer Reviewed verified by ORBi

Hiligsmann, M., Bruyère, O., Pire, G., & Reginster, J.-Y. (June 2011). Economic evaluation of osteoporosis screening strategy conducted in the Province of Liège with the cooperation of Liège Province Santé [Paper presentation]. WHO European Healthy Cities Networks Phase V (2009-2013). Third Annual Business & Technical Conference, Liège, Belgium.

Reginster, J.-Y., DEBERG, M., Henrotin, Y., & Christgau, S. (29 March 2011). Detection of specific nitrated markers.

Bruyère, O., Hiligsmann, M., Zegels, B., Neuprez, A., & Reginster, J.-Y. (March 2011). Risk of hip fracture in community-dwelling and institutionalized osteoporotic patients: a 3-year study. Osteoporosis International, 22 (Suppl.1), 332-333.
Peer Reviewed verified by ORBi

Bruyère, O., Detilleux, J., Chines, A., & Reginster, J.-Y. (March 2011). Relationship between changes in bone mineral density or bone turnover markers and vertebral fracture incidence in patients treated with Bazedoxifene. Osteoporosis International, 22 (Suppl.1), 324.
Peer Reviewed verified by ORBi

Rabenda, V., Hiligsmann, M., & Reginster, J.-Y. (March 2011). Compliance to daily placebo treatment in a postmenopausal osteoporotic women population: characteristics and impact on mortality. Osteoporosis International, 22 (Suppl.1), 287-288.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Kaufman, J.-M., Devogelaer, J.-P., Benhamou, C. L., & Roux, C. (March 2011). Long-term efficacy and safety of strontium ranelate in postmenopausal osteoporotic women: results over 10 years. Osteoporosis International, 22 (Suppl.1), 110-111.
Peer Reviewed verified by ORBi

Merville, M.-P., Deroyer, C., Bruyère, O., & Reginster, J.-Y. (March 2011). Strontium ranelate increases cell viability in IL-1 beta stimulated human chondrocytes [Paper presentation]. 1st IOF-ESCEO Pre-clinical Symposium (2011), European Congress on Osteoporosis and Osteoarthritis ECCEO11-IOF, Valencia, Spain.

Hiligsmann, M., & Reginster, J.-Y. (March 2011). Cost-effectiveness of Denosumab compared with generic alendronate in the treatment of postmenopausal osteoporotic women. Osteoporosis International, 22 (Suppl.1), 112-113.
Peer Reviewed verified by ORBi

Hiligsmann, M., Gathon, H.-J., Bruyère, O., Daubie, M., Parmentier, Y., Dercq, J.-P., & Reginster, J.-Y. (March 2011). Hospitalisation costs of hip fractures in Belgium. Osteoporosis International, 22 (Suppl.1), 332.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Binkley, N., Boonen, S., Kiel, D., Ralston, S., Roux, C., Chen, L., Rosenberg, E., & Santora, A. (March 2011). Weekly alendronate plus vitamin D3 5,600 IU vs. standard care: effect on serum 25(OH) vitamin D, bone turnover markers, and BMD in osteoporotic postmenopausal women with vitamin D inadequacy - 1 year results of a randomized trial. Osteoporosis International, 22 (Suppl.1), 291-292.
Peer Reviewed verified by ORBi

Papapoulos, S., Man, Z., Mellstrom, D., Radominski, S., Reginster, J.-Y., Resch, H., Roman, J., Roux, C., Cummings, S., Bone, H., Chapurlat, R., Brandi, M., Brown, J., Czerwinski, E., Daizadeh, N., Grauer, A., Krieg, M. A., & Libanati, C. (March 2011). Five-year Denosumab treatment of postmenopausal women with osteoporosis: results from the first two years of the freedom trial extension. Osteoporosis International, 22 (Suppl.1), 107-108.
Peer Reviewed verified by ORBi

Boonen, S., Su, G., Incera, E., Orwoll, E., Kaufman, J.-M., Reginster, J.-Y., Rizzoli, R., Lippuner, K., Vanderschueren, D., Bucci-Rechtweg, C., Antunez, O., & Papanastasiou, P. (March 2011). Antifracture efficacy and safety of once-yearly Zoledronic acid 5mg in men with osteoporosis: a prospective, randomized, controlled trial. Osteoporosis International, 22 (Suppl.1), 112.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (March 2011). Protecting men and women from fracture. Osteoporosis International, 22 (Suppl.1), 413-414.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (March 2011). The true clinical relevance of crystalline glucosamine sulphate in the treatment of knee osteoarthritis. Osteoporosis International, 22 (Suppl.1), 410.
Peer Reviewed verified by ORBi

Bruyère, O., Neuprez, A., Fossi, M., Zegels, B., LEONORI, L., Hiligsmann, M., & Reginster, J.-Y. (March 2011). Reimbursement of drugs against osteoporosis based on FRAX® instead of the current criteria would reduce by 30% the cost (in a societal perspective) of anti-osteoporosis treatment in Belgium. Osteoporosis International, 22 (Suppl.1), 333-334.
Peer Reviewed verified by ORBi

DEROISY, R., Bruyère, O., & Reginster, J.-Y. (March 2011). Stable precision over time when assessing the cartilage loss on knee osteoarthritis radiograph [Paper presentation]. 1st IOF-ESCEO Pre-clinical Symposium (2011), European Congress on Osteoporosis and Osteoarthritis ECCEO11-IOF, Valencia, Spain.

Bruyère, O., Rabenda, V., & Reginster, J.-Y. (March 2011). A new definition of progressor in osteoarthritis clinical trial that takes into account intermediate visits: a proof of concept study. Osteoporosis International, 22 (Suppl.1), 367-368.
Peer Reviewed verified by ORBi

Hiligsmann, M., Gathon, H.-J., Bruyère, O., Beaudart, C., Kolh, P., JACQUES, J., Gillet, P., & Reginster, J.-Y. (March 2011). Patient out-of-pocket contributions related to hip fracture hospital costs in Belgium. Osteoporosis International, 22 (Suppl.1), 333.
Peer Reviewed verified by ORBi

Hiligsmann, M., Bruyère, O., Detilleux, J., Gillet, P., Parmentier, Y., Dercq, J.-P., Carton, J., & Reginster, J.-Y. (March 2011). Incidence of hip fracture in Belgium between 2000 and 2007 and future projections. Osteoporosis International, 22 (Suppl.1), 145.
Peer Reviewed verified by ORBi

Cummings, S. R., McClung, M., Reginster, J.-Y., Cox, D., Mitlak, B., Stock, J., Amewou-Atisso, M., Powles, T., Miller, P., Zanchetta, J., & Christiansen, C. (February 2011). Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. Journal of Bone and Mineral Research, 26 (2), 397-404. doi:10.1002/jbmr.191
Peer Reviewed verified by ORBi

Rabenda, V., Bruyère, O., & Reginster, J.-Y. (2011). Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression. Osteoporosis International, 22, 893-901. doi:10.1007/s00198-010-1469-x
Peer Reviewed verified by ORBi

Brown, J. P., Bone, H. G., Chapurlat, R., Libanati, C., Brandi, M. L., Czerwinski, E., Krieg, M. A., Man, Z., Mellstrom, D., Radominski, S. C., Reginster, J.-Y., Resch, H., Roman Ivorra, J. A., Roux, C., Daizadeh, N. S., Grauer, A., Cummings, S. R., & Papapoulos, S. (2011). Extended safety observations from denosumab administration in postmenopausal women from FREEDOM and FREEDOM extension trials. Arthritis and Rheumatism, 63 (S10), 431-432.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2011). What's new on the horizon in therapy. Osteoporosis International, 22 (S5), 682.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2011). Ostéroporose, le mal sournois. Athena, 276, 22-25.

Chapurlat, R., Bone, H. G., Brandi M L, Brown, J. P., Czerwinski, E., Daizadeh, N. S., Grauer, A., Krieg, M. A., Libanati, C., Man, Z., Mellstrom, D., Radominski, S., Reginster, J.-Y., & Resch, H. (2011). Treatment of postmenopausal women with osteoporosis for 5 years with denosumab : two-year results from the FREEDOM trial extension. Annals of the Rheumatic Diseases, 70 (S3), 166-167.
Peer Reviewed verified by ORBi

Body, J. J., Bergmann, P., Boonen, S., Boutsen, Y., Bruyère, O., Devogelaer, J.-P., Goemaere, S., Hollevoet, N., Kaufman, J.-M., Milisen, K., Rozenberg, S., & Reginster, J.-Y. (2011). Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club. Osteoporosis International, 22 (11), 2769-88. doi:10.1007/s00198-011-1545-x
Peer Reviewed verified by ORBi

Hiligsmann, M., McGowan, B., Bennett, K., Barry, M., & Reginster, J.-Y. (2011). The clinical and economic burden of poor adherence with osteoporosis medications in Ireland. Value in Health, 14, 312.
Peer Reviewed verified by ORBi

Bruyère, O., & Reginster, J.-Y. (2011). Les allégations de santé dans le domaine de la santé osseuse. Ortho-Rhumato, 9 (6), 215.
Peer reviewed

Boonen, S., Kaufman, J. M., Reginster, J.-Y., Rizzoli, R., Lippuner, K., Vanderschueren, D., Hruska, J., Antunez, O., Papanastasiou, P., Su, G., & Orwoll, E. (2011). Reduction in incidence of vertebral fractures with once yearly zoledronic acid in men with osteoporosis. Journal of Bone and Mineral Research, 26 (S1), 23.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Kaufman, J. M., Devogelaer, J. D., Benhamou, C. L., & Roux, C. (2011). Long-term treatment of postmenopausal osteoporotic women with strontium ranelate : results at 10 years. Annals of the Rheumatic Diseases, 70 (S3), 167.
Peer Reviewed verified by ORBi

Bruyère, O., Nicolet, D., Compère, S., Rabenda, V., Jeholet, P., Maassen, P., Pire, G., & Reginster, J.-Y. (2011). Perception, connaissance et utilisation de l'outil FRAX auprès des médecins généralistes de la Province de Liège (Belgique). Revue du Rhumatisme, 78 (S5), 142.
Peer Reviewed verified by ORBi

Bruyère, O., & Reginster, J.-Y. (2011). Relation entre les variations de densité minérale osseuse et l'incidence des fractures vertébrales : analyse des 2 dernières années de 10 ans de traitement par ranélate de strontium. Revue du Rhumatisme, 78 (S5), 217.
Peer Reviewed verified by ORBi

Bone, H., Chapurlat, R., Brandi, M., Brown, J., Czerwinski, E., Daizadeh, N., Grauer, A., Krieg, M., Man, Z., Mellstrom, D., Radominski, S., Reginster, J.-Y., Resch, H., Roman, J., Roux, C., Cummings, S., Libanati, C., Papopoulos, S., & Thiebaud, D. (2011). Long-term denosuamab treatment in postmenopausal women with osteoporosis : results from the first two years of the FREEDOM trial extension. Osteoporosis International, 22 (S4), 527-S528.
Peer Reviewed verified by ORBi

Orwoll, E., Stubbe Teglbjaerg, C., Langdahl, B., Chapurlat, R., Czerwinski, E., Kenkler, D. L., Reginster, J.-Y., Kivitz, A., Lewieck, E. M., Miller, P., Bolognese, M. A., Bone, H. G., Ljunggren, O., Abrahamsen, B., Yan, Y.-C., Grauer, A., Libanati, C., Hall, J. W., & Boonen, S. (2011). A phase 3 study of the efficacy and safety of Denosumab in men with low bone mineral density : design of the ADAMO. Journal of Bone and Mineral Research, 26 (S1), 511.
Peer Reviewed verified by ORBi

Rizzoli, R., & Reginster, J.-Y. (2011). Adverse drug reactions to osteoporosis treatments. Expert Review of Clinical Pharmacology, 4 (5), 593-604. doi:10.1586/ecp.11.42
Peer Reviewed verified by ORBi

Smolen, J. S., Boers, M., Abadie, E., Breedveld, F. C., Emery, P., Bardin, T., Goel, N., Ethgen, D. J., Avouac, B. P., Dere, W. H., Durez, P., Matucci-Cerinic, M., Flamion, B., Laslop, A., Lekkerkerker, F. J., Miossec, P., Mitlak, B. H., Ormarsdottir, S., Paolozzi, L., ... Reginster, J.-Y. (2011). Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. Current Medical Research and Opinion, 27 (2), 315-25. doi:10.1185/03007995.2010.542135
Peer Reviewed verified by ORBi

Miossec, P., Verweij, C. L., Klareskog, L., Pitzalis, C., Barton, A., Lekkerkerker, F., Reiter, S., Laslop, A., Breedveld, F., Abadie, E., Flamion, B., Dere, W., Mpofu, S., Goel, N., Ethgen, O., Mitlak, B., Ormarsdottir, S., RAO, R. F., Tsouderos, Y., & Reginster, J.-Y. (2011). Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Annals of the Rheumatic Diseases, 70 (10), 1713-8. doi:10.1136/ard.2011.154252
Peer Reviewed verified by ORBi

Johansson, H., Kanis, J. A., McCloskey, E. V., Oden, A., Devogelaer, J. P., Kaufman, J. M., Neuprez, A., Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (2011). A FRAX(R) model for the assessment of fracture probability in Belgium. Osteoporosis International, 22 (2), 453-61. doi:10.1007/s00198-010-1218-1
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2011). Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs, 71 (1), 65-78. doi:10.2165/11587570-000000000-00000
Peer Reviewed verified by ORBi

Reginster, J.-Y., Kaufman, J. M., Devogelaer, J. P., Benhamou, C. L., & Roux, C. (2011). Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Arthritis and Rheumatism, 63 (S10), 436.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2011). Glucosamine sulfate for structure modification in osteoarthritis : fact of fantasy ? Ortopedia, Traumatologia, Rehabilitacja, 13 (S1), 44.
Peer Reviewed verified by ORBi

Rizzoli, R., Akesson, K., Bouxsein, M., Kanis, J. A., Napoli, N., Papapoulos, S., Reginster, J.-Y., & Cooper, C. (2011). Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporosis International, 22, 373-390. doi:10.1007/s00198-010-1453-5
Peer Reviewed verified by ORBi

Bone, H. G., Chapurlat, R., Brandi, M. L., Brown, J. P., Czerwinski, E., Daizadeh, N., Grauer, A., Krieg, M.-A., Man, Z., Mellstrom, D., Radominski, S., Reginster, J.-Y., Resch, H., Roman, J. A., Roux, C., Cummings, S. R., Libanati, C., & Papapoulos, S. (2011). Denosumab therapy in postmenopausal women with osteoporosis : results from the first two years of the freedom trial extension. Endocrine Reviews, 32, 29-1.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Chapurlat, R., Christiansen, C., Genant, H., Bellamy, N., Bensen, W., Navarro, F., Badurski, J., Nasonov, E., Chevalier, X., Sambrook, P. N., & Cooper, C. (2011). Efficacy and safety of strontium ranelate in the treatment of knee ostoarthritis : a randomized, double-blind, placebo-controlled international trial. Osteoporosis International, 22 (S5), 742-S743.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2011). Strontium ranelate : an effective solution whatever the patient profiles. Osteoporosis International, 22 (S5), 756-S757.
Peer Reviewed verified by ORBi

LECART, M.-P., & Reginster, J.-Y. (2011). Current options for the management of postmenopausal osteoporosis. Expert Opinion on Pharmacotherapy, 12 (16), 2533-52. doi:10.1517/14656566.2011.618123
Peer Reviewed verified by ORBi

Chapurlat, R., Roux, C., Papapoulos, S., Man, Z., Mellstrom, D., Radominski, S., Reginster, J.-Y., Resch, H., Roman, J., Cummings, S., Bone, H., Brandi, M., Brown, J., Czerwinski, E., Daizadeh, N., Grauer, A., Krieg, M. A., & Libanati, C. (2011). Traitement durant cinq ans par denosumab (DMAb) chez des femmes ménopausées ostéoporotiques : résultats d'efficacité des deux premières années de l'extension de l'essai FREEDOM. Revue du Rhumatisme, 78 (S5), 214.
Peer Reviewed verified by ORBi

Hiligsmann, M., & Reginster, J.-Y. (2011). Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. PharmacoEconomics, 29 (10), 895-911. doi:10.2165/11539980-000000000-00000
Peer Reviewed verified by ORBi

Smolen, J. S., Boers, M., Abadie, E., Breedveld, F. C., Emery, P., Bardin, T., Goel, N., Ethgen, D. J., Avouac, B. P., Durez, P., Flamion, B., Laslop, A., Miossec, P., Reiter, S., & Reginster, J.-Y. (2011). Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis. Rheumatology, 50 (10), 1732-6. doi:10.1093/rheumatology/keq413
Peer Reviewed verified by ORBi

Rizzoli, R., Reginster, J.-Y., Boonen, S., Breart, G., Diez-Perez, A., Felsenberg, D., Kaufman, J.-M., Kanis, J. A., & Cooper, C. (2011). Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcified Tissue International, 89 (2), 91-104. doi:10.1007/s00223-011-9499-8
Peer Reviewed verified by ORBi

Kanis, J. A., Cooper, C., Hiligsmann, M., Rabenda, V., Reginster, J.-Y., & Rizzoli, R. (2011). Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporosis International, 22 (10), 2565-73. doi:10.1007/s00198-011-1668-0
Peer Reviewed verified by ORBi

Ralston, S. H., Binkley, N., Boonen, S., Kiel, D. P., Reginster, J.-Y., Roux, C., Chen, L., Rosenberg, E., & Santora, A. (2011). Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency. Calcified Tissue International, 88 (6), 485-94. doi:10.1007/s00223-011-9482-4
Peer Reviewed verified by ORBi

Miller, P. D., Recker, R. R., Reginster, J.-Y., Riis, B. J., Czerwinski, E., Masanauskaite, D., Kenwright, A., Lorenc, R., Stakkestad, J. A., & Lakatos, P. (2011). Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study. Osteoporosis International. doi:10.1007/s00198-011-1773-0
Peer Reviewed verified by ORBi

Bone, H. G., Chapurlat, R., Libanati, C., Brandi ML, Brown, J. P., Czerwinski, E., Krieg, M. A., Man, Z., Mellstrom, D., Radominski, S. C., Reginster, J.-Y., Resch, H., Roman Ivorra, J. A., Roux, C., Daizadeh, N. S., Grauer, A., Cummings, S. R., & Papapoulos, S. (2011). Safety observations from denosumab long-term extension and cross-over studies in postmenopausal women with osteoporosis. Journal of Bone and Mineral Research, 26 (S1), 22-23.
Peer Reviewed verified by ORBi

Roux, C., Chartier, C., Boonen, S., Douglas, K., Ralston, S., Reginster, J.-Y., Chen, L., Rosenberg, E., & Santora, A. (2011). Taux sérique de vitamine D et réponse au traitement par alendronate. Revue du Rhumatisme, 78 (S5), 102.
Peer Reviewed verified by ORBi

Musette, P., Kaufman, J.-M., Rizzoli, R., Cacoub, P., Brandi, M. L., & REGINSTER, J.-Y. (2011). Cutaneous side effects of antiosteoporosis treatments. Therapeutic Advances in Musculoskeletal Disease, 3 (1), 31-41. doi:10.1177/1759720X10387202
Peer Reviewed verified by ORBi

Reginster, J.-Y., & Neuprez, A. (November 2010). Strontium ranelate: a look back at its use for osteoporosis. Expert Opinion on Pharmacotherapy, 11 (17), 2915-2927. doi:10.1517/14656566.2010.533170
Peer Reviewed verified by ORBi

Merville, M.-P., Deroyer, C., Bruyère, O., & Reginster, J.-Y. (November 2010). Le ranélate de strontium augmente la viabilité de chondrocytes humains stimulés par IL-1 bêta. Revue du Rhumatisme, 77 (Suppl.3), 222.
Peer Reviewed verified by ORBi

Bruyère, O., Neuprez, A., Fossi, M., Beaudart, C., Zegels, B., Leonori, L., Hiligsmann, M., & Reginster, J.-Y. (November 2010). Le remboursement des traitements contre l'ostéoporose basé sur l'utilisation de l'outil FRAX plutôt que sur les critères actuels permettrait de réduire de 30% le coût, dans une perspective sociétale, du traitement de l'ostéoporose en Belgique. Revue du Rhumatisme, 77 (Suppl.3), 66-67.
Peer Reviewed verified by ORBi

Bruyère, O., Hiligsmann, M., Zegels, B., Neuprez, A., & Reginster, J.-Y. (November 2010). Résider en institution : un facteur de risque indépendant de fractures de hanche ? Une étude prospective d’une durée de 3 ans. Revue du Rhumatisme, 77 (Suppl.3), 67-68.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Kaufman, J.-M., Goemaere, S., Benhamou, C. L., Balogh, A., Albanese, C., Badurski, J., & Roux, C. (November 2010). Ranélate de strontium : efficacité à long terme sur 10 ans chez les femmes ménopausées ostéoporotiques. Revue du Rhumatisme, 77 (Suppl.3), 99-100.
Peer Reviewed verified by ORBi

Hiligsmann, M., & Reginster, J.-Y. (November 2010). Intérêts des analyses économiques dans la prise en charge de l’ostéoporose postménopausée.

Hiligsmann, M., & Reginster, J.-Y. (November 2010). Cost-effectiveness of denosumab compared with generic alendronate in the treatment of postmenopausal osteoporotic women. Value in Health, 13 (7), 309. doi:10.1016/S1098-3015(11)72193-3
Peer Reviewed verified by ORBi

Hiligsmann, M., Bruyère, O., Detilleux, J., Gillet, P., Parmentier, Y., Dercq, J.-P., Carton, J., & Reginster, J.-Y. (November 2010). Trend of hip fracture incidence in Belgium between 2000 and 2007 and future projections. Value in Health, 13 (7), 303. doi:10.1016/S1098-3015(11)72162-3
Peer Reviewed verified by ORBi

Bruyère, O., Ethgen, O., Neuprez, A., Zegels, B., Gillet, P., Huskin, J.-P., & Reginster, J.-Y. (November 2010). Etude de la qualité de vie après la mise en place d’une prothèse de hanche ou de genou pour cause d’arthrose : une étude de cohorte avec un suivi de 7 ans. Revue du Rhumatisme, 77 (Suppl.3), 141.
Peer Reviewed verified by ORBi

Bruyère, O., Collette, J., & Reginster, J.-Y. (November 2010). Effet à long terme du ranélate de strontium sur le taux sérique de propeptide C-terminal du collagène de type I (PICP) et sur le taux urinaire de télopeptide N-terminal du collagène de type I (U-NTX) chez des femmes ménopausées atteintes d’ostéoporose. Revue du Rhumatisme, 77 (Suppl.3), 183.
Peer Reviewed verified by ORBi

Collette, J., Bruyère, O., & Reginster, J.-Y. (November 2010). Effet du ranélate de strontium sur le taux d’ostéoprotégérine sérique chez des femmes ménopausées ostéoporotiques traitées pendant 3 ans. Revue du Rhumatisme, 77 (Suppl.3), 184.
Peer Reviewed verified by ORBi

Chapurlat, R., Papapoulos, S., Bone, H. G., Brandi, M. L., Brown, J., Czerwinski, E., Daizadeh, N. S., Grauer, A., Haller, C., Krieg, M.-A., Libanati, C., Man, Z., Mellstrom, D., Radominski, S., Reginster, J.-Y., Resch, H., Roman Ivora, J. A., & Cummings, S. R. (October 2010). Long-term denosumab treatment of postmenopausal women with osteoporosis: results from the first year extension study of the FREEDOM trial. Arthritis and Rheumatism, 62 (10), 903.
Peer Reviewed verified by ORBi

Saag, K., Roux, C., Devogelaer, J. P., Lau, C. S., Reginster, J.-Y., Bucci-Rechtweg, C., Su, G., Sambrook, P. N., & Reid, D. M. (October 2010). Effectiveness of zoledronic acid in the prevention and treatment of glucocorticoid-induced osteoporosis in men and premenopausal women. Arthritis and Rheumatism, 62 (10), 902-S903.
Peer Reviewed verified by ORBi

Bruyère, O., Detilleux, J., Akadi, C., & Reginster, J.-Y. (October 2010). Relationship between changes in bone mineral density or bone turnover markers and vertebral fracture incidence in patients treated with bazedoxifene. Arthritis and Rheumatism, 62 (10), 406-S407.
Peer Reviewed verified by ORBi

Reginster, J.-Y., DEBERG, M., Henrotin, Y., & Christgau, S. (01 June 2010). Method for monitoring collagen type II degradation in cartilage.

Reginster, J.-Y., Hiligsmann, M., & Bruyère, O. (June 2010). Strontium ranelate: long-term efficacy against vertebral, nonvertebral and hip fractures in patients with postmenopausal osteoporosis. Therapeutic Advances in Musculoskeletal Disease, 2 (3), 133-143. doi:10.1177/1759720X10362824
Peer Reviewed verified by ORBi

Reginster, J.-Y. (June 2010). Preparing new regulatory guidelines: the role of the Group for the Respect of Ethics and Excellence in Science (GREES). Annals of the Rheumatic Diseases, 69 (Suppl.3), 42.
Peer Reviewed verified by ORBi

Bruyère, O., Collette, J., & Reginster, J.-Y. (June 2010). Long-term effect of strontium ranelate on serum C-terminal propeptide of type I Procollagen (PICP) and urine cross-linked N-telopeptide (U-NTX) in women with postmenopausal osteoporosis. Annals of the Rheumatic Diseases, 69 (Suppl.3), 602.
Peer Reviewed verified by ORBi

Collette, J., Bruyère, O., Vanoverberghe, M., & Reginster, J.-Y. (June 2010). Effect of strontium ranelate on serum osteoprotegerin in women with postmenopausal osteoporosis treated over three years. Annals of the Rheumatic Diseases, 69 (Suppl.3), 602.
Peer Reviewed verified by ORBi

Bruyère, O., Vanoverberghe, M., Neuprez, A., Ethgen, O., Zegels, B., Gillet, P., Huskin, J.-P., & Reginster, J.-Y. (June 2010). Health-related quality of life after total knee or hip replacement: a 7-year prospective study. Annals of the Rheumatic Diseases, 69 (Suppl.3), 469.
Peer Reviewed verified by ORBi

Zegels, B., Theiler, M., Crozes, P., Uebelhart, D., & Reginster, J.-Y. (May 2010). Single oral dose of (1200 mg) sachet of chondroitin 4&6 sulfate (CS) relieves pain and improves function. Results of a double-blind study, versus placebo and an active treatment in knee OA patients. Osteoporosis International, 21 (Suppl.1), 356.
Peer Reviewed verified by ORBi

Bruyère, O., Vanoverberghe, M., Neuprez, A., Ethgen, O., Zegels, B., Gillet, P., Huskin, J.-P., & Reginster, J.-Y. (May 2010). Health-related quality of life after total knee or hip replacement : a 7-year prospective study. Osteoporosis International, 21 (Suppl.1), 26.
Peer Reviewed verified by ORBi

SCHOLTISSEN, S., Bruyère, O., Neuprez, A., Severens, H., Herrero-Beaumont, G., Rovati, L., Hiligsmann, M., & Reginster, J.-Y. (May 2010). Cost-effectiveness of glucosamine sulfate compared to acetaminophen in the treatment of knee osteoarthrits: a French health care perspective. Osteoporosis International, 21 (Suppl.1), 167.
Peer Reviewed verified by ORBi

Sambrook, P. N., Roux, C., Devogelaer, J. P., Saag, K., Lau, C. S., Reginster, J.-Y., Bucci-Rechtweg, C., Su, G., & Reid, D. M. (May 2010). Bisphosphonates and glucocorticoid osteoporosis in men : results of a randomized controlled trial comparing zoledronic acid with risedronate. Osteoporosis International, 21 (Suppl.1), 19.
Peer Reviewed verified by ORBi

Hiligsmann, M., & Reginster, J.-Y. (May 2010). Cost-effectiveness of denosumab compared with oral bisphosphonates in the treatment of postmenopausal osteoporotic women. Osteoporosis International, 21 (S1), 30.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (May 2010). Interpreting the current evidence on glucosamine sulfate effects as a symptom-modifying drug in knee osteoarthtritis. Osteoporosis International, 21 (Suppl.1), 395.
Peer Reviewed verified by ORBi

Reginster, J.-Y., & De Vriese, S. (May 2010). The impact of nutrition on bone health. Osteoporosis International, 21 (Suppl.1), 389. doi:10.1007/s00198-010-1245-y
Peer Reviewed verified by ORBi

Reginster, J.-Y., McClung, M., Cox, D., Mitlak, B., Stock, J., Amewou-Atisso, M., Miller, P., Christiansen, C., & Cummings, S. (May 2010). Effects of arzoxifene on fracture incidence in postmenopausal women with osteoporosis or with low bone mass. Osteoporosis International, 21 (Suppl.1), 23-24.
Peer Reviewed verified by ORBi

Hiligsmann, M., Rabenda, V., Bruyère, O., & Reginster, J.-Y. (May 2010). The burden of non-adherence with oral bisphosphonates and the potential cost-effectiveness of adherence-enhancing interventions. Osteoporosis International, 21 (S1), 381.
Peer Reviewed verified by ORBi

Deroisy, R., Roux, J. P., Bruyère, O., Gensburger, D., Chapurlat, R., & Reginster, J.-Y. (May 2010). Long term agreement between two different centres regarding joint space narrowing measurement in knee osteoarthritis. Osteoporosis International, 21 (Suppl.1), 233-234.
Peer Reviewed verified by ORBi

Neuprez, A., Johansson, H., Kanis, J., McCloskey, E. V., Oden, A., Bruyère, O., Hiligsmann, M., Devogelaer, J., Kaufman, J., & Reginster, J.-Y. (May 2010). A FRAX® model for the assessment of fracture probability in Belgium. Osteoporosis International, 21 (Suppl.1), 255.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Neuprez, A., Hiligsmann, M., & Bruyère, O. (February 2010). Oral calcitonin in the management of osteoarthritis: hope or fantasy ? International Journal of Clinical Rheumatology, 5 (1), 53-58. doi:10.2217/ijr.09.68
Peer Reviewed verified by ORBi

Collette, J., Bruyère, O., Vanoverberghe, M., & Reginster, J.-Y. (2010). Effect of strontium ranelate on serum osteoprotegerin in women with postmenopausal osteoporosis treated over three years. Osteoporosis International, 21 (Suppl.1), 311-312.
Peer Reviewed verified by ORBi

Rabenda, V., Bruyère, O., & Reginster, J.-Y. (2010). Relationship between bone mineral density changes and risk of nonvertebral fractures among women receiving calcium with or without vitamin D supplementation: a meta-analysis. Osteoporosis International, 21 (Suppl.1), 268.
Peer Reviewed verified by ORBi

Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (2010). Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. BONE, 46 (2), 440-6. doi:10.1016/j.bone.2009.08.052
Peer Reviewed verified by ORBi

Hiligsmann, M., Gathon, H.-J., Bruyère, O., Ethgen, O., Rabenda, V., & Reginster, J.-Y. (2010). Cost-Effectiveness of Osteoporosis Screening Followed by Treatment: The Impact of Medication Adherence. Value in Health, 13 (4), 394-401. doi:10.1111/j.1524-4733.2009.00687.x
Peer Reviewed verified by ORBi

Bruyère, O., Cavalier, E., Collette, J., & Reginster, J.-Y. (2010). La vitamine D en association avec le calcium dans le traitement de l’ostéoporose. Ortho-Rhumato, 8, 53-55.

Hiligsmann, M., Rabenda, V., Gathon, H.-J., Ethgen, O., & Reginster, J.-Y. (2010). Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications. Calcified Tissue International, 86, 202-210. doi:10.1007/s00223-009-9329-4
Peer Reviewed verified by ORBi

Pelletier, J.-P., Martel-Pelletier, J., & Reginster, J.-Y. (2010). Osteoarthritis in 2010. Therapy, 7 (6), 575-577. doi:10.2217/thy.10.71
Peer Reviewed verified by ORBi

Devogelaer, J. P., Reginster, J.-Y., Rompen, E., Boutsen, Y., Body, J. J., Bergmann, P., Rozenberg, S., GASPARD, U., & Reychler, H. (2010). L'ostéonécrose maxillaire associée aux traitements aux bisphosphonates dans le traitement de l'ostéoporose. Consensus interdisciplinaire. Louvain Medical, 129 (8), 305-309.
Peer reviewed

Reginster, J.-Y. (2010). National implementation of the ESCEO guidance and its consequences. Medicographia, 32, 67-70.
Peer reviewed

Reginster, J.-Y., & Brandi, M. L. (2010). Fracture prevention in osteoporosis: assessing risks, providing solutions. Osteoporosis International, 21 Suppl 2, 401-2. doi:10.1007/s00198-010-1243-0
Peer Reviewed verified by ORBi

Scheen, A., Hanssens, L., Wampers, M., Van Winkel, R., Collette, J., Reginster, J.-Y., & de Hert, M. A. (2010). Effets contrastés de l’olanzapine et de la rispéridone sur les taux plasmatiques d’adiponectine chez les patients schizophrènes nouvellement traités. In Diabetes and Metabolism (pp. 21, O78). Elsevier.
Peer reviewed

Bruyère, O., Reginster, J.-Y., Croisier, J.-L., Crielaard, J.-M., & Maquet, D. (2010). Rehabilitation in osteoarthritis. Therapy, 7 (6), 669-674. doi:10.2217/thy.10.76
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2010). Interest of lasofoxifene in the treatment of osteoporosis. Evaluation of "Lasofoxifene in postmenopausal women with osteoporosis". N Engl J Med 2010;362:686-96. Expert Opinion on Pharmacotherapy, 11 (10), 1773-5. doi:10.1517/14656561003785755
Peer Reviewed verified by ORBi

Bruyère, O., Collette, J., & Reginster, J.-Y. (2010). Long-term effect of strontium ranealte on serum C-terminal propeptide of type I procollagen (PICP) and urine cross-linked N-telopeptide (U-NTX) in women with postmenopausal osteoporosis. Osteoporosis International, 21 (Suppl.1), 312.
Peer Reviewed verified by ORBi

Rabenda, V., & Reginster, J.-Y. (2010). Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures. Osteoporosis International, 21 (12), 1993-2002. doi:10.1007/s00198-009-1155-z
Peer Reviewed verified by ORBi

Bruyère, O., Collette, J., & Reginster, J.-Y. (2010). The effects of strontium ranelate on biochemical markers of bone turnover and their relationship with bone mineral density: reply to Stepan et al. Osteoporosis International, 21, 1039-1040. doi:10.1007/s00198-009-1156-y
Peer Reviewed verified by ORBi

Collette, J., Bruyère, O., Kaufman, J. M., Lorenc, R., Felsenberg, D., Spector, T. D., Diaz-Curiel, M., Boonen, S., & Reginster, J.-Y. (2010). Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover. Osteoporosis International, 21 (2), 233-41. doi:10.1007/s00198-009-0940-z
Peer Reviewed verified by ORBi

Bruyère, O., Kanis, J. A., Ibar-Abadie, M.-E., Alsayed, N., Brandi, M. L., Burlet, N., Cahall, D. L., Chines, A., Devogelaer, J.-P., Dere, W., Goel, N., Hughes, N., Kaufman, J.-M., Korte, S., Mitlak, B. H., Niese, D., Rizzoli, R., Rovati, L. C., & Reginster, J.-Y. (2010). The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). Osteoporosis International, 21 (5), 713-22. doi:10.1007/s00198-010-1190-9
Peer Reviewed verified by ORBi

Seeman, E., Boonen, S., Borgstrom, F., Vellas, B., Aquino, J.-P., Semler, J., Benhamou, C.-L., Kaufman, J.-M., & Reginster, J.-Y. (2010). Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. BONE, 46 (4), 1038-42. doi:10.1016/j.bone.2009.12.006
Peer Reviewed verified by ORBi

Bruyère, O., Reginster, J.-Y., Croisier, J.-L., Crielaard, J.-M., & Maquet, D. (2010). Rehabilitation in osteoporotic subjects - Myth or reality? European Musculoskeletal Review, 5 (1), 36-39.
Peer reviewed

Hiligsmann, M., Rabenda, V., Bruyère, O., & Reginster, J.-Y. (2010). The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy, 96, 170-176. doi:10.1016/j.healthpol.2010.01.014
Peer reviewed

Body, J. J., Bergmann, P., Boonen, S., Boutsen, Y., Devogelaer, J. P., Goemaere, S., Kaufman, J. M., Rozenberg, S., & Reginster, J.-Y. (2010). Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporosis International, 21 (10), 1657-80. doi:10.1007/s00198-010-1223-4
Peer Reviewed verified by ORBi

Rabenda, V., & Reginster, J.-Y. (2010). Prévention et traitement de l’ostéoporose: éviter l’inertie clinique et motiver l’adhésion au traitement. Revue Médicale de Liège, 65, 358-365.
Peer reviewed

Reginster, J.-Y., Altman, R. D., & Hochberg, M. C. (2010). Prescribed regimen is effective [letter to the editor]. BMJ: British Medical Journal, 341, 6335. doi:10.1136/bmj.c6335
Peer Reviewed verified by ORBi

Bruyère, O., Collette, J., Rizzoli, R., Decock, C., Ortolani, S., Cormier, C., Detilleux, J., & Reginster, J.-Y. (2010). Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years. Osteoporosis International, 21, 1031-1036. doi:10.1007/s00198-009-1078-8
Peer Reviewed verified by ORBi

Musette, P., Brandi, M. L., Cacoub, P., Kaufman, J. M., Rizzoli, R., & Reginster, J.-Y. (2010). Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporosis International, 21, 723-732. doi:10.1007/s00198-009-1097-5
Peer Reviewed verified by ORBi

Breart, G., Cooper, C., Meyer, O., Speirs, C., Deltour, N., & Reginster, J.-Y. (2010). Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database. Osteoporosis International, 21, 1181-1195. doi:10.1007/s00198-009-1050-7
Peer Reviewed verified by ORBi

Neuprez, A., & Reginster, J.-Y. (2010). Prevention and treatment of postmenopausal osteoporosis. In R. Rizzoli (Ed.), Atlas of postmenopausal osteoporosis (Third edition, pp. 83-114). London, United Kingdom: Current Medicine Group Publ.

Hiligsmann, M., & Reginster, J.-Y. (2010). Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. BONE, 47, 34-40. doi:10.1016/j.bone.2010.03.009
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2010). Strontium ranelate: a new era in the management of osteoporosis. In Chinese Journal of Osteoporosis (pp. 1).
Peer reviewed

Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (2010). Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporosis International, 21, 157-165. doi:10.1007/s00198-009-0924-z
Peer Reviewed verified by ORBi

SCHOLTISSEN, S., Bruyère, O., NEUPREZ, A., Severens, J. L., Herrero-Beaumont, G., Rovati, L., Hiligsmann, M., & Reginster, J.-Y. (2010). Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. International Journal of Clinical Practice, 64 (6), 756-62. doi:10.1111/j.1742-1241.2010.02362.x
Peer Reviewed verified by ORBi

Rabenda, V., & Reginster, J.-Y. (2010). Overcoming problems with adherence to osteoporosis medication. Expert Review of Pharmacoeconomics and Outcomes Research, 10 (6), 677-89. doi:10.1586/erp.10.76
Peer Reviewed verified by ORBi

Hiligsmann, M., Vanoverberghe, M., Neuprez, A., Bruyère, O., & Reginster, J.-Y. (2010). Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis. Expert Review of Pharmacoeconomics and Outcomes Research, 10 (4), 359-366. doi:10.1586/erp.10.53
Peer Reviewed verified by ORBi

Bergmann, P., Body, J. J., BOONEN, S., Boutsen, Y., Devogelaer, J. P., Goemaere, S., Kaufman, J., Reginster, J.-Y., & Rozenberg, S. (2010). Loading and skeletal development and maintenance. Journal of Osteoporosis, 2011, 786752. doi:10.4061/2011/786752
Peer Reviewed verified by ORBi

Neuprez, A., Johansson, H., Kanis, J., McCloskey, E. V., Oden, A., Bruyère, O., Hiligsmann, M., Devogelaer, J.-P., Kaufmann, J.-M., & Reginster, J.-Y. (December 2009). Rationalisation du remboursement des médicaments de l'ostéoporose : de la mesure isolée de la densité osseuse à l’intégration des facteurs cliniques de risque fracturaire. Validation de l’algorithme FRAX®. Revue Médicale de Liège, 64 (12), 612-619.
Peer reviewed

Hiligsmann, M., Rabenda, V., Bruyère, O., & Reginster, J.-Y. (October 2009). The clinical and economic burden of nonadherence with osteoporosis medications. Value in Health, 12 (7), 444. doi:10.1016/S1098-3015(10)75197-4
Peer Reviewed verified by ORBi

Hiligsmann, M., Rabenda, V., Bruyère, O., & Reginster, J.-Y. (October 2009). The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Arthritis and Rheumatism, 60 (number 10 (suppl.)), 328.
Peer Reviewed verified by ORBi

Bruyère, O., COLLETTE, J., DEROISY, R., Rabenda, V., Neuprez, A., Hiligsmann, M., & Reginster, J.-Y. (October 2009). Biochemical markers of bone and cartilage remodelling: interest in the prediction of lumbar disc degeneration progression and effects of strontium ranelate over a 3-year period. Arthritis and Rheumatism, 60 (number 10 (suppl.)), 313.
Peer Reviewed verified by ORBi

Hiligsmann, M., Rabenda, V., & Reginster, J.-Y. (June 2009). The clinical and economic burden of nonadherence with oral bisphosphonates in osteoporotic patients. Annals of the Rheumatic Diseases, 68 (S3), 667.
Peer Reviewed verified by ORBi

Haris, S. T., Reginster, J.-Y., Harley, C., Blumentals, W. A., Poston, S. A., & Silverman, S. L. (May 2009). Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. BONE, 44, 758-765.
Peer Reviewed verified by ORBi

Sambrook, P., Reid, D., Devogelaer, J.-P., Reginster, J.-Y., Saag, K., Roux, C., Papanastasiou, P., Maylandt, K., Fashola, T., & Mesenbrink, P. (April 2009). Effect of single annual infusion of zoledronic acid on bone turnover markers versus daily oral risedronate in patients with glucocorticoid-induced osteoporosis. Osteoporosis International, 20 (Suppl.1), 128-129.
Peer Reviewed verified by ORBi

Bruyère, O., Collette, J., Deroisy, R., Rabenda, V., Hiligsmann, M., & Reginster, J.-Y. (March 2009). Prediction of spinal osteoarthritis progression by assessment of biochemical markers of bone and cartilage remodelling: a 3-year study. Osteoporosis International, 20 (Suppl.1), 8.
Peer Reviewed verified by ORBi

Felsenberg, D., Czerwinski, E., Stakkestad, J., Neate, C., Masanauskaite, D., & Reginster, J.-Y. (March 2009). Efficacy of monthly oral ibandronate is maintained over 5 years: The MOBILE LTE study. Osteoporosis International, 20 (Suppl.1), 15.
Peer Reviewed verified by ORBi

Richy, F., Dukas, L., & Reginster, J.-Y. (March 2009). Prevention of falls, bone loss and fractures : D-hormone analogs or native vitamin D? a meta-perspective. Osteoporosis International, 20 (Suppl.1), 90.
Peer Reviewed verified by ORBi

Hiligsmann, M., Neuprez, A., Scholtissen, S., & Reginster, J.-Y. (March 2009). Cost-effectiveness of strontium ranelate versus intravenous ibandronate in the treatment of postmenopausal women. Osteoporosis International, 20 (S1), 130.
Peer Reviewed verified by ORBi

Hiligsmann, M., & Reginster, J.-Y. (March 2009). Cost-utility of denosumab for the treatment of postmenopausal osteoporotic women. Osteoporosis International, 20 (S1), 5.
Peer Reviewed verified by ORBi

Goemaere, S., Pornel, B., Mathy, L., van Steenberghe, Thomas, M., & Reginster, J.-Y. (March 2009). BEATRIS - Better adherence to treatment with ibandronate in osteoporosis: bone markers feedback study. Osteoporosis International, 20 (Suppl.1), 23.
Peer Reviewed verified by ORBi

Bruyère, O., Detilleux, J., Decock, C., & Reginster, J.-Y. (March 2009). Relationship between changes in bone mineral density and vertebral fracture incidence: an analysis of the last 3 years of an 8-year treatment with strontium ranelate. Osteoporosis International, 20 (Suppl.1), 11.
Peer Reviewed verified by ORBi

Siverman, S., Poston, S., Blumenthals, W., & Reginster, J.-Y. (March 2009). Fracture risk in women ≥ 65 years with once-monthly oral bisphosphonate compared with weekly bisphosphonates: subanalysis from the evaluation of ibandronate efficacy (VIBE) database study. Osteoporosis International, 20 (Suppl.1), 153.
Peer Reviewed verified by ORBi

Rabenda, V., & Reginster, J.-Y. (March 2009). Positive impact of compliance to strontium ranelate on the risk of non-vertebral osteoporotic fractures. Osteoporosis International, 20 (Suppl.1), 89.
Peer Reviewed verified by ORBi

Bruyère, O., Hiligsmann, M., Frankinet, P., Detilleux, J., & Reginster, J.-Y. (March 2009). Association between changes in bone mineral density and fracture incidence in postmenopausal women receiving calcium and vitamin D : A 3-year study. Osteoporosis International, 20 (Suppl.1), 87-88.
Peer Reviewed verified by ORBi

Scholtissen, S., Bruyère, O., Hiligsmann, M., Neuprez, A., Pavelka, K., Rovati, L., & Reginster, J.-Y. (March 2009). Effect of glucosamine sulfate on health utility data in patients with knee osteoarthritis : reanalysis of two 3-year prospective studies. Osteoporosis International, 20 (Suppl.1), 18.
Peer Reviewed verified by ORBi

Rabenda, V., Bruyère, O., & Reginster, J.-Y. (March 2009). Relationship between changes in bone mineral density and compliance to strontium ranelate. Osteoporosis International, 20 (Suppl.1), 152-153.
Peer Reviewed verified by ORBi

Bruyère, O., & Reginster, J.-Y. (March 2009). Treatment of osteoarthritis with glucosamine sulftate: from clinical to economic data. Osteoporosis International, 20 (Suppl.1), 182.
Peer Reviewed verified by ORBi

Bruyère, O., Decock, C., Collette, J., Ortolani, S., Cormier, C., Detilleux, J., Frankinet, P., & Reginster, J.-Y. (March 2009). Relationship between 3-month changes in biochemical markers of bone remodelling and 3-year changes in bone mineral density in patients treated with strontium ranelate. Osteoporosis International, 20 (Suppl.1), 86-87.
Peer Reviewed verified by ORBi

Hiligsmann, M., Rabenda, V., Gathon, H.-J., Ethgen, O., & Reginster, J.-Y. (March 2009). Clinical en economic implications of non-adherence with osteoporosis medications. Osteoporosis International, 20 (S1), 16.
Peer Reviewed verified by ORBi

Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (March 2009). Cost-utility of strontium ranelate for the prevention and treatment of postmenopausal osteoporotic women. Osteoporosis International, 20 (S1), 129.
Peer Reviewed verified by ORBi

Roux, C., Fashola, T., Reid, D., Devogelaer, J.-P., Saag, K., Lau, C., Reginster, J.-Y., Papanastasiou, P., Ferreira, A., & Hartl, F. (March 2009). Effect on single annual infusion of zoledronic acid (5mg) on lumbar spine bone mineral density versus daily oral risedronate (5mg) in subgroups of patients receiving glucocorticoid therapy. Osteoporosis International, 20 (Suppl.1), 7-8.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Devogelaer, J.-P., Hiligsmann, M., Kaufman, J.-M., Neuprez, A., Johansson, H., & Kanis, J. A. (March 2009). FRAX(r) and the assessment of fracture probability in men and women from Belgium. Osteoporosis International, 20 (Suppl.1), 38-39.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (March 2009). How does the efficacy of Protelos translate into patient benefits ? Osteoporosis International, 20 (Suppl.1), 178.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (March 2009). The antifracture efficacy of ibandronate: a compendium of evidence. Osteoporosis International, 20 (Suppl.1), 182-183.
Peer Reviewed verified by ORBi

Scholtissen, S., Bruyère, O., Hiligsmann, M., Neuprez, A., Herrero-Beaumont, G., Rovati, L., & Reginster, J.-Y. (March 2009). Glucosamine sulfate in the treatment of knee osteoarthritis: impact on health utility. Osteoporosis International, 20 (Suppl.1), 149.
Peer Reviewed verified by ORBi

Kahan, A., Uebelhart, D., De Vathaire, F., Delmas, P. D., & Reginster, J.-Y. (2009). Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism, 60 (2), 524-33. doi:10.1002/art.24255
Peer Reviewed verified by ORBi

Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2009). The International Osteoporosis Foundation: history, objectives and achievements. Osteoporosis International, 20 Suppl 3, 241-2. doi:10.1007/s00198-008-0700-5
Peer Reviewed verified by ORBi

Bruyère, O., Varela, A. R., Adami, S., Detilleux, J., Rabenda, V., Hiligsmann, M., & Reginster, J.-Y. (2009). Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women. European Journal of Epidemiology, 24, 707-712. doi:10.1007/s10654-009-9381-4
Peer Reviewed verified by ORBi

Bruyère, O., Scholtissen, S., Neuprez, A., Severens, H., Herrero-Beaumont, G., Rovati, L., Hiligsmann, M., & Reginster, J.-Y. (2009). Analyses coût-efficacité du sulfate de glucosamine chez des patients gonarthrosiques : comparaison avec le paracétamol. Revue du Rhumatisme, 76, 1097.
Peer Reviewed verified by ORBi

Bruyère, O., Scholtissen, S., Neuprez, A., Hiligsmann, M., & Reginster, J.-Y. (2009). Effets du sulfate de chondroitine sur les indices d'utilité de santé chez des sujets gonarthrosiques et analyses économiques préliminaires. Revue du Rhumatisme, 76, 1051.
Peer Reviewed verified by ORBi

Rizzoli, R., Bruyère, O., Cannata-Andia, J. B., Devogelaer, J.-P., Lyritis, G., Ringe, J. D., Vellas, B., & Reginster, J.-Y. (2009). Management of osteoporosis in the elderly. Current Medical Research and Opinion, 25 (10), 2373-2387. doi:10.1185/03007990903169262
Peer Reviewed verified by ORBi

Bergmann, P., Body, J.-J., Boonen, S., Boutsen, Y., Devogelaer, J.-P., Goemaere, S., Kaufman, J.-M., Reginster, J.-Y., & Gangji, V. (2009). Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. International Journal of Clinical Practice, 63 (1), 19-26. doi:10.1111/j.1742-1241.2008.01911.x
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2009). Strontium ranelate in the therapeutic strategies for osteoporosis, including glucocorticoid-induced osteoporosis (GIO). In Bone (pp. 45, S3, 131).
Peer reviewed

NEUPREZ, A., Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (2009). Efficacite anti-fracturaire de l'ibandronate administre par voie intraveineuse: de la complexite des etudes epidemiologiques interventionnelles a la pratique quotidienne. Revue Médicale de Liège, 64 (10), 525-9.
Peer reviewed

Sambrook, P., Devogelaer, J. P., Reginster, J.-Y., Saag, K., Roux, C., Lau, C., Papanastasiou, P., Schoenborn-Kellenberger, O., Maylandt, K., Fashola, T., Mesenbrink, P., & Reid, D. (2009). Effect of a single i.v. infusion of zoledronic acid on bone turnover markers versus oral risedronate in patients with glucocorticoid-induced osteoporosis. In Bone (pp. 44, 96). New York, United States - New York: Elsevier Science.
Peer reviewed

Cranney, A., Wells, G. A., Yetisir, E., Adami, S., Cooper, C., Delmas, P. D., Miller, P. D., Papapoulos, S., Reginster, J.-Y., Sambrook, P. N., Silverman, S., Siris, E., & Adachi, J. D. (2009). Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporosis International, 20 (2), 291-7. doi:10.1007/s00198-008-0653-8
Peer Reviewed verified by ORBi

Hiligsmann, M., Ethgen, O., Bruyère, O., Richy, F., Gathon, H.-J., & Reginster, J.-Y. (2009). Development and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in Osteoporosis. Value in Health, 12 (5), 687-696. doi:10.1111/j.1524-4733.2008.00497.x
Peer Reviewed verified by ORBi

Kaux, J.-F., Le Goff, C., Debray, F.-G., Crielaard, J.-M., & Reginster, J.-Y. (2009). Le cas clinique du mois. Osteogenesis imperfecta. Revue Médicale de Liège.
Peer reviewed

Reid, D. M., Devogelaer, J.-P., Saag, K., Roux, C., Lau, C.-S., Reginster, J.-Y., Papanastasiou, P., Ferreira, A., Hartl, F., Fashola, T., Mesenbrink, P., & Sambrook, P. N. (2009). Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. The Lancet, 373 (9671), 1253-63. doi:10.1016/S0140-6736(09)60250-6
Peer Reviewed verified by ORBi

Bruyère, O., De Cock, C., Deroisy, R., & Reginster, J.-Y. (2009). Bone mineral density and health related quality of life: a 3-year follow-up study of osteoportic postmenopaul women. The Open Geritric Medicine Journal, 2, 44-52.
Peer reviewed

Bruyère, O., SCHOLTISSEN, S., NEUPREZ, A., Hiligsmann, M., Toukouki, A., & Reginster, J.-Y. (2009). Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis. Journal of Medical Economics, 12 (4), 356-360. doi:10.3111/13696990903438617
Peer Reviewed verified by ORBi

Scholtissen, S., Guillemin, F., Bruyère, O., Collette, J., Dousset, B., Kemmer, C., Culot, S., Cremer, D., Dejardin, H., Hubermont, G., Lefebvre, D., Pascal-Vigneron, V., Weryha, G., & Reginster, J.-Y. (2009). Assessment of determinants for osteoporosis in elderly men. Osteoporosis International, 20 (7), 1157-66. doi:10.1007/s00198-008-0789-6
Peer Reviewed verified by ORBi

Bruyère, O., & Reginster, J.-Y. (2009). The need for economic evaluation in osteoarthritis. Aging Health, 5 (5), 591-594. doi:10.2217/ahe.09.57
Peer Reviewed verified by ORBi

Ethgen, O., Hiligsmann, M., & Reginster, J.-Y. (2009). Modelling the uptake and diffusion of innovative technology: a critical and strategic feature of budget impact analysis and risk-sharing agreements. In Value in Health (pp. 12, A395).
Peer reviewed

Chapurlat, R., Felsenberg, F., & Reginster, J.-Y. (2009). L'efficacité de l'ibandronate oral mensuel est maintenue sur 5 ans : l'étude MOBILE extension long terme (ELT). In Revue du Rhumatisme (pp. 76, 1069).
Peer reviewed

Neuprez, A., Johansson, H., Kanis, J., Mc Closkey, E., Oden, A., Bruyère, O., Hiligsmann, M., Devogelaer, J.-P., Kaufman, J.-M., & Reginster, J.-Y. (2009). Rationalisation du remboursement des médicaments de l'ostéoporose : de la mesure isolée de la densité osseuse à l'intégration des facteurs cliniques de risque fracturaire. Validation de l'algorithme FRAX(r). Revue du Rhumatisme, 76, 1070-1.
Peer Reviewed verified by ORBi

Rabenda, V., Hiligsmann, M., & Reginster, J.-Y. (2009). Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opinion on Pharmacotherapy, 10 (14), 2303-15. doi:10.1517/14656560903140533
Peer Reviewed verified by ORBi

Bruyère, O., Decock, C., Delhez, M., Collette, J., & Reginster, J.-Y. (2009). Highest prevalence of vitamin D inadequacy in institutionalized women compared with noninstitutionalized women: a case-control study. Women's Health, 5 (1), 49-54. doi:10.2217/17455057.5.1.49
Peer Reviewed verified by ORBi

Meunier, P., Roux, C., Ortolani, S., Diaz-Curiel, M., Compston, J., Marquis, P., Cormier, C., Isaia, G., Badurski, J., Wark, J. D., Collette, J., & Reginster, J.-Y. (2009). Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporosis International, 20, 1663-73. doi:10.1007/s00198-008-0825-6
Peer Reviewed verified by ORBi

Bruyère, O., DeCock, C., Mottet, C., Neuprez, A., MALAISE, O., & Reginster, J.-Y. (2009). Low dietary calcium in European postmenopausal osteoporotic women. Public Health Nutrition, 12 (1), 111-114. doi:10.1017/S1368980008002024
Peer Reviewed verified by ORBi

Bruyère, O., Brandi, M. L., Burlet, N., Harvey, N., Lyritis, G., Minne, H., Boonen, S., REGINSTER, J.-Y., Rizzoli, R., & Akesson, K. (2009). La gestione post-frattura del paziente con frattura di femore: Una visione prospettica. Clinical Cases in Mineral and Bone Metabolism, 6 (3), 270-279.
Peer Reviewed verified by ORBi

ZEGELS, B., Theiler, R., Crozes, P., Uebelhart, D., & Reginster, J.-Y. (2009). Une prise orale unique (1200 mg) de sulfate de chondroïtine 4 & 6 (CS) réduit la douleur et améliore la fonction. Résultats d'une étude en double insu, contre placebo et un comparateur actif, chez des patients souffrants de gonarthrose (OA). Revue du Rhumatisme, 76, 1071.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Bruyère, O., Sawicki, A., Roces-Varela, A., Fardellone, P., Roberts, A., & Devogelaer, J.-P. (2009). Long-term treatment of postmenopausal osteoporosis with strontium ranelate: Results at 8 years. BONE, 45, 1059-64. doi:10.1016/j.bone.2009.08.004
Peer Reviewed verified by ORBi

Bruyère, O., Detilleux, J., Decock, C., & Reginster, J.-Y. (2009). Relations entre les variations de densité minérale osseuse et l'incidence des fractures vertébrales: analyse des 3 dernières années d'un traitement de 8 ans sous ranélate de strontium. Revue du Rhumatisme, 76, 1070.
Peer Reviewed verified by ORBi

Richy, F., Scarpignato, C., Lanas, A., & Reginster, J.-Y. (2009). Efficacy and safety of piroxicam revisited. A global meta-analysis of randomised clinical trials. Pharmacological Research, 60, 254-263. doi:10.1016/j.phrs.2009.03.021
Peer Reviewed verified by ORBi

Reginster, J.-Y., Hiligsmann, M., Rabenda, V., Zegels, B., Neuprez, A., & Bruyère, O. (2009). Ibandronate in the management of postmenopausal osteoporosis. Clinical Medicine. Therapeutics, 1, 1409-1421.
Peer reviewed

Compston, J., Reid, D. M., Boisdron, J., Brandi, M.-L., Burlet, N., Cahall, D., Delmas, P. D., Dere, W., Devogelaer, J.-P., Fitzpatrick, L. A., Flamion, B., Goel, N., Korte, S., Laslop, A., Mitlak, B., Ormarsdottir, S., Ringe, J., Rizzoli, R., Tsouderos, Y., ... REGINSTER, J.-Y. (2009). Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: An update from the Group for the Respect of Ethics and Excellence in Science (Osteoporosis International DOI: 10.1007/s00198-008-0670-7). Osteoporosis International, 20 (3), 497-498. doi:10.1007/s00198-008-0735-7
Peer Reviewed verified by ORBi

Bruyère, O., & Reginster, J.-Y. (2009). Place de la densitométrie osseuse dans le diagnostic et le suivi des patients ostéoporotiques. Ortho-Rhumato, 7, 3-5.

Reginster, J.-Y., Deroisy, R., NEUPREZ, A., Hiligsmann, M., Zegels, B., & Bruyère, O. (2009). Strontium ranelate: new data on fracture prevention and mechanisms of action. Current Osteoporosis Reports, 7 (3), 96-102. doi:10.1007/s11914-009-0016-1
Peer Reviewed verified by ORBi

Hiligsmann, M., Rabenda, V., Gathon, H.-J., Ethgen, O., Bruyère, O., & Reginster, J.-Y. (December 2008). Impact of medication non-compliance and non-persistence on pharmacoeconomic evaluations in osteoporosis. Osteoporosis International, 19 (S2), 282.
Peer Reviewed verified by ORBi

Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (December 2008). Cost-utility of calcium and vitamin D supplementation in the treatment of postmenopausal osteoporotic women. Osteoporosis International, 19 (S2), 363.
Peer Reviewed verified by ORBi

Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (December 2008). Cost-utility of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women. Osteoporosis International, 19 (S2), 450.
Peer Reviewed verified by ORBi

Rabenda, V., & Reginster, J.-Y. (November 2008). Effet positif de l'observance au ranélate de strontium sur le risque de fractures ostéoporotiques non vertébrales. Revue du Rhumatisme, 75 (10-11), 1127.
Peer Reviewed verified by ORBi

Hiligsmann, M., Rabenda, V., Gathon, H.-J., Ethgen, O., & Reginster, J.-Y. (November 2008). Impact of medication non-compliance and non-persistence on pharmacoeconomic evaluations in osteoporosis. Value in Health, 11 (6), 542. doi:10.1016/S1098-3015(10)66788-5
Peer Reviewed verified by ORBi

Bruyère, O., Hiligsmann, M., FRANKINET, P., Detilleux, J., & Reginster, J.-Y. (October 2008). Association between changes in bone mineral density and fracture incidence in postmenopausal osteoporotic women receiving calcium and vitamin D: a 3-year follow-up study. Arthritis and Rheumatism, 58 (Suppl.1), 743.
Peer Reviewed verified by ORBi

Rabenda, V., & Reginster, J.-Y. (October 2008). Positive impact of compliance of strontium ranelate on the risk of nonvertebral osteoporotic fractures. Arthritis and Rheumatism, 58, 99.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Sawicki, A., Roces-Varela, A., Fardellone, P., & Roberts, A. (October 2008). Strontium ranelate : long-term efficacy over 8 years in postmenopausal osteoporotic women. Arthritis and Rheumatism, 58, 941.
Peer Reviewed verified by ORBi

Bruyère, O., Decock, C., COLLETTE, J., Ortolani, S., Cormier, C., Detilleux, J., FRANKINET, P., & Reginster, J.-Y. (October 2008). Relationship between 3-month changes in biochemical markers of bone remodelling and 3-year changes in bone mineral density in patients treated with strontium ranelate. Arthritis and Rheumatism, 58 (Suppl.1), 743.
Peer Reviewed verified by ORBi

REGINSTER, J.-Y., DEBERG, M., Henrotin, Y., & Christgau, S. (12 August 2008). Method for monitoring collagen type II degradation in cartilage.

Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (July 2008). Efficiency of calcium and vitamin D in the management of osteoporosis [Paper presentation]. 7th European Conference on Health Economics, Rome, Italy.

REGINSTER, J.-Y., DEBERG, M., Henrotin, Y., & Christgau, S. (01 July 2008). Detection of specific nitrated markers.

DeCock, C., Bruyère, O., Collette, J., & Reginster, J.-Y. (July 2008). Déficit en vitamine D chez les femmes françaises ostéoporotiques et ostéopéniques. Revue du Rhumatisme, 75, 839-844. doi:10.1016/j.rhum.2007.10.623
Peer Reviewed verified by ORBi

Hiligsmann, M., Bruyère, O., Ethgen, O., Pire, G., Gathon, H.-J., & Reginster, J.-Y. (July 2008). Efficiency and recommendations for osteoporosis screening strategy [Paper presentation]. 7th European Conference on Health Economics, Rome, Italy.

Reginster, J.-Y., Felsenberg, D., Boonen, S., Diez-Perez, A., Rizzoli, R., Brandi, M. L., Spector, T. D., Brixen, K., Goemaere, S., Cormier, C., Balogh, A., Delmas, P. D., & Meunier, P. J. (June 2008). Strontium ranelate decreases the risk of hip fracture over 3 and 5 years in post menopausal women at high risk. Annals of the Rheumatic Diseases, 67 (Suppl.II), 540.
Peer Reviewed verified by ORBi

Bruyère, O., Collette, J., Christiansen, F., Fardellone, F., Detroz, A., Deroisy, R., & Reginster, J.-Y. (June 2008). Association between lumbar disc degeneration and biochemical markers of bone and cartilage remodelling. Annals of the Rheumatic Diseases, 67 (Suppl.II), 231.
Peer Reviewed verified by ORBi

Bruyère, O., Delhez, M., Collette, J., & Reginster, J.-Y. (June 2008). Prevalence of vitamin D inadequacy in institutionalized osteoporotic postmenopausal women. Annals of the Rheumatic Diseases, 67 (Suppl.II), 403.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Boisdron, J., & Barr, C. E. (June 2008). Vertebral fracture efficacy of monthly ibandronate versus weekly bisphosphonates: analysis of a retrospective cohort study. Annals of the Rheumatic Diseases, 67 (Suppl.II), 539.
Peer Reviewed verified by ORBi

Saag, K. G., Devogelaer, J.-P., Reid, D. M., Sambrook, P., Goemaere, S., Ish-Shalom, S., Collette, J., Papanastasiou, P., Ferreira, A., Eriksen, E. F., Fashola, T., Schoenborn-Kellenberger, O., Chappard, D., & Reginster, J.-Y. (June 2008). Effects of a single 5 mg infusion of zoledronic acid and oral risedronate (5 mg/day) on bone remodeling over one year in patients with glucocorticoid-induced osteoporosis. Annals of the Rheumatic Diseases, 67 (Suppl.II), 542.
Peer Reviewed verified by ORBi

Bruyère, O., Roces-Varela, A., Adami, S., & Reginster, J.-Y. (June 2008). Association between changes in bone mineral density and vertebral fracture incidence in untreated postmenopausal women : a 3-year prospective study. Annals of the Rheumatic Diseases, 67 (Suppl.II), 89.
Peer Reviewed verified by ORBi

Reid, D. M., Devogelaer, J.-P., Saag, K., Roux, C., Lau, C., Reginster, J.-Y., Papanastasiou, P., Ferreira, A., Hartl, F., Fashola, T., Mesenbrink, P., & Sambrook, P. (June 2008). A single infusion of zoledronic acid 5 mg is significantly more effective than daily oral risedronate 5 mg in increasing bone mineral density of the lumbar spine, hip, femoral neck and trochanter in patients with glucocorticoid-induced osteoporosis. Annals of the Rheumatic Diseases, 67 (Suppl.II), 56.
Peer Reviewed verified by ORBi

Bruyère, O., Pieck, C., Hiligsmann, M., Zegels, B., Delhez, M., Mottet, C., & Reginster, J.-Y. (June 2008). Place of residence as a risk factor for hip fracture? A case-control 3-year study. Annals of the Rheumatic Diseases, 67 (Suppl.II), 428.
Peer Reviewed verified by ORBi

Bruyère, O., Brandi, M., Vellas, B., Hiligsmann, M., & Reginster, J.-Y. (June 2008). Relationship between long-term changes in femoral neck bone mineral density and hip fracture incidence in untreated postmenopausal osteoporotic women. Annals of the Rheumatic Diseases, 67 (Suppl.II), 403.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Barr, C. E., Blumentals, W. A., & Harris, S. T. (June 2008). Similar non-vertebral antifracture efficacy demonstrated with monthly ibandronate versus weekly bisphosphonate therapy: A retrospective cohort study. Annals of the Rheumatic Diseases, 67 (Suppl.II), 539.
Peer Reviewed verified by ORBi

Goemaere, S., Bergman, P., Body, J. J., Boonen, S., Devogelaer, J.-P., Kaufman, J.-M., Rozenberg, S., & Reginster, J.-Y. (April 2008). Utility audit of Belgian DXA centers. Osteoporosis International, 19 (Suppl.1), 205.
Peer Reviewed verified by ORBi

Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (April 2008). Cost-utility of strontium ranelate in the treatment of postmenopausal women. Osteoporosis International, 19 (S1), 6.
Peer Reviewed verified by ORBi

Hiligsmann, M., Bruyère, O., Ethgen, O., Pire, G., & Reginster, J.-Y. (April 2008). Efficiency and recommendations for osteoporosis screening strategy. Osteoporosis International, 19 (S1), 116.
Peer Reviewed verified by ORBi

DeCock, C., Bruyère, O., & Reginster, J.-Y. (April 2008). Bone Mineral Density and health-related quality of life: a 3-year follow-up in osteoporotic postmenopausal women. Osteoporosis International, 19 (Suppl.1), 54.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Sawicki, A., Roces-Varela, A., Fardellone, P., & Roberts, A. (April 2008). Strontium ranelate: 8 years efficacy on vertebral and nonvertebral fractures in postmenopausal osteoporotic women. Osteoporosis International, 19 (Suppl.1), 131-132.
Peer Reviewed verified by ORBi

Bruyère, O., Brandi, M. L., Vellas, B., Hiligsmann, M., & Reginster, J.-Y. (April 2008). Changes in femoral neck bone mineral density are associated with hip fracture incidence in untreated postmenopausal women. Osteoporosis International, 19 (Suppl.1), 18-19.
Peer Reviewed verified by ORBi

Bruyère, O., Collette, J., Christiansen, C., Padrino, J. M., Fardellone, J. P., Detroz, A., Deroisy, R., & Reginster, J.-Y. (April 2008). Association between spinal osteoarthritis and biochemical markers of bone and cartilage remodelling. Osteoporosis International, 19 (Suppl.1), 200.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Felsenberg, D., Boonen, S., Diez-Perez, A., Rizzoli, R., Brandi, M. L., Spector, T., Brixen, K., Goemaere, S., & Cormier, C. (April 2008). Strontium ranelate demonstrates efficacy against hip fracture over 3 and 5 years in postmenopausal women at high risk of hip fracture. Osteoporosis International, 19 (Suppl.1), 26-27.
Peer Reviewed verified by ORBi

Bruyère, O., Pieck, C., Hiligsmann, M., Zegels, B., Delhez, M., Mottet, C., & Reginster, J.-Y. (April 2008). Place of residence as a risk factor for hip fracture? A case-control 3-year study. Osteoporosis International, 19 (Suppl.1), 200.
Peer Reviewed verified by ORBi

Scholtissen, S., Guillemin, F., Kemmer, C., Culot, S., Bruyère, O., & Reginster, J.-Y. (April 2008). Assessement of risk factors for osteoporotic fractures in elderly men. Osteoporosis International, 19 (Suppl.1), 200-201.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Blumentals, W., Barr, C., Silverman, S., & Poston, S. (April 2008). Fracture efficacy of monthly ibandronate and weekly bisphosphonate therapy: a retrospective cohort study. Osteoporosis International, 19 (Suppl.1), 9.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (April 2008). Reducing non-vertebral fracture risk: ibandronate doses used in clinical practice. Osteoporosis International, 19 (Suppl.1), 221.
Peer Reviewed verified by ORBi

Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (April 2008). Efficiency of calcium and vitamin D supplementation in the management of osteoporosis. Osteoporosis International, 19 (S1), 113.
Peer Reviewed verified by ORBi

Reid, D. M., Devogelaer, J.-P., Saag, K., Roux, C., Lau, C. S., Reginster, J.-Y., Papanastasiou, P., Ferreira, A., Fashola, T., & Sambrook, P. (April 2008). A single infusion of zoledronic acid 5 mg (ZOL) is significantly more effective than daily oral risedronate 5 mg (RIS) in increasing bone mineral density (BMD) of the lumbar spine (LS), hip, femoral neck and trochanter in patients with glucocorticoid-induced osteoporosis (GIO). Osteoporosis International, 19 (Suppl.1), 23-24.
Peer Reviewed verified by ORBi

Collette, J., Reginster, J.-Y., Zerbini, C., Neate, C., Sederati, F., & Delmas, P. D. (April 2008). Reduction in bone remodelling markers with monthly oral ibandronate (150 mg) and weekly alendronate (70 mg): results from the motion study. Osteoporosis International, 19 (Suppl.1), 207.
Peer Reviewed verified by ORBi

Bruyère, O., Roces-Varela, A., Adami, S., & Reginster, J.-Y. (April 2008). Association between changes in bone mineral density and vertebral fracture incidence in untreated postmenopausal women. Osteoporosis International, 19 (Suppl.1), 199.
Peer Reviewed verified by ORBi

Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (April 2008). Cost-effectiveness of mass screening and targeted biphosphonates treatment in osteoporosis. Osteoporosis International, 19 (S1), 117.
Peer Reviewed verified by ORBi

Bruyère, O., Delferriere, D., Roux, C., Wark, J. D., Spector, T., Devogelaer, J.-P., Brixen, K., Adami, S., Fechtenbaum, J., Kolta, S., & Reginster, J.-Y. (March 2008). Effects of Strontium Ranelate on Spinal Osteoarthritis Progression. Annals of the Rheumatic Diseases, 67 (3), 335-9. doi:10.1136/ard.2007.075572
Peer Reviewed verified by ORBi

Reginster, J.-Y., Collette, J., NEUPREZ, A., Zegels, B., Deroisy, R., & Bruyère, O. (10 February 2008). Role of Biochemical Markers of Bone Turnover as Prognostic Indicator of Successful Osteoporosis Therapy. BONE, 42, 832-836. doi:10.1016/j.bone.2008.01.021
Peer Reviewed verified by ORBi

Bruyère, O., Pavelka, K., Rovati, L. C., Gatterova, J., Giacovelli, G., Olejarova, M., Deroisy, R., & Reginster, J.-Y. (February 2008). Total Joint Replacement after Glucosamine Sulphate Treatment in Knee Osteoarthritis: Results of a Mean 8-Year Observation of Patients from Two Previous 3-Year, Randomised, Placebo-Controlled Trials. Osteoarthritis and Cartilage, 16 (2), 254-60. doi:10.1016/j.joca.2007.06.011
Peer Reviewed verified by ORBi

Reginster, J.-Y., Collette, J., Neuprez, A., & Bruyère, O. (2008). Strontium ranelate in the management of spinal and peripheral osteoporosis. Review of Endocrinology, 26-33.
Peer reviewed

Rizzoli, R., Burlet, N., Cahall, D., Delmas, P. D., Eriksen, E. F., Felsenberg, D., Grbic, J., Jontell, M., Landesberg, R., Laslop, A., Wollenhaupt, M., Papapoulos, S., Sezer, O., Sprafka, M., & Reginster, J.-Y. (2008). Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. BONE, 42 (5), 841-7. doi:10.1016/j.bone.2008.01.003
Peer Reviewed verified by ORBi

MacDonald, T. M., Reginster, J.-Y., Littlejohn, T. W., Richard, D., Lheritier, K., Krammer, G., & Rebuli, R. (2008). Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. Journal of Hypertension, 26 (8), 1695-702. doi:10.1097/HJH.0b013e328302c9fe
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2008). Protelos – unrivalled efficacy in the short-and long-term. OsteOpinion, 4, 4-5.
Peer reviewed

Seeman, E., Devogelaer, J.-P., Lorenc, R., Spector, T., Brixen, K., Balogh, A., Stucki, G., & Reginster, J.-Y. (2008). Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. Journal of Bone and Mineral Research, 23 (3), 433-8. doi:10.1359/jbmr.071105
Peer Reviewed verified by ORBi

Compston, J., Reid, D. M., Boisdron, J., Brandi, M.-L., Burlet, N., Cahall, D., Delmas, P. D., Dere, W., Devogelaer, J.-P., Fitzpatrick, L. A., Flamion, B., Goel, N., Korte, S., Laslop, A., Mitlak, B., Ormarsdottir, S., Ringe, J., Rizzoli, R., Tsouderos, Y., ... Reginster, J.-Y. (2008). Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporosis International, 19 (9), 1247-50. doi:10.1007/s00198-008-0670-7
Peer Reviewed verified by ORBi

Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (2008). Risque à long terme de survenue d'une fracture ostéoporotique en Belgique. Revue Médicale de Liège, 63 (7-8), 480-487.
Peer reviewed

Kanis, J. A., Burlet, N., Cooper, C., Delmas, P. D., Reginster, J.-Y., Borgstrom, F., & Rizzoli, R. (2008). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International, 19 (4), 399-428. doi:10.1007/s00198-008-0560-z
Peer Reviewed verified by ORBi

Reginster, J.-Y., & Poston, S. (2008). Risque de fracture chez les femmes atteintes d'ostéoporose post-ménopausique primaire sous ibandronate oral mensuel ou bisphosphonates hebdomadaires : analyse additionnelle de l'étude des fractures sur base de données VIBE (eValuation of IBandronate Efficacy). Revue du Rhumatisme, 75, 1030.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Sawicki, A., Races-Varela, A., Fardellone, P., & Roberts, A. (2008). Le ranélate de strontium maintient son efficacité sur 8 ans chez les femmes ménopausées ostéoporotiques. Revue du Rhumatisme, 75, 998.
Peer Reviewed verified by ORBi

Hiligsmann, M., Bruyère, O., Pire, G., & Reginster, J.-Y. (2008). Evaluation économique de la campagne de dépistage de l'ostéoporose menée en Province de Liège avec le concours de Liège Province Santé. Revue Médicale de Liège, 63 (10), 588-94.
Peer reviewed

Reginster, J.-Y. (2008). Treating bone as a living tissue : a step forward in fracture prevention. Osteoporosis International, 19 (2), 506.
Peer Reviewed verified by ORBi

Goldhahn, J., Scheele, W. H., Mitlak, B. H., Abadie, E., Aspenberg, P., Augat, P., Brandi, M.-L., Burlet, N., Chines, A., Delmas, P. D., Dupin-Roger, I., Ethgen, D., Hanson, B., Hartl, F., Kanis, J. A., Kewalramani, R., Laslop, A., Marsh, D., Ormarsdottir, S., ... Reginster, J.-Y. (2008). Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis. BONE, 43 (2), 343-7. doi:10.1016/j.bone.2008.04.017
Peer Reviewed verified by ORBi

REGINSTER, J.-Y., Adami, S., Lakatos, P., Greenwald, M., Stepan, J. J., & Silverman, S. L. (2008). Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 Year results from the MOBILE study (Annals of the Rheumatic Diseases (2006) 65, (654-661)). Annals of the Rheumatic Diseases, 67 (2), 280. doi:10.1136/ard.2005.044958.corr1
Peer Reviewed verified by ORBi

Bruyère, O., Hiligsmann, M., FRANKINET, P., Detilleux, J., & Reginster, J.-Y. (2008). Association between changes in bone mineral density and fracture incidence in postmenopausal osteoporotic women receiving calcium and vitamin D : a 3-year follow-up study. Osteoporosis International, 19 (S2), 274.
Peer Reviewed verified by ORBi

Bruyère, O., Decock, C., Collette, J., Ortolani, S., Cormier, C., Detilleux, J., Franquinet, P., & Reginster, J.-Y. (2008). Relationship between 3-month changes in biochemical markers of bone remodelling and 3-year changes in bone mineral density in patients treated with strontium ranelate. Osteoporosis International, 19 (S2), 244.
Peer Reviewed verified by ORBi

NEUPREZ, A., & Reginster, J.-Y. (2008). Bone-forming agents in the management of osteoporosis. Best Practice and Research. Clinical Endocrinology and Metabolism, 22 (5), 869-83. doi:10.1016/j.beem.2008.06.003
Peer Reviewed verified by ORBi

Reginster, J.-Y., NEUPREZ, A., & Bruyère, O. (2008). Ibandronate in profile: drug characteristics and clinical efficacy. Expert Opinion on Drug Metabolism and Toxicology, 4 (7), 941-51. doi:10.1517/17425255.4.7.941
Peer Reviewed verified by ORBi

Devogelaer, J.-P., Bergmann, P., Body, J.-J., Boutsen, Y., Goemaere, S., Kaufman, J.-M., Reginster, J.-Y., Rozenberg, S., & Boonen, S. (2008). Management of patients with Paget's disease: a consensus document of the Belgian Bone Club. Osteoporosis International, 19 (8), 1109-17. doi:10.1007/s00198-008-0629-8
Peer Reviewed verified by ORBi

Rabenda, V., & Reginster, J.-Y. (2008). Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures. Osteoporosis International, 19 (S2), 366-367.
Peer Reviewed verified by ORBi

Bruyère, O., & Reginster, J.-Y. (2008). Vitamin D status and response to antiosteoporotic therapy. Women's Health, 4 (5), 445-7. doi:10.2217/17455057.4.5.445
Peer Reviewed verified by ORBi

Goldhahn, J., Mitlak, B., Aspenberg, P., Kanis, J. A., Rizzoli, R., & Reginster, J.-Y. (2008). Critical issues in translational and clinical research for the study of new technologies to enhance bone repair. Journal of Bone and Joint Surgery. American Volume, 90 Suppl 1, 43-7. doi:10.2106/JBJS.G.01090
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2008). L’osteoporosi nel nuovo millennio : la crescente domanda di risorse sanitarie. Clinical Cases in Mineral and Bone Metabolism, 5 (3), 269.
Peer Reviewed verified by ORBi

Chappard, D., Saag, K., Devogelaer, J., Reid, D., Sambrook, P., Goemaere, S., COLLETTE, J., Ish-Shalom, S., Papanastasiou, P., Ferreira, A., Eriksen, E., Schoenborn-Kellenberger, O., & Reginster, J.-Y. (2008). Effets d'une perfusion unique d'acide zolédronique 5 mg versus risédronate (5 mg/jour) sur le remodelage osseux sur 1 an chez des patients avec ostéroporose cortisonique. Revue du Rhumatisme, 75, 1036.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Blumentals, W., & Harris, S. (2008). Efficacité comparable de l'ibandronate mensuel ou d'un bisphosphonate hebdomadaire sur les fractures non vertébrales : une étude de cohorte rétrospective (VIBE, eValuation of IBandronate Efficacy). Revue du Rhumatisme, 75, 1020.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2008). New developments in the management of osteoporosis. Climacteric: the Journal of the International Menopause Society, 11 (S2), 30.
Peer Reviewed verified by ORBi

Hiligsmann, M., Ethgen, O., Bruyère, O., & Reginster, J.-Y. (2008). An Economic Evaluation of Quantitative Ultrasonometry as Pre-Screening Test for the Identification of Patients with Osteoporosis. Disease Management and Health Outcomes, 16 (6), 429-438. doi:10.2165/0115677-200816060-00008
Peer Reviewed verified by ORBi

Kanis, J. A., & Reginster, J.-Y. (2008). European guidance for the diagnosis and management of osteoporosis in postmenopausal women--what is the current message for clinical practice? Polskie Archiwum Medycyny Wewnetrznej, 118 (10), 538-40.
Peer reviewed

De Cock, C., Bruyère, O., Collette, J., & Reginster, J.-Y. (2008). Vitamin D inadequacy in French osteoporotic and osteopenic women. Joint Bone Spine, 75 (5), 567-72. doi:10.1016/j.jbspin.2007.10.012
Peer Reviewed verified by ORBi

Stakkestad, J. A., Lakatos, P., Lorenc, R., Sedarati, F., Neate, C., & Reginster, J.-Y. (2008). Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clinical Rheumatology, 27 (8), 955-60. doi:10.1007/s10067-007-0824-6
Peer Reviewed verified by ORBi

Rizzoli, R., Boonen, S., Brandi, M. L., Burlet, N., Delmas, P., & Reginster, J.-Y. (2008). The role of calcium and vitamin D in the management of osteoporosis. BONE, 42 (2), 246-9. doi:10.1016/j.bone.2007.10.005
Peer Reviewed verified by ORBi

Reginster, J.-Y., Felsenberg, D., Boonen, S., Diez-Perez, A., Rizzoli, R., Brandi, M.-L., Spector, T. D., Brixen, K., Goemaere, S., Cormier, C., Balogh, A., Delmas, P. D., & Meunier, P. J. (2008). Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis and Rheumatism, 58 (6), 1687-95. doi:10.1002/art.23461
Peer Reviewed verified by ORBi

Hiligsmann, M., Bruyère, O., Ethgen, O., Gathon, H.-J., & Reginster, J.-Y. (2008). Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women. BONE, 43 (6), 991-4. doi:10.1016/j.bone.2008.08.119
Peer Reviewed verified by ORBi

Bruyère, O., & Reginster, J.-Y. (2008). Correlation between increased bone mineral density and decreased fracture risk - Bone mineral density as a tool to monitor postmenopausal osteoporosis treatment. Medicographia, 30 (4), 355-359.
Peer reviewed

Hanssens, L., van Winkel, R., Wampers, M., Van Eyck, D., Scheen, A., Reginster, J.-Y., Collette, J., Peuskens, J., & De Hert, M. (2008). A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. Schizophrenia Research, 106 (2-3), 308-14. doi:10.1016/j.schres.2008.09.008
Peer Reviewed verified by ORBi

Hanssens, L., Scheen, A., van Winkel, R., Van Eyck, D., Reginster, J.-Y., & De Hert, M. (2008). Le cerveau au centre des regulations metaboliques: anomalies chez les patients schizophrenes traites par antipsychotiques atypiques. Revue Médicale de Liège, 63 (5-6), 417-23.
Peer reviewed

Miller, P. D., Epstein, S., Sedarati, F., & Reginster, J.-Y. (2008). Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Current Medical Research and Opinion, 24 (1), 207-13. doi:10.1185/030079908X253889
Peer Reviewed verified by ORBi

Rabenda, V., Mertens, R., Fabri, V., Vanoverloop, J., Sumkay, F., Vannecke, C., Deswaef, A., Verpooten, G. A., & Reginster, J.-Y. (2008). Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporosis International, 19 (6), 811-8. doi:10.1007/s00198-007-0506-x
Peer Reviewed verified by ORBi

Hiligsmann, M., Ethgen, O., Richy, F., & Reginster, J.-Y. (2008). Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcified Tissue International, 82 (4), 288-92. doi:10.1007/s00223-008-9117-6
Peer Reviewed verified by ORBi

Roux, C., Reid, D., Devogelaer, J. P., Saag, K., Lau, C., Reginster, J.-Y., Papanastasiou, P., Ferreira, A., Hartl, F., Fashola, T., Mesenbrink, P., & Sambrook, P. (2008). Effect of zoledronic acid (single 5 mg infusion) on lumbar spine bone mineral density versus oral risedronate (5 mg/day) over one year in subgroups of patients receiving glucocorticoid therapy. Osteoporosis International, 19 (S2), 248-249.
Peer Reviewed verified by ORBi

Ormarsdottir, S., Reginster, J.-Y., & Abadie, E. (2008). European regulatory perspectives for innovative therapies. Osteoporosis International, 19 (6), 725-31. doi:10.1007/s00198-008-0576-4
Peer Reviewed verified by ORBi

Bruyère, O., Burlet, N., Delmas, P. D., Rizzoli, R., Cooper, C., & Reginster, J.-Y. (2008). Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskeletal Disorders, 9, 165. doi:10.1186/1471-2474-9-165
Peer Reviewed verified by ORBi

Malaise, O., Neuprez, A., & Reginster, J.-Y. (2008). Traitements non hormonaux de l’ostéoporose postménopausique. Gynécologie Obstétrique et Fertilité, 36, 815-822. doi:10.1016/j.gyobfe.2007.05.026
Peer Reviewed verified by ORBi

Fleischmann, R., Tannenbaum, H., Patel, N. P., Notter, M., Sallstig, P., & Reginster, J.-Y. (2008). Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis. BMC Musculoskeletal Disorders, 9, 32. doi:10.1186/1471-2474-9-32
Peer Reviewed verified by ORBi

Roux, C., Reid, D., Devogelaer, J. P., Saag, K., Lau, C., Reginster, J.-Y., Papanastasiou, P., Ferreira, A., Harti, F., Fashola, T., Mesenbrink, P., & Sambrook, P. (2008). Une perfusion d'acide zolédronique 5 mg est plus efficace que le risédronate 5 mg/j per os sur l'augmentation de la densité lombaire et fémorale au cours de l'ostéoporose cortisonique. Revue du Rhumatisme, 75, 1020.
Peer Reviewed verified by ORBi

Eisman, J. A., Civitelli, R., Adami, S., Czerwinski, E., Recknor, C., Prince, R., Reginster, J.-Y., Zaidi, M., Felsenberg, D., Hughes, C., Mairon, N., Masanauskaite, D., Reid, D. M., Delmas, P. D., & Recker, R. R. (2008). Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. Journal of Rheumatology, 35 (3), 488-97.
Peer Reviewed verified by ORBi

Reginster, J.-Y. (2008). Structure modification in osteoarthritis : fact or fantasy ? Osteoporosis International, 19 (S2), 230-231.
Peer Reviewed verified by ORBi

Rabenda, V., Vanoverloop, J., Fabri, V., Mertens, R., Sumkay, F., Vannecke, C., Deswaef, A., Verpooten, G. A., & Reginster, J.-Y. (2008). Low incidence of anti-osteoporosis treatment after hip fracture. Journal of Bone and Joint Surgery. American Volume, 90 (10), 2142-8. doi:10.2106/JBJS.G.00864
Peer Reviewed verified by ORBi

Bruyère, O., Detilleux, J., Decock, C., & Reginster, J.-Y. (2008). Relationships between changes in bone mineral density and vertebral fracture incidence : an analysis of the last 3 years of an 8-year treatment with strontium ranelate. Osteoporosis International, 19 (S2), 459.
Peer Reviewed verified by ORBi

Sambrook, P., Devogelaer, J., Reginster, J.-Y., Saag, K., Roux, C., Lau, C., Papanastasiou, P., Schoenborn-Kellenberger, O., Maylandt, K., Fashola, T., Mesenbrink, P., & Reid, D. (2008). Effect of a single 5 mg infusion of zoledronic acid on bone turnover markars vs. oral risedronate (5 mg/day